Protocol 156-13-211  
Confidential - Proprietary Information ï‚·Protocol number: 156-13-211
ï‚·Document title:   A Phase 3b, Multi-center, Open-label Trial to 
Evaluate the Long Term Safety of Immediate-release Tolvaptan 
(OPC-41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With 
Autosomal Dominant Polycystic Kidney Disease  
ï‚·Versio n number : 2.0
ï‚·Date of the document: 06 March 2015
ï‚·NCT number:   [STUDY_ID_REMOVED]
1
2
128Protocol and/or  Protocol Amendments
Table of Contents
Table of Contents ..................................................................................................
Study  156
-13-211 Protocol Amendment 2; 06 March 2015 .................................
Study  156
-13-211 Protocol Amendment 3 -UK; 06 March 2015 ..........................
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re
-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
1
2WVXND3KDUPDFHXWLFDO
'HYHORSPHQW	&RPPHUFLDOL]DWLRQ,QF
,QYHVWLJDWLRQDO0HGLFLQDO3URGXFW
7ROYDSWDQ23&
5(9,6('&/,1,&$/35272&2/
$3KDVHE0XOWLFHQWHU2SHQODEHO7ULDOWR(YDOXDWHWKH/RQJ 7HUP6DIHW\RI
,PPHGLDWHUHOHDVH7ROYDSWDQ23&PJWRPJGD\6SO LWGRVHLQ6XEMHFWV
ZLWK$XWRVRPDO'RPLQDQW3RO\F\VWLF.LGQH\'LVHDVH
3URWRFRO1R
,1'1R
(XGUD&71R
&21),'(17,$/Â± 35235,(7$5<,1)250$7,21
&OLQLFDO'HYHORSPHQW3KDVH E
6SRQVRU 2WVXND3KDUPDFHXWLFDO'HYHORSPHQW	
&RPPHUFLDOL]DWLRQ,QF5HVHDUFK%RXOHYDUG5RFNYLOOH0DU\ODQG86$
6SRQVRU5HSUHVHQWDWLYHV*OREDO&OLQLFDO'LUHFWRU0HGLFDO'LUHFWRU
3KRQH )D[(PDLO
*OREDO&OLQLFDO'LUHFWRU
0HGLFDO'LUHFWRU
3KRQH )D[(PDLO
6U0DQDJHU&OLQLFDO'HYHORSPHQW
3KRQH
(PDLO
,PPHGLDWHO\5HSRUWDEOH(YHQW &OLQLFDO6DIHW\DQG3KDUPDFRYLJLODQ FH
3KRQH )D[
,VVXH'DWH  0D\
'DWHRI$PHQGPHQW  -XO\
'DWHRI$GPLQLVWUDWLYH&KDQJH 6HSWHPEHU
'DWHRI$PHQGPHQW  0DUFK 
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
PPD
PPD
PPD PPD
PPD
PPD
PPD
PPD PPD
PPD
PPD
PPD
PPD
PPD
PPD PPD
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 2 06 March 2015Protocol Sy nopsis 
Name of Sponsor:  Otsuka Pharmaceutical Development 
& Commercialization, Inc.
Name of Investigational Medicinal Prod uct: Tolvaptan 
(OPC -41061)Protocol # 156-13-211
IND#72,975
EudraCT# 2014-001516-
19
Protocol Title: A Phase 3b, Multi- center, Open- label Trial to Evaluate the 
Long Term Safet y of Immediate -release Tolvaptan 
(OPC -41061, 30 mg to 120 mg/day , Split dose) in Subjects 
with Autosomal Dominant Polycystic Kidney  Disease
Clinical Phase/Trial 
Type:Phase 3b/ Therapeutic use
Treatment Indication: Autosomal Dominant Polycystic Kidney  Disease (ADPKD)
Objective : The primary  objective of this trial is:
ï‚·To evaluate and describe the long -term safety  oftolvaptan.   
Trial Design: This trial is a phase 3b, multi -center, open- label extension trial.
Subjects will be eligible for screening into this trial if they :
ï‚·Completed and transferred from the double -blind 
Trial 156-13- 210 (12 -month period including 
post-treatment follow -up, regardless of whether this 
was on -treatment or off -treatment), or have completed 
all but the last follow -up visit, which will be combined 
with the first visit in this trial or
ï‚·Completed Trial 156-08- 271 or a prior tolvaptan 
ADPKD trial, or have completed all but the end of trial 
visit, which will be combined with the first visit in this 
trial or
ï‚·Interrupted or discontinued treatment in a prior 
tolvaptan ADPKD trial (other than Trial 156-13- 210).  
Subjects may  be enrolled with medic al monitor 
approval, and additional close monitoring may  be 
required at the beginning of the trial
For purposes of ensuring subject safet y, all subjects will be 
monitored for hepatic safety  monthl y until they have 
accumulated 18 months of tolvaptan exposur e.  After that, and 
following the approval from the medical monitor, hepatic 
monitoring will be required every  3months.  If subjects 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
3
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 3 06 March 2015approaching the 18 -month threshold have had prior 
transaminase abnormalities (> 2 Ã—upper limit of normal 
[ULN]), the inve stigator is responsible for contacting the 
medical monitor to confirm the change in frequency  from 
monthly to every  3 months.  Until their prior treatment 
assignment is unblinded, all Trial 156-13- 210 subjects who are 
eligible for this trial are scheduled to have trialvisits/ hepatic 
monitoring monthly  for the first 18 months of this trial.  Once 
unblinding occurs, it can be determined which subjects 
received tolvaptan in Trial 156-13-210.  These subjects may 
have their trial visits/hepatic t ransaminase monitoring change 
to every  3months sooner as their previous tolvaptan exposure 
in Trial 156-13- 210 can count towards the 18- month threshold. 
Enrollment in this trial will be closed when the final eligible 
subject from Trial 156-13-210 enrolls in this trial.
Subject Population: This trial will include approximately 2,500 subjects over the 
age of 18 years with ADPKD diagnosed b y Pei -Ravine criteria
(modified by  magn etic resonance imaging [MRI ]), and who
have completed or participated in a prior ADPKD 
interventional investigational medicinal product (IMP) trial.
Inclusion/Exclusion 
Criteria:Main inclusion criteria:
ï‚·Male and female subjects ï‚³18 years with a confirmed 
diagnosis of ADPKD (during participation in prior 
tolvaptan trials) who have 
ï‚·Completed and transferred from the double -blind 
Trial 156-13- 210 (12 -month period including 
post-treatment follow -up, regardless of whether this 
was on -treatment or off -treatment), or 
ï‚·Completed Tr ial156-08- 271 or a prior ADPKD 
tolvaptan trial, or
ï‚·Interrupted or discontinued treatment in a prior 
tolvaptan ADPKD trial other than Trial 156-13- 210.  
Subjects may  be enrolled with the medical monitor 
approval, and additional close monitoring may  be 
required at the beginning of the trial
ï‚·Estimated glomerular filtration rate 
(eGFR )ï‚³20mL/min/1.73m2within 3months of the 
baseline visit.  Subjects who have an eGFR 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
4
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 4 06 March 2015â‰¤ 20 mL/min/1.73m2may be enrolled with medical 
monitor and sponsor approval and increased frequency  of 
monitoring to ensure subjectsâ€™ safety .
ï‚·Renal function will be assessed during screening by  using 
historical laboratory  values ( within 3 months from the 
screening visit) for serum creatinine levels to calculate the 
eGFR.  The eGF R values will be estimated based on the 
Chronic Kidney  Disease - Epidemiology  (CKD -EPI) 
formula
Main exclusion criteria:
ï‚·Need for chronic diuretic use
ï‚·Hepatic impairment based on hepatic laboratory
assessments (a lanine aminotransferase [ALT], a spartate 
aminotransferase [AST], bilirubin , total [BT] ) other than 
that expected for ADPKD with cy stic liver disease
Trial Site(s): Approximately 220 enrolling sites including but not limite d to 
the following regions: North America, South America, Eastern 
Europe, Western Europe, Russian Federation , and Australia.
Investigational 
Medicinal Product(s), 
Dose, Dosage 
regimen, Treatment 
period, Formulation, 
Mode of 
Administration:The dose regimens to be used in this trial are 15/15 mg, 
30/15 mg, 45/15 mg, 60/30 mg , and 90/30 mg.
Tolvaptan tablets (15 mg or 30 mg ) will be self- administered 
orally  as split- dose regimens, twice dail y, once upon 
awakening and another approximately  8 to 9 hours later. 
Doses will be recorded as ea rly dose/late dose (eg, 60/ 30mg).  
Subjects will receive open-label tolvaptan for the duration of 
the trial. 
A subject â€™s starting dose in this trial will be dependent on the
trial in which they  were previously  enrolled :
ï‚·156-13-210- initiated on tolvaptan at a split- dose of 
45/15 mg with upward titration every  3 to 4 day s to 
60/30 mg or 90/30 mg per day  according to tolerability
ï‚·156-08-271- will retain the last dose level from 271 
and start at the same dose in this trial
ï‚·Prior tolvaptan trials -initiated on tolvapt an at a 
split-dose of 45/15 mg with upward titration every 3 to 
4 day s to 60/30 mg or 90/30 mg per day  according to 
tolerability
Down titration to 30/15 mg or 15/15 mg will be allowed at the 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
5
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKGLVFUHWLRQRIWKHLQYHVWLJDWRUDFFRUGLQJWRLQGLYLGXDO
WROHUDELOLW\DQGZLWKPHGLFDOPRQLWRUQRWLILFDWLRQ)XUWKHUGRZQWLWUDWLRQWRRU PJRQFHGDLO\PD\EHDOORZHG RQO\
IRUPHWDEROLFGUXJGUXJLQWHUDFWLRQDQGUHTXLUHVPHGLFDOPRQLWRUDSSURYDO
7ULDO$VVHVVPHQWV 6FUHHQLQJ,QIRUPHGFRQVHQWPHGLFDOKLVWRU\ LQFOXGLQJ
$'3.'XSGDWHVDVUHTXLUHGGHWHUPLQDWLRQRIHOLJLELOLW\
WKURXJKLQFOXVLRQH[FOXVLRQFULWHULD GLHWDU\UHYLHZYLWDOVLJ QV
FOLQLFDOODERUDWRU\DVVHVVPHQWVSK\VLFDOH[DPLQDWLRQXULQHSUHJQDQF\WHVWZRPHQRIFKLOGEHDULQJSRWHQWLDORQO\>:2&%3@FRQFRPLWDQWPHGLFDWLRQVDQGODERUDWRU\WHVWVWRGHWHUPLQHHOLJLELOLW\
6DIHW\$GYHUVHHYHQWV $(VYLWDOVLJQVGLUHFWHGSK\VLFDO
H[DPLQDWLRQGLHWDU\UHYLHZVHOIDVVHVVHGGUXJWROHUDELOLW\
VHUXPFKHPLVWU\WHVWVLQFOXGLQJVHUXPWUDQVDPLQDVHVDONDOLQHSKRVSKDWDVHELOLUXELQDQGVHUXPVRGLXPDQGFRQFRPLWDQWPHGLFDWLRQV




&ULWHULDIRU(YDOXDWLRQ6DIHW\
â€¢$(V
â€¢9LWDOVLJQV
â€¢&OLQLFDOODERUDWRU\DVVHVVPHQWV
â€¢6HUXPWUDQVDPLQDVHHOHYDWLRQV IRUIUHTXHQF\[[
[DQG[8/1WLPHWRRQVHWWLPHWRSHDNOHYHOV
WLPHRIRIIVHW[[RU[ 8/1UHVSRQVHWRGHFKDOOHQJHDQGUHFKDOOHQJHDQGIUHTXHQF\RISURJUHVVLRQWR+\Â¶VODERUDWRU\FULWHULD$/7RU$67![8/1DQG%7![8/1ZLWKRXWDONDOLQH
SKRVSKDWDVH â‰¥[ 8/1
â€¢6HUXPVRGLXPH[FXUVLRQVDERYH RU
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKPPRO/RUEHORZRUPPRO/



6WDWLVWLFDO0HWKRGV 6DPSOHVL]H6DPSOHVL]HZDVQRWGHWHUPLQH GE\DIRUPDO
FRPSXWDWLRQWRDFKLHYHDWDUJHWSRZHU1RHIILFDF\DQDO\VHV
DUHSODQQHG,WLVH[SHFWHGWKDWDSSUR[LPDWHO\VXEMHFWVPD\HQUROOIURPSUHYLRXVWROYDSWDQWULDOV
$QDO\VLVGDWDVHWV
â€¢(QUROOHG3RSXODWLRQDOOVXEMHFWVZKRZHUHHQUROOHGWR
WKLVRSHQODEHOWULDO
â€¢6DIHW\3RSXODWLRQDOOVXEMHFWV LQWKH(QUROOHG
3RSXODWLRQZKRWDNHDWOHDVWGRVHRI,03
6DIHW\DQDO\VHV6DIHW\DQDO\VLVZLOOEHFRQGXFWHGEDVHGRQ
VWDQGDUGVDIHW\YDULDEOHVLQFOXGLQJ$(VFOLQLFDOODERUDWRU\
GDWDSK\VLFDOH[DPLQDWLRQVDQGYLWDOVLJQV3RWHQWLDOO\FOLQLFDOO\VLJQLILFDQWUHVXOWVLQODERUDWRU\WHVWVLGHQWLILHGX VLQJ
SURVSHFWLYHO\GHILQHGFULWHULDLQFOXGLQJFULWHULDRQOLYHUHQ]\PHHOHYDWLRQVZLOOEHVXPPDUL]HG
7ULDO'XUDWLRQ 7ULDOGXUDWLRQLVSODQQHGWRFRQWLQXH
â€¢8QWLOWKHODVWVXEMHFW IURP7ULDO FRPSOHWHV
 PRQWKVRIWROYDSWDQWUHDWPHQW LQWKLVWULDO
â€¢6XEMHFWVHQUROOLQJIURPRWKHUWULDOVZLOOFRQFOXGHWKHLU
SDUWLFLSDWLRQRQFHWROYDSWDQEHFRPHVDYDLODEOHWKURXJK
URXWLQHSUHVFULSWLRQRUWKURXJKD RUQDPHGSDWLHQWSURJUDP7ULDO VXEMHFWVPD\RSWWRFRQFOXGHWKHLUSDUWLFLSDWLRQLQWKLVWULDOLIWROYDSWDQEHFRPHVDYDLODEOHEHIRUHWKH\FRPSOHWHPRQWKVRIWUHDWPHQWLQWKLVWULDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK7DEOH RI&RQWHQWV
3URWRFRO6\QRSVLV  
7DEOHRI&RQWHQWV  
/LVWRI,QWH[W7DEOHV  
/LVWRI,QWH[W)LJXUHV  
/LVWRI$SSHQGLFHV  
/LVWRI$EEUHYLDWLRQVDQG'HILQLWLRQVRI7HUPV  
 ,QWURGXFWLRQ  
 1RQFOLQLFDO'DWD  
 &OLQLFDO'DWD  
 .QRZQDQG3RWHQWLDO5LVNVDQG%HQHILWV  
 7ULDO5DWLRQDOHDQG2EMHFWLYHV  
 7ULDO5DWLRQDOH  
 'RVLQJ5DWLRQDOH  
 7ULDO2EMHFWLYHV  
 7ULDO'HVLJQ  
 7\S H'HVLJQRI7ULDO  
 7UHDWPHQWV  
 'RVLQJZLWK&<3$3RWHQW,QKLELWRUV  
 'RVLQJZLWK&<3$0RGHUDWH,QKLELWRUV  
 7ULDO3RSXODWLRQ  
 (OLJLELOLW\&ULWHULD  
 ,QIRUPHG&RQVHQW  
 ,QFOXVLRQ&ULWHULD  
 ([FOXVLRQ&ULWHULD  
 7ULDO(QGSRLQWV  
 6DIHW\(QGSRLQWV  
 
 
 0HDVXUHVWR0LQLPL]H$YRLG%LDV  
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 7ULDO3URFHGXUHV  
 6FKHGXOHRI$VVHVVPHQWV  
 6FUHHQLQJGD\V WRGD\SULRUWR%DVHOLQH 
 %DVHOLQH'D\  
 0RQWKO\9LVLW Â±GD\V  
 (YHU\0RQWKV Â±GD\V  
 (DUO\7HUPLQDWLRQ(QGRI7UHDWPHQWGD\V  
 GD\)ROORZXS9LVLWGD\V  
 6DIHW\$VVHVVPHQWV  
 $GYHUVH(YHQWV  
 &OLQLFDO/DERUDWRU\$VVHVVPHQWV  
 3K\VLFDO([DPLQDWLRQDQG9LWDO6LJQV  
 $VVHVVPHQWRI/LYHU6\PSWRPV6LJQVRU7HVW$EQRUPDOLWLH V 
 
 
  
  
  
 7UHDWPHQW,QWHUUXSWLRQDQG'LVFRQWLQXDWLRQ  
 (QGRI7ULDO  
 ,QGHSHQGHQW'DWD0RQLWRULQJ&RPPLWWHH  
 6WRSSLQJ5XOHV:LWKGUDZDO&ULWHULDDQG3URFHGXUHV  
 (QWLUH7ULDO  
 ,QGLYLGXDO6LWH  
 ,QGLYLGXDO6XEMHFW  
 6FUHHQ)DLOXUHV  
 'HILQLWLRQRI&RPSOHWHG6XEMHFWV  
 'HILQLWLRQRI6XEMHFWV/RVWWR)ROORZXS  
 6XEMHFW&RPSOLDQFH  
 3URWRFRO'HYLDWLRQV  
 5HVWULFWLRQV  
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCICCICCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 3URKLELWHGRU5HVWULFWHG0HGLFDWLRQV  
 'LHWDU\5HVWULFWLRQVDQG5HFRPPHQGDWLRQV  
 5HSRUWLQJRI$GYHUVH(YHQWV  
 'HILQLWLRQV  
 (OLFLWLQJDQG5HSRUWLQJ$GYHUVH(YHQWV  
 ,PPHGLDWHO\5HSRUWDEOH(YHQWV  
 3UHJQDQF\  
 )ROORZXSRI$GYHUVH(YHQWV  
 )ROORZXSRI1RQVHULRXV$GYHUVH(YHQWV  
 )ROORZXSRI3RVW7ULDO6HULRXV$GYHUVH(YHQWV  
 )ROORZXSDQG5HSRUWLQJRI6HULRXV$GYHUVH(YHQWV2FFXUULQ JDIWHU
/DVW6FKHGXOHG&RQWDFW  
 
 6WDWLVWLFDO$QDO\VLV  
 6DPSOH6L]H  
 'DWDVHWIRU$QDO\VLV  
 +DQGOLQJRI0LVVLQJ'DWD  
 ,QWHULP$QDO\ VLV  
 7ULDO2XWFRPH$QDO\VHV  
 $QDO\VLVRI'HPRJUDSKLFDQG%DVHOLQH&KDUDFWHULVWLFV  
 6DIHW\$QDO\VLV  
 $GYHUVH(YHQWV  
 9LWDO6LJQV  
 &OLQLFDO/DERUDWRU\$VVHVVPHQWV  
 6HUXP6RGLXP  
 
  
 
 0DQDJHPHQWRI,QYHVWLJDWLRQDO0HGLFLQDO3URGXFW 
 3DFNDJLQJDQG/DEHOLQJ  
 6WRUDJH  
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCICCICCI
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 10 06 March 20158.3 Accountability ...................................................................................................58
8.4 Returns and Destruction ....................................................................................58
9 Records Management ......................................................................... 58
9.1 Source Documents .............................................................................................58
9.2 Data Collection ..................................................................................................58
9.3 File Management at the Trial Site .....................................................................59
9.4 Records Retention at the Trial Site ....................................................................59
10 Quality Control and Quality Assurance ........................................... 60
10.1 Monitoring .........................................................................................................60
10.2 Auditing .............................................................................................................60
11 Ethics and Responsibility ................................................................... 60
12 Confidentiality .................................................................................... 60
13 Amendment Policy .............................................................................. 61
14 References ............................................................................................ 62
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
11
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 11 06 March 2015List of In-text Tables
Table 1.2-1 Vasopressin Blockade Across Differing Severities of 
ADPKD: Effect on Rate of Estimated Glomer ular Filtration 
Decline in Chronic Kidney  Disease Stages 1 -3 .............................18
Table 3.2-1 Trial Treatments .............................................................................25
Table 3.4.2 -1 Inclusion Criteria ...........................................................................27
Table 3.4.3 -1 Exclusion Criteria ..........................................................................28
Table 3.7-1 Schedule of Assessments ...............................................................30
Table 3.7.2.2 -1 Clinical L aboratory  Assessments ...................................................39
Table 4.1-1 Strong and Moderate CYP3A I nhibitors (partial list) ....................47
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
12
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 12 06 March 2015List of In-text Figures
Figure 3.1 -1 Trial Design Schematic ..................................................................23
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
13
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/LVWRI$SSHQGLFHV
$SSHQGL[ 1DPHVRI6SRQVRU3HUVRQQHO  
$SSHQGL[ ,QVWLWXWLRQV&RQFHUQHG:LWKWKH7ULDO  
$SSHQGL[ 
$SSHQGL[   
$SSHQGL[  3URWRFRO$PHQGPHQWVDQG$GPLQLVWUDWLYH&KDQJHV 
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/LVWRI$EEUHYLDWLRQVDQG'HILQLWLRQVRI7HUPV
$EEUHYLDWLRQ 'HILQLWLRQ
$'3.' $XWRVRPDOGRPLQDQWSRO\F\VWLFNLGQH\GLVHDVH
$( $GYHUVHHYHQW$/7 $ODQLQHDPLQRWUDQVIHUDVH$67 $VSDUWDWHDPLQRWUDQVIHUDVH$93 $UJLQLQHYDVRSUHVVLQ%7 %LOLUXELQWRWDOF$03 &\FOLFDGHQRVLQHPRQRSKRVSKDWH&.' &KURQLFNLGQH\GLVHDVH&.'(3, &KURQLF.LGQH\'LVHDVH(SLGHPLRORJ\&5) &DVHUHSRUWIRUP&65 &OLQLFDOVWXG\UHSRUW',/, 'UXJLQGXFHGOLYHULQMXU\',/,1 'UXJLQGXFHGOLYHULQMXU\QHWZRUN
H&5) (OHFWURQLFFDVHUHSRUWIRUP
H*)5 (VWLPDWHGJORPHUXODUILOWUDWLRQUDWHH*)5&.'(3((VWLPDWHGJORPHUXODUILOWUDWLRQUDWHFDOFXODWHGE\WKH&KURQLF .LGQH\
'LVHDVH(SLGHPLRORJ\ &.'(3,IRUPXOD
(0$ (XURSHDQ0HGLFLQHV$JHQF\(R7[ (QGRIWUHDWPHQW(65' (QGVWDJHUHQDOGLVHDVH(XGUD&7 (XURSHDQ&OLQLFDO7ULDO'DWD%DVH*&3 *RRG&OLQLFDO3UDFWLFH+$& +HSDWLFDGMXGLFDWLRQFRPPLWWHH,% ,QYHVWLJDWRUÂ¶VEURFKXUH,&) ,QIRUPHGFRQVHQWIRUP,&+ ,QWHUQDWLRQDO&RQIHUHQFHRQ+DUPRQLVDWLRQ,' ,GHQWLILFDWLRQ,'0& ,QGHSHQGHQWGDWDPRQLWRULQJFRPPLWWHH,(& ,QGHSHQGHQWHWKLFVFRPPLWWHH,03 ,QYHVWLJDWLRQDOPHGLFLQDOSURGXFW,1' ,QYHVWLJDWLRQDOQHZGUXJ,5% ,QVWLWXWLRQDOUHYLHZERDUG,5( ,PPHGLDWHO\UHSRUWDEOHHYHQW,57 ,QWHUDFWLYHUHVSRQVHWHFKQRORJ\0HG'5$ 0HGLFDO'LFWLRQDU\ IRU5HJXODWRU\$FWLYLWLHV
05, 0DJQHWLFUHVRQDQFHLPDJLQJ23& 2WVXND3KDUPDFHXWLFDO&R23'& 2WVXND3KDUPDFHXWLFDO'HYHORSPHQW	&RPPHUFLDOL]DWLRQ,QF3.' 3RO\F\VWLFNLGQH\GLVHDVH6$( 6HULRXVDGYHUVHHYHQW6$3 6WDWLVWLFDO$QDO\VLV3ODQ
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 15 06 March 2015SD Standard deviation
TEAE Treatment -emergent adverse event
ULN Upper limit of normal
US or USA United States or United States of America
WOCBP Women of childbearing potential
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
16
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 16 06 March 20151 Introduction
Tolvaptan (OPC -41061) is a selective arginine vasopressin (AVP) t ype 2 (V 2) receptor 
antagonist that is currently  approved in the United States (US), Europe, Australia, 
Canada, China, Hong Kong, Indonesia, Japan, Repu blic of Korea, and Taiwan, for 
various forms of h yponatremia, and in Japan for volume overload in heart failure or liver 
cirrhosis.
Tolvaptan is also being investigated for the use in adults to treat autosomal dominant 
polycystic kidney  disease (ADPKD), an inherited condition which leads to progressive 
destruction of normal kidney  structure leading to end -stage renal disease (ESRD).  The 
disease affects the structure of the kidney s through proliferation and growth of numerous 
fluid- filled cy sts.  The expanding cy sts compress normal tissue and blood vessels 
resulting in ischemia, inflammation and fibrosis leading to progressive nephron loss.  The 
remaining nephrons are initially  able to compensate through glomerular hyperfiltration up 
to a point when nephron loss is so great that compensation is no longer adequate and 
renal function begins to decline.  Clinical manifestations of kidney  disease may  be 
sporadic (hematuria, infections, pain) or chronic (hy pertension, albuminuria, renal 
insufficiency ) and indicate ongoing and cumulative damage to the kidney .
The number of diagnosed ADPKD cases was estimated at 116,228 in the US in 2009.  
The estimated prevalence of diagnosed ADPKD is similar in Europe and estimated to be 
< 5 per 10,000.1  Though a rare genetic disease, it ranks as the 6thleading cause of ESRD 
in the US (2.3% of the new ESRD cases).2  An estimated 45% to 70% of patients with 
ADPKD progress to ESRD by  age 65.3  Over the past 30 y ears, the age of onset for 
ESRD among ADPKD patients has remained the same (median age of 54).  I n contrast, 
effective therap y has delayed the onset of ESRD in patients with nephropathy due to 
hypertension, diabetes, and glomerulonephritis.
There are currently  no therapies which can slow the deterioration of kidney  function in 
ADPKD.  Current management focuses on ameliorating s ymptoms of pain, control of 
blood pressure, and treatment of infections with antibiotics.  None of these treatmen ts 
target the underly ing cause of the disease.  Often, the only  definitive intervention for 
renal complications in ADPKD is kidney  transplantation, which ty pically  occurs after 
years of hemodialysis.
In the US, the development program for tolvaptan for ADP KD was granted Fast -track 
designation on 20 Jan 2006 and orphan drug designation on 06 Apr 2012.  Tolvaptan was 
designated as an orphan drug for prevention of the progression of ADPKD in Japan on 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
17
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 17 06 March 201511Aug 2006.  The European Medicines Agency (EMA) granted or phan designation for 
the use of tolvaptan for the treatment of ADPKD on 5 Aug 2013.
If approved, tolvaptan would be the first available therap y to slow kidney  disease 
progression in adults with ADPKD .4 5  Refer to the Tolvaptan Investigatorâ€™s Brochure 
(IB) for more information.4
1.1 Nonclinical Data
Rodent models of ADPKD and ex -vivo human ADPKD cell and tissue cultures have 
implicated AVP as a promoter of kidney  cyst growth.6 7  AVP -induced cyclic adenosine 
monophosphate (cAMP) increases proliferation of ADPKD renal tubular epithelium and 
chloride -mediated, intra -cystic, fluid secretion.  This leads to cy st expa nsion which 
disrupts renal architecture leading to ischemia, kidney fibrosis, and irreversible damage 
to the kidney , ultimatel y impairing its function.  Tolvaptan inhibits cAMP production by  
blocking AVP binding to the renal AVP -V2receptor.  For informati on on nonclinical 
toxicology  and absorption, distribution and metabolism data on tolvaptan please refer to 
the most current version of the IB.4
1.2 Clinical Data
Tolvaptan was clinically  effective in delay ing decline of renal function, as determined b y 
changes in serum creatinine concentrations over 3 years, in an international, multicenter, 
clinical trial in subjects with chronic kidney disease (CKD) stage 1 to 3 due to ADPKD.8  
These effects were consi stent across each of these CKD stages, supporting tolvaptanâ€™s 
potential utility  in earl y tomid-stage disease (Table 1.2-1) , and creating a compelling
argument for long- term effectiveness in those initiating therapy  at an earl y stage and 
adhering to therap y as the disease progresses.  This trial also demonstrated an acute and 
persistent reduction on rate of kidney  cystic growth.  The reductions in rate of kidney  
growth correlated with reductions in kidney  pain and with preservation of renal function.  
Similar correlations were observed in a smaller, matched -control study  
(Study 156-09- 283).9  Thus, the clinical data ha ve confirmed the non -clinical effects seen 
in animals (see Section 1.1) and support approval of tolvaptan as the first agent to slow 
the progression of ADPKD.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
18
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK7DEOH 9DVRSUHVVLQ%ORFNDGH$FURVV'LIIHULQJ6HYHULWLHVRI
$'3.'(IIHFWRQ5DWHRI(VWLPDWHG*ORPHUXODU)LOWUDWLRQ
'HFOLQHLQ&KURQLF.LGQH\'LVHDVH6WDJHV
&.'6WDJH
E\H*)5 &.'(3,
P/PLQP1
7ROYDSWDQ
3ODFHERH*)56ORSH
7ROYDSWDQH*)56ORSH
3ODFHER (IIHFW6L]H5HODWLYH
(IIHFW6L]H
6WDJHâ‰¥   D 
6WDJH   D 
6WDJHE
D     
E     
H*)5&.'(3( HVWLPDWHGJORPHUXODUILOWUDWLRQUDWHFDOFXODWHG E\WKH&KURQLF.LGQH\'LVHDVH
(SLGHPLRORJ\&.'(3,IRUPXOD
D$OOS
E&.'6WDJHUHODWLYHHIIHFWVL]H 1 WROYDSWDQSODFHER 
6RXUFH7ULDO FOLQLFDOVWXG\UHSRUW&65'DWDRQ ILOH






 .QRZQDQG3RWHQWLDO5LVNVDQG%HQHILWV
$'3.'LVDGHYDVWDWLQJSURJUHVVLYHGLVHDVHWKDWSODFHVDWUHPH QGRXVEXUGHQRQSDWLHQWV
DQGWKHLUIDPLOLHV7KHULVNDSDWLHQWLVZLOOLQJWRDFFHSWLV DSHUVRQDOGHFLVLRQEDVHGRQ
KLVKHULQGLYLGXDODQGIDPLOLDOH[SHULHQFHZLWKWKHGLVHDVH7 ROYDSWDQLVSRWHQWLDOO\WKH
ILUVWWKHUDS\WKDWRIIHUVSDWLHQWVDWUHDWPHQWRSWLRQWRVORZWK HLUGLVHDVHSURJUHVVLRQ
KRZHYHUDVRI-DQXDU\LWKDVQRW\HWEHHQDSSURYHGIRUW KLVLQGLFDWLRQ7KH
WUHDWPHQWULVNVDUHZHOOFKDUDFWHUL]HGPDQDJHDEOHDQGPXVWEH ZHLJKHGDJDLQVWWKH
FRQVHTXHQFHVRIQRWUHDWPHQW
$VRI0DUSRROHGH[SRVXUHGDWDDUHDYDLODEOHIURPWU LDOVLQYROYLQJ
 VXEMHFWVZRUOGZLGHFRPSULVLQJVXEMHFWVLQWULDOVIRU ZLWKKHDUWIDLOXUH
VXEMHFWVLQWULDOVIRUK\SRQDWUHPLDVXEMHFWVLQDORQJ WHUPWULDOIRU$'3.'
 VXEMHFWVLQDVKRUWWHUPWULDOIRU$'3.'RUUHQDOLPSDLUPHQW VXEMHFWVLQWULDOV
IRUFDUGLDFHGHPDVXEMHFWVLQWULDOVIRUKHSDWLFHGHPD VXEMHFWVZLWKUHQDO
LPSDLUPHQWLQDSKDVHWULDODQGKHDOWK\VXEMHFWVLQFO LQLFDOSKDUPDFRNLQHWLF
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 19 06 March 2015trials.  Overall, subjects were exposed to ora l doses of tolvaptan ranging from 3.75 to 
480 mg.  The median exposure for all doses of oral formulations combined was 29 day s, 
with a mean exposur e of 228days (ï‚±346 day s).
Pooled safet y data from 80 trials indicate that the most commonly  reported (> 3%) 
treatment -emergent adverse events (TEAEs) for tolvaptan -treated subjects were thirst 
(25.8%), dr ymouth (10.8%) and pollakiuria (9.9%).
The most notable safet y issue associated with chronic tolvaptan use, which was new ly 
identified in Trial 156 -04-251, was the potential for idiosy ncratic hepatic toxicity . An 
imbalance in the proportion of subjects with elevated transaminases (tolvaptan > placebo) 
led to identification of 3 subjects (total, combined from Trials 156 -04-251 and 
156-08- 271) with laboratory and clinical evidence of potentially  serious drug -induced 
liver injury  (DILI).10Based on the available data from the afore -mentioned trials, the 
sponsor proposes that appropriate subj ect monitoring and management be implemented to 
mitigate this potential risk in the ADPKD population.  
In this extension trial, subjects enrolling from the double -blind Trial 156- 13-210 will 
have monthly  visits and transaminase level assessments for the f irst 18 months while the 
treatment code from Trial 156-10- 210 remains blinded, to ensure that all subjects have 
adequate safet y monitoring during this period of susceptibility .  Once unblinding occurs, 
it can be determined which subjects received tolvaptan in Trial 156-13- 210.  These 
subjects may  have their trial vis its/hepatic transaminase monitoring change to every  
3months sooner as their previous tolvaptan exposure in Trial 156-13- 210 can count 
towards the 18- month threshold.  If subjects approaching th e 18-month threshold have 
had prior transaminase abnormalities (> 2 Ã—upper limit of normal [ ULN ]),the 
investigator is responsible for contacting the medical monitor to confirm the change in 
frequency from monthl y to every  3months.  Subjects enrolling fr om the open- label 
Trial 156-08-271 will have transaminase assessments conducted every  3months , since 
they will have already  received tolvapt an for at least 18 months. The current IB lists all 
of the tolvaptan trials.   Subjects enrolling in this trial who were in a previous ADPKD 
tolvaptan trial other than Trials 156-13- 210 and 156-08- 271 will have monthly  visits and 
alanine aminotransferase (ALT) level assessments for the first 18 months .
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
20
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 7ULDO5DWLRQDOHDQG2EMHFWLYHV
 7ULDO5DWLRQDOH
(YLGHQFHIURPSUHYLRXVVWXGLHVVXJJHVWVWKDWGXULQJWKHILUVW PRQWKVRIORQJWHUP
WUHDWPHQWLQVXEMHFWVZLWK$'3.'$/7DQGRUDVSDUWDWHDPLQRWUD QVIHUDVH$67
HOHYDWLRQVDQGHYLGHQFHRILGLRV\QFUDWLF',/,RFFXUVDWDJUHDWH UIUHTXHQF\LQWROYDSWDQ
WUHDWHGVXEMHFWV+RZHYHUWKHUDWHRIQHZWUDQVDPLQDVHHOHYDW LRQVEH\RQGPRQWKV
DQGXSWR\HDUVZDVVLPLODUEHWZHHQWROYDSWDQWUHDWPHQWDQG SODFHERVXEMHFWV
2YHUWKH\HDUVRISODFHERFRQWUROOHGWUHDWPHQW$/7ZDVHOHYD WHGWRDJUHDWHUWKDQ
WKUHHWLPHVWKHXSSHUOLPLWRIQRUPDO! Ã®8/1LQRIWRO YDSWDQVXEMHFWV
FRPSDUHG ZLWKRISODFHERVXEMHFWV7RGDWH WROYDSWDQVXEMH FWVÂ¶WUDQVDPLQDVHVDQG
ELOLUXELQOHYHOVUHDFKHG+\Â¶VODERUDWRU\FULWHULD!Ã®DQG!Ã® 8/1UHVSHFWLYHO \
8SRQGLVFRQWLQXDWLRQDOOVXEMHFWVÂ¶OLYHUWHVWVVKRZHGUHYHUVLE LOLW\RIWKHHOHYDWLRQZLWKLQ
DSSUR[LPDWHO\PRQWKVDIWHUWROYDSWDQZDVGLVFRQWLQXHG1HYHU WKHOHVVZLWKRXW
DGHTXDWHPRQLWRULQJDQGPDQDJHPHQWLWLVHVWLPDWHGWKDWD ULVNIRULUUHYHUVLEOH
OLYHULQMXU\PD\ H[LVW
7KURXJKPRUHIUHTXHQWHJPRQWKO\PRQLWRULQJRIOLYHUWUDQVDP LQDVHV WKHFXUUHQWWULDO
ZLOOPRUHSUHFLVHO\GHILQHWKHSRWHQWLDOIRU',/,SUHYLRXVO\RE VHUYHGLQ
7ULDO )UHTXHQWPRQLWRULQJZLOO DOVRGHWHFW VPDOOHUHO HYDWLRQVHDUOLHU
SHUPLWWLQJFORVHUDQGPRUHWKRURXJKHYDOXDWLRQDQGLQWHUYHQWLRQ LQFOXGLQJGUXJ
LQWHUUXSWLRQRUGLVFRQWLQXDWLRQ7KLVLVH[SHFWHGWRPLWLJDWH WKHULVNRIVHULRXVRU
LUUHYHUVLEOHLQMXU\













8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK
7KLVWULDOZLOOH[WHQGRXUXQGHUVWDQGLQJRIWROYDSWDQÂ¶VORQJWH UPVDIHW\LQ$'3.'
SDWLHQWV
 'RVLQJ5DWLRQDOH
,QDQLPDOPRGHOVRIF\VWLFGLVHDVHVXFFHVVIXOWUHDWPHQWRIGLV HDVHSURJUHVVLRQDV
LQGLFDWHGE\NLGQH\VL]HDSSHDUHG WRUHTXLUHHDUO\FRQVWDQWLQKL ELWLRQRIWKHYDVRSUHVVLQ
9UHFHSWRU7KHFOLQLFDO IRUPXODWLRQRIWROYDSWDQUHTXLUHV VSOLWG RVLQJWRPDLQWDLQ
VXSSUHVVLRQRI$93DFWLRQDFURVVKRXUV$KLJKHUGRVHLVXV HGHDUO\LQWKHGD\ZLWKD
ORZHUGRVHDSSUR[LPDWHO\WRKRXUVODWHULQRUGHUWRSURGXFH DPD[LPDOLQKLELWLRQRQ
ZDNLQJZLWKDJUDGXDOIDOORIIRIHIIHFWGXULQJWKHQLJKWZKHQ IUHTXHQWXULQDWLRQFRXOG
OHDGWRDQLQWHUUXSWLRQRIVOHHS
 7ULDO2EMHFWLYHV
7KHSULPDU\REMHFWLYHRIWKLVWULDOLV
â€¢7RHYDOXDWHDQGGHVFULEHWKHORQJWHUPVDIHW\RIWROYDSWDQ
 7ULDO'HVLJQ
 7\SH'HVLJQRI 7ULDO
7KLVWULDOLVDSKDVHEPXOWLFHQWHURSHQODEHOWULDO
(OLJLEOHVXEMHFWVZLOOKDYHDQRSSRUWXQLW\WRHQUROOLQWR7ULDO IROORZLQJ
FRPSOHWLRQRIWKHIROORZXSYLVLWVRIWKHSUHYLRXVWULDO(OLJ LEOHVXEMHFWVIURP
7ULDOV  DQGFDQKDYHWKHODVWYLVLWDVVHVVPH QWVIURPWKHLUSUHYLRXV
UHVSHFWLYHSURWRFROVHQGRIWULDOYLVLWIRUVXEMHFW VDQGODVWIROORZXSYLVLWIRU
VXEMHFWVRYHUODSWKHILUVWYLVLWLQWKLVWULDO7K HVHODVWYLVLWDVVHVVPHQWVFDQ
EHFRPELQHGZLWKWKHVFUHHQLQJDQGEDVHOLQHYLVLWV IRUWKLVWULD OZLWKDOOUHTXLUHG
DVVHVVPHQWVIURPHDFKYLVLWSHUIRUPHGRQO\RQFHVRORQJDVWKH WLPHEHWZHHQWKHODVW
YLVLWDVVHVVPHQWVIURPWKHSUHYLRXVWULDODQGWKHVFUHHQLQJYLV LWIRUWKLVWULDOLVZLWKLQ
 GD\V,IWKHILUVWYLVLWLQWKLVWULDOFRPELQHVWKHODVWYLV LWIURPDSUHYLRXVWULDOZLWK
ERWK WKHVFUHHQLQJDQGWKHEDVHOLQHYLVLWVLQWKLVWULDOWKHUH VXOWVIURPODERUDWRU\
DVVHVVPHQWVSHUIRUPHGDWWKLVFRPELQHGYLVLWZLOOQRWEHLPPHGL DWHO\DYDLODEOH6KRXOG
DQ\ODERUDWRU\DEQRUPDOLWLHVEHLGHQWLILHGWKHLQYHVWLJDWRUZL OOQHHGWRQRWLI\WKHVXEMHFW
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKDQGSURYLGHLQVWUXFWLRQVUHJDUGLQJGRVLQJRUUHWXUQLQJWRWKHV LWHIRUDGGLWLRQDO
DVVHVVPHQWV
0HGLFDOPRQLWRUDSSURYDOLVQHHGHGIRUHQUROOPHQWRIVXEMHFWVZ KRVHFRPSOHWLRQRIWKH
SUHFHGLQJWULDOSULRUWRHQWU\LQWKLVWULDO H[FHHGV PRQWKVDQ GWKHVHVXEMHFWVZLOOEH
UHTXLUHGWRXQGHUJRDOOVFUHHQLQJDQGEDVHOLQHDVVHVVPHQWV
$IWHUFRQVHQWLQJVXEMHFWVZLOOEHDVVLJQHGDQHZVFUHHQLQJQXP EHU6XEMHFWVZKRDUH
IRXQGWREHHOLJLEOHZLOOUHWDLQWKHVDPHVXEMHFWQXPEHUWKH\K DGEHHQDVVLJQHGLQWKHLU
SUHYLRXVWULDO)RUSXUSRVHVRIHQVXULQJVXEMHFWVDIHW\WROYD SWDQH[SRVXUHRIDWOHDVW
 PRQWKVLVUHTXLUHGIRUDOOVXEMHFWV:KLOH7ULDO U HPDLQVEOLQGHGVXEMHFWV
HQUROOLQJIURPDQ\SULRUWULDOEHVLGHV7ULDODUHVFKH GXOHGWRKDYHPRQWKO\
KHSDWLFPRQLWRULQJIRUWKHILUVWPRQWKVRIWKLVWULDO$IWHU WKDWIROORZLQJWKHDSSURYDO
RIWKHPHGLFDOPRQLWRUKHSDWLFPRQLWRULQJZLOOWDNHSODFHHYHU \PRQWKV6XEMHFWV
HQUROOLQJIURP7ULDO ZLOOKDYHKHSDWLFPRQLWRULQJHYH U\PRQWKV$OO
7ULDO VXEMHFWVZKRDUHHOLJLEOHIRUWKLVWULDOZLOOL QLWLDOO\EHVFKHGXOHGWRKDYH
WULDOYLVLWV DQGKHSDWLFPRQLWRULQJPRQWKO\IRUWKHILUVWPRQ WKVWKHQHYHU\PRQWKV
WKHUHDIWHUEHFDXVHWKHLUWROYDSWDQH[SRVXUHFDQQRWEHGHWHUPLQ HGVLQFH7ULDO 
LVDGRXEOHEOLQGWULDO2QFHXQEOLQGLQJRFFXUVLWFDQEHGHW HUPLQHGZKLFKVXEMHFWV
UHFHLYHGWROYDSWDQLQ7ULDO7KHVHVXEMHFWVPD\KDYH WKHLUWULDOYLVLWVKHSDWLF
WUDQVDPLQDVHPRQLWRULQJFKDQJHGWRHYHU\PRQWKVVRRQHUDVWKHLU SUHYLRXVWROYDSWDQ
H[SRVXUHLQ7ULDO FDQFRXQWWRZDUGVWKHPRQWKWKUH VKROG6XEMHFWVIURP
SULRUWROYDSWDQWULDOVRWKHUWKDQ7ULDOZLOOKDYHPR QWKO\WULDOYLVLWV$/7OHYHO
DVVHVVPHQWVIRUWKHILUVWPRQWKV$IWHUWKDWWKHWULDOYLV LWV$/7PRQLWRULQJZLOOEH
FRQGXFWHGHYHU\PRQWKVDIWHUWKHFKDQJHLQIUHTXHQF\LVFRQIL UPHG ZLWKWKHPHGLFDO
PRQLWRU
(QUROOPHQWLQWKLVWULDOZLOOEHFORVHGZKHQWKHODVWHOLJLEOHVX EMHFWIURP
7ULDO HQUROOVLQWKLVWULDO
7KHGXUDWLRQRIWKLVWULDOLVSODQQHGWRFRQWLQXH
â€¢8QWLOWKHODVWVXEMHFW IURP7ULDO FRPSOHWHV PRQWKVR IWROYDSWDQ
WUHDWPHQW LQWKLVWULDO
â€¢6XEMHFWVHQUROOLQJIURPRWKHUWULDOVZLOOFRQFOXGHWKHLUSDUWLF LSDWLRQRQFH
WROYDSWDQEHFRPHVDYDLODEOHWKURXJKURXWLQHSUHVFULSWLRQRUWKUR XJKD
7ULDO VXEMHFWVPD\
RSWWRFRQFOXGHWKHLUSDUWLFLSDWLRQLQWKLVWULDOLIWROYDSWDQ EHFRPHVDYDLODEOH
EHIRUHWKH\FRPSOHWH PRQWKVRIWUHDWPHQWLQWKLVWULDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 23
 06 March 2015Figure 3.1-1 Trial Design Schematic
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka confidential information and should not be duplicated 
or re -distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
24
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 24 06 March 20153.2 Treatments
The dose regimens to be used in this trial are 15/15 mg, 30/15 mg, 45/15 mg, 60/30 mg ,
and 90/30 mg.
Following consent , and once subjects have satisfied all of the inclusion criteria and none 
of the exclusion criteria , subjects will retain the subject number assigned from their 
previous trial .  Subjects will receive open -label tolvaptan for the duration of the trial. All 
subjects will be administered tolvaptan tablets in a daily  split -dose, once upon awakening 
and another approximately  8 to 9 hours later (twice daily  dosing).  The exact time of 
dosing may  be adjusted based on wake/sleep hab its (eg, standard 8 AM and 5 PM may  be 
switched to 10 PM and 7 AM if working a night shift).  However, dosing times should be 
consistent for each individualâ€™s daily dose to maximize receptor suppression.  Doses will 
be recorded as early  dose/late dose (eg, 60/30 mg). 
A subjectâ€™s starting dose in this trial will be dependent on the trial in which they  were 
previously  enrolled:
ï‚·156-13-210- initiated on tolvaptan at a split- dose of 45/15 mg with upward 
titration every  3 to 4 days to 60/30 mg or 90/30 mg per day according to 
tolerability
ï‚·156-08-271- will retain the last dose level from 271 and start at the same dose in 
this trial
ï‚·Prior tolvaptan trials -initiated on tolvapt an at a split -dose of 45/15 mg with 
upward titration every  3 to 4 day s to 60/30 mg or 90/30 mg per day  according to 
tolerability
Down titration to 30/15 mg and 15/15 mg is also permitted at the discretion of the 
investigator according to subject tolerability with medical monitor notification.  Further 
down titration to 30 or15 mg once dail y may be allowed only  for metabolic drug -drug 
interaction and requires medical monitor approval.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
25
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 25 06 March 2015Table 3.2-1 Trial Treatments
Trial Day Time Dose
Day 1 to last on -treatment visit 8:00 am 1to 6tolvaptan tablets (15 mg or 30 mg each)
4:00 to 5:00 pm 1to 2tolvaptan tablets (15 mg or 30 mg each)
Allowed doses are 45/15 mg, 60/30 mg, 
90/30 mg.  D own titration to 30/15 mg and 
15/15 mg will be allow ed after discussion 
with the medical monitor.  Further down 
titration to 30 or 15 mg once daily may be 
allow ed only for metabolic drug -drug 
interaction and requires medical monitor 
approval .
For subjects moving from the 156-13-210 trial and requiring tolvaptan titration ,it will be 
conducted in the following way : subjects will be instructed to take tolvaptan starting at a 
split dose of 45/15 mg (as 3 tablets upon waking and 1 tablet approximately 8 to9 hours 
later) and to titrate up every  3 to 4 day s; first to 60/30 mg, then up to the maximum dose 
of 90/30 mg.  Titration will be accomplished b y increasing the number of tablets/dose 
and/or switching from 15 mg tablets to 30 mg tablets.  Prior to each upward titration, the 
subjectâ€™s tolerability  to the current dose will be assessed by  asking, â€œCould y ou tolerate 
this dose of trial medication for the rest of your life?â€ Subjects will continue in the trial
with the regimen to which tolerability  was established.
While taking tolvaptan, all subjects should be instructed to ingest fluids in anticipation of, 
or at the first sign of thirst in order to avoid excessive thirst or dehy dration.  Additionally , 
subjects should ingest 1 to 2 cups of water before bedtime regardless of perceived thirst 
and replenish fluids overnight with each episode of nocturia.
3.2.1 Dosing with CYP3A 4 Potent Inhib itors
Tolvaptan is a sensitive CYP3A4 substrate with 4- fold or higher increases in exposure 
following administration with potent CYP3A4 inhibitors.4  
For subjects requiring treatment with a potent CYP3A4 inhibitor and on a total daily  
tolvaptan dose of 90 or 120 mg, tolvaptan treatment should be reduced to 30 mg once 
daily .  The dose may  be reduced to 15 mg once daily  for tolerability .  For subjects on a 
total daily  dose of 60 mg, tolvaptan treatment should be reduced t o 15 mg once dail y.  
For subjects on lower total daily  doses, tolvaptan interruption should be considered if no 
alternative medications can be used. 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
26
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 26 06 March 20153.2.2 Dosing with CYP3A 4 Moderate Inhibitors
For subjects who require dosing with a moderate inhibitor, initial tolvaptan reductions as 
shown below should be tried, with further dose reductions or interruption as necessary  for 
tolerability .
ï‚·90/30 mg to 45/15 mg
ï‚·60/30 mg to 30/15 mg
ï‚·45/15 mg to 15/15 mg
ï‚·30/15 mg to 15 mg once daily
ï‚·15/15 mg to 15 mg once daily
A par tial list of strong and moderate CYP3A4 inhibitors can be found in Section 4.1.
3.3 Trial Population
This trial will include approximately 2,500 subjects over the age of 18 y ears with 
ADPKD diagnosed b y Pei-Ravine criteria11 12(modified by magnetic resonance imaging 
[MRI ])who completed or participated in a prior tolvaptan trial.  
3.4 Eligibility  Criteria
3.4.1 Informed Consent
Each investigator has both ethical and legal responsibility  to ensure that subjects being 
considered for inclusion in this trial are given a full explanation of the protocol and of 
their role and responsibilities in the propo sed research.  This shall be documented on a 
written informed consent form ( ICF)that shall be approved b y the same institutional 
review board/independent ethics committee (I RB/IEC) responsible for approval of this 
protocol.  Each ICF will comply  with the International Conference on Harmonisation 
(ICH) Good Clinical Practice (GCP) Guideline14and local regulatory  requirements, and 
must adhere to the ethical principles that have their origin in the Declaration of Helsinki .  
The investigator agrees to obtain sponsor approval of any  written ICF used in the trial 
prior to submission to the I RB/IEC.
Investigators may discuss trial availability  and the possibility  for entry  with a potential 
subject without first obtaining consent.   Howe ver, informed consent will be obtained 
from all subjects (or their guardian or legal representative) and documented prior to 
initiation of any  procedures that are performed solely  for the purpose of determining 
eligibility  for this trial, including withdraw al from current medication(s).
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
27
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK2QFHDSSURSULDWHHVVHQWLDOLQIRUPDWLRQKDVEHHQSURYLGHGDQGIX OO\H[SODLQHGLQ
OD\PDQÂ¶VODQJXDJHWRWKHVXEMHFWE\WKHLQYHVWLJDWRURUDTXDO LILHGGHVLJQHHWKH
,5%,(&DSSURYHGZULWWHQ,&)ZLOOEHVLJQHGDQGGDWHGE\ERWKW KHVXEMHFWDQGWKH
SHUVRQREWDLQLQJFRQVHQWLQYHVWLJDWRURUGHVLJQHHDVZHOODV E\DQ\RWKHUSDUWLHV
UHTXLUHGE\WKH,5 %,(&7KHVXEMHFWZLOOUHFHLYHDFRS\RIWK HVLJQHG,&)WKHRULJLQDO
VKDOOEHNHSWRQILOHE\WKHLQYHVWLJDWRU





 ,QFOXVLRQ&ULWHULD
6XEMHFWVDUHUHTXLUHGWRPHHWWKHIROORZLQJLQFOXVLRQFULWHULDL Q7DEOH 
7DEOH ,QFOXVLRQ&ULWHULD
0DOHDQGIHPDOHVXEMHFWVDJHG â‰¥\HDUVZLWKFRQILUPHGGLDJQRVLVRI$'3.'GXULQJ
SDUWLFLSDWLRQLQSULRUWROYDSWDQWULDOVZKRKDYH
â€¢&RPSOHWHGDQGWUDQVIHUUHGIURPWKHGRXEOH EOLQG7ULDO PRQWKSHULRG
LQFOXGLQJSRVWWUHDWPHQWIROORZXSUHJDUGOHVVRIZKHWKHUWKLV ZDVRQWUHDWPHQWRURII
WUHDWPHQWRU
â€¢&RPSOHWHG7ULDO RUDSULRUWROYDSWDQWULDORU
â€¢,QWHUUXSWHGRUGLVFRQWLQXHGWUHDWPHQWLQDWROYDSWDQWULDORWKH UWKDQ7ULDO
6XEMHFWVPD\EHHQUROO HGZLWKWKHPHGLFDOPRQLWRUDSSURYDODQG DGGLWLRQDOFORVHPRQLWRULQJ
PD\EHUHTXLUHGDWWKHEHJLQQLQJRIWKHWULDO
â€¢5HQDOIXQFWLRQZLOOEHDVVHVVHGGXULQJVFUHHQLQJE\XVLQJKLVWR ULFDOODERUDWRU\YDOXHVLQWKH
ODVWPRQWKVIRUVHUXPFUHDWLQLQHOHYHOVWRFDOFXODWHWKHH*)5 7KHH*)5YDOXHVZLOOEH
HVWLPDWHGEDVHGRQWKH&.'(3,IRUPXOD/HYH\$6HWDO$QQ,QW HUQ0HGÂ±

(VWLPDWHGJORPHUXODUILOWUDWLRQUDWH â‰¥P/PLQPFDOFXODWHGXVLQJWKH&.'(3,IRUPXOD
ZLWKLQPRQWKVSULRUWRWKHEDVHOLQHYLVLW6XEMHFWVZKRKDYHDQH *)5Â”P/PLQP
PD\EHSHUPLWWHGWRHQWHUWKHWULDOZLWKPHGLFDOPRQLWRUDQGVS RQVRUDSSURYDODQGLQFUHDVHG
IUHTXHQF\RIPRQLWRULQJWRHQVXUHVDIHW\RIVXEMHFWV
H*)5 HVWLPDWHGJORPHUXODUILOWUDWLRQUDWH&.'(3, &KURQLF.LGQ H\'LVHDVH(SLGHPLRORJ\
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 28 06 March 20153.4.3 Exclusion Criteria
Subjects will be excluded if they  meet any  of the exc lusion criteria in Table 3.4.3-1.
Table 3.4.3-1 Exclusion Criteria
1. WOCBP who do not agree to practice 2 different methods of birth control or remain abstinent 
during the trial and for 30 days after the last dose of IMP. Ifemploying birth control, 2 of the 
following precautions must be used: vasectomy of partner, tubal ligation, vaginal diaphragm, 
intrauterine device, birth con trolpill, birth control implant, birth control depot injection, condom, 
or sponge with spermicide.
2. Wom en who are breast -feeding and/or who have a positive pregnancy test result prior to receiving
IMP.
3. Need for chronic diuretic use .
4. Hepatic impairm ent based on liver function abnormalities other than that expected for ADPKD 
with cystic liver disease during screening based on recent historical laboratory values (in the last 
3months) .  
5. Subjects with contraindications to required trial assessments (contraindications to optional 
assessments, eg, MRI are not a limitation) .
6. Subjects who, in the opinion of the investigator or medical monitor, have a medical history or 
medical finding inconsistent with safety or trial compliance.  This in cludes prior evidence of 
significant hepatic injury deemed to be related to tolvaptan use .
WOCBP=w omen of childbearing potential ; IMP=i nvestigational medicinal product
Non-childbea ring potential in women is defined as female subjects who are surgically  
sterile (ie, have undergone bilateral oophorectom y or hysterectom y) orfemale subjects 
who have been postmenopausal for at least 12 consecutive months.
Subjects may  be rescreened, at the discretion of the medical monitor, if the exclusion 
characteristic has changed or resolved.  In the event that a subject is rescreened, a new 
ICF must be signed and a new screening number assigned and screening procedures 
repeated.
3.5 Trial Endpoints
3.5.1 Safety Endpoints
This trial will have no formal endpoints.  Safet y variables w ill be summarized by  
descriptive statistics, (eg, proportion, mean, median, standard deviation [SD], minimum, 
and maximum values).  In general, summary statistics, including changes from baseline, 
will be provided for safety  variables based on all availabl e data.  Safet y endpoints will be
as follows:
ï‚·Adverse events
ï‚·Vital signs
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
29
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKâ€¢&OLQLFDOODERUDWRU\DVVHVVPHQWV
â€¢6HUXPWUDQVDPLQDVHHOHYDWLRQV IRUIUHTXHQF\[[[DQG[ 8 /1WLPHWR
RQVHWWLPHWRSHDNOHYHOVWLPHRIRIIVHW[[RU[8/1 UHVSRQVHWR
GHFKDOOHQJHDQGUHFKDOOHQJHDQGIUHTXHQF\RISURJUHVVLRQWR+ \Â¶VODERUDWRU\
FULWHULD$/7RU$67![8/1DQGELOLUXELQ WRWDO%7 ![ 8/1Z LWKRXW
DONDOLQHSKRVSKDWDVH â‰¥[8/1
â€¢6HUXPVRGLXPH[FXUVLRQVDERYHRUPPRO/RUEHORZ  RU
PPRO/



 0HDVXUHVWR0LQLPL]H$YRLG%LDV
7KLVLVDQRSHQODEHOWULDO)RUVXEMHFWVHQWHULQJIURPSODFHER FRQWUROOHGWULDOVSULRU
WKHUDS\SODFHERRUWROYDSWDQZLOOQRWEHNQRZQE\WULDO VLWH LQYHVWLJDWRURUVSRQVRU
DWWKHWLPHRIHQWU\LQWRWKLVWULDO
$OOEORRGDQGXULQHFKHPLVWU\ZLOOEHDQDO\]HGDQGUHSRUWHGE\ DFHQWUDO ODERUDWRU\
 7ULDO3URFHGXUHV
7ULDODVVHVVPHQWWLPHSRLQWVDUHVXPPDUL]HGLQ 7DEOH 
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK7DEOH 6FKHGXOHRI$VVHVVPHQWV
6FUHHQLQJ
WR  GD\V
SULRUWR%DVHOLQHD%DVHOLQH
'D\0RQWKO\E
Â“GD\V(YHU\
 PRQWKVE
Â±Â± GD\V(DUO\
7HUPLQDWLRQ(QG
RI7UHDWPHQW
GD\V7LWUDWLRQ
&RQWDFW
SKRQH
FRQWDFW)ROORZXS
GD\VSRVW
WUHDWPHQW
GD\V
,QIRUPHGFRQVHQW ;
,QFOXVLRQ([FOXVLRQ ; ;
'HPRJUDSKLFV0HGLFDO$'3.'KLVWRU\
F;
'LHWDU\UHYLHZ ; ; ; ; ;
9LWDOVLJQVG;; ; ; ; ;
&KHPLVWU\%ORRG 6DPSOHVH
6HUXP&KHPLVWU\3DQHO ;I;
/LYHU)XQFWLRQWHVWVJ;; ; ; ;
6RGLXP ; ; ; ;
&UHDWLQLQH ; ; ; ; ;
+HPDWRORJ\DQGFRDJXODWLRQ ;;
8ULQDO\VLV ;; ; ;
8ULQHRVPRODOLW\K;; ; ;
8ULQHVSHFLILFJUDYLW\ ;; ; ;
8ULQHSUHJQDQF\WHVW:2&%3
RQO\L;; ; ; ;
8ULQHDWKRPHSUHJQDQF\WHVWNLWVGLVSHQVHG
M;; ;
3K\VLFDOH[DPLQDWLRQN;; ; ; ;
7ROHUDELOLW\'RVLQJ5HYLHZ ; ; ; ; ;
,QWHUDFWLYH5HVSRQVH7HFKQRORJ\(QWU\;; ; ; ; ;
O;
'UXJGLVSHQVDWLRQ ; ; ; ;O
'UXJUHFRQFLOLDWLRQ ; ; ; ;O



8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCICCI
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 31 06 March 2015Screening 
(-30to-1days 
prior to Baseline)aBaseline/ 
Day 0Monthlyb
(Â± 7 days)Every 
3monthsb
(ï‚±14days)Early 
Termination/End 
of Treatm ent
(+ 7 day s)Titration 
Contact 
(phone 
contact)Follow -up
7 days post -
treatm ent
(+ 7 days)
Adverse events Xnï‚¬------------------------------------------------------------------------------------------------------------------- ï‚®
Concomitant medicationso ï‚¬------------------------------------------------------------------------------------------------------------------- ï‚®
aThe last visit assessments from the previous trial can be combined with the screening and baseline visitsfor this trial, with all requir ed assessments from each 
visit performed o nly o nce. 
bMonthly visits are for subjects < 18 months on tolvaptan, and every 3 month visits are for subjects > 18 months on tolvaptan. 
cIncludes prior trial identifiers (screening identification [ID], subject ID, site ID, prior tolvaptan ADPKD trial protocol number).
dVital signs at each visit include seated heart rate, calibrated blood pressure and post void body weight.  Height should be perform ed only at screening.
eCentral laboratory non -fasting serum labor atory tests will be performed.  All subjects must be monitored for hepatic safety monthly until they have known 
tolvaptan exposure data of at least 18 months.  After that, and follow ing the approval of the medical monitor, hepatic monitoring will take plac e every 
3months.  Trial 156 -13-210 subjects who are eligible for this trial will have trial vis its/hepatic monitoring monthly for the first 18 months of this trial then 
every 3 months thereafter, because their tolvaptan exposure will be unknown.   Once unb linding occurs, it can be determined which subjects received 
tolvaptan in Trial 156 -13-210.  These subjects may have their trial vis its/hepatic transaminase monitoring change dto every 3 months sooner as their 
previous tolvaptan exposure in Trial 156 -13-210 can count tow ards the 18 month threshold. Subjects w ho enroll from other ADPKD tolvaptan trials will 
be monitored for hepatic safely monthly for their first 18 months they are in this trial.
fHepatitis testing at screening will be optional.  If hepatiti s testing is performed, then both pre- and post -counseling activities relating to hepatitis testing are to 
be carried out based on local requirements and best practices.  Upon request, if clinically indicated and approved by the medical monitor, subjects may have 
the following evaluations in addition to the protocol -specified chemistry panel: serum calcium, phosphorous, parathyroid hormone, vitamin D, and 
bicarbonate levels .  
gA full liver function panel (AST, ALT, alkaline phosphatase, BT) w ill be done at screeni ng.  All other liver function tests at subsequent visits are for ALT 
only, unless otherwise clinically indicated.  An ALT elevation > 2 Ã— ULN should trigger prom pttesting of hepatic function within 72 hours .  Any 
transaminase or bilirubin values which exceed 2 Ã—ULN should prompt immediate retesting within 72 hours.  While values remain in an abnormal range, 
testing frequency should be increased to at least w eekly for the first month, gradually returning to monthly, and every 3 months as indicated by the results.  
Local liver function panel analyses will also be performed more frequently, if necessary .  
hUrine osmolality is optional.
iA urine pregnancy test for pre gnancy for w omen of childbearing potential (WOCBP) will be performed at screening, at every 3 months visits, at the End of 
Treatment ( EoTx )visit,and at the follow -up visit.  On suspicion of pregnancy, an unscheduled urine or serum pregnancy testing will be performed.  
Positive urine pregnancy tests should be confirmed with a serum pregnancy test. 
jAt-home urine pregnancy test kits will be dispensed to WOCBP to be used if a menstrual period is missed betw een visits.  Kits wi ll be dispensed as needed 
throu ghout the trial. 
kA full physical examination is required at screening.  At other visits, an optional â€œdirectedâ€ physical examination may be perf ormed to focus on PKD -related 
signs and symptoms . 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka confidential information and should not be duplicated 
or re -distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
32
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKO,IGXULQJWKHWLWUDWLRQFRQWDFWWKHGHWHUPLQDWLRQLVPDGHWRDG MXVWWKHGRVH UHJLPHQGRVHDGMXVWPHQWVZLOOEHPDGHXVLQJGLVSH QVHGVXSSO\DQGGRVHLQVWUXFWLRQV
ZLOOEHSURYLGHGE\WKHLQYHVWLJDWRU7KHVXEMHFWÂ¶VFXUUHQWGR VHZLOOEHHQWHUHGLQWRWKHLQWHUDFWLYHUHVSRQVHWHFKQRORJ\,5 7DWHDFKYLVLW'UXJ
GLVSHQVDWLRQUHFRQFLOLDWLRQZLOOEHFRQGXFWHGRQDPRQWKO\EDVL VIRUVXEMHFWVZKRKDYHPRQWKO\WULDOYLVLWVDQGRQFHHYHU\ PR QWKVIRUVXEMHFWVZKRKDYH
WULDOYLVLWVHYHU\ PRQWKV,IDGGLWLRQDOGUXJVXSSO\LVUHTXL UHGIRUWLWUDWLRQSXUSRVHVWKHVLWHZLOODUUDQJHDVXEMHFWYLV LWIRUGLVSHQVDWLRQ

Q$WVFUHHQLQJ$(VUHSRUWHGDVRQJRLQJRUUHVROYHGDWWKHHQGRI WKHSULRUWULDOZLOOEHDVVHVVHGWRGHWHUPLQHHQWU\DVHLWKHU PHGLFDOKLVWRU\RURQJRLQJHYHQWIRU
WKLVWULDO
R2QO\FRQFRPLWDQWPHGLFDWLRQVRQJRLQJDWWKHEDVHOLQHYLVLWDQG WKURXJKRXWWKHWULDOZLOOEHUHFRUGHG7KLVZRXOGRFFXUDWWKH VFUHHQLQJYLVLWRQO\LIWKH
VFUHHQLQJYLVLWRFFXUVVLPXOWDQHRXVO\ZLWKWKHODVWYLVLWIURP DSUHYLRXVWROYDSWDQWULDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 33 06 March 20153.7.1 Schedule of A ssessments
3.7.1.1 Screening (-30 days to 1 day prior to Baseline)
Screening for eligibility is required for all subjects. The screening and baseline visit may  
be combined with the last visit from either Trials 156-08- 271 or 156-13- 210 with all 
required assessments from each visit performed only once . Therefore, i n some cases, if a 
subject enrolls in this trial from a prior tolvaptan trial, the end of trial or last follow -up 
visit for that trial and the screening and baseline visit for this one may  occur 
simultaneously .  Required assessments for the screening visit are as follows :
1.Obtain subject consent .
2.Obtain subject â€™snew screening identification (ID) assigned by interactive 
response technology  (IRT).
3.Determine subject eligibility  through inclusion/exclusion criteria
4.Record demographic information and prior trial identifiers (screening ID, subject 
ID, site ID , prior tolvaptan ADPKD trial protocol n umber ).
5.Record medical/ADPKD history  using prior trial data .
6.Review dietary  recommendations and compliance
7.Record vital signs (post -void weight and seated heart rate) and in -clinic calibrated 
blood pressure (BP) measurement.  Record height.
8.Collect bloo d for serum chemistry ,liver function panel (ALT, AST, BT , bilirubin 
[direct ], and alkaline phosphatase) , serum sodium, serum creatinine ,and 
hematology  and coagulation .Hepatitis testing is optional .If hepatitis testing is 
performed, then both pre -and post-counseling activities relating to hepatitis 
testing are to be carried out based on local requirements and best practices.  
9.Collect urine for urinal ysis, urine osmolality  (optional) , and urine specific gravity .
10. Perform urine pregnancy test on women of childbearing potential (WOCBP).  If 
positive, a follow- up serum test will be performed .
11.Conduct full phy sical examination .
12. Enter subject into interactive response technology  (IRT) including prior trial 
identifier/information (protocol number, subject ID), confirmed dose regimen,
and scheduled date of next visit .
13.Assess AEs reported as ongoing or resolved from prior trial to determine entry as 
medical history  or ongoing event for this trial.
14. Record ongoing concomitant medications . (This will happen only  if the screening 
visit occurs simultaneously  with the last visit from a previous tolvaptan trial) .
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
34
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK %DVHOLQH 'D\
7KHEDVHOLQHYLVLWLVWKHEHJLQQLQJRIWKHWUHDWPHQWSHULRGLQ WKLVWULDO$W WKHEDVHOLQH
YLVLWVXEMHFWVZLOOUHWDLQWKHVXEMHFWQXPEHUDVVLJQHGLQWKHSUH YLRXVWROYDSWDQWULDO DQG
WKHIROORZLQJDVVHVVPHQWVDQGSURFHGXUHVZLOOEH SHUIRUPHG
 5HYLHZLQFOXVLRQH[FOXVLRQFULWHULD
 5HYLHZGLHWDU\UHFRPPHQGDWLRQVDQGFRPSOLDQFH
 5HFRUGYLWDOVLJQVSRVWYRLGZHLJKWVHDWHGKHDUWUDWHDQG FDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 'LVSHQVHDWKRPHXULQHSUHJQDQF\WHVWNLWVWR:2&%3 WREHXVHG LIDPHQVWUXDO
SHULRGLVPLVVHGEHIRUHWKHQH[WYLVLW
 $QRSWLRQDO GLUHFWHGSK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWR IRFXVRQ
3.'UHODWHGVLJQVDQGV\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJUHYLHZRILQYHVWLJDWLRQDOPHGLFLQD OSURGXFW,03
 (QUROOVXEMHFWLQWRWULDOWKURXJK,57DQGREWDLQ,03
 'LVSHQVH,03 VXIILFLHQWIRUPRQWKRU PRQWKVRIGRVLQJEDVHG RQWKH
VXEMHFWÂ¶VUHTXLUHGYLVLWVFKHGXOHIRUKHSDWLFHYDOXDWLRQDVHLWKH UPRQWKO\RUHYHU\
PRQWKV
3URYLGHVXEMHFWZLWKGRVLQJLQVWUXFWLRQVWREHJLQRQWKHIRO ORZLQJGD\
 5HFRUGRQJRLQJFRQFRPLWDQWPHGLFDWLRQV
 $VVHVV$(V
 0RQWKO\ 9LVLW Â±
Â±GD\V
7KHIROORZLQJVXEMHFWVZLOOUHWXUQ IRUDPRQWKO\YLVLWWRDVVHVV VDIHW\DQGWROHUDELOLW\RI
,03 DQGWRPRQLWRUOLYHUIXQFWLRQ
â€¢6XEMHFWVHQUROOLQJIURPWKHGRXEOHEOLQG7ULDOZLOO KDYHPRQWKO\WULDO
YLVLWV$/7OHYHODVVHVVPHQWV IRUWKHILUVWPRQWKV ZKLOHWUHDWP HQWFRGHIURP
7ULDOUHPDLQVEOLQGHGWRHQVXUHWKDWWKH\KDYHDGHTX DWHVDIHW\
PRQLWRULQJGXULQJWKLVSHULRGRIVXVFHSWLELOLW\ 2QFHXQEOLQGLQJ RFFXUVLWFDQEH
GHWHUPLQHGZKLFKVXEMHFWVUHFHLYHGWROYDSWDQLQ7ULDO 7KHVH
VXEMHFWVPD\KDYHWKHLUWULDOYLVLWVKHSDWLFWUDQVDPLQDVHPRQLW RULQJFKDQJHWR
HYHU\PRQWKVVRRQHUDVWKHLUSUHYLRXVWROYDSWDQH[SRVXUHLQ7 ULDO 
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKFDQFRXQWWRZDUGVWKHPRQWKWKUHVKROG7KHLQYHVWLJDWRUZLO OQHHGWRGLVFXVV
WKHFKDQJHLQIUHTXHQF\ZLWKWKHPHGLFDOPRQLWRUEHIRUHLQVWLWX WLQJWKHFKDQJH
â€¢6XEMHFWVIURPSULRUWROYDSWDQWULDOVRWKHUWKDQ7ULDO  ZLOOKDYHPRQWKO\
WULDOYLVLWV$/7OHYHODVVHVVPHQWVIRUWKHILUVWPRQWKV$I WHUWKDWWKHWULDO
YLVLWV$/7PRQLWRULQJZLOOEHFRQGXFWHGHYHU\ PRQWKVDIWHUWKH FKDQJHLQ
IUHTXHQF\LVFRQILUPHGZLWKWKHPHGLFDOPRQLWRU
â€¢6XEMHFWVHQUROOLQJIURPWKHRSHQODEHO7ULDOZKR KDYH JUHDWHUWKDQ
PRQWKVRIH[SRVXUHWRWROYDSWDQZLOOKDYHWULDOYLVLWV$/7PR QLWRULQJ
FRQGXFWHGHYHU\ PRQWKV
7KHIROORZLQJZLOOEHDVVHVVPHQWV ZLOOEHFRPSOHWHG
 5HYLHZGLHWDU\UHFRPPHQGDWLRQVDQGFRPSOLDQFH
 5HFRUGYLWDOVLJQVSRVWYRLGZHLJKWVHDWHGKHDUWUDWHDQG FDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUFHQWUDOODERUDWRU\DVVHVVPHQWVIRUVHUXPVRG LXP VHUXP
FUHDWLQLQHDQG$/7VHH 6HFWLRQ  
 
 
 8ULQDO\VLVXULQHRVPRODOLW\RSWLRQDOXULQHVSHFLILFJUDYL W\
 3HUIRUPXULQHSUHJQDQF\WHVWRQ:2&%3HYHU\PRQWKV,IS RVLWLYHD
IROORZXSVHUXPWHVWZLOOEHSHUIRUPHG
 'LVSHQVHDWKRPHXULQHSUHJQDQF\WHVWNLWVWR:2&%3DVUHTXL UHG
 $QRSWLRQDO GLUHFWHGSK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWR IRFXVRQ
3.'UHODWHGVLJQVDQGV\PSWRPV
$VVHVVWROHUDELOLW\GRVLQJUHYLHZRI ,03
(QWHUVXEMHFWVWDWXVLQ,57LQFOXGLQJDQ\GRVHUHJLPHQFKDQJH VDQGREWDLQ,03
DVVLJQPHQW
 &ROOHFWDQGUHFRQFLOHUHWXUQHG,03DVVHVVFRPSOLDQFH 'LVSHQVH,03 EDVHGRQVXEMHFWÂ¶VUHTXLUHGYLVLWVFKHGXOHDQG SURYLGHVXEMHFWZLWK
GRVLQJLQVWUXFWLRQV
 8SGDWHFRQFRPLWDQWPHGLFDWLRQV $VVHVV$(V
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK (YHU\0RQWKV Â±Â±GD\V
 5HYLHZGLHWDU\UHFRPPHQGDWLRQVDQGFRPSOLDQFH

 5HFRUGYLWDOVLJQVSRVWYRLGZHLJKWVHDWHGKHDUWUDWHDQG FDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUFHQWUDO ODERUDWRU\DVVHVVPHQWV VHUXPVRGLXP VHUXPFUHDWLQLQH
$/7VHH 6HFWLRQ 

 8ULQDO\VLVXULQHRVPRODOLW\RSWLRQDOXULQHVSHFLILFJUDYL W\
 3HUIRUPXULQHSUHJQDQF\WHVWRQ:2&%3,ISRVLWLYHDIROORZ XSVHUXPWHVWZLOO
EHSHUIRUPHG
 'LVSHQVHDWKRPHXULQHSUHJQDQF\WHVWNLWVWR:2&%3DV UHTXLU HG
 

 $QRSWLRQDOGLUHFWHGSK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGW RIRFXVRQ
3.'UHODWHGVLJQVDQGV\PSWRPV
$VVHVVWROHUDELOLW\GRVLQJUHYLHZRI,03(QWHUVXEMHFWVWDWXVLQ,57LQFOXGLQJDQ\GRVHUHJLPHQFKDQ JHVDQGREWDLQ,03
DVVLJQPHQW
 &ROOHFWDQGUHFRQFLOHUHWXUQHG,03DVVHVVFRPSOLDQFH
(QWHUVXEMHFWVWDWXVLQ,57LQFOXGLQJDQ\GRVHUHJLPHQFKDQ JHV
'LVSHQVH,03EDVHGRQVXEMHFWÂ¶VYLVLWVFKHGXOHDQGSURYLGH VXEMHFWZLWKGRVLQJ
LQVWUXFWLRQV
 8SGDWHFRQFRPLWDQWPHGLFDWLRQV
 $VVHVV$(V
 (DUO\ 7HUPLQDWLRQ(QGRI7UHDWPHQW  GD\V
$WWKHHDUO\WHUPLQDWLRQHQGRIWUHDWPHQW (R7[YLVLWWKHIROOR ZLQJZLOOEHDVVHVVHG
 5HYLHZGLHWDU\UHFRPPHQGDWLRQVDQGFRPSOLDQFH

8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 5HFRUGYLWDOVLJQVSRVWYRLGZHLJKWVHDWHGKHDUWUDWHDQG FDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUVHUXPFKHPLVWU\VHUXPFUHDWLQLQH$/7VHU XPVRGLXPDQG
KHPDWRORJ\DQGFRDJXODWLRQ
 
 
 &ROOHFWXULQHIRUXULQDO\VLVXULQHRVPRODOLW\RSWLRQDOXU LQHVSHFLILFJUDYLW\
 3HUIRUPXULQHSUHJQDQF\WHVWRQ:2&%3,ISRVLWLYHDIROORZ XSVHUXPWHVWZLOO
EHSHUIRUPHG
 $QRSWLRQDO GLUHFWHGSK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWR IRFXVRQ
3.'UHODWHGVLJQVDQGV\PSWRPV
$VVHVVWROHUDELOLW\GRVLQJUHYLHZRI,03(QWHUVXEMHFWVWDWXVLQ,57LQFOXGLQJDQ\GRVHUHJLPHQFKDQ JHV VLQFHWKH
SUHYLRXVHQWU\
 &ROOHFWDQGUHFRQFLOHUHWXUQHG,03DVVHVVFRPSOLDQFH 8SGDWHFRQFRPLWDQWPHGLFDWLRQV $VVHVV$(V
 GD\)ROORZ XS9LVLWGD\V
 5HFRUGYLWDOVLJQVSRVWYRLGZHLJKWVHDWHGKHDUWUDWHDQG FDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUVHUXPFUHDWLQLQHDQG$/7
 

 3HUIRUPXULQHSUHJQDQF\WHVWRQ:2&%3,ISRVLWLYHDIROORZ XSVHUXPWHVWZLOO
EHSHUIRUPHG
 (QWHUVXEMHFWVWDWXVLQ,57 8SGDWHFRQFRPLWDQWPHGLFDWLRQV
 $VVHVV$(V
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 6DIHW\$VVHVVPHQWV
 $GYHUVH(YHQWV
5HIHUWR6HFWLRQ5HSRUWLQJRI$GYHUVH(YHQWV 
 &OLQLFDO/DERUDWRU\$VVHVVPHQWV
&HQWUDOODERUDWRU\QRQIDVWLQJVHUXPODERUDWRU\WHVWVZLOOEHS HUIRUPHG,WLVSUHIHUDEOH
WRFROOHFWWKHFOLQLFDOODERUDWRU\VDPSOHVIURPHDFKVXEMHFWDW DFRQVLVWHQWWLPHRIGD\
WKURXJKRXWWKHWULDODQGWRUHFRPPHQGWKDWWKHVXEMHFWKDYHD VLPLODUGLHWDYRLGLQJ
YDULDWLRQLQSURWHLQLQWDNHHVSHFLDOO\FRRNHGPHDWSURWHLQDQ GH[HUFLVHSDWWHUQLQRUGHU
WRUHGXFHYDULDELOLW\LQWKHVDPSOHVRYHUWLPH








$OLVWRIWKHVSHFLILFFOLQLFDOODERUDWRU\DVVHVVPHQWVLVSUHVH QWHGLQ7DEOH 
&OLQLFDOODERUDWRU\VDPSOHVZLOOEHFROOHFWHGDQGVHQWWRWKHF HQWUDOODERUDWRU\DWWKH
IROORZLQJWLPHSRLQWV
6FUHHQLQJ +HPDWRORJ\DQGFRDJXODWLRQSDQHOVHUXPFKHPLVWU\SDQ HOOLYHUIXQFWLRQ
SDQHO $67$/7DONDOLQHSKRVSKDWDVHELOLUXELQGLUHFW >%7@VHUX PVRGLXPVHUXP
FUHDWLQLQHXULQDO\ VLVSDQHOXULQHRVPRODOLW\RSWLRQDOXULQ HVSHFLILFJUDYLW\XULQH
SUHJQDQF\WHVW:2&%3DQGKHSDWLWLVRSWLRQDO
0RQWKO\YLVLWV Â“GD\V $/7IRUWKHILUVWPRQWKVIRUVXEMHF WVHQUROOHGIURP RWKHU
WROYDSWDQ$'3.'WULDOVDQG7ULDO  ZKLOHWULDOUHPDLQVEO LQGHG VHUXP
VRGLXPDQGVHUXPFUHDWLQLQHDOOVXEMHFWVXULQDO\VLVXULQHRVP RODOLW\RSWLRQDOXULQH
VSHFLILFJUDYLW\DQGXULQHSUHJQDQF\WHVWHYHU\PRQWKVLQ: 2&%3 
(YHU\PRQWKV Â“GD\V$/7DIWHUPRQWKVRIWUHDWPHQW I RUVXEMHFWVHQUROOHG
IURPRWKHU$'3.'WROYDSWDQWULDOVRUIURP7ULDODIW HUWKHWULDOLVXQEOLQGHG
DQGIRUVXEMHFWVHQUROOHGIURP7ULDOVHUXPVRGLXP DQGVHUXPFUHDWLQLQH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKXULQDO\VLVSDQHOXULQHSUHJQDQF\WHVW:2&%3XULQHRVPRODOLW \RSWLRQDODQGXULQH
VSHFLILFJUDYLW\3
(DUO\7HUPLQDWLRQ(R7[  GD\ V 6HUXPFKHPLVWU\SDQHOKHPDWROR J\DQGFRDJXODWLRQ
SDQHO$/7VHUXPVRGLXPDQGVHUXPFUHDWLQLQH XULQDO\VLV
SDQHOXULQHSUHJQDQF\WHVW:2&%3XULQHRVPRODOLW\RSWLRQDO DQGXULQHVSHFLILF
JUDYLW\
GD\)ROORZXSYLVLW GD\V $/7VHUXPFUHDWLQLQHDQGXULQ HSUHJQDQF\WHVW
:2&%3
7DEOH &OLQLFDO/DERUDWRU\$VVHVVPHQWV
+HPDWRORJ\DQG&RDJXODWLRQ3DQHO
+HPRJORELQ
3ODWHOHWFRXQW0HDQFRUSXVFXODUKHPRJORELQFRQFHQWUDWLRQ0&+&0HDQFRUSXVFXODUYROXPH 0&95HGEORRGFHOO 5%&FRXQW
:KLWHEORRGFHOO:%&FRXQWZLWKGLIIHUHQWLDO
3URWKURPELQWLPH37DVLQWHUQDWLRQDOQRUPDOL]HGUDWLR ,15$FWLYDWHGSDUWLDOWKURPERSODVWLQWLPHD377
8ULQDO\VLV3DQHO
$SSHDUDQFH
&RORU%ORRG*OXFRVH0LFURVFRSLFDQDO\VLV:%&5%&FRXQWVSHUKLJK
SRZHUILHOG
S+3URWHLQ
8ULQH&KHPLVWU\
2VPRODOLW\RSWLRQDO
6SHFLILFJUDYLW\
$GGLWLRQDO7HVWV
8ULQHRUVHUXPSUHJQDQF\IRU:2&%3
+HSDWLWLVRSWLRQDO6HUXP&KHPLVWU\3DQHO
$OEXPLQ
%ORRGXUHDQLWURJHQ%816HUXPFDOFLXP&DUERQGLR[LGH6HUXPFKORULGH*DPPDJOXWDP\OWUDQVSHSWLGDVH
&KROHVWHUROWRWDO
*OXFRVH/DFWDWHGHK\GURJHQDVH /'+3KRVSKRUXV3RWDVVLXP3URWHLQWRWDO
8ULFDFLG
/LYHU)XQFWLRQ3DQHO
$ONDOLQHSKRVSKDWDVH$/3
$ODQLQHDPLQRWUDQVIHUDVH$/7
$VSDUWDWHDPLQRWUDQVIHUDVH$67
%LOLUXELQWRWDO%7%LOLUXELQGLUHFW
&UHDWLQLQH 6RGLXP
,IOLYHUIXQFWLRQSDQHOVRGLXPDQGRUVHUXPFKH PLVWU\DVVHVVPH QWVDUHVFKHGXOHG DWWKH
VDPHYLVLWDOOYDOXHVVKRXOGEHGHWHUPLQHGIURPWKHVDPHEORRG VDPSOH%ORRGWHVWLQJ
IRUKHSDWLWLVZLOOEHRSWLRQDOIRUDOOVXEMHFWV8ULQHSUHJQDQ F\WHVWLQJZLOOEHSHUIRUPHG
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 40 06 March 2015with commerciall y available, high- sensitivity  kits supplied to the su bject by the site 
(acquired b y the sponsor ).
3.7.2.3 Physical Examination and Vital Signs
A full phy sical ex amination will be performed and documented at the s creening visit 
although this may  be combined with the last visit from the previous trial. At other visit s, 
an optional directed ph ysical examination may be performed to focus on AD PKD -related 
signs and s ymptoms.  In some geographic regions, more frequent subject visits may  be 
the norm; however vital signs and clinically  significant phy sical findings will be recorded 
as an unscheduled visit in the electronic case report form (e CRF )as applicable. Any 
changes in medication or AEs will be recorded in the eCRF.
Height will be measur ed only  at screening.  Body weight will be taken post -void.  I t is 
preferable to use the same scale for each measurement.  Clinic scales should be calibrated 
at least y early . The i nvestigator or his/her appoi nted designee is primarily  responsible to 
perform the ph ysical examination .  If the appointed designee is to perform the phy sical 
exam ination , he/she must be permitted to do so by  local regulations and his/her name 
must be included on an y globall y and loca lly required documents (eg, individual must be 
added for all sites on a US F ood and D rug Administration (FDA) Form 1572, where local 
regulations allow, while local regulations determine their being named in the I CF).  
Whenever possible, the same individual should perform all ph ysical exam ination s.  Any  
undesirabl e condition present at a post -treatment phy sical exam ination that was not 
present at the b aseline exam ination should be documented as an AEand followe d to a 
satisfactory  conclusion.
Vital sign data ,including seated blood pressure ,heart rate , height, and weight will be 
taken at the visits identified in the Schedule of Assessments ( Table 3.7-1 ).
3.7.2.4 Assessment of Liver Sy mptoms, Signs or Test A bnormalities
Testing for hepatic transaminase (ALT/AST) , alkaline phosphatase, bilirubin direct, and 
BT will be perfo rmed during screening.  Subjects enrolling from the double -blind Trial 
156-13- 210 will have mo nthly  ALT assessments for the first 18 months while the 
treatment code from Trial 156-13- 210 remains blinded to ensure that all subjects have 
adequate safet y monitoring during this period of susceptibility .  Once unblinding occurs, 
it can be determined whi ch subjects received tolvaptan in Trial 156-13- 210.  These 
subjects may  have their trial vis its/hepatic transaminase monitoring change dto every  
3months sooner as their previous tolvaptan exposure in Trial 156-13- 210 can count 
towards the 18- month thresho ld.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
41
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 41 06 March 2015Following the first 18months, AL T assessments will be made every  3months for 
Trial 156-13-210 subjects and for subjects from other tolvaptan ADPKD trials besides 
Trial 156-08-271.  
Subjects enrolling from the open -label Trial 156 -08-271 who have tolvaptan exposure 
greater than 18 months will continue with ALT monitoring every  3months.
Subjects enrolling from prior tolvaptan trials besides Trial 156-08- 271 will have monthly  
ALT assessments for the first 18 months.  Upon reaching 18 mont hs of exposure and 
after confirmation from the medical monitor, the frequency  of ALT monitoring for these 
subjects will occur every  3months.
ALT will also be assessed at the Earl y Termination/E oTxvisit and at the 7-day Follow -
up visit.
Management of liver abnormalities is disc ussed in the paragraphs below.
3.7.2.4.1 Liver Test A bnormalities and Interruption/Discontinuation of 
Investigational Medicinal Product
An ALT elevation 2 Ã—ULN orthe appearance of any  suspicious s ymptom or sign should 
trigger prompt testing of hepatic function (ie, within 72 hours) .  Local laboratory  testing 
is acceptable, ideall y with a concurrent central laboratory  sample for confirmation.   
Any transaminase or bilirubin values which exceed 2 Ã—ULN should also prompt 
immediate retesting within 72 hours.  While values remain in an abnormal range, testing 
frequency  should be increase dto at least weekl y for the first month, gradually returning 
to monthly , or every  three months as indicated b y the results .
Liver transaminase or bilirubin le vels reaching or exceeding 2 Ã—ULN thathave an 
uncertain or rapidl y increasing trajectory should prompt at least temporary IMP 
interruption. Tolvaptan should not be resumed until monitoring indicates abnormalities 
have resolve d, are stable, or are not rapidly  increasing, and then onl y with an incr eased 
frequency  of monitoring.
Subjects would not ty pically  be allo wed to resume treatment with tolv aptanif they  have:
ï‚·transaminase levels rise above 8 Ã—ULN,
ï‚·transaminase levels are > 5 Ã—ULN for more than 2 weeks, or
ï‚·concurrent elevations of transaminase > 3 Ã—ULN and BT > 2 Ã—ULN.
Subjects with these levels of abnormality  may  be re -challenged with IMP if abnormalities 
were adjudicated as having a < 50% likelihood of being related to IMP (per DILI network 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
42
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK>',/,1@SUREDELOLW\ FULWHULDE\DQLQGHSHQGHQWKHSDWLFDGMXGLFDWLRQFRPPLWWHH+$&
DQGWKHLQYHVWLJDWRUDQGPHGLFDOPRQLWRUDJUHHWRDQLQWHQVLYH PRQLWRULQJSODQWR
PLWLJDWHULVN7KHVXEMHFWPXVWDOVREHZLOOLQJWRFRPSO\ZLWK WKHVHPRQLWRULQJ
PHDVXUHVEHLQIRUPHGRIWKHSRWHQWLDOULVNVDQGFRQVHQWWR,0 3UHFKDOOHQJH
 5HTXLUHPHQWVIRU6SHFLDO5HSRUWLQJ8VLQJWKH/LYHU'LV HDVH
(OHFWURQLF&DVH5HSRUW)RUPDQG,PPHGLDWHO\5HSRUWDEOH(YHQW)RUP
7KHSXUSRVHRIWKHOLYHUGLVHDVHH&5)DQGRSWLRQDODGGLWLRQDOW HVWLQJLVWRIDFLOLWDWH
UHYLHZRIHDFKVXEMHFWZKRSUHVHQWVZLWKRUGHYHORSVDOLYHUDE QRUPDOLW\GXULQJWKHWULDO
DQGWRGHWHUPLQHWKHSUREDEOHFDXVHVRIWKHVHDEQRUPDOLWLHV 7KHUHYLHZZLOOEH
SHUIRUPHGE\DEOLQGHGLQGHSHQGHQW +$&XVLQJ',/,1SUREDELOLW\ FULWHULD
 XQOLNHO\WR SRVVLEO\WR SUREDEO\W R YHU\
OLNHO\! GHILQLWH7KHUHVXOWRIWKHVHDQDO\VHVPD\EHSUHVHQWHGVHSDUDWHO\
IURPWKH&65
7KHLQYHVWLJDWRUPXVWFRPSOHWHDVSHFLDOOLYHUGLVHDVHH&5)IRU DQ\VXEMHFWZKR
 'LVFRQWLQXHVWUHDWPHQWGXHWRDOLYHUUHODWHG$(
 5HSRUWVDVHULRXVOLYHUUHODWHG$(
 +DVQRUPDOVFUHHQLQJOHYHOVDQGGHYHORSV$/7RU$67OHYHOV â‰¥[8/1
 +DVQRUPDOVFUHHQLQJOHYHOVDQGGHYHORSV%7OHYHOV â‰¥[8/1RU
 +DVDQDEQRUPDOVFUHHQLQJOHYHODQGGHYHORSVDEQRUPDOLWLHVLQW KDWWHVWWKDWDUH
![WKHXSSHUOLPLWRIWKHLUKLJKHVWVFUHHQLQJYDOXH


$GGLWLRQDOFOLQLFDOWHVWLQJVXFKDVWHVWLQJIRUKHSDWLWLVVH URORJ\
PD\DOVREHLQGLFDWHGDQGWKHLUUHVXOWVUHSRUWHGDFFRUGLQJWRO RFDOJXLGHOLQHV7KHOLYHU
H&5)DQG,PPHGLDWHO\5HSRUWDEOH(YHQW,5(IRUPVHH 6HFWLRQ VKRXOGEHXSGDWHG
DVQHZLQIRUPDWLRQEHFRPHVDYDLODEOH




8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK
















8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK
 7UHDWPHQW,QWHUUXSWLRQDQG'LVFRQWLQXDWLRQ
,QWKLVWULDOLWLVH[SHFWHGWKDWVXEMHFWVPD\ SRVVLEO\KDYHR QHRUPRUHSODQQHGRU
XQSODQQHGWUHDWPHQWLQWHUUXSWLRQV,IDVXEMHFWÂ¶V,03WUHDWPHQ WPXVWEHLQWHUUXSWHGIRU
PHGLFDORUVXUJLFDOUHDVRQV OLYHUWHVWDEQRUPDOLWLHV XVHRIDS URKLELWHGPHGLFDWLRQRU
RWKHUUHDVRQVHJKRVSLWDODGPLVVLRQIRUDQLQYDVLYHSURFHGXUH DPDMRUPHGLFDO
FRQGLWLRQVXUJHU\GHQWDOZRUNRUDWHPSRUDU\VLWXDWLRQWKDWS UHYHQWVVXEMHFWFRPSOLDQFH
ZLWKWKH,03DGPLQLVWUDWLRQVFKHGXOHWKHLQYHVWLJDWRUVKRXOG EHQRWLILHGDVVRRQDV
SRVVLEOHDQGWKHUHDVRQIRUWUHDWPHQWLQWHUUXSWLRQPXVWEHGRFX PHQWHGLQWKHVRXUFH
GRFXPHQWVDQGFDVHUHSRUWIRUP&5),ISHUPLVVLEOHWKHVXEM HFWÂ¶V,03PD\EH
UHVXPHGIROORZLQJDSSURYDOE\WKHPHGLFDOPRQLWRU
,I,03WUHDWPHQWLVSHUPDQHQWO\GLVFRQWLQXHGWKHUHDVRQIRUGLV FRQWLQXDWLRQPXVWEH
UHFRUGHGDSSURSULDWHO\LQWKHVRXUFHGRFXPHQWDQGLQWKH&5)
$VXEMHFWZKRSHUPDQHQWO\GLVFRQWLQXHV,0 3WUHDWPHQWHQGV WULDO S DUWLFLSDWLRQDQGWKH
HDUO\WHUPLQDWLRQYLVLW VKRXOGEHFRPSOHWHG
 (QGRI7ULDO
7KH(QGRI7ULDOGDWHLVGHILQHGDVWKHODVWGDWHRIFRQWDFWRU WKHGDWHRIILQDOFRQWDFW
DWWHPSWIURPWKHSRVWWUHDWPHQW)ROORZXS&5)SDJHIRUWKHODVW VXEMHFWFRPSOHWLQJRU
ZLWKGUDZLQJIURPWKHWULDO
 ,QGHSHQGHQW'DWD0RQLWRULQJ&RPPLWWHH
)RUWKLVWULDODQ,QGHSHQGHQW'DWD0RQLWRULQJ&RPPLWWHH,'0& DOVRNQRZQDVD'DWD
6DIHW\DQG0RQLWRULQJ&RPPLWWHHZLOOEHHVWDEOLVKHG7KHUROHR IWKH,'0&VKDOOEH
GHOLQHDWHGLQDVHSDUDWH,'0&&KDUWHUGRFXPHQWEXWLQJHQHUDO WKLVJURXSZLOOPHHWRQD
UHJXODUEDVLVWRHQVXUHWKHVDIHDQGHWKLFDOWUHDWPHQWRIWULDO VXEMHFWVHQVXUHWKHVFLHQWLILF
LQWHJULW\RIWKHWULDO DQGWRHQVXUHWKHWULDOLVFRQGXFWHGZLW KLQWKHERXQGVRIHWKLFDO
PHGLFDOSUDFWLFH$GMXGLFDWLRQUHVXOWVDVGHWHUPLQHGE\WKH+$& ZLOOEHUHSRUWHGWRWKH
,'0&RQDTXDUWHUO\EDVLVRUPRUHIUHTXHQWO\DVQHFHVVDU\ 7KLV ,'0&PD\PDNH
UHFRPPHQGDWLRQVWRWKHVSRQVRUDQGWULDOVWHHULQJFRPPLWWHHWR DPHQGRUWHUPLQDWHWKH
WULDOEDVHGRQJURXQGVRIVDIHW\IXWLOLW\ RUJUHDWHUWKDQH[SH FWHGHIILFDF\DVGHILQHGE\
WKHDFFHSWHGVWDWLVWLFDOSUDFWLFHVDQGSURFHGXUHVGHWDLOHGLQW KHLU&KDUWHU
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 45 06 March 20153.8 Stopping Rules, Withdrawal Criteria, and Procedures
3.8.1 Entire Trial 
If the sponsor terminates or suspends the trial for safet y or unanticipated other reasons, 
prompt notification will be given to investigators, I RBs/IECs, and regulatory authorities 
in accordance with regulatory  requirements.
3.8.2 Individual Si te
The investigator will notify  the sponsor promptly  if the trial is terminated by  the 
investigator or the IRB/IEC at the site. If the investigator, IRB/IEC or sponsor decides to 
terminate or suspend the trialâ€™s conduct at a particular center for safet y, non-enrollment 
of subjects, non -compliance with the protocol, or unanticipated other reasons, the above 
and other parties, as required by the applicable regulatory requirements, will be promptly  
notified.
3.8.3 Individual Subject
If a subject discontinues the trial prematurel y, the reason must be fully evaluated and 
recorded appropriatel y in source documents and the CRF.  If the subject is being 
withdra wn because of an AE, that AE should be indicated as the reason for withdrawal.  
All subjects have the right to withdraw at an y time during treatment without prejudice.  
The investigator can discontinue a subjectâ€™s participation in the trial at any  time if 
medically  necessary .  It is preferred that subjects who permanently  discontinue I MP will 
have the option to continue participation off IMP with regular scheduled visits or with a 
modified (ie, less frequent) schedule.  If subjects are unable or unwilling to complete the 
visits and procedures off IMP, the earl y termination/EoTx visit should be completed .  
The investigator may continue to contact those who discontinue I MP through to the final 
completion date of the trial or thereafter if needed to determine outcomes ie, vital status.  
In addition, subjects meeting the following criteria must be withdrawn fr om the trial:
a) Occurrence of an y AE, intercurrent illness, or abnormality  in a laboratory  assessment 
which, in the opinion of the investigator, warrants the subjectâ€™s permanent withdrawal 
from the trial;
b) Subject noncompliance, defined as refusal or in ability  to adhere to the trial schedule or 
procedures (see Section 3.12);
c) At the request of the subject, investigator, sp onsor, or regulatory  authority ;
d) Subject is lost to follow-up.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
46
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 46 06 March 2015The investigator will notify  the sponsor promptly  when a subject is withdrawn.
3.9 Screen Failures
A screen failure subject is one from whom informed consent is obtained and is 
documented in writing (ie, subject signs an ICF), but who is not starte d on treatment .
3.10 Definition of Completed Subjects
For purposes of this tria l, subjec ts who complete the E oTxvisit will be defined as trial 
completers.
3.11 Definition of Subjects Lost to Follo w-up
Subjects, or the subjectâ€™s parent/guardian who cannot be contacted on or before their final 
visit prior to the trial termination date, who do not have a known reason for 
discontinuation (eg, withdrew consent or AE) and for whom a current health status at the 
end of the trial cannot be determined will be classified as â€œlost to follow -upâ€ as the 
reason for discontinuation.  Current health status can be determined from a variet y of 
sources, either by obtaining acceptable documentation for death (ie, death certificate, 
medical records, public records, or statement b y a family member or primary care 
physician) or acceptable documentation for life (ie, direct contact with the subject, 
medical records, successful telephone contact with the subject, statement b y a family 
member or primary  care phy sician, or public records).  I t is expected that 3 documented 
attempts will be made to determine a subjectâ€™s current health status before assigning a 
â€œlost to follow -upâ€ status.
3.12 Subject Compliance 
Subject compliance will be monitored by pill counts as IMPis returned.  Any  subject 
who, without the instruction of the investigator, discontinues tolvaptan investigational 
product, discontinues tolvaptan for 30consecutive day s or misses > 30% of the doses 
intended for a period between visits (whichever is greater) will be deemed non compliant. 
Depending on the circumstances leading to noncompliance, the subject may be 
withdrawn from the trial or discontinued from investigational product administration by
the investigator and/or sponsor.  I t is preferred that subjects who discontinue tolvaptan, or 
are withdrawn b y the investig ator for reasons other than noncompliance or lost to follow -
up, will continue with regularl y scheduled visits completing all procedu res as provided in 
the protocol.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
47
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 47 06 March 20153.13 Protocol Deviations
This trial is to be conducted as described in this protocol.  I n the event of a significant 
deviation from the protocol due to an emergency , accident or mistake (eg, violation of 
informed consent process , IMP dispensing or subject dosing error, subject enrolled in 
violation of eligibility  criteria or concomitant medication criteria) , the investigator or 
designee must contact the sponsor at the earliest possible time.  This will allow an earl y 
joint decisi on regarding the subjectâ€™s continuation in the trial.  This decision will be 
documented b y the investigator and the sponsor, and reviewed b y the site monitor.
4 Restrictions
4.1 Prohibited or Restricted Medications
Medications or surgical therapies used for the purpose or potential for modify ing the 
progression of PKD cy st growth or development will be prohibited.  These include, but 
are not restricted to, somatostatin agonists, rapamune (sirolimus), a nti-sense ribonucleic 
acid therapies, vasopressin antagonists other than tolvaptan ,(eg, OPC -31260 
(mozavaptan), Vaprisol (conivaptan), agonists (eg, desmopressin) and cy st 
decompression surgery .
Continuous or short -term use of other medications, while not prohibited, may  be 
restricted b y the investigator because of their potential for interference with tolvaptan 
metabolism (see Section 3.2.1 and Section 3.2.2). 
A partial list of strong and moderate CYP3A4 inhibitors can be found in Table 4.1-1
below:
Table 4.1-1 Strong and Moderate CYP3A Inhibitors (partial list)
amprenavir atorvastin aprepitant chloramphenicol (if 
used orally)
cimetidine clarithromycin clotrimazole (if used 
orally)danazol
delavirdine diltiazem erythromycin fluconazole
fluvoxamine indinavir isoniazid itraconzazole
josamycin ketoconazole (if used 
orally)nelfinavir nefazadone
quinupristin/ dalfopristin ritonavir saquinavir troleandomycin
verapamil Seville orange products grapefruit products
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
48
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 48 06 March 2015Pharmacod ynamic interactions are a consideration for the use of diuretics, which may  be
only used intermittently , andnot within 7 da ys of a urine assessment.  D iuretics are not 
generall y recommended in ADPKD due to their tendency to increase AVP levels through 
relative deh ydration or volume depletion; thus, chronic use of diuretics (eg, for 
hyperte nsion) will be prohibited and is an ex clusionary  criterion for this trial. 
Some drugs are known to alter creatinine concentrations so, while not prohibited, subjects 
should alert their trial doctor, and an y other health -care providers, to take this into 
consideration when considering changes in their prescribed or over- the-counter 
medications.  A list would include:  non- steroidal anti -inflammatory  drugs like aspirin or 
ibuprofen, chemotherap y drugs, cephalosporin, the combination of elvitegravir, 
cobicistat, emtricitabine, and tenofovir (Stri bildïƒ”), dolutegravir, dronedarone, 
ranolazine, metformin, and trimethoprim.
4.2 Dietary  Restrictions and Recommendations
Restriction of excess dietary  sodium and cooked meat protein may  prove beneficial to 
subjects with a history of, or predisposition for, hyp ertension or kidney  disease in general 
and should be applied to all subjects diagnosed with advanced ADPKD, particularl y if 
there is evidence for a propensity  for rapid progression.  I n the absence of alternate 
regional prac tices, dietary  salt < 5g/day , dietary cooked meat protein < 1 g/kg/day  and a
limit on caffeinated drinks/foods should also be given (no more than 2 coffee equivalents 
per day ).  A history  of alcohol and smoking intake will be collected at screening.  
Alcohol and tobacco consumption should be avoided or minimized as much as possible.
Additionally , fluid intake is generall y encouraged in subjects with PKD.  Given the 
potential for deh ydration with tolvaptan treatment, all subjects should be instructed to 
ingest fluids in anticipation of, or at the first sign of thirst in order to avoid excessive 
thirst or dehy dration.  Upon consent, all subjects should receive the recommendation to 
ingest at least 2 to 3 liters of fluid (including in solid, semi -solid, and liquid foods) per 
day, unless otherwise directed b y their trialdoctor.  This recommendation should start 
during screening and continue through the end of the trial.  Additionally , subjects should 
ingest 1 to 2 cups of water before bedtime regardless of perceived thirst , and replenish
fluids overnight with each episode of nocturia.  Dehy dration will be monitored by  subject 
self-assessment of changes in body  weight and reporting of s ymptoms.  Acute changes of 
>3% of bod y weight (increase or decrease) over any 7 -day period should be not ed.  
Subjects should be instructed to report acute changes in bod y weight to the trial physician 
for further evaluation and recommendations.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
49
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 49 06 March 2015Subjects should be advised that the ingestion of pomelo, grapefruit, or Seville orange 
products would be expected to increase tolvaptan concentrations and these should be 
avoided.  In the event of an unintentional ingestion of such products, the investigator may  
ask the subject to temporarily  interrupt the IMP. 
5 Reporting of A dverse Events
The following describes the methods and timing for assessing, recording, and anal yzing 
safet y parameters, as well as the procedures for eliciting reports of and recording and 
reporting AEs and intercurrent illnesses and the t ype and duration of the follow -up of 
subjects after AEs.
Medical follow up is expected for AEs which lead to discontinuation which are serious, 
or which are of special interest (eg, liver abnormalities, skin neoplasms, glaucoma).
ADPKD is a progressive disorder involving the kidney , liver and occasionally  other 
organ s ystems.  A number of AEs may  be associated with this disorder including urine 
concentration defects, hypertension, renal pain, renal infection, nephrolithiasis, 
hematuria, and ESRD.  As such, these events are considered â€œexpectedâ€ in this trial 
popula tion and will not qualify  for the purposes of regulatory  expedited reporting (eg, 
Suspected Unexpected Serious Adverse Reaction and investigational new drug [IND] 
safet y reports).
5.1 Definitions
An AE is defined as an y untoward medical occurrence associated w ith the use of a n IMP
in humans, whether or not considered IMP related.
A suspected adverse reaction means any  AE for which there is a reasonable possibility  
that the IMPcaused the AE. For the purpose of IND safet y reporting, â€œreasonable 
possibility â€ mea ns there is evidence to suggest a causal relationship between the IMPand 
the AE. Suspected adverse reaction implies a lesser degree of certainty  about causality .
Aserious adverse event (SAE )includes an y event that results in any of the following 
outcom es:
1. D eath
2. L ife-threatening, ie, the subject was, in the opinion of the investigator, at 
immediate risk of death from the event as it occurred.  I t does not include an 
event that, had it occurred in a more severe form, might have caused death.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
50
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 50 06 March 20153. P ersistent or significant incapacity  or substantial disruption of the ability  to 
conduct normal life functions.
4. R equires inpatient hospitalization or prolongs hospitalization
NOTE: A pre -scheduled hospitalization is not considered an SAE.
5. C ongenital anomal y/birth defect
6. O ther medicall y significant events that, based upon appropriate medical 
judgment, may  jeopardize the subject and may  require medical or surgical 
intervention to prevent one of the outcomes listed above, eg, allergic 
bronchospasm requiring int ensive treatment in an emergency  room or home, 
blood dy scrasias or convulsions that do not result in hospitalization, or the 
development of drug dependency  or drug abuse.
Nonserious AEs are all AE s that do not meet the criter ia for a "serious" AE .
Immediat ely Reportable Event (IRE):
ï‚·Any SAE
ï‚·Any AE (whether serious or nonserious) that necessitates discontinuation of I MP.
ï‚·Any subject with a new liver test abnormalit y meeting the AE (whether serious or 
nonserious) or laboratory threshold criteria (whether cons idered an AE or not) for 
hepatic eCRF reporting.
ï‚·Any subject reporting an AE of special interest (eg, skin neoplasms or glaucoma).
ï‚·Pregnancies are also defined as IREs.  Although normal pregnancy  is not an AE, 
it will mandate IMP discontinuation and must be reported on an IRE form to 
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).  
Pregnancy  will only  be documented on the AE eCRF if there is an abnormality  or 
complication.
ï‚·Additionally , in the EU region, events involving overdose, misus e and abuse as 
well as reported lack of efficacy  must also be reported as IREs.
Clinical L aboratory  Changes :  It is the investigatorâ€™s responsibility  to review the results 
of all laboratory  tests as they  become available.  This review will be documented b y the 
investigatorâ€™s dated signature on the laboratory  report.  For each abnormal laboratory  test 
result, the investigator needs to ascertain if this is an abnormal (ie, clinically  significant) 
change from baseline for that individual subject. This determ ination, however, does not 
necessarily  need to be made the first time an abnormal value is observed.  The 
investigator may  repeat the laboratory  test or request additional tests to verify  the results 
of the original laboratory tests.  I f this laboratory  value is determined b y the investigator 
to be an abnormal change from baseline for that sub ject, this is considered an AE.
Severity :  Adverse events will be graded on a 3-point scale and reported as indicated on 
the CRF .  The intensity  of an adverse experien ce is defined as follows:
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
51
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 51 06 March 20151 = Mild: Discomfort noticed, but no disruption to daily  activity .
2 = Moderate: Discomfort sufficient to reduce or affect normal daily  activit y.
3 = Severe: Inability  to work or perform normal daily  activity .
IMP Causalit y:Asse ssment of causal relationship of an AE to the use of the IMP:
Related : There is a reasonable probability  or possibility  of a temporal and 
causal relationship between the IMP and the AE .
Not Related : There is no temporal or causal relationship to the IMP 
administration.
5.2 Eliciting and Reporting A dverse Events
The investigator will periodically  assess subjects for the occurrence of AEs.  I n order to 
avoid bias in eliciting AEs, subjects should be asked the following non -leading question: 
â€œHow have you felt since your last visit? â€  All AEs (serious and non serious) reported b y 
the subject must be recorded on the source documents and eCRFs provided by  the 
sponsor.
In addition, Quintiles (drug safet y service) must be notified immediately by telephone or 
fax of any  immediately  reportable events according to the procedure outlined below in
Section 5.3.  Special attention should be paid to recording hospitalization and 
concomitant medications.
5.3 Immediately  Reportable Events
The investigator must immediately report within 24 hours after either the investigator or 
site personnel become aware of any SAE , new liver laboratory  abnormality  requiring 
special liver eCRF completion, or confirmed pregnancy ,by telephone or by  fax to 
Quintiles ( drug safet y service )as outlined in A ppendix 1.  An I RE form must be 
completed and sent b y fax, email or overnight courier to the sponsor.  (Please note that 
the IRE form is NOT the AE eCRF ).
Nonserious events that require discontinuation of IMP (including laboratory 
abno rmalit ies) should be reported to the s ponsor within 3 working day s.  The I RE form 
must be completed and sent by  fax, email ,or ove rnight courier to the sponsor.
Subjects experiencing SAEs should be followed clinically  until their health has returned 
to baseline status, or until all parameters have returned to normal, or have otherwise been 
explained.  I t is expected that the investigator will provide or arrange appropriate 
supportive care for the subject.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
52
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 52 06 March 20155.4 Pregnancy
Women o f childbearing potential who are sexually active must use an effective method of 
birth control during the course of the trial and for 30 day s after the last dose of IMP in a 
manner such that risk of failure is minimized.  Unless the subject is sterile (ie, women 
who have had an bilateral oophor ectomy  and/or hy sterectom y or have been 
postmenopausal for at least 12 consecu tive months or remain s abstinent, 2 of the 
following precautions must be used: vasectom y, tubal lig ation, intrauterine device , birth 
control pills, birth control depot injection, birth control implant, condom or occlusive cap 
(diaphragm or cervical/vault caps) with spermicide.  Any  single method of birth control, 
including vasectomy  and tubal ligation, may  fail, leading to pregnancy .
Before enrolling WOCBP in this clinical trial, investigators must review guidelines about 
trial participation for WOCBP.  The topics should generall y include:
ï‚·General information
ï‚·ICF
ï‚·Pregnancy  prevention information
ï‚·Drug interactions with hormonal contraceptives.
ï‚·Contraceptives in current use.
ï‚·Guidelines for the follow -up of a reported pregnancy .
Prior to trial enrollment, WOCBP must be advised of the importance of avoiding 
pregnancy  during trial participation and the pot ential risk factors for an unintentional 
pregnancy .  The subject must sign an ICFstating that the above -mentioned risk factors 
and the consequences were discussed with her.
During the trial, all WOCBP should be instructed to contact the investigator immed iately  
if they  suspect they  might be pregnant (eg, missed or late menstrual cy cle).
If a subject or investigator suspects that thesubject may  be pregnant prior to I MP 
administration, the I MP administration must be withheld until the results of serum 
pregn ancy  tests are available.  If the pregnancy  is confirmed, the subject must not receive 
the IMP and must not be enrolled in the trial.  If pregnancy  is suspected while the subject 
is taking IMP, the IMP must be withheld immediately  (if reasonable, taking in to 
consideration an y potential withdrawal risks) until the result of the pregnancy is known.  
If pregnancy  is confirmed, the I MP will be interrupted or withheld in an appropriate 
manner (eg, dose tapering if necessary  for subject safet y) and the subject wi ll continue to 
be monitored for the duration of the remainder of the trial or of their pregnancy .
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
53
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 53 06 March 2015The investigat or must immediately  notify  the s ponsor of any pregnancy  associated with 
IMP exposure, during the trial and for 30 day s after the last dose of IMP and record the 
event on the IRE form and forward it to the sponsor.  The s ponsor will forward 
Pregnancy  Surveillance Form(s) for monitorin g the outcome of the pregnancy .
Protocol required procedures for trial discontinuation and follow -up must be perform ed 
on the subject unless contraindicated b y pregnancy (eg, x -ray studies).  Other appropriate 
pregnancy  follow -up procedures should be considered if indicated.  In addition, the 
investigator must report to the s ponsor, on appropriate Pregnancy  Surveillance form(s), 
follow -up information regarding the course of the pregnancy , including perinatal and 
neonatal outcome.  Infants will be followed for a minimum of 6 months.
5.5 Follow -up of A dverse Events
For this trial, AEs will be followed up for 7daysafter the l ast dose of tolvaptan has been 
administered (follow -up period).
Subjects experiencing SAEs should be followed clinically until their health has returned 
to baseline status, or until all parameters have returned to normal, or have otherwise been 
explained.
5.5.1 Follow -up of Non serious A dverse Events
Nonserious AE s that are identified on the last scheduled contact must be recorded on the 
AE eCRF wi th the current status noted.  All nonserious events that are ongoing at this 
time will be recorded as ongoing on the eCRF.
5.5.2 Follow -up o f Post -Trial Serious A dverse Events
Serious AEs that are identified on the last scheduled contact must be recorded on the 
AE eCRF page and reported to the s ponsor according to the reporting procedures outlined 
in Section 5.3.  This may include unresolved previously reported SAE s, or new SAE s.  
The investigator w ill follow SAE s until the events are reso lved, or the subject is lost to 
follow -up.  Resolution means the subject has returned to the baseline state of health, or 
the investigator does not expect any further improvement or worsening of the subjectâ€™s 
condition.  The investigator will continue to r eport any  significant follow -up information 
to OPDC up to the point the event has been resolved.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
54
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK )ROORZXSDQG5HSRUWLQJRI6HU LRXV$GY HUVH(YHQWV2FFXUULQ J
DIWHU/DVW6FKHGXOHG&RQWDFW
$Q\QHZ6$(VUHSRUWHGE\WKHVXEMHFWWRWKHLQYHVWLJDWRUWKDWR FFXUDIWHUWKHODVW
VFKHGXOHGFRQWDFW DQGDUHGHWHUPLQHGE\WKHLQYHVWLJDWRUWREHUHDVRQDEO\DVVRF LDWHG
ZLWKWKHXVHRIWKH,03VKRXOGEHUHSRUWHGWR23'&7KLVPD\ LQFOXGH6$(VWKDWDUH
FDSWXUHGRQIROORZXSWHOHSKRQHFRQWDFWRUDWDQ\RWKHUWLPHSR LQWDIWHUWKHGHILQHGWULDO
SHULRGLHXSWRODVWVFKHGXOHGFRQWDFW7KHLQYHVWLJDWRUVKR XOGIROORZVHULRXVUHODWHG
$(VLGHQWLILHGDIWHUWKHODVWVFKHGXOHGFRQWDFWXQWLOWKHHYHQW VDUHUHVROYHGRUWKHVXEMHFW
LVORVWWRIROORZXS7KHLQYHVWLJDWRUVKRXOGFRQWLQXHWRUHSR UWDQ\VLJQLILFDQWIROORZXS
LQIRUPDWLRQWR23'&XSWRWKHSRLQWWKHHYHQWKDVEHHQUHVROYHG 





 6WDWLVWLFDO$QDO\VLV
 6DPSOH6L]H
6DPSOHVL]HZDVQRWGHWHUPLQHGE\DIRUPDOFRPSXWDWLRQWRDFKLH YHDWDUJHWSRZHU1R
HIILFDF\DQDO\VHVDUHSODQQHG,WLVH[SHFWHGWKDWDSSUR[LPDWH O\VXEMHFWVPD\
HQUROO IURPSUHYLRXVWROYDSWDQWULDOV
 'DWDVHW IRU$QDO\VLV
7KHIROORZLQJGDWDVHWVDUHGHILQHGIRUWKLVWULDO
â€¢(QUROOHG3RSXODWLRQDOOVXEMHFWVZKRZHUHHQUROOHGWRWKLVRSHQ ODEHOWULDO
â€¢6DIHW\3RSXODWLRQDOOVXEMHFWVLQWKH(QUROOHG6DPSOHZKRWDNH DWOHDVWRQHGRVHRI
,03
 +DQGOLQJRI0LVVLQJ'DWD
1RPLVVLQJGDWDZLOOEHLPSXWHGXQGHUWKHDVVXPSWLRQRIPLVVLQJ DWUDQGRP
 ,QWHULP$QDO\VLV
1RLQWHULPDQDO\VLVIRUWKLVWULDO LVSODQQHG
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
C
CI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 7ULDO 2XWFRPH$QDO\VHV
 $QDO\VLVRI'HPRJUDSKLFDQG%DVHOLQH&KDUDFWHULVWLFV
'HPRJUDSKLFFKDUDFWHULVWLFVGLVHDVHVHYHULW\DQGPHGLFDOKLVW RU\DWSUHWUHDWPHQW
EDVHOLQHZLOOEHVXPPDUL]HGE\GHVFULSWLYHVWDWLVWLFVHJSURS RUWLRQPHDQPHGLDQ6'
PLQLPXPDQGPD[LPXPYDOXHV
 6DIHW\$QDO\VLV
6DIHW\DQDO\VLVZLOOEHFRQGXFWHGEDVHGRQWKH6DIHW\3RSXODWLR QZKLFKLVGHILQHGDVDOO
VXEMHFWVLQWKH(QUROOHG3RSXODWLRQZKRWDNHDWOHDVWRQHGRVHR I,036DIHW\YDULDEOHV
WREHDQDO\]HGLQFOXGHFOLQLFDOODERUDWRU\WHVWVYLWDOVLJQV DQG$(V 

,QJHQHUDOEDVHOLQHPHDVXUHPHQWVRIVDIHW\YDULDEOHVDUHGHILQ HGDVWKHODVW
PHDVXUHPHQWVSULRUWRWKHILUVWGRVHRI,03 LQ7ULDO  6DIHW\YDULDEOHVZLOOEH
VXPPDUL]HGE\GHVFULSWLYHVWDWLVWLFVHJSURSRUWLRQPHDQPH GLDQ6'PLQLPXPDQG
PD[LPXPYDOXHV6XPPDU\VWDWLVWLFVLQFOXGLQJFKDQJHVIURPED VHOLQHZLOOEH
SURYLGHGIRUVDIHW\YDULDEOHVEDVHGRQDOODYDLODEOHGDWD
 $GYHUVH(YHQWV
$OO$(VZLOOEHFRGHGE\V\VWHPRUJDQFODVV62&DQG0HGLFDO' LFWLRQDU\IRU
5HJXODWRU\$FWLYLWLHV0HG'5$SUHIHUUHGWHUP7KHLQFLGHQFHR IWKHIROORZLQJHYHQWV
ZLOOEHVXPPDUL]HG
D 7($(VE\VHYHULW\
E 7($(VSRWHQWLDOO\FDXVDOO\UHODWHGWRWROYDSWDQF 7($(VZLWKDQRXWFRPHRIGHDWKG 6HULRXV7($(VH 'LVFRQWLQXDWLRQVGXHWR7($(V
 9LWDO6LJQV
6XPPDU\VWDWLVWLFVIRUFKDQJHVIURPEDVHOLQHLQYLWDOVLJQVDQG SRWHQWLDOO\FOLQLFDOO\
VLJQLILFDQWUHVXOWVLQYLWDOVLJQVZLOOEHVXPPDUL]HG
 &OLQLFDO/DERUDWRU\$VVHVVPHQWV
6XPPDU\VWDWLVWLFVIRUFKDQJHVIURPEDVHOLQHLQFOLQLFDOODERUD WRU\PHDVXUHPHQWVZLOOEH
SURYLGHGIRUWKH6DIHW\3RSXODWLRQ3RWHQWLDOO\FOLQLFDOO\VLJ QLILFDQWUHVXOWVLQODERUDWRU\
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKWHVWVLGHQWLILHGXVLQJSURVSHFWLYHO\GHILQHGFULWHULDLQFOXGLQ JFULWHULDIRUOLYHUHQ]\PH
HOHYDWLRQVZLOODOVREHVXPPDUL]HGIRUWKH6DIHW\3RSXODWLRQ ,QDGGLWLRQE\VXEMHFW
OLVWLQJVZLOOEHSURYLGHGIRUGDWDRIORFDOODERUDWRU\WHVWV
,QDGGLWLRQODERUDWRU\PHDVXUHPHQWVWKDWVLJQDOWKHSRWHQWLDO IRU+\Â¶V/DZZLOOEH
UHSRUWHG$QLQFLGHQFHWDEOHDQGDOLVWLQJZLOOEHSURYLGHGIR UVXEMHFWVZKRPHHWRQHRU
FRPELQDWLRQVRIIROORZLQJFULWHULDZLWKRXWLQLWLDOILQGLQJVRI FKROHVWDVLV$/3DFWLYLW\
! Ã®8/1
â€¢$/7RU$67 â‰¥ Ã®8/1
â€¢%LOLUXELQ â‰¥ Ã®8/1
 6HUXP6RGLXP
7KHIROORZLQJZLOOEHVXPPDUL]HG
â€¢6HUXPVRGLXPH[FXUVLRQVDERYHRUPPRO/RUEHORZ RU
PPRO/
â€¢,QWHUUXSWLRQVRISURWRFROVSHFLILHGWKHUDSLHVIRUK\SHUQDWUHPLD RUK\SRQDWUHPLD











8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK












 0DQDJHPHQWRI,QYHVWLJDWLRQDO0HGLFLQDO3URGXFW
 3DFNDJLQJDQG/DEHOLQJ
7ROYDSWDQZLOOEHSURYLGHGWRWKHLQYHVWLJDWRUVE\WKHVSRQVRU RUGHVLJQDWHGDJHQWDV
WDEOHWVRIRUPJWROYDSWDQ23&(DFKERWWOHZLOOEH ODEHOHGWRFOHDUO\
GLVFORVHWKHVXEMHFW,'FRPSRXQG,'WULDOQXPEHUVSRQVRU
VQ DPHDQGDGGUHVV
LQVWUXFWLRQVIRUXVHURXWHRIDGPLQLVWUDWLRQDSSURSULDWHSUHF DXWLRQDU\VWDWHPHQWVDQG
RWKHULQIRUPDWLRQUHTXLUHGE\ORFDOUHJXODWRU\DXWKRULWLHV$Q \UHJLRQVSHFLILF
UHTXLUHPHQWVZLOODSSHDULQWKHRIILFLDOODQJXDJHRIWKHFRXQWU \LQZKLFKWKH,03 LVWREH
XVHG
 6WRUDJH
7ROYDSWDQZLOOEHVWRUHGLQDVHFXUHO\ORFNHGFDELQHWRUHQFORVX UH$FFHVVZLOOEHOLPLWHG
WRLQYHVWLJDWRUVDQGWKHLUGHVLJQHHV1HLWKHULQYHVWLJDWRUVQR UDQ\GHVLJQHHVPD\SURYLGH
WROYDSWDQWRDQ\VXEMHFWQRWSDUWLFLSDWLQJLQWKLVSURWRFRO
7ROYDSWDQZLOOEHVWRUHGDW WKHFRQGLWLRQVVSHFLILHGLQWKH,03O DEHO7KHFOLQLFDOVLWH
VWDIIZLOOPDLQWDLQDWHPSHUDWXUHORJLQWKH,03 VWRUDJHDUHDUH FRUGLQJWKHWHPSHUDWXUHDW
OHDVWRQFHHDFKZRUNLQJGD\
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 58 06 March 20158.3 Accountability
The investigator or designee must maintain an inventory record of IMP received, 
dispensed, administered, and returned.
8.4 Returns and Destruction
Upon completion or terminatio n of the trial, all unused and/or partially  used I MP must be 
returned to the sponsor or a designated agent.
All IMP returned to the sponsor must be accompanied by  appropriate documentation and 
be identified by protocol number with trial site number on the outermost shipping 
container.  Returned supplies should be in the original containers (eg, subject kits).  The 
assigned trial monitor will facilitate the return of unused and/or partially  used IMP.
9 Records Management
9.1 Source Documents
Source documents are d efined as the results of original observations and activities of a 
clinical investigation.  Source documents will include but are not limited to progress 
notes, electronic data, screening logs, and recorded data from automated instruments.  All 
source docu ments pertaining to this trial will be maintained by  the investigators. 
Investigator(s)/institution(s) will permit trial- related monitoring, audits, I RB/IEC review, 
and regulatory  inspection(s) by  providing direct access to source data/documents by
authori zed persons as defined in the I CF.
9.2 Data Collection
During each subjectâ€™s visit to the clinic, a clinician participating in the trial will record 
progress notes to document all significant observations.  At a minimum, these notes will 
contain:
ï‚·Documentation of the informed consent process, including an y revised consents;
ï‚·The date of t he visit and the corresponding v isit or Day  in the trial schedule;
ï‚·General subject status remarks, including an y significant medical findings.  The 
severit y, frequency, duration, action taken, and outcome of any  AEs and the 
investigator's assessment of relationship to IMP must also be recorded;
ï‚·Any changes in concomitant medications or dosages;
ï‚·A general reference to the procedures completed; 
ï‚·The signature (or initials) and date of each clinician (or designee) who made an entry  
in the progress notes.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
59
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 59 06 March 2015In addition, any  contact with the subject via telephone or other means that provides 
significant clinical information will also be documented in the progress notes as 
describ ed above.  An y changes to information in the trial progress notes and other source 
documents will be initialed and dated on the day  the change is made by a site staff 
member authorized to make the change.  Changes will be made b y striking a single line 
through erroneous data (so as not to obliterate the original data), and clearly entering the 
correct data (eg, wrong data right data).  If the reason for the change is not apparent, a 
brief explanation for the change will be written in the source documentati on by  the 
clinician.
Information from the trial progress notes and other source documents will be entered b y 
investigative site personnel directl y onto eCRFs in the sponsorâ€™s electronic data capture
system. Changes to the data will be captured by  an autom atic audit trail.
9.3 File Management at the Trial Site
The investigator will ensure that the trial site file is maintained in accordance with 
Section 8 of the I CH GCP Guideline and as required by  applicable local regulations. The 
investigator/institution will take measures to prevent accidental or premature destruction 
of these documents.
9.4 Records Retention at the Trial Site
Regulatory  requirements for the archival of records for this trial necessitate that 
participating investigators maintain detailed clinical data for the longest of the following 
three periods:
ï‚·A period of at least 2 y ears following the date on which approval to market the IMPis 
obtained (or if IMP development is discontinued, the date regulatory  authorities were 
notified of discontinuation); OR
ï‚·A period of at least 3 y ears after the sponsor notifies the investigator that the final 
report has been filed with regulatory  authorities.
ï‚·Longer, region -specific storage requirements, if applicable .The investigator must not 
dispose of an y records rel evant to this trial without either (1) written permission from the 
sponsor or (2) provision of an opportunity for sponsor to collect such records.  The 
investigator will be responsible to maintain adequate and accurate electronic or hard cop y 
source docume nts of all observations and data generated during this trial.  Such 
documentation is subject to inspection by  the sponsor and relevant regulatory  authorities.  
If the investigator withdraws from the trial (eg due to relocation or retirement), all trial -
related records should be transferred to a mutuall y agreed -upon designee within a 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
60
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 60 06 March 2015sponsor -specified timeframe.  Notice of such transfer will be gi ven to the sponsor in 
writing.
10 Quality  Control and Quality  Assurance 
10.1 Monitoring
The sponsor has ethical, legal, and scientific obligations to follow this trial carefully  in a 
detailed and orderl y manner in accordance with established research principles, the I CH 
GCP Guideline, and applicable regulatory  requirements and local laws.  As part of a 
concerted effort to f ulfill these obligations (maintain current personal knowledge of the 
progress of the trial), the sponsor's monitors will visit the site during the trial, as well as 
communicate frequentl y via telepho ne and written communications.
10.2 Auditing
The sponsor's Qua lity Management Unit (or representative) may  conduct trial site audits.  
Audits will include but are not limited to IMPsupply , presence of required documents, 
the informed consent process, and comparison of e CRFs with source documents.  The 
investigator agrees to participate with audits.
Regulatory  authorities may  inspect the investigator site during or after the trial.  The 
investigator will cooperate with such inspections and will contact the sponsor 
immediately  if such an inspection occurs.
11 Ethics and Responsibility
This trial must be conducted in compliance with the protocol, the ICH GCP Guideline, 
and applicable local laws and regulatory  requirements. Each trial site will seek approval 
by an IRB or IEC according to regional requirements. The I RB/IEC will evaluate the 
ethical, scientific and medical appropriateness of the trial. Further, in preparing and 
handling CRFs, the investigator, sub -investigator and their staff will take measures to 
ensure adequate care in protecting subject privacy . To this end, a subject number and 
subject ID code will be used to identify  each subject. 
Financial aspects, subject insurance and the publication policy  for the trial will be 
documented in the agreement between the sponsor and the investigator.
12 Confidentiality
All information generated in this trial will be considered confidential and will not be 
disclosed to any one not directly  concerned with the trial without the sponsorâ€™s prior 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
61
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 61 06 March 2015written permission.  Subject confidentialit y requirements of the region(s) where th e trial 
is conducted will be met.  However, authorized regulatory  officials and sponsor personnel 
(or their representatives) will be allowed full access to inspect and cop y the records.  All 
IMPs, subject bodily fluids, and/or other materials collected sha ll be used solely  in 
accordance with this protocol, unless otherwise agreed to in writing b y the sponsor.
Subjects will be identified only  by initials and unique subject numbers in e CRFs.  Their 
full names may , however, be made known to a regulatory  agency or other authorized 
officials if necessary .
13 Amendment Policy
The investigator will not make an y changes to this protocol without the sponsorâ€™s prior 
written consent and subsequent approval by  the IRB/IEC.  Any  permanent change to the 
protocol, whether it be an overall change or a change for specific trial site(s), m ust be 
handled as a protocol amendment.  An y amendment will be written by the sponsor.  Each 
amendment will be submitted to the I RB/IEC.  Except for â€œadministrativeâ€ or â€œnon -
substantialâ€ amendments, investigators will wait for I RB/IEC approval of the amended 
protocol before implementing the change(s).  Administrative amendments are defined as 
having no effect on the safet y of subjects, conduct or management of the trial, trial 
design, or the quality  or safet y of IMP(s) used in the trial.  A protocol change intended to 
eliminate an apparent immediate hazard to s ubjects should be implemented immediately , 
followed b y IRB/IEC notification within 5 working day s.  The sponsor will submit 
protocol amendments to the applicable regulatory  agencies.
When the I RB/IEC, investigators, and/or the sponsor conclude that the protocol 
amendment substantially  alters the trial design and/or increases the potential risk to the 
subject, the currently  approved written ICF will require similar modification.  I n such 
cases, repeat informed consent will be obtained from subjects enrolled in the trial before 
expecting continued participation.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
62
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 62 06 March 201514 References
1European Medicines Agency , Public summary  of opinion on orphan designation: 
Tolvaptan for the treatment of autosomal dominant poly cystic kidney  disease. 
Committee for Orphan Medicinal Products. 2013; EMA/COMP/444684/2013.
2U S Renal Data S ystem, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney  
Disease and End- Stage Renal Disease in the United States, National Institutes of 
Heal th, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 
MD, 2012
3Lentine KL, Xiao H, Machnicki G, Gheorghian A, Schnitzler MA. Renal function 
and healthcare costs in patients with poly cystic kidney  disease. Clin J Am Soc 
Nephrol. 2010 Aug;5(8):1471-9.
4OPC -41061 I nvestigatorâ€™s Brochure. Rockville (MD): Otsuka Pharmaceutical 
Development & Commercialization, I nc.; Edition 19 Otsuka Report, issued 11 July  
2013.
5OPC -41061 Common Technical Document.  Rockville (MD): Otsuka Pharmaceut ical 
Development & Commercialization, I nc.; Section 2.5: Clinical Overview; 2013.
6Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 
receptor antagonists OPC -31260 and OPC -41061 on poly cystic kidney  disease 
development in the PC K rat. J Am Soc Nephrol. 2005 Apr;16(4):846 -51. 
7Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP. Tolvaptan 
inhibits ERK -dependent cell proliferation, Cl- secretion, and in vitro cy st growth of 
human ADPKD cells stimulated by  vasopressin. Amer J Phy siol Ren al Phy siol. 2011 
Nov;301(5):F1005 -13.
8Torres VE, Chapman AB, Devuy st O, Gansevoort RT, Grantham JJ, Higashihara E, 
et al for the TEMPO 3:4 Trial Investigators.  Tolvaptan in patients with autosomal 
dominant poly cystic kidney  disease. N Engl J Med 2012;367:2407 -18.
9Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, et al. 
Tolvaptan in autosomal dominant poly cystic kidney  disease: three y ears' experience. 
Clin J Am Soc Nephrol. 2011 Oct;6(10):2499 -507.
10U.S. Food and Drug Administration. Guidance for Industry . Drug -induced liver 
injury : premarketing clinical evaluation [report on the internet]. 2009 Jul [cited 2012 
Oct 10];[about 23 p.].  Available from: 
http://www.fda.gov/downloads/Drugs/GuidanceCompliance
Regulatory Information/Guidances/UCM174090.pdf .
11Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of 
ADPKD. J Am Soc Nephrol 2010 20: 205-212.
12Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic 
criter ia for autosomal dominant poly cystic kidney disease 1. Lancet 1994; 343:824-
827.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
63
Protocol 156 -13-211
Confidential -Otsuk a Proprietary Information 63 06 March 201513Levey  AS, Stevens LA, et al. A new equation to estimate glomerular filtration rate.  
Ann Intern Med. 2009; 150:604-612.
14International Conference on Harmonisation; Good Clinical Practice: Consolidated 
Guideline; Notice of Availability , 62 C.F.R. Sect. 90 (1997).
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
64
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK$SSHQGL[ 1DPHVRI6SRQVRU3HUVRQQHO
5HSRUW,PPHGLDWHO\5HSRUWDEOH(YHQWVVHULRXVDGYHUVHHYHQWVS RWHQWLDO+\Â¶V/DZFDVHV
SUHJQDQFLHVDQGDGYHUVHHYHQWVUHTXLULQJGLVFRQWLQXDWLRQRI,03 WR
4XLQWLOHV
&OLQLFDO6DIHW\DQG3KDUPDFRYLJLODQFH6RXWK0LDPL%OYG0RUULVYLOOH1&86$3KRQH)D[(PDLO
)RU0HGLFDO (PHUJHQFLHV XVHRQO\LIVSRQVRUSHUVRQQHOOLVWHGDERYHDUHXQDYDLODEOH
*OREDO3URMHFW/HDGHUV
*OREDO&OLQLFDO'LUHFWRU
0HGLFDO'LUHFWRU3URJUDP/HDG 2WVXND3KDUPDFHXWLFDO'HYHORSPHQW	
&RPPHUFLDOL]DWLRQ,QF5HVHDUFK%OYG5RFNYLOOH0'86$3KRQH )D[
*OREDO&OLQLFDO'LUHFWRU 
0HGLFDO'LUHFWRU3URMHFW/HDG 2WVXND3KDUPDFHXWLFDO'HYHORSPHQW	
&RPPHUFLDOL]DWLRQ,QF&DUQHJLH&HQWHU'ULYH6XLWH3ULQFHWRQ1-86$3KRQH )D[
*OREDO&OLQLFDO0DQDJHPHQW
*OREDO&OLQLFDO0DQDJHPHQW
86$
3KRQH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
PPDPPD
PPD
PPD
PPD
PPD
PPD
PPD PPD
PPD
PPD
PPD PPD
PPD
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK$SSHQGL[ ,QVWLWXWLRQV&RQFHUQHG:LWKWKH7ULDO
/HDG3ULQFLSDO&RPPXQLFDWLQJ
,QYHVWLJDWRU6WHHULQJ&RPPLWWHH&KDLU
86$
3KRQH
,QGHSHQGHQW'DWD0RQLWRULQJ
&RPPLWWHH&KDLU
3KRQH
+HSDWLF$GMXGLFDWLRQ&RPPLWWHH&KDLU

3KRQH
)D[
*OREDO0HGLFDO0RQLWRULQJ 4XLQWLOHV
6RXWK0LDPL%OYG
0RUULVYLOOH1&86$
3KRQH
0RELOH
)D[
7ULDO0DQDJHP HQW 4XLQWLOHV
6RXWK0LDPL%OYG
0RUULVYLOOH1&86$
2IILFH
0RELOH
)D[
6DIHW\5HSRUWLQJ 4XLQWLOHV
'UXJ6DIHW\6HUYLFH
6RXWK0LDPL%OYG
0RUULVYLOOH1&86$
3KRQH
)D[
,QYHVWLJDWLRQDO0DWHULDOV $OPDF
)UHW]5G
6RXGHUWRQ3$ 86$
3KRQH
%XGJHWDQG&RQWUDFW1HJRWLDWLRQ ,1&5HVHDUFK//&
%HHFKOHDI&W
5DOHLJK1&86$
3KRQH
,QYHVWLJDWRU3D\PHQWV 4XLQWLOHV,QF
,QYHVWLJDWRU3D\PHQW$GPLQLVWUDWLRQ'HSDUWPHQW
7HOHVLV&RXUW6XLWH
6DQ'LHJR&$86$
3KRQH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK(OHFWURQLF'DWD&DSWXUH 0HGL'DWD6ROXWLRQV
)LIWK$YHQXHWK)ORRU
1HZ<RUN1< 86$
3KRQH
)D[
,576\VWHPV $OPDF&OLQLFDO7HFKQRORJLHV
)UHW]5RDG
6RXGHUWRQ3$86$
867HO
5R:7HO
&HQWUDO/DERUDWRU\6HUYLFHV &RYDQFH&HQWUDO/DERUDWRU\6HUYLFHV
6FL&RU'U
,QGLDQDSROLV,186$
3KRQH
7ROOIUHH
)D[ 
&RYDQFH$VLD3WH/WG
&HQWUDO/DERUDWRU\6HUYLFHV6LQJDSRUH
,QWHUQDWLRQDO%XVLQHVV3DUN
7KH6\QHUJ\6LQJDSRUH
3KRQH
&RYDQFH&HQWUDO/DERUDWRU\6HUYLFHV6 \GQH\
(SSLQJ5G1RUWK5\GH
16:$XVWUDOLD
3KRQH
&RYDQFH&HQWUDO/DERUDWRU\6HUYLFHV*HQHYD
5XH0RLVH0DUFLQKHV
0H\ULQ*HQHYD &+
6ZLW]HUODQG
3KRQH

3KRQH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCIPPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK$SSHQGL[






















8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK













8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK













8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK$SSHQGL[  3URWRFRO$PHQGPHQWVDQG$GPLQLVWUDWLYH&KDQJHV
$PHQGPHQW1XPEHU 
,VVXH'DWH -XO\
385326(
7KHSXUSRVHRIWKLVDPHQGPHQWZDVWRUHYLVHSURWRFROSURFHGXUHV WRDFFRPPRGDWHWKH
WUHDWPHQWDQGPRQLWRULQJRIVXEMHFWVZLWK$'3.'HQUROOLQJLQWR WKHSURWRFROIURP
DGGLWLRQDOWROYDSWDQWULDOV&RQVHTXHQWO\VDPSOHVL]HZDVLQFU HDVHGWKHLQFOXVLRQ
FULWHULDZHUHVOLJKWO\PRGLILHGVFKHGXOHVIRULQLWLDWLRQRIWU HDWPHQWDQGOLYHUIXQFWLRQ
WHVWLQJZHUHIXUWKHUGHILQHG 
'RZQWLWUDWLRQIRUPHWDEROLFGUXJGUXJLQWHUDFWLRQVZDVDGGHG WRWKH
V\QRSVLVDQGDGGLWLRQDOO\LWZDVUHTXLUHGWKDWPHGLFDOPRQLWRU DSSURYDOLVQHHGHG $
WDEOHRIVWURQJDQGPRGHUDWH&<3$LQKLELWRUVZDVDGGHGWRWKH WH[W7KHOLVWRI
YHQGRUVDQGVWXG\SHUVRQQHOZDVXSGDWHG0LQRUOLQJXLVWLFFKDQJ HVZHUHPDGHIRUFODULW\
DQGW\SRJUDSKLFDOHUURUVZHUHFRUUHFWHG
%$&.*5281'
,WZDVGHFLGHGWRDOORZVXEMHFWVIURPDGGLWLRQDOWROYDSWDQWULD OVHQWU\LQWRWKLVVDIHW\WULDO
IRUDQLQFUHDVHGXQGHUVWDQGLQJRIWROYDSWDQÂ¶VORQJWHUPVDIHW\ LQ$'3.'SDWLHQWVDQG
SURYLGHH[SDQGHGDFFHVVWRWROYDSWDQIRUWKRVHVXEMHFWVZKRZRX OGOLNHWRFRQWLQXH
WUHDWPHQWDIWHUFRPSOHWLQJWKHLUSUHYLRXVWULDO

2WKHU5HYLVLRQV
)LJXUH7ULDO'HVLJQ6FKHPDWLF
7DEOH7ULDO7UHDWPHQWV7DEOH ,QFOXVLRQ&ULWHULD7DEOH6FKHGXOHRI$VVHVVPHQWV
6HFWLRQDO5HYLVLRQV
/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
6\QRSVLV7ULDO'HVLJQ 6XEMHFWVZLOOEHHOLJLEOHIRUVFUHHQLQJ
LQWRWKLVWULDOLIWKH\6XEMHFWVZLOOEHHOLJLEOHIRU
VFUHHQLQJLQWRWKLVWULDOLIWKH\
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 71 06 Ma rch 2015Location Old Text Updated Text
ï‚·ï€ Participated in the double -blind 
Trial 156 -13-210 (only
upon successful completion of their 
randomized 12-month period 
including post -treatment follow -
up,regardless of whether this was on -
treatment or off -treatment),or
ï‚·ï€ Participated in the open -label 
Trial 156-08-271.
After consenting and screening, 
eligible subjects w ill be assigned a 
new subject number and adm inistered 
tolvaptan at a split-dose of 45/15 mg. 
Subjects will have the opportunity for
either up or dow n-titration to a 
maximum split tolvaptan dose of 
90/30 mg or a minimum split dose of 
15/15 mg at the discretion of the 
investigator according to individual
tolerability.
Subjects entering the trial from 
Trial 156-08-271 may receive up to 
33 months of open -label tolvaptan 
therapy, and subjects entering the trial 
from Trial 156 -13-210 may receive 
up to 15 to 21 months of open -label 
tolvaptan therapy .ï‚·Completed and 
transferred from  the 
double- blind 
Trial 156-13-210 
(12-month period 
including post -treatm ent 
follow -up, regardless of 
whether this was on -
treatm ent or off -
treatm ent), or 
ï‚·Completed 
Trial 156-08-271 or a 
prior tolvaptan ADPKD 
trial, or
ï‚·Interrupted or 
discontinued treatm ent in 
a prior tolvaptan ADPKD 
trial (other than 
Trial 156-13-210) .  
Subjects may be enrolled 
with the m edical monitor 
approval, and additional 
close m onitori ng m ay be 
required at the beginning 
of the trial
For purposes of ensuring subject 
safety, all subjects will be 
monitored for hepatic safety 
monthly until 18 months of 
tolvaptan exposure has been 
collected. .  After that, and 
following the approval fromthe 
medical monitor, hepatic 
monitoring will berequired every 
3months.  Until their prior 
treatm ent assignment is 
unblinded, a ll Trial 156-13-210 
subjects who are eligible for this 
trial are scheduled to have trial 
visits/ hepatic monitoring monthly 
for the first 18 months of this trial.  
Once unblinding occurs, it can be 
determined which subjects 
received tolvaptan in Trial 156-13-
210.  These subjects may have 
their trial vis its/hepatic 
transam inase monitoring change 
to every 3 months sooner as their 
previous tolvaptan exposure in 
Trial 156-13-210 can count 
towards the 18 -month threshold.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
72
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 72 06 Ma rch 2015Location Old Text Updated Text
Enrollment in this trial will be 
closed when the final eligible 
subject from  Trial 156-13-210 
enrolls in this trial.
Synopsis, Subject 
PopulationThis trial will in clude up to 2,450 
subjects over the age of 18 years w ith  
ADPKD diagnosed by Pei -Ravine 
criteria (modified by magnetic 
resonance imaging [MRI]) .
Renal function will be assessed 
during screening by using historical 
laboratory values for serum creatinine 
levels to calculate the estimated 
glomerular filtration rate (eGFR).  
The eGFR values will be estimated 
based on the Chronic Kidney Disease 
-Epidem iology (CKD -EPI) formula.This trial w ill include 
approximately 2,500 subjects over 
the age of 18 years with ADPKD 
diagnosed by Pei -Ravine criteria 
(modified by magnetic resonance 
imaging [MRI]) , and who have 
completed or participated in a 
prior tolvaptan ADPKD 
interventional investigational 
medicinal product (IMP) trial.
Synopsis, 
Inclusion/Exclusion 
CriteriaMain inclusion criteria:
ï‚·ï€ Male and female subjects 
ï‚³ï€ 18years with ADPKD who have 
completed either Trial 156 -13-210 or 
Trial 156 -08-271
ï‚·ï€ Diagnosis of ADPKD by modified 
Pei-Ravine criteria
ï‚·ï€ eGFR ï‚³ï€ 20 mL/min/1.73m2within 
45 days of the baseline visit. Subjects 
who have an eGFR between 15 and 
19mL/min/1.73m2may be enrolled 
with medical monitor approval
Main exclusion criteria:
ï‚·Need for chronic diuretic use
ï‚·Hepatic impairment based on 
liver function assessments other 
than that expected for ADPKD 
with c ystic liver diseaseMain inclusion criteria:
ï‚·Male and female subjects 
ï‚³18years with confirmed 
diagnosis of ADPKD (during 
participation in prior 
tolvaptan trials) who have 
ï‚·Completed and 
transferred from  the 
double- blind 
Trial 156-13-210 
(12-month period
including post -treatm ent 
follow -up, regardless of 
whether this was on -
treatm ent or off -
treatm ent), or 
ï‚·Completed 
Trial 156-08-271 or a 
prior ADPKD t olvaptan 
trial, or
ï‚·Interrupted or 
discontinued treatm ent in 
a prior tolvaptan ADPKD 
trial other than 
Trial 156-13-210.  
Subjects may be enrolled 
with the m edical monitor 
approval, and additional 
close m onitoring m ay be 
required at the beginning 
of the trial
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
73
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 73 06 Ma rch 2015Location Old Text Updated Text
ï‚·Estimated glomerular 
filtration rate
(eGFR )ï‚³20mL/min/1.73m2 
within 45 days of the baseline 
visit.  Subjects who have an 
eGFR between 15 and 
19mL/min/1.73m2 may be 
enrolled w ith medical monitor 
approval
ï‚·Renal function will be assessed 
during screening by using 
historical laboratory values (in 
the last 30 days) for serum  
creatinine levels to calculate 
the eGFR.  the eGFR values 
will be estim ated based on the 
Chronic Kidney Disease -
Epide miology (CKD -EPI) 
form ula
Main exclusion criteria:
ï‚·Need for chronic diuretic use
ï‚·Hepatic impairment based on 
hepatic laboratory assessments
(alanine am inotransferase 
[ALT], aspartate 
aminotransferase [AST], 
bilirubin, total [BT]) other than 
that expected for ADPKD with 
cystic liver disease
Synopsis, Trial Site(s) Up to 220 sites which may include 
North America, South America, 
Russian Federation and Australia.  Approxim ately 220 enrolling sites 
including but not limited to the 
following regions: North America, 
South America, Eastern Europe, 
Western Europe, Russian 
Federation, and Australia.   
Synopsis, 
Investigational 
Medicinal Product(s), 
Dose, Dosage regimen, 
Treatment period, 
Form ulation, Mode of 
AdministrationTolvaptan tablets (15 mg or 30 mg) 
will be self -administered orally as 
split-dose regimens, once upon 
awakening and another approximately 
8 to 9 hours later. Doses w ill be 
expressed as early dose/late d ose (eg, 
60/30 mg). Allowed doses are 
15/15 mg, 30/15 mg, 45/15 mg, 
60/30 mg and 90/30 mg.
All subjects will be st arted at a split -
dose of tolvaptan 45/15 mg and 
titrated according to tolerability. The 
dose range permitted will be a The dose regimen s to be used in 
this trial are 15/15 m g, 30/15 m g, 
45/15 m g, 60/30 m g, and 90/30 m g.
Tolvaptan tablets (15 mg or 30 mg) 
will be self -administered orally as 
split-dose regimens, twice daily,
once upon awakening and another 
approximately 8 to 9 hours later.  
Doses will be record edas early 
dose/late dose (eg, 60/30 mg).  
Subjects will receive open -label 
tolvaptan for the duration of the 
trial.  
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
74
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
PD[LPXPRIPJDQGD
PLQLPXPRIPJ $VXEMHFWÂ¶VVWDUWLQJGRVHLQWKLV
WULDOZLOOEHGHSHQGHQWRQWKH WULDOLQZKLFKWKH\ZHUHSUHYLRXVO\HQUROOHG
â€¢LQLWLDWHGRQ
WROYDSWDQDWDVSOLWGRVHRI
 PJZLWKXSZDUGWLWUDWLRQHYHU\WRGD\VWRPJRUPJSHUGD\DFFRUGLQJWRWROHUDELOLW\
â€¢ ZLOOUHWDLQWKHODVW
GRVHOHYHOIURPDQGVWDUWDWWKHVDPHGRVHLQWKLVWULDO
â€¢3ULRUWROYDSWDQWULDOV
LQLWLDWHGRQWROYDSWDQDWDVSOLWGRVHRIPJZLWK
XSZDUGWLWUDWLRQHYHU\WR
 GD\VWRPJRU PJSHUGD\DFFRUGLQJWRWROHUDELOLW\
'RZQWLWUDWLRQWRPJRU
PJGDLO\ZLOOEHDOORZHGDW
WKHGLVFUHWLRQRIWKHLQYHVWLJDWRUDFFRUGLQJWRLQGLYLGXDOWROHUDELOLW\DQGZLWKPHGLFDOPRQLWRUQRWLILFDWLRQ)XUWKHUGRZQWLWUDWLRQWRRUPJRQFHGDLO\
PD\EHDOORZHGRQO\IRUPHWDEROLF
GUXJGUXJLQWHUDFWLRQDQGUHTXLUHVPHGLFDOPRQLWRUDSSURYDO
6\QRSVLV7ULDO$VVHVVPHQWVÂ«
6FUHHQLQJ ,QIRUPHGFRQVHQWPHGLFDO
KLVWRU\LQFOXGLQJ$'3.'XSGDWHV
DVUHTXLUHGGHWHUPLQDWLRQRI
HOLJLELOLW\WKURXJKLQFOXVLRQH[FOXVLRQFULWHULDGLHWDU\UHYLHZYLWDOVLJQVFOLQLFDOODERUDWRU\DVVHVVPHQWVFRPSOHWHSK\VLFDOH[DPLQDWLRQXULQHSUHJQDQF\WHVWZRPHQRIFKLOG
EHDULQJSRWHQWLDORQO\>:2&%3@
FRQFRPLWDQWPHGLFDWLRQVDQGODERUDWRU\WHVWVWRGHWHUPLQHHOLJLELOLW\Â«
6FUHHQLQJ ,QIRUPHGFRQVHQW
PHGLFDOKLVWRU\LQFOXGLQJ$'3.'
XSGDWHVDVUHTXLUHGGHWHUPLQDWLRQ
RIHOLJLELOLW\WKURXJKLQFOXVLRQH[FOXVLRQFULWHULDGLHWDU\UHYLHZYLWDOVLJQVFOLQLFDOODERUDWRU\DVVHVVPHQWVSK\VLFDOH[DPLQDWLRQXULQHSUHJQDQF\WHVW
ZRPHQRIFKLOGEHDULQJSRWHQWLDO
RQO\>:2&%3@FRQFRPLWDQWPHGLFDWLRQVDQGODERUDWRU\WHVWVWRGHWHUPLQHHOLJLELOLW\





8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 75 06 Ma rch 2015Location Old Text Updated Text
Synopsis, Criteria for 
EvaluationSafety :
ï‚·AEs
ï‚·Vital signs
ï‚·Clinical laboratory 
assessments
ï‚·Serum transaminase 
elevations for frequency (2x, 
3x, 5x and 10x upper limit 
norm al [ULN]), time to 
onset, time to peak levels, 
time of offset (< 3x, 2x, or 
1xULN), response to de -
challenge and re- challenge 
and frequency of progression 
to Hyâ€™s laboratory criteria 
(alanine aminotransferase 
(ALT )or aspartate 
aminotransferase ( AST )> 3x 
ULN and bilirubin, total 
(BT)> 2x ULN without 
alkaline phosphatase 
ï‚³2xULN)
ï‚·Serum sodium excursions 
above 145, 150 or 
155mmol/L or below  135, 
130 or 125 mmol/L
ï‚·Interruptions of protocol 
specified therapies for 
hypernatremia or 
hyponatremiaSafety :
ï‚·AEs
ï‚·Vital signs
ï‚·Clinical laboratory 
assessments
ï‚·Serum transaminase 
elevations for frequency 
(2x, 3x, 5x and 10x ULN), 
time to onset, time to peak 
levels, time of offset (< 3x, 
2x, or 1x ULN), response to 
de-challenge and 
re-challenge and frequency 
of progression to Hyâ€™s 
laboratory criteria (ALT or 
AST > 3x UL N and BT 
>2x ULN without alkaline 
phosphatase ï‚³2xULN)
ï‚·Serum sodium excursions 
above 145, 150, or 
155mmol/L or below  135, 
130, or 125 mmol/L
Synopsis, Statistical 
MethodsSample size:   Sam ple size was not 
determined by a formal computation 
to achieve a target power.  No 
efficacy analyses are planned.  It is 
expected that approximately 2,450 
subjects may enroll from previous 
tolvaptan trials.Sample size:   Sam ple size was not 
determined by a formal computation 
to achieve a target power.  No 
efficacy analyses are planned.  It is 
expected that approximately 2,500
subjects may enroll from previous 
tolvaptan trials.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
76
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
$QDO\VLVGDWDVHWV
â€¢(QUROOHG3RSXODWLRQDOO
VXEMHFWVZKRZHUHHQUROOHGWRWKLVRSHQODEHOWULDO
â€¢6DIHW\3RSXODWLRQDOO
VXEMHFWVLQWKH(QUROOHG
3RSXODWLRQZKRWDNHDWOHDVW
GRVHRILQYHVWLJDWLRQDOPHGLFLQDOSURGXFW,03$QDO\VLVGDWDVHWV
â€¢(QUROOHG3RSXODWLRQDOO
VXEMHFWVZKRZHUHHQUROOHGWRWKLVRSHQODEHOWULDO
â€¢6DIHW\3RSXODWLRQDOO
VXEMHFWVLQWKH(QUROOHG
3RSXODWLRQZKRWDNHDWOHDVW
GRVHRI,03
6\QRSVLV7ULDO'XUDWLRQ7KLVWULDOLVSODQQHGWREHFRQWLQXHG
XQWLORQHRIWKHIROORZLQJKDVRFFXUUHG$OOVXEMHFWVHQWHULQJIURP7ULDOZLOOEH HOLJLEOHIRUXSWR
PRQWKVLQ7ULDO
$IWHUXSWRPRQWKVSDUWLFLSDWLRQIRUVXEMHFWVIURP7ULDO 
DQGIRUDOOVXEMHFWVHQWHULQJIURP7ULDO SDUWLFLSDWLRQPD\
FRQWLQXHXQWLOWKH ILUVWRI
â€¢ WKHWULDOFRQFOXGHVODVWVXEMHFWIURP
7ULDO UHDFKHVDWOHDVW
 PRQWKVSDUWLFLSDWLRQ RU-XO\RU
â€¢ WROYDSWDQLVDSSURYHGIRUXVHLQ
$'3.'LQWKHLU UHJLRQRU
â€¢ 7ULDOGXUDWLRQLVSODQQHGWR
FRQWLQXH
â€¢8QWLOWKHODVWVXEMHFWIURP
7ULDO
FRPSOHWHV PRQWKVRI
WROYDSWDQWUHDWPHQWLQWKLVWULDO
â€¢6XEMHFWVHQUROOLQJIURP
RWKHUWULDOVZLOOFRQFOXGHWKHLUSDUWLFLSDWLRQRQFH
WROYDSWDQEHFRPHV
DYDLODEOH WKURXJKURXWLQHSUHVFULSWLRQRUWKURXJKD

7ULDO VXEMHFWV
PD\RSWWRFRQFOXGHWKHLU
SDUWLFLSDWLRQLQWKLVWULDOLIWROYDSWDQEHFRPHVDYDLODEOHEHIRUHWKH\FRPSOHWHPRQWKVRI
WUHDWPHQWLQWKLVWULDO
6HFWLRQ&OLQLFDO
'DWD1$ 
















8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCICCI
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 77 06 Ma rch 2015Location Old Text Updated Text
.
Section 1.3, Known and 
Potential Risks and 
BenefitsIn this extension trial, subjects 
enrolling from the double -blind 
Trial 156-13-210 w ill have monthly 
transaminase level assessments for 
the first 18 months while the 
treatment code from Trial 156 -10-210 
remains blinded, to ensure that all 
subjects have adequate safety 
monitoring during this period of 
susceptibility. Monitoring will be 
quarterly for these subjects follow ing 
the first 18 months of known 
exposure to tolvaptan. Subjects 
enrolling from the open -label Trial 
156-08-271 w ill have quarterly 
transaminase assessments conducted, 
since they will have already received 
tolvaptan for 2 years or more.In this extension trial, subjects 
enrolling from the double -blind 
Trial156-13-210 w ill have monthly 
visits and transaminase level 
assessments for the first 18 months 
while the treatment code from 
Trial 156-10-210 remains blinded, to 
ensure that all subjects have 
adequate safety monitoring during 
this period of susceptibili ty.  Once 
unblinding occurs, it can be 
determined which subjects 
received tolvaptan in 
Trial 156-13-210.  These subjects 
may have their trial visits/hepatic 
transam inase monitoring change d
to every 3 months sooner as their 
previous tolvaptan exposure in 
Trial156-13-210 can count 
towards the 18 -month threshold.  
If subjects approaching the 
18-month threshold have had 
prior transam inase abnormalities 
(>2 Ã—upper limit of normal 
[ULN ]), the investigator is 
responsible for contacting the 
medical monitor to co nfirm  the 
change in frequency from  monthly 
to every 3 months.  Subjects 
enrolling from the open -label Trial 
156-08-271 w ill have transaminase 
assessments conducted every 
3months, since they will have 
already received tolvaptan for at 
least 18 months.    T he current IB 
lists all of the tolvaptan trials.   
Subjects enrolling in this trial who 
were in a previous ADPKD trial 
other than Trials 156-13-210 and 
156-08-271 will have m onthly 
visits and transaminase level 
assessments for the first 18 
months.
Section 2.1, Trial 
Rationale...
Over the 3 years of placebo -
controlled treatment, ALT w as 
elevated to a greater than three times 
the upper limit of normal (> 3 Ã— 
ULN) in 4.4% of tolvaptan subjects 
compared with 1% of placebo 
subjects.  To date, 3 tolvaptan â€¦
Over the 3 years of placebo -
controlled treatment, ALT w as 
elevated to a greater than three times 
the upper limit of normal (> 3 Ã— 
ULN) in 4.4% of tolvaptan subjects 
compared with 1% of placebo 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
78
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 78 06 Ma rch 2015Location Old Text Updated Text
subjectsâ€™ transaminases and bilirubin 
levels reached Hyâ€™s laboratory 
criteria (> 3 Ã— and > 2 Ã— ULN, 
respectively).  Upon discontinuation, 
all subjectsâ€™ liver tests showed 
reversibility of the elevation within 
approximately 4 months after 
tolvaptan was discontinued.  
Nevertheless, without adequate 
monitoring and management, it is 
estimated that a 1:3,000 risk for 
irreversible liver injury may existsubjects.  To date, 3 tolvaptan 
subjectsâ€™ transaminases and bil irubin 
levels reached Hyâ€™s laboratory 
criteria (> 3 Ã— and > 2 Ã— ULN, 
respectively).  Upon discontinuation, 
all subjectsâ€™ liver tests showed 
reversibility of the elevation within 
approximately 4 months after 
tolvaptan was discontinued.  
Nevertheless, withou t adequate 
monitoring and management, it is 
estimated that a 1: 4,000 risk for 
irreversible liver injury may exist
Section 3.1, 
Type/Design of TrialThis trial is a phase 3b, multi -center, 
open -label trial.
Subjects will be eligible for screening 
into t his trial if they:
ï‚·ï€ Participated in the double -blind 
Trial 156 -13-210 (only upon 
successful completion of their 
randomized 12 -month period 
including post -treatment follow -up, 
regardless of whether this was on -
treatment or off -treatment), or
ï‚·ï€ Participate d in the open -label 
Trial 156-08-271
Upon the successful completion of 
Trial 156 -13-210 or Trial 156 -08-
271, subjects w ill have an opportunity 
to enroll into Trial 156 -13-211 
immediately following completion of 
the follow -up visit(s) of the previous 
trial. The last follow -up visit 
assessments can be utilized for 
screening into this trial. However, for 
subjects who require a longer period 
betw een com pletion of the preceding 
trial and entry into this trial, this may 
be allow ed at the discretion of the 
medical monitor.
After consenting and screening, 
eligible subjects w ill be assigned a 
new subject number and administered 
tolvaptan at a split -dose of 45/15 mg. 
Subjects will have the opportunity for This trial is a phase 3b, multi -center, 
open -label trial.
Eligible subjec ts will have an 
opportunity to enroll into 
Trial 156-13-211 immediately 
following completion of the 
follow -up visit(s) of the previous 
trial.  The last visit assessments 
from  the previous protocol can be 
combined with the screening visit 
for this trial, wi th all required 
assessments from each visit only 
perform ed once, as long as the 
time between the last follow -up 
visit assessments from the 
previous trial and the screening 
visit for this trial is within 30 days.  
Medical m onitor approval is 
needed for enrollment of subjects 
whose com pletion of the preceding 
trial prior to entry in this trial 
exceeds 3 months , and these 
subjects will be required to 
undergo all screening and baseline 
assessments.
After consenting, subjects will be 
assigned a new screening number.  
Subjects who are found to be 
eligible will retain the sam e 
subject number they had been 
assigned in their previous trial. .  
For purposes of ensuring subject 
safety, tolvaptan exposure of at 
least 18 months is required for all 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
79
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
HLWKHUXSRUGRZQWLWUDWLRQWRD
PD[LPXPWROYDSWDQVSOLW GRVHRI
PJRUDPLQLPXPVSOLWGRVHRIPJDWWKHGLVFUHWLRQRIWKHLQYHVWLJDWRUDFFRUGLQJWRLQGLYLGXDOWROHUDELOLW\
6XEMHFWVHQWHULQJWKHWULDOIURP7ULDO
PD\UHFHLYHXSWR
PRQWKVRIRSHQODEHOWROYDSWDQWKHUDS\DQGVXEMHFWVHQWHULQJWKHWULDOIURP7ULDO PD\UHFHLYH
XSWRWRPRQWKVRIRSHQODEHO
WROYDSWDQWKHUDS\
7KLVWULDOLVSODQQHGWRFRQWLQXHXQWLO
RQHRIWKHIROORZLQJKDVRFFXUUHG
$OOVXEMHFWVHQWHULQJIURP7ULDO
Z LOOEHHOLJLEOHIRUXSWR
PRQWKVLQ7ULDO$IWHUXSWRPRQWKVSDUWLFLSDWLRQIRUVXEMHFWVIURP7ULDODQGIRUDOOVXEMHFWVHQWHULQJIURP
7ULDO SDUWLFLSDWLRQPD\
FRQWLQXHXQWLOWKHILUVWRI
â€¢ WKHWULDOFRQFOXGHVODVWVXEMHFWIURP
7ULDO UHDFKHVDWOHDVW
 PRQWKVRU-XO\RU
â€¢ WROYDSWDQLVDSSURYHGIRUXVHLQ
$'3.'LQWKHLUUHJLRQRU
â€¢ VXEMHFWV:KLOH7ULDO
UHPDLQVEOLQGHG VXEMHFWV
HQUROOLQJIURPDQ\SULRUWULDOEHVLGHV7ULDO  DUH
VFKHGXOHGWRKDYHPRQWKO\KHSDWLFPRQLWRULQJIRUWKHILUVWPRQWKVRIWKLVWULDO$IWHUWKDWIROORZLQJ
WKHDSSURYDORIWKHPHGLFDO
PRQLWRUKHSDWLFPRQLWRULQJZLOOWDNHSODFHHYHU\ PRQWKV6XEMHFWVHQUROOLQJIURP7ULDOZLOOKDYHKHSDWLF
PRQLWRULQJHYHU\PRQWKV$OO
7ULDOVXEMHFWVZKRDUHHOLJLEOHIRUWKLVWULDOZLOOLQLWLDOO\EHVFKHGXOHGWRKDYHWULDO YLVLWVDQGKHSDWLFPRQLWRULQJPRQWKO\IRUWKHILUVW PRQWKVWKHQHYHU\
PRQWKVWKHUHDIWHUEHFDXVHWKHLU
WROYDSWDQH[SRVXUHFDQQRWEHGHWHUPLQHGVLQFH7ULDOLVDGRXEOHEOLQGWULDO2QFHXQEOLQGLQJRFFXUVLWFDQEHGHWHUPLQHGZKLFKVXEMHFWV
UHFHLYHGWROYDSWDQLQ
7ULDO7KHVHVXEMHFWVPD\KDYHWKHLUWULDO YLVLWVKHSDWLFWUDQVDPLQDVHPRQLWRULQJFKDQJHGWRHYHU\ PRQWKVVRRQHUDVWKHLU
SUHYLRXVWROYDSWDQH[SRVXUHLQ
7ULDOFDQFRXQWWRZDUGVWKHPRQWKWKUHVKROG
(QUROOPHQWLQWKLVWULDOZLOOEH
FORVHGZKHQWKHODVWHOLJLEOHVXEMHFWIURP7ULDO
HQUROOVLQWKLVWULDO
7KHGXUDWLRQRIWKLV WULDOLVSODQQHG
WRFRQWLQXH
â€¢8QWLOWKHODVWVXEMHFW IURP
7ULDO FRPSOHWHV
 PRQWKVRIWROYDSWDQ
WUHDWPHQWLQWKLVWULDO
â€¢6XEMHFWVHQUROOLQJIURP
RWKHUWULDOVZLOOFRQFOXGHWKHLUSDUWLFLSDWLRQLQWKLVWULDORQFHWROYDSWDQ
EHFRPHVDYDLODEOH
WKURXJKURXWLQHSUHVFULSWLRQRUWKURXJKD

8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 80 06 Ma rch 2015Location Old Text Updated Text
Trial 156-13-210 subjects 
may opt to conclude their 
participation in this trial 
if tolvaptan becom es 
available before they 
complete 18 months of 
treatm ent in this trial 
Section 3.1.1, Figure 
3.1-1See previous Figure at the end of 
Appendix 5.See previous Figure at the end of 
Appendix 5
Section 3.2 Treatments Follow ing consent, and once subjects 
have satisfied all of the inclusion 
criteria and none of the exclusion 
criteria, subjects w ill be assigned a 
new subject number and administered 
tolvaptan at a split -dose of 45/15 mg.  
Subjects will be titrated up to 
60/30 mg and 90/30 mg according to 
subject tolerability.  Down titration to 
30/15 mg and 15/15 mg is also 
permitted at the discretion of the 
medical monitor and individual 
subject tolerability.
All subjects will be administered 
tolvaptan tablets in a daily split-dose, 
once upon awakening and another 
approximately 8 to 9 hours later. The 
exact time of dosing may be adjusted 
based on w ake/sleep habits (eg, 
standard 8 AM and 5 PM may be 
switched to 10 PM and 7 AM if 
working a night shift). How ever, 
dosing times should be consistent for 
each individualâ€™s daily dose to 
maximize receptor suppression. 
Doses will be expressed as early 
dose/late dose (eg, 60/30 mg).
While taking tolvaptan, all subjects 
should be instructed to ingest fluids in 
anticipation of, or at the first sign of 
thirst in order to avoid excessive 
thirst or dehydration.  Additionally, 
subjects should ingest 1 to 2 cups of 
water before bedtime regardless of 
perceived thirst and replenish fluids 
overnight with each episode of 
nocturia.The dose regimens to be used in 
this trial are 15/15 m g, 30/15 m g, 
45/15 mg, 60/30 m g, and 90/30 mg.
Follow ing consent, and once 
subjects have satisfied all of the 
inclusion criteria and none of the 
exclusion criteria, subjects will 
retain their subject number 
assig ned from their previous trial.  
Subjects will receive open -label 
tolvaptan for the duration of the 
trial. All subjects w ill be 
administered tolvaptan tablets in a 
daily split -dose, once upon 
awakening and another 
approximately 8 to 9 hours later 
(twice da ily dosing).  The exact time 
of dosing may be adjusted based on 
wake/sleep habits (eg, standard 8 
AM and 5 PM may be switched to 
10 PM and 7 AM if working a night 
shift).  How ever, dosing times 
should be consistent for each 
individualâ€™s daily dose to maxim ize 
receptor suppression.  Doses will be 
record edas early dose/late dose (eg, 
60/30 mg). 
A subject â€™s starting dose in this 
trial will be dependent on thetrial 
in which they were previously 
enrolled:
ï‚·156-13-210- initiated on 
tolvaptan at a split -dose of 
45/15 m g with upward 
titration every 3 to 4 days to 
60/30 m g or 90/30 m g per day 
according to tolerability
ï‚·156-08-271- will retain the last 
dose level from  271 and start 
at the sam e dose in this trial 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
81
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 81 06 Ma rch 2015Location Old Text Updated Text
ï‚·Prior tolvaptan trials -
initiated on tolvaptan at a
split-dose of 45/15 m g with 
upward titration every 3 to 
4days to 60/30 m g or 90/30 
mg per day according to 
tolerability
Down titration to 30/15 mg and 
15/15 mg is also permitted at the 
discretion of the investigator 
according to subject tolerability 
with medical monitor notification .  
Further down titration to 30 or 
15mg once daily may be allowed 
only for m etabolic drug -drug 
interaction and requires medical 
monitor approval.
For subjects m oving from  the 
156-13-210 trial and requiring 
tolvaptan titration itwill be
conducted in the following way: 
Subjects will be instructed to take 
tolvaptan starting at a split dose of 
45/15 mg (as 3 tablets upon 
waking and 1 tablet approximately 
8to9hours later) and to titrate up 
every 3 to 4 days; first to 60/30 mg, 
then up to the m aximum dose of 
90/30 m g.  Titration will be 
accom plished by increasing the 
number of tablets/dose and /or 
switching from  15 m g tablets to 
30mg tablets.  Prior to each 
upward titration, the subjectâ€™s 
tolerability to the current dose will 
be assessed by asking, â€œCould you 
tolerate this dose of trial 
medication for the rest of your 
life?â€ Subjects will continue in the 
trialwith the regim en to which 
tolerability was established.
While taking tolvaptan, all subjects 
should be instructed to ingest fluids 
in anticipation of, or at the first sign 
of thirst in order to avoid excessive 
thirst or dehydration.  Additionally, 
subjects should ingest 1 to 2 cups of 
water before bedtime regardless of 
perceived thirst and replenish fluids 
overnight with each episode of 
nocturia.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
82
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
7DEOH7ULDO
7UHDWPHQWV3UHYLRXV7DEOHLVDWWKHHQGRI
$SSHQGL[8SGDWHG7DEOHZLWKWUDFNHGFKDQJHV
LVDWWKHHQGRI $SSHQGL[
6HFWLRQ'RVLQJ
ZLWK&<3$0RGHUDWH,QKLELWRUV)RUVXEMHFWVZKRUHTXLUHGRVLQJZLWK
DPRGHUDWHLQKLELWRULQLWLDOWROYDSWDQUHGXFWLRQVDVVKRZQEHORZVKRXOGEHWULHGZLWKIXUWKHUGRVHUHGXFWLRQVRULQWHUUXSWLRQDVQHFHVVDU\IRUWROHUDELOLW\
â€¢PJWRPJ
â€¢PJWRPJ
â€¢PJWRPJ
â€¢PJWRPJRQFHGDLO\
â€¢PJWRPJRQFHGDLO\)RUVXEMHFWVZKRUHTXLUHGRVLQJZLWK
DPRGHUDWHLQKLELWRULQLWLDOWROYDSWDQUHGXFWLRQVDVVKRZQEHORZVKRXOGEHWULHGZLWKIXUWKHUGRVHUHGXFWLRQVRULQWHUUXSWLRQDVQHFHVVDU\IRUWROHUDELOLW\
â€¢PJWRPJ
â€¢PJWRPJ
â€¢PJWRPJ
â€¢PJWRPJRQFHGDLO\
â€¢PJWRPJRQFHGDLO\
$SDUWLDOOLVWRIVWURQJDQG
PRGHUDWH &<3$LQKLELWRUVFDQEHIRXQGLQ6HFWLRQ
6HFWLRQ7ULDO
3RSXODWLRQ7KLVWULDOZLOOLQFOXGHXSWR
VXEMHFWVRYHUWKHDJHRI\HDUVZLWK$'3.'GLDJQRVHGE\3HL5DYLQH
FULWHULD
PRGLILHGE\PDJQHWLF
UHVRQDQFHLPDJLQJ>05,@5HQDOIXQFWLRQZLOOEHDVVHVVHGGXULQJVFUHHQLQJXVLQJKLVWRULFDOODERUDWRU\YDOXHVIRUVHUXPFUHDWLQLQH
OHYHOVWRFDOFXODWHWKHHVWLPDWHG
JORPHUXODUILOWUDWLRQUDWHH*)57KHH*)5YDOXHVZLOOEHHVWLPDWHGEDVHGRQWKH&KURQLF.LGQH\'LVHDVHÂ±(SLGHPLRORJ\&.'(3,IRUPXOD
7KLVWULDOZLOOLQFOXGH
DSSUR[LPDWHO\ VXEMHFWVRYHU
WKHDJHRI \HDUVZLWK$'3.'
GLDJQRVHGE\3HL5DYLQHFULWHULD 
PRGLILHGE\PDJQHWLFUHVRQDQFHLPDJLQJ>05,@ ZKRFRPSOHWHGRU
SDUWLFLSDWHGLQDSULRUWROYDSWDQ
WULDO
7DEOH,QFO XVLRQ
&ULWHULD3UHYLRXV7DEOHLVDWWKHHQGRI
$SSHQGL[8SGDWHG7DEOHZLWKWUDFNHGFKDQJHV
LVDWWKHHQGRI$SSHQGL[
6HFWLRQ6DIH W\
(QGSRLQWV,QWHUUXSWLRQRISURWRFROVSHFLILHG
WKHUDSLHVIRUK\SHUQDWUHPLDRU
K\SRQDWUHPLD(QGSRLQWGHOHWHG



6HFWLRQ
([SORUDWRU\(QGSRLQWV 











8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W














6HFWLRQ0HDVXUHV
WR0LQLPL]H$YRLG%LDVROGWH[WVHFWLRQQXPEHUZDV$OOEORRGDQGXULQHFKHPLVWU\ZLOOEH
DQDO\]HGDQGUHSRUWHGE\DORFDOODERUDWRU\$OOEORRGDQGXULQHFKHPLVWU\ZLOO
EHDQDO\]HGDQGUHSRUWHGE\DFHQWUDOODERUDWRU\
6HFWLRQ
7DEOH 6FKHGXOH
RI$VVHVVPHQWV6HHSUHYLRXVWDEOHDWWKHHQGRI
$SSHQGL[6HHUHYLVHG7DEOHDWWKHHQGRI
$SSHQGL[ 
7KHFKDQJHVPDGHLQFOXGH6FUHHQLQJFKDQJHGIURPWR GD\V/DQJXDJHRXWOLQLQJDVVHVVPHQWVEDVHGRQVXEMHFWVÂ¶SUHYLRXVWULDO
H[SDQGHG
&HQWUDOUDWKHUWKDQORFDOODERUDWRU\ZLOOEHXVHG

+HSDWLWLVWHVWLQJZRUGLQJDGGHG
6HFWLRQ6FUHHQLQJROGWH[W
6HFWLRQ6FUHHQLQJGD\VWRGD\VSULRUWR
%DVHOLQH
6FUHHQLQJIRUHOLJLELOLW\LVUHTXLUHG
IRUDOOVXEMHFWV7KHVFUHHQLQJDQGEDVHOLQHYLVLWVPD\EHFRPELQHGZLWKWKH(R7[YLVLWIURPWKHSUHYLRXVSURWRFROZLWKDOOUHTXLUHGDVVHVVPHQWV
IURPHDFKYLVLWRQO\SHUIRUPHGRQFH
5HTXLUHGDVVHVVPHQWVDUHDVIROORZV
 2EWDLQVXEMHFWFRQVHQW
 'HWHUPLQHVXEMHFWHOLJLELOLW\
WKURXJKLQFOXVLRQH[FOXVLRQ
FULWHULD
 5HFRUGGHPRJUDSKLF
LQIRUPDWLRQDQGSULRUWULDOLGHQWLILHUVVFUHHQLQJ6FUHHQLQJ GD\VWRGD\SULRU
WR%DVHOLQH
6FUHHQLQJIRUHOLJLELOLW\LVUHTXLUHG
IRUDOOVXEMHFWV 7KHVFUHHQLQJDQGEDVHOLQHYLVLWVPD\EHFRPELQHGZLWKWKHODVWYLVLWIURPWKHSUHYLRXV
SURWRFROZLWKDOOUHTXLUHG
DVVHVVPHQWVIURPHDFKYLVLWRQO\
SHUIRUPHGRQFH ,QVRPHFDVHVLID
VXEMHFWHQUROOVLQWKLVW ULDOIURPD
SULRU WROYDSWDQWULDOWKHHQGRIWULDO YLVLWIRUWKDWWULDODQGWKHVFUHHQLQJYLVLWIRUWKLVRQHPD\
RFFXUVLPXOWDQHRXVO\ 5HTXLUHG
DVVHVVPHQWVDUHDVIROORZV
 2EWDLQVXEMHFWFRQVHQW
 'HWHUPLQHVXEMHFW
HOLJLELOLW\WKURXJK
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 84 06 Ma rch 2015Location Old Text Updated Text
identification [ID], subject 
ID, site ID)
4.Record medical/ADPKD 
history using prior trial data
5.Revie w dietary 
recommendations and 
compliance
6.Record vital signs (post -void 
weight and seated heart rate) 
and in -clinic calibrated 
blood pressure (BP) 
measurement.  Record 
height
7.Collect blood for serum 
chemistry, liver function 
panel (ALT, AST, bilirubin, 
total (BT), bilirubin (direct), 
and alkaline phosphatase), 
serum sodium, creatinine 
and hematology and 
coagulation .  Hepatitis 
testing is optional
8.Collect urine for urinalysis, 
urine osmolality (optional), 
and urine specific gravity
9.Perform urine pregnancy test 
onwomen of childbearing 
potential (WOCBP).  If 
positive, a follow -up serum 
test will be performed
10.Conduct full physical 
examination
11.Enter subject into interactive 
response technology (IRT) 
including prior trial 
identifier/information 
(protocol number, subje ct 
ID), confirmed dose regimen 
and scheduled date of next 
visit
12.Assess AEs reported as 
ongoing or resolved from inclusion/exclusion criteria.
3.Record demographic 
information and prior trial 
identifiers (screening 
identification [ID], subject 
ID, site ID) , prior 
tolvaptan ADPKD trial 
protocol number).
4.Record medical/ADPKD 
history using prior trial 
data.
5.Revie w dietary 
recommendations and
compliance.
6.Record vital signs (post -
void w eight and seated 
heart rate) and in -clinic 
calibrated blood pressure 
(BP) measurement.  Record 
height .
7.Collect blood for serum 
chemistry, liver function 
panel (ALT, AST, bilirubin, 
total [BT], bilirubin 
[direct], and alkaline 
phosphatase), serum 
sodium, creatinine, and 
hematology and 
coagulation .  Hepatitis 
testing is optional .  If 
hepatitis testing is 
perform ed, then both pre -
and post -counseling 
activities relating to 
hepatitis testing are to be 
carried out based on local 
requirements and best 
practices.  
8.Collect urine for urinalysis, 
urine osmolality (optional), 
and urine specific gravity .
9.Perform urine pregnancy 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
85
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
SULRUWULDOWRGHWHUPLQHHQWU\
DVPHGLFDOKLVWRU\RU
RQJRLQJHYHQWIRUWKLVWULDOWHVWRQZRPHQRI
FKLOGEHDULQJSRWHQWLDO
:2&%3,ISRVLWLYHDIROORZXSVHUXPWHVWZLOOEHSHUIRUPHG
 &RQGXFWIXOOSK\VLFDO
H[DPLQDWLRQ
 (QWHUVXEMHFWLQWR
LQWHUDFWLYHUHVSRQVHWHFKQRORJ\,57LQFOXGLQJ
SULRUWULDO
LGHQWLILHULQIRUPDWLRQSURWRFROQXPEHUVXEMHFW,'FRQILUPHGGRVHUHJLPHQ DQGVFKHGXOHG
GDWHRIQH[WYLVLW
 $VVHVV$(VUHSRUWHGDV
RQJRLQJRUUHVROYHGIURPSULRUWULDOWRGHWHUPLQH
HQWU\DVPHGLFDOKLVWRU\RU
RQJRLQJHYHQWIRUWKLVWULDO
5HFRUGRQJRLQJ
FRQFRPLWDQWPHGLFDWLRQV7KLVPD\EHGRQHLIWKH
VFUHHQLQJYLVLWRFFXUV
VLPXOWDQHRXVO\ZLWKWKHODVWYLVLWIURPDSUHYLRXVWROYDSWDQWULDO
6HFWLRQ
%DVHOLQHROGWH[W
6HFWLRQ7KHEDVHOLQHYLVLWLVWKHEHJLQQLQJRI
WKHWUHDWPHQWSHULRGLQWKLVWULDO$W
WKHEDVHOLQHYLVLWVXEMHFWVZ LOOEH
DVVLJQHGDQHZVXEMHFWQXPEHUDQGWKHIROORZLQJDVVHVVPHQWVDQG
SURFHGXUHVZLOOEHSHUIRUPHG
 5HYLHZLQFOXVLRQH[FOXVLRQ
FULWHULD
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQG
FRPSOLDQFH
 7KHEDVHOLQHYLVLWLVWKHEHJLQQLQJRI
WKHWUHDWPHQWSHULRGLQWKLVWULDO$W
WKHEDVHOLQHYLVLWVXEMHFWVZLOOUHWDLQWKH VXEMHFWQXPEHU DVVLJQHG
LQWKH SUHYLRXVWROYDSWDQWULDO DQG
WKHIROORZLQJDVVHVVPHQWVDQG
SURFHGXUHVZLOOEHSHUIRUPHG
 5HYLHZLQFOXVLRQH[FOXVLRQ
FULWHULD
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQG
FRPSOLDQFH
 
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
 5HFRUGYLWDOVLJQVSRVWYRLG
ZHLJKWVHDWHGKHDUWUDWHDQG
FDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 'LVSHQVHDWKRPH XULQH
SUHJQDQF\WHVWNLWVWR
:2&%3WREHXVHGLIDPHQVWUXDOSHULRGLVPLVVHGEHIRUHWKHQH[WYLVLW
 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EH
SHUIRUPHGWRIRFXVRQ3.'UHODWHGVLJQVDQGV\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QUROOVXEMHFWLQWRWULDO
WKURXJK,57DQGREWDLQ,03
 'LVSHQVH,03VXIILFLHQWIRU
PRQWKRIGRVLQJ
 3URYLGHVXEMHFWZLWKGRVLQJ
LQVWUXFWLRQVWREHJLQRQWKHIROORZLQJGD\
 5HFRUGRQJRLQJFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V
 5HFRUGYLWDOVLJQVSRVW
YRLGZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 'LVSHQVHDWKRPHXULQH
SUHJQDQF\WHVWNLWVWR:2&%3WREHXVHGLIDPHQVWUXDOSHULRGLVPLVVHGEHIRUHWKHQH[WYLVLW
 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ3.'UHODWHGVLJQVDQGV\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QUROOVXEMHFWLQWRWULDO
WKURXJK,57DQGREWDLQ
,03
 'LVSHQVH,03VXIILFLHQW
IRUPRQWK RU PRQWKV RI
GRVLQJEDVHGRQVXEMHFWÂ¶V
UHTXLUHGYLVLWVFKHGXOH IRU
KHSDWLFHYDOXDWLRQDV
HLWKHUPRQWKO\RUHYHU\
 PRQWKV 
 3URYLGHVXEMHFWZLWKGRVLQJ
LQVWUXFWLRQVWREHJLQRQWKH
IROORZLQJGD\
 5HFRUGRQJRLQJ
FRQFRPLWDQWPHGLFDWLRQV
 $VVHVV$(V
6HFWLRQ
0RQWKO\9LVLWROGWH[W6HFWLRQ0RQWKO\9LVLWÂ“GD\V
6XEMHFWVZLOOUHWXUQIRUDPRQWKO\
YLVLWWRDVVHVVVDIHW\DQGWROHUDELOLW\RI,03DQGWRPRQLWRUOLYHUIXQFWLRQ6XEMHFWVHQUROOLQJIURPWKHGRXEOH
EOLQG7ULDOZLOOKDYH
PRQWKO\$/7OHYHODVVHVVPHQWVIRUWKHILUVWPRQWKVZKLOHWUHDWPHQWFRGHIURP7ULDO UHPDLQV0RQWKO\9LVLWÂ“ GD\V
7KHIROORZLQJV XEMHFWVZLOOUHWXUQ
IRUDPRQWKO\YLVLWWRDVVHVVVDIHW\DQGWROHUDELOLW\RI,03DQGWRPRQLWRUOLYHUIXQFWLRQ
â€¢6XEMHFWVHQUROOLQJIURPWKH
GRXEOHEOLQG7ULDOZLOOKDYHPRQWKO\ WULDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
EOLQGHGWRHQVXUHWKDWWKH\KDYH
DGHTXDWHVDIHW\PRQLWRULQJGXULQJ
WKLVSHULRGRIVXVFHSWLELOLW\7KHIROORZLQJZLOOEHDVVHVVHG
 &ROOHFWEORRGIRUVRGLXP
DQGFUHDWLQLQH
 &ROOHFWEORRGIRU$/7IRU
WKHILUVWPRQWKVRIWROYDSWDQWUHDWPHQWLQVXEMHFWVHQUROOLQJIURP7ULDO
,IDWDQ\WLPH
ZLWKLQWKHILUVWPRQWKVRIWROYDSWDQWUHDWPHQWWKH$/7HOHYDWHVWR![8/1WR[8/1$/7ZLOOEH
PRQLWRUHGPRQWKO\IRUDQ
DGGLWLRQDOPRQWKVEH\RQGWKHGDWHRIHOHYDWLRQWRHQVXUHWKDWWKHOHYHOLVVWDEOH
DQGGRHVQRWH[FHHGWKLV
WKUHVKROG,IDWDQ\WLPHWKH
$/7HOHYDWHV â‰¥[8/1D
IXOOOLYHUIXQFWLRQSDQHOLV
UHTXLUHG$/7$67%7
DQGDONDOLQHSKRVSKDWDVHZLWKLQKRXUVRIWKHVLWHEHLQJDZDUHRIWKLVUHVXOW






 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ3.'
UHODWHGVLJQVDQGV\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QWHUVXEMHFWVWDWXVLQ,57
LQFOXGLQJDQ\GRVHUHJLPHQYLVLWV$/7OHYHO
DVVHVVPHQWVIRUWKHILUVW
 PRQWKVZKLOHWUHDWPHQWFRGHIURP7ULDOUHPDLQVEOLQGHGWRHQVXUH
WKDWWKH\KDYHDGHTXDWH
VDIHW\PRQLWRULQJGXULQJWKLVSHULRGRIVXVFHSWLELOLW\
2QFHXQEOLQGLQJRFFXUVLW
FDQEHGHWHUPLQHGZKLFK
VXEMHFWVUHFHLYHG
WROYDSWDQLQ7ULDO 7KHVHVXEMHFWVPD\KDYHWKHLUWULDOYLVLWVKHSDWLF
WUDQVDPLQDVHPRQLWRULQJ
FKDQJHWRHYHU\PRQWKVVRRQHUDVWKHLUSUHYLRXVWROYDSWDQH[SRVXUHLQ
7ULDOFDQ
FRXQWWRZDUGVWKHPRQWKWKUHVKROG7KHLQYHVWLJDWRUZLOOQHHGWRGLVFXVVWKHFKDQJHLQ
IUHTXHQF\ZLWKWKH
PHGLFDOPRQLWRUEHIRUHLQVWLWXWLQJWKHFKDQJH
â€¢6XEMHFWVIURPSULRU
WROYDSWDQWULDOVRWKHUWKDQ
7ULDOZLOOKDYHPRQWKO\WULDOYLVLWV$/7OHYHODVVHVVPHQWVIRUWKHILUVWPRQWKV$IWHU
WKDWWKHWULDOYLVLWV$/7
PRQLWRULQJZLOOEHFRQGXFWHGHYHU\PRQWKVDIWHUWKHFKDQJHLQ
IUHTXHQF\LVFRQILUPHG
ZLWKWKHPHGLFDOPRQLWRU
â€¢6XEMHFWVHQUROOLQJIURP
WKHRSHQODEHO7ULDOZKR
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
FKDQJHVDQGREWDLQ,03
DVVLJQPHQW
 &ROOHFWDQGUHFRQFLOH
UHWXUQHG,03
 'LVSHQVH,03
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(VKDYHJUHDWHUWKDQ
 PRQWKVRIFXPXODWLYH
H[SRVXUHWRWROYDSWDQZLOOKDYHWULDOYLVLWV$/7PRQLWRULQJFRQGXFWHG
HYHU\ PRQWKV
7KHIROORZLQJ DVVHVVPHQWV ZLOOEH
FRPSOHWHG 
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQG
FRPSOLDQFH
 
 5HFRUGYLWDOVLJQVSRVW
YRLGZHLJKWVHDWHGKHDUW
UDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRG IRUFHQWUDO
ODERUDWRU\DVVHVVPHQWV IRU
VHUXPVRGLXPVHUXP
FUHDWLQLQH DQG$/7VHH
6HFWLRQ 
 









 8ULQDO\VLVXULQH
RVPRODOLW\RSWLRQDO
XULQHVSHFLILFJUDYLW\
 3HUIRUPXULQHSUHJQDQF\
WHVWRQ:2&%3HYHU\
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
PRQWKV,ISRVLWLYHD
IROORZXSVHUXPWHVWZLOO
EHSHUIRUPHG
 'LVSHQVHDWKRPHXULQH
SUHJQDQF\WHVWNLWVWR
:2&%3DVUHTXLUHG
 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ3.'UHODWHGVLJQVDQG
V\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QWHUVXEMHFWVWDWXVLQ,57
LQFOXGLQJDQ\GRVHUHJLPHQ
FKDQJHVDQGREWDLQ,03
DVVLJQPHQW
 &ROOHFWDQGUHFRQFLOH
UHWXUQHG,03 DVVHVV
FRPSOLDQFH
 'LVSHQVH,03 EDVHGRQ
VXEMHFWÂ¶VUHTXLUHGYLVLW
VFKHGXOH DQGSURYLGHVXEMHFWZLWK
GRVLQJLQVWUXFWLRQV
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V
6HFWLRQ(YHU\
 0RQWKV(YHU\ 0RQWKVÂ“ GD\V
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH

 5HFRUGYLWDOVLJQVSRVWYRLG
ZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUORFDO
VWDQGDUGRIFDUHODERUDWRU\DVVHVVPHQWV(YHU\ 0RQWKVÂ“ GD\V
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH

 5HFRUGYLWDOVLJQVSRVW
YRLGZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRU FHQWUDO
ODERUDWRU\DVVHVVPHQWV
VHUXPVRGLXPVHUXP
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
 8ULQDO\VLVXULQHRVPRODOLW\
RSWLRQDOXULQHVSHFLILF
JUDYLW\
 3HUIRUPXULQHSUHJQDQF\WHVW
RQ:2&%3,ISRVLWLYHD
IROORZXSVHUXPWHVWZLOOEH
SHUIRUPHG
 'LVSHQVHDWKRPHXULQH
SUHJQDQF\WHVWNLWVWR:2&%3DVUHTXLUHG
 &ROOHFWEORRGIRU$/7,IDW
DQ\WLPHWKH$/7HOHYDWHVWR![8/1WR[8/1$/7ZLOOEHPRQLWRUHGPRQWKO\IRUDQDGGLWLRQDO
PRQWKVEH\RQGWKHGDWHRI
HOHYDWLRQWRHQVXUHWKDWWKHOHYHOLVVWDEOHDQGGRHVQRWH[FHHGWKLVWKUHVKROG,IDW
DQ\WLPHWKH$/7HOHYDWHV â‰¥
[8/1DIXOO OLYHUIXQFWLRQ
SDQHOLVUHTXLUHG$/7$67%7DQGDONDOLQH
SKRVSKDWDVHZLWKLQ
KRXUVRIWKHVLWHEHLQJDZDUHRIWKLVUHVXOW 




 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(VFUHDWLQLQH$/7VHH
6HFWLRQ 
 


 8ULQDO\VLV XULQHRVPRODOLW\
RSWLRQDOXULQHVSHFLILFJUDYLW\
 3HUIRUPXULQHSUHJQDQF\
WHVWRQ:2&%3,I
SRVLWLYHDIROORZXSVHUXPWHVWZLOOEHSHUIRUPHG
 'LVSHQVHDWKRPHXULQH
SUHJQDQF\WHVWNLWVWR
:2&%3DVUHTXLUHG
 






 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ3.'UHODWHGVLJQVDQG
V\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QWHUVXEMHFWVWDWXVLQ
,57LQFOXGLQJDQ\GRVH
UHJLPHQFKDQJHVDQG
REWDLQ,03DVVLJQPHQW
 &ROOHFWDQGUHFRQFLOH
UHWXUQHG,03DVVHVV
FRPSOLDQFH
 (QWHUVXEMHFWVWDWXVLQ
,57LQFOXGLQJDQ\GRVHUHJLPHQFKDQJHV
 'LVSHQVH,03EDVHGRQ
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
VXEMHFWÂ¶VYLVLWVFKHGXOH
DQGSURYLGHVXEMHFWZLWK
GRVLQJLQVWUXFWLRQV
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V
6HFWLRQ (DUO\
7HUPLQDWLRQ(QGRI7UHDWPHQWROGWH[W6HFWLRQ(DUO\7HUPLQDWLRQ(QGRI7UHDWPHQW
  PRQWKV
$WWKHHDUO\WHUPLQDWLRQHQGRI
WUHDWPHQWYLVLWWKHIROORZLQJZLOOEH
DVVHVVHG
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH

 5HFRUGYLWDOVLJQVSRVWYRLG
ZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUVHUXP
FKHPLVWU\FUHDWLQLQHVHUXPVRGLXPDQGKHPDWRORJ\DQGFRDJXODWLRQ
 &ROOHFWEORRGIRU$/7,I
WKH$/7HOHYDWHV â‰¥[8/1
DIXOOOLYHUIXQFWLRQSDQHOLV
UHTXLUHG$/7$67%7
DQGDONDOLQHSKRVSKDWDVH
ZLWKLQKRXUVRIWKHVLWHEHLQJDZDUHRIWKLVUHVXOW






 &ROOHFWXULQHIRUXULQDO\VLV
XULQHRVPRODOLW\RSWLRQDOXULQHVSHFLILFJUDYLW\(DUO\7HUPLQDWLRQ(QGRI7UHDWPHQW
 GD\V
$WWKHHDUO\WHUPLQDWLRQHQGRI
WUHDWPHQWYLVLWWKHIROORZLQJZLOOEH
DVVHVVHG
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH

 5HFRUGYLWDOVLJQVSRVW
YRLGZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUVHUXP
FKHPLVWU\ VHUXP
FUHDWLQLQH $/7VHUXP
VRGLXPDQGKHPDWRORJ\DQG
FRDJXODWLRQ
 






 

 &ROOHFWXULQHIRUXULQDO\VLV
XULQHRVPRODOLW\RSWLRQDO
XULQHVSHFLILFJUDYLW\
 3HUIRUPXULQHSUHJQDQF\
WHVWRQ:2&%3,I
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI CCI
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
 3HUIRUPXULQHSUHJQDQF\
WHVWRQ:2&%3,ISRVLWLYH
DIROORZXSVHUXPWHVWZLOOEHSHUIRUPHG
 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EH
SHUIRUPHGWRIRFXVRQ3.'UHODWHGVLJQVDQGV\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QWHUVXEMHFWVWDWXVLQ,57
LQFOXGLQJDQ\GRVHUHJLPHQFKDQJHVVLQFHWKHSUHYLRXVHQWU\
 &ROOHFWDQGUHFRQFLOH
UHWXUQHG,03
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(VSRVLWLYHDIROORZXSVHUXP
WHVWZLOOEHSHUIRUPHG
 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ
3.'UHODWHGVLJQVDQG
V\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QWHUVXEMHFWVWDWXVLQ,57
LQFOXGLQJDQ\GRVHUHJLPHQ
FKDQJHVVLQFHWKHSUHYLRXVHQWU\
 &ROOHFWDQGUHFRQFLOH
UHWXUQHG,03 DVVHVV
FRPSOLDQFH
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V
6HFWLRQ
)ROORZXS9LVLW)ROORZXS9LVLW'D\VGD\V GD\)ROORZXS9LVLWGD\V
6HFWLRQ
)ROORZXS9LVLWROGWH[W6HFWLRQ 5HFRUGYLWDOVLJQVSRVWYRLG
ZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUFUHDWLQLQH
 &ROOHFWEORRGIRU$/7,I
WKH$/7HOHYDWHV â‰¥[8/1
DIXOOOLYHUIXQFWLRQSDQHOLV
UHTXLUHG$/7$67%7
DQGDONDOLQHSKRVSKDWDVHZLWKLQKRXUVRIWKHVLWHEHLQJDZDUHRIWKLVUHVXOW






 3HUIRUPXULQHSUHJQDQF\WHVW 5HFRUGYLWDOVLJQVSRVW
YRLGZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRU VHUXP
FUHDWLQLQH DQG$/7
 






 3HUIRUPXULQHSUHJQDQF\
WHVWRQ:2&%3,ISRVLWLYHDIROORZXSVHUXPWHVWZLOOEHSHUIRUPHG
 (QWHUVXEMHFWVWDWXVLQ
,57
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
RQ:2&%3,ISRVLWLYHD
IROORZXSVHUXPWHVWZLOOEH
SHUIRUPHG
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V
6HFWLRQ&OLQLFDO
/DERUDWRU\$VVHVVPHQWVROGWH[W6HFWLRQ,WLVSUHIHUDEOHWRFROOHFWWKHFOLQLFDO
ODERUDWRU\VDPSOHVIURPHDFKVXEMHFWDWDFRQVLVWHQWWLPHRIGD\WKURXJKRXWWKHWULDODQGWRUHFRPPHQGWKDWWKHVXEMHFWKDYHDVLPLODUGLHWDYRLGLQJ
YDULDWLRQLQSURWHLQLQWDNHHVSHFLDOO\
FRRNHGPHDWSURWHLQDQGH[HUFLVHSDWWHUQLQRUGHUWRUHGXFHYDULDELOLW\LQWKHVDPSOHVRYHUWLPH:KLOHVHUXPFUHDWLQLQHLVEHLQJFROOHFWHGSULPDULO\IRUVDIHW\
UHSRUWLQJSXUSRVHVLWLVDNH\
PHDVXUHLQWKHPDQDJHPHQWRISDWLHQWVZLWK$'3.' 




7KHUHIRUHJUHDW
FDUHVKRXOGEHWDNHQLQHQVXULQJWKHVHPHDVXUHPHQWVDUHFROOHFWHGDQGDQDO\]HGLQDVXQLIRUPDPDQQHUDV
SRVVLEOHSUHIHUDEO\XVLQJLVRWRSH
GLOXWLRQPDVVVSHFWURVFRS\,'06WUDFHDEOHPHWKRGRORJLHV
&OLQLFDOODERUDWRU\VDPSOHVZLOOEH
FROOHFWHGDWWKHIROORZLQJWLPHSRLQWV
6FUHHQLQJ+HPDWRORJ\DQG
FRDJXODWLRQSDQHOVHUXPFKHPLVWU\
SDQHOOLYHUIXQFWLRQSDQHO$67$/7DONDOLQHSKRVSKDWDVHELOLUXELQ
GLUHFW>%7@VHUXPVRGLXPXULQDO\VLV
SDQHOXULQHRVPRODOLW\RSWLRQDOXULQHVSHFLILFJUDYLW\XULQHSUHJQDQF\WHVW:2&%3DQGKHSDWLWLVRSWLRQDO
0RQWKO\YLVLWVÂ“GD\V$/7IRU
WKHILUVWPRQWKVLQVXEMHFWV&HQWUDOODERUDWRU\QRQIDVWLQJ
VHUXPODERUDWRU\WHVWVZLOOEH
SHUIRUPHG ,WLVSUHIHUDEOHWR
FROOHFWWKHFOLQLFDOODERUDWRU\
VDPSOHVIURPHDFKVXEMHFWDWD
FRQVLVWHQWWLPHRIGD\WKURXJKRXWWKHWULDODQGWRUHFRPPHQGWKDWWKHVXEMHFWKDYHDVLPLODUGLHWDYRLGLQJYDULDWLRQLQSURWHLQLQWDNHHVSHFLDOO\
FRRNHGPHDWSURWHLQDQGH[HUFLVH
SDWWHUQLQRUGHUWRUHGXFHYDULDELOLW\LQWKHVDPSOHVRYHUWLPH
:KLOHVHUXPFUHDWLQLQHLVEHLQJ
FROOHFWHGSULPDULO\IRUVDIHW\
UHSRUWLQJSXUSRVHVLWLVDNH\
PHDVXUHLQWKHPDQDJHPHQWRISDWLHQWVZLWK$'3.' 





7KHH*)5YDOXHVZLOOEH
FDOFXODWHGE\&.'(3,IURPWKH
FHQWUDOODERUDWRU\VHUXP
FUHDWLQLQHFRQFHQWUDWLRQVWDNHQGXULQJHYHU\WULDOYLVLW
&OLQLFDOODERUDWRU\VDPSOHVZLOOEH
FROOHFWHG DQGVHQWWRWKHFHQWUDO
ODERUDWRU\ DWWKHIROORZLQJWLPH
SRLQWV6FUHHQLQJ+HPDWRORJ\DQG
FRDJXODWLRQSDQHOVHUXPFKHPLVWU\
SDQHOOLYHUIXQFWLRQSDQHO$67
$/7DONDOLQHSKRVSKDWDVHELOLUXELQ
GLUHFW>%7@VHUXPVRGLXP VHUXP
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
HQUROOHGIURP7ULDODQG
VHUXPVRGLXPFUHDWLQLQHDOO
VXEMHFWV
(YHU\PRQWKV Â“GD\V$/7
DIWHUPRQWKVRIWUHDWPHQWLQ
VXEMHFWVHQUROOHGIURP
7ULDO DQGIRUDOOVXEMHFWV
HQUROOHGIURP7ULDOVWDQGDUGRIFDUHODERUDWRU\DVVHVVPHQWVXULQDO\VLVSDQHOXULQH
SUHJQDQF\WHVW:2&%3XULQH
RVPRODOLW\RSWLRQDODQGXULQHVSHFLILFJUDYLW\
(DUO\7HUPLQDWLRQ(QGRI7UHDWPHQW
 PRQWKV6HUXPFKHPLVWU\
SDQHOKHPDWRORJ\DQGFRDJXODWLRQ
SDQHO$/7FUHDWLQLQHVHUXPVRGLXPXULQDO\VLVSDQHOXULQHSUHJQDQF\WHVW:2&%3XULQH
RVPRODOLW\RSWLRQDODQGXULQH
VSHFLILFJUDYLW\
)ROORZXSYLVLWGD\V $/7
FUHDWLQLQHDQGXULQHSUHJQDQF\WHVW
:2&%3
Â«
,IOLYHUIXQFWLRQSDQHOVRGLXPDQGRUVHUXPFKHPLVWU\DVVHVVPHQWVDUHVFKHGXOHGDWWKHVDPHYLVLWDOOYDOXHVVKRXOGEHGHWHUPLQHGIURPWKHVDPH
EORRGVDPSOH8ULQHSUHJQDQF\
WHVWLQJZLOOEHSHUIRUPHGZLWKFRPPHUFLDOO\DYDLODEOHKLJKVHQVLWLYLW\NLWVVXSSOLHGWRWKHVXEMHFWE\WKHVLWHDFTXLUHGE\WKHVSRQVRUFUHDWLQLQH XULQDO\VLVSDQHOXULQH
RVPRODOLW\RSWLRQDOXULQHVSHFLILF
JUDYLW\XULQHSUHJQDQF\WHVW:2&%3DQGKHSDWLWLVRSWLRQDO
0RQWKO\YLVLWVÂ“GD\V$/7IRU
WKHILUVWPRQWKV IRUVXEMHFWV
HQUROOHGI URPRWKHUWROYDSWDQ
$'3.'WULDOVDQG
7ULDO ZKLOHWULDO
UHPDLQVEOLQGHG VHUXPVRGLXP
DQGVHUXP FUHDWLQLQHDOOVXEMHFWV
XULQDO\VLVXULQHRVPRODOLW\
RSWLRQDOXULQHVSHFLILFJUDYLW\DQGXULQHSUHJQDQF\WHVWHYHU\PRQWKVLQ:2&%3 

(YHU\PRQWKV Â“ GD\V$/7
DIWHU PRQWKVRIWUHDWPHQW IRU
VXEMHFWVHQUROOHGIURP RWKHU
$'3.'WROYDSWDQWULDOVRUIURP
7ULDO DIWHUWKH WULDOLV
XQEOLQGHG DQGIRUVXEMHFWVHQUROOHG
IURP7ULDO VHUXP
VRGLXPDQGVHUXPFUHDWLQLQH
XULQDO\VLVSDQHOXULQHSUHJQDQF\WHVW
:2&%3XULQHRVPRODOLW\RSWLRQDODQGXULQHVSHFLILFJUDYLW\

(DUO\7HUPLQDWLRQ(QGRI7UHDWPHQW
 GD\V6HUXPFKHPLVWU\SDQHO
KHPDWRORJ\DQGFRDJXODWLRQSDQHO
$/7VHUXPVRGLXPDQG VHUXP
FUHDWLQLQH 
XULQDO\VLVSDQHOXULQH
SUHJQDQF\WHVW:2&%3XULQHRVPRODOLW\RSWLRQDODQGXULQHVSHFLILFJUDYLW\
GD\)ROORZXSYLVLWGD\V
$/7VHUXPFUHDWLQLQHDQGXULQH
SUHJQDQF\WHVW:2&%3
Â«
,IOLYHUIXQFWLRQSDQHOVRGLXPDQGRUVHUXPFKHPLVWU\DVVHVVPHQWVDUHVFKHGXOHGDWWKHVDPHYLVLWDOO
YDOXHVVKRXOGEHGHWHUPLQHGIURP
WKHVDPHEORRGVDPSOH %ORRG
WHVWLQJIRUKHSDWLWLVZLOOEH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
C
CI
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 95 06 Ma rch 2015Location Old Text Updated Text
optional for all subjects.  Urine 
pregnancy testing will be performed 
with commercially available, high -
sensitivity kits supplied to the 
subject by the site (acquired by the 
sponsor).
Table 3.7.2.2 -, Clinical 
Laboratory 
AssessmentsPlease see original table at the end of 
Appendix 5,Please see revised tabl e at the end of 
Appendix 5,
Section 3.7.2.3, 
Physical Examination 
and Vital Signs (old 
text, Section 3.6.2.3)A full physical examination will be 
performed and documented at the 
screening visit although this may be 
combined with the EoTx visit from 
the pr evious trial.  At other visits, an 
optional directed physical 
examination may be performed to 
focus on ADPKD- related signs and 
symptoms.  In some geographic 
regions, more frequent subject visits 
may be the norm; however vital signs 
and clinically significant physical 
findings will be recorded as an 
unscheduled visit in the electronic 
case report form (eCRF) as 
applicable.  Any changes in 
medication or AEs will be recorded in 
the eCRF.
Body  weight will be taken post -void.  
It is preferable to use the same scale 
for each measurement.  Clinic scales 
should be calibrated at least yearly.  
The investigator or his/her appointed 
designee is primarily responsible to 
perform the physical examination.  ...A full physical examination will be 
performed and documented at the 
screening visit although this may be 
combined with the lastvisit from the 
previous trial.  At other visits, an 
optional directed physical 
examination may be performed to 
focus on ADPKD- related signs and 
symptoms.  In some geographic 
regions, more frequent subject visits 
may be the norm; however vital 
signs and clin ically significant 
physical findings will be recorded as 
an unscheduled visit in the electronic 
case report form (eCRF) as 
applicable.  Any changes in 
medication or AEs will be recorded 
in the eCRF.
Height will be measur ed only at 
screening.   Body  weight will be 
taken post -void.  It is preferable to 
use the same scale for each 
measurement.  Clinic scales should 
be calibrated at least yearly.  The 
investigator or his/her appointed 
designee is primarily responsible to 
perform the physical exami nation.  
...Section 3.7.2.4, 
Assessment of Liver 
Symptoms, Signs or 
Test Abnormalities (old 
text, Section 3.6.2.4)Testing for hepatic transaminase 
(ALT/AST), alkaline phosphatase, 
bilirubin direct, and BT w ill be 
performed during screening.  Subjects 
enrolling from the double -blind Trial 
156-13-210 w ill have monthly ALT 
assessments for the first 18 months 
while the treatment code from Trial 
156-13-210 remains blinded to ensure 
that all subjects have adequate safety 
monitoring during this period of 
suscep tibility.  Following the first 
18months, ALT assessments will be 
made quarterly for these subjects.  
Subjects enrolling from the open -Testing for hepatic transaminase 
(ALT/AST), alkaline phosphatase, 
bilirubin direct, and BT w ill be 
performed during screening .  
Subjects enrolling from the double -
blind Trial 1 56-13-210 w ill have 
monthly ALT assessments for the 
first 18 months while the treatment 
code from Trial 156 -13-210 remains 
blinded to ensure that all subjects 
have adequate safety monitoring 
during this period of susceptibility.  
Once unblinding occurs, it can be 
determined which subjects 
received tolvaptan in Trial 156-13-
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
96
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 96 06 Ma rch 2015Location Old Text Updated Text
label Trial 156 -08-271 will have 
quarterly ALT assessments since they 
will have already received tolvaptan 
for 2 years or more.  Management of 
liver abnormalities is discussed in the 
paragraphs below .210.  These subjects may have 
their trialvisits/hepatic 
transam inase monitoring change d
to every 3 months sooner as their 
previous tolvaptan exposure in 
Trial 156-13-210 can count 
toward s the 18 -month threshold.
Follow ing the first 18 months, ALT 
assessments will be made every 
3months forTrial 156-13-210 
subjects and for subjects from 
other tolvaptan ADPKD trials 
besides Trial 156-08-271.  Subjects 
enrolling from the open -label Trial 
156-08-271 who have tolvaptan 
exposure greater than 18 m onths 
will continue with ALT 
monitoring every 3 months.  
Subjects enrolling from  prior 
tolvaptan trials besides 
Trial 156-08-271 will have 
monthly ALT assessments for the 
first 18 months.   Upon reaching 
18months of exposure and after 
confirm ation from  the medical 
monitor, the frequency of ALT 
monitoring for these subjects will 
occur every 3 months.
ALT will also be assessed at the 
Early Termination/End of 
Treatm ent visit and at the 7-day
Follow -up visit.
Management of liver abnormalities 
is discussed in the paragraphs below .
Section 3.7.2.4.1, Liver 
Test Abnormalities and 
Interruption/
Discontinuation of 
Investigational 
Medicinal Product
(old text 
Section 3.6.2.4.1)The appearance of any suspicious 
symptom or sign should trigger 
prom pt testing of hepatic function (ie, 
within 72 hours).  Liver transaminase 
or bilirubin levels ï‚³2 Ã—ULN should 
prom pt immediate retesting within 
72hours and tolvaptan should be 
temporaril y interrupted.  Tolvaptan 
should not be resumed until 
monitoring indicates abnormalities 
have resolved, are stable or are not The appearance of any suspicious 
symptom or sign should tr igger 
prom pt testing of hepatic function 
(ie, w ithin 72 hours).  Local 
laboratory testing is acceptable, 
ideally with a concurrent central 
laboratory sam ple for 
confirm ation.
Any transam inase or bilirubin 
values which exceed 2 Ã— ULN 
should also prompt im mediate 
retesting within 72 hours.  While 
values rem ain in an abnormal 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
97
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
LQFUHDVLQJDQGWKHQRQO\ZLWKDQ
LQFUHDVHGIUHTXHQF\RIPRQLWRULQJ
6XEMHFWVZRXOGQRWW\SLFDOO\EH
DOORZHGWRUHVXPHWUHDWPHQWZLWKWROYDSWDQLIWKH\KDYH
â€¢WUDQVDPLQDVHOHYHOVULVH
DERYH Ã® 8/1
â€¢WUDQVDPLQDVHOHYHOVDUH
!  Ã® 8/1IRUPRUHWKDQ ZHHNVRU
â€¢FRQFXUUHQWHOHYDWLRQVRI
WUDQVDPLQDVH!  Ã® 8/1DQG
%7!  Ã® 8/1UDQJHWHVWLQJIUHTXHQF\VKRXOGEH
LQFUHDVHGWRDWOHDVWZHHNO\IRUWKH
ILUVWPRQWKJUDGXDOO\UHWXUQLQJWRPRQWKO\RUHYHU\WKUHHPRQWKVDVLQGLFDWHGE\WKHUHVXOWV
/LYHUWUDQVDPLQDVHRUELOLUXELQ
OHYHOVUHDFKLQJRUH[FHHGLQJ Ã®8/1WKDWKDYHDQXQFHUWDLQRUUDSLGO\LQFUHDVLQJWUDMHFWRU\VKRXOGSURPSWDWOHDVWWHP SRUDU\
,03LQWHUUXSWLRQ 7ROYDSWDQ
VKRXOGQRWEHUHVXPHGXQWLO
PRQLWRULQJLQGLFDWHVDEQRUPDOLWLHVKDYHUHVROYHGDUHVWDEOH RUDUHQRWUDSLGO\LQFUHDVLQJDQGWKHQRQO\
ZLWKDQLQFUHDVHGIUHTXHQF\RIPRQLWRULQJ
6XEMHFWVZRXOGQRWW\SLFDOO\EH
DOORZHGWRUHVXPHWUHDWPHQWZLWKWROYDSWDQLIWKH\KDYH
â€¢WUDQVDPLQDVHOHYHOVULVH
DERYH Ã® 8/1
â€¢WUDQVDPLQDVHOHYHOVDUH
!  Ã® 8/1 IRUPRUHWKDQ ZHHNVRU
â€¢FRQFXUUHQWHOHYDWLRQVRI
WUDQVDPLQDVH!  Ã® 8/1
DQG%7!  Ã® 8/1
1$










8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI CCI
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 98 06 Ma rch 2015Location Old Text Updated Text
Section 3.7.5, 
Treatment Interruption 
and DiscontinuationN/A In this trial, it is expected that 
subjects may possibly have one or 
more planned or unplanned 
treatment interruptions.  If a 
subjectâ€™s IMP treatment must be 
interrupted for medical or surgical 
reasons, liver test abnormalities, use 
of a prohibited medication, or other 
reasons (eg, hospital admission for 
an invasive procedure, a major 
medical condition, surgery, dental 
work, or a temporary situation that 
prevents subject compliance with the 
IMP administration schedule), the 
investigator should be notified as 
soon as possible and the reason for 
treatment interruption must be 
documented in the source documents 
and CRF.  If permissible, the 
subjectâ€™s IMP maybe resumed 
following approval by the medical 
monitor.
If IMP treatment is permanently 
discontinued ,the reason for 
discon tinuation must be recorded 
appropriately in the source document 
and in the CRF.
A subject who perm anently 
discontinues IMP treatment may
have the option to end trial
participation (complete the early 
termination visit) or to continue 
participation off IMP and complete 
ongoing trial assessments as per 
protocol or with a modified (ie, less 
frequent) schedule as outlined in 
Section 3.8.3 .
Section 3.8.1 3.7.1 Entire Trial or Treatment 
Arm(s)3.8.1 Entire Trial
Section 3.8.3, 
Individual Subject...  
All subjects have the right to 
withdraw at any time during 
treatment without prejudice.  The 
investigator can discontinue a 
subjectâ€™s participation in the trial at 
any time if medically necessary.  In 
addition, subjects meeting the 
following criteria must be w ithdrawn 
from the trial:
a) Occurrence of any AE, intercurrent ...
All subjects have the right to 
withdraw at any time during 
treatment without prejudice.  The 
investigator can discontinue a 
subjectâ€™s participation in the trial at 
any time if medically necessary.  It 
is preferred that subjects who 
perm anently discontinue IMP will 
have the option to continue 
participation off IMP with regular 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
99
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 99 06 Ma rch 2015Location Old Text Updated Text
illness, or abnormality in a laboratory 
assessment which, in the opinion of 
the investigator, w arrants the 
subjectâ€™s permanent withdrawal from 
the trial;
b) Treatment with a prohibited 
concomit ant medication other than 
the use of appropriate medications for 
the treatment of AEs under direction 
of the investigator;
c) Subject noncompliance, defined as 
refusal or inability to adhere to the 
trial schedule or procedures (see 
Section 3.12);
d) At the request of the subject, 
investigator, sponsor, or regulatory 
authority;
e) Subject becomes pregnant; or 
f) Subject is lost to follow -up.
The investigator will notify the 
sponsor prom ptly when a subject is 
withdrawn.scheduled visits or with a modified 
(ie, less frequent) schedule.  If 
subjects are unable or unwilling to 
complete the visits and procedures 
off IMP, the early 
term ination/EoTx visit should be 
completed.  The investigator may
continue to contact those who 
discontinue IMP through to the 
final com pletion date of the trial 
or thereafter if needed to 
determine outcomes ie, vital 
status.  
In additio n, subjects meeting the 
following criteria must be w ithdrawn 
from the trial:
a) Occurrence o f any AE, 
intercurrent illness, or abnormality in 
a laboratory assessment which, in 
the opinion of the investigator, 
warrants the subjectâ€™s permanent 
withdrawal fro m the trial;
b) Subject noncompliance, defined 
as refusal or inability to adhere to the 
trial schedule or procedures (see 
Section 3.11);
c) At the request of the subject, 
investigator, sponsor, or regulatory 
authority;
d) Subject is lost to follow -up.
The investigator will notify the 
sponsor promptly when a subject is 
withdrawn.
Section 3.12, Subject 
Com plianceSubject compliance will be monitored 
by pill counts as IMP is returned.  
Any subject who, without the 
instruction of the investigator, 
discontinues tolvaptan investigational 
product w ithout the instruction of the 
investigator, discontinues tolvaptan 
for 30 consecutive days or misses > 
30% of the doses intended for a 
period betw een visits (whichever is 
greater) w ill be deemed 
noncompliant.  ...Subject compliance will be 
monitored by pill counts as IMP is 
returned.  Any subject w ho, without 
the instruction of the investigator, 
discontinues tolvaptan 
investigational product, discontinues 
tolvaptan for 30 consecutive days or 
misses > 30% of the dos es intended 
for a period betw een visits 
(whichever is greater) w ill be 
deemed noncompliant.  ...
Section 3.13, Protocol
DeviationsThis trial is to be conducted as 
described in this protocol.  In the 
event of a significant deviation from 
the protocol due to an emergency, This trial is to be conducted as 
described in this protocol.  In the 
even t of a significant deviation from 
the protocol due to an emergency, 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
100
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 100 06 Ma rch 2015Location Old Text Updated Text
accident or mistake, the investigator 
or designee must contact the sponsor 
at the earliest possible time.  This wil l 
allow  an early joint decision 
regarding the subjectâ€™s continuation 
in the trial.  This decision will be 
documented by the investigator and 
the sponsor, and reviewed by the 
monitor.accident or mistake (eg, violation of 
inform ed consent process, IMP 
dispensing or subject dosing error, 
subject enrolled in violation of 
eligibility criteria or concomitant 
medication crit eria) , the 
investigator or designee must contact 
the sponsor at the earliest possible 
time.  This will allow an early joint 
decision regarding the subjectâ€™s 
continuation in the trial.  This 
decision will be documented by the 
investigator and the sponsor, a nd 
reviewed by the sitemonitor.
Section 4.1, Prohibited 
or Restricted 
Medications Medications or surgical therapies 
used for the purpose or potential for 
modifying the progression of PKD 
cyst growth or development will be 
prohibited.  These include, but are not 
restricted to, somatostatin agonists, 
rapamune (sirolimus), anti -sense 
ribonucleic acid therapies, tolvaptan, 
and other vasopressin antagonists, 
(eg, OPC -31260 (mozavaptan), 
Vaprisol (conivaptan), agonists (eg, 
desm opressin) and cyst 
decompression surgery.
Continuous or short -term use of other 
medications, while not prohibited, 
may be restricted by the investigator 
because of their potential for 
interference with tolvaptan 
metabolism (see Section 3.2.1 and 
Section 3.2.2 ). 
...
Some drugs are known to alter 
creatinine concentrations so, while 
not prohibited, subjects should alert 
their trial doctor, and any other 
health -care providers, to take this into 
consideration when considering
changes in their prescribed or over -
the-counter medications.  A list 
would include:  cimetidine, non -
steroidal anti -inflammatory drugs like 
aspirin or ibuprofen, chemotherapy 
drugs, cephalosporin, the 
combination of elvitegravir, 
cobicistat, emtricitabine , and 
tenofovir (StribildTM), dolutegravir, 
dronedarone, ranolazine, metformin, Medications or surgical therapies 
used for the purpose or potential for 
modifying the progression of PKD 
cyst growth or development will be 
prohibited.  These include, but are 
not restricted to, somatostatin 
agonists, rapamune (sirolimus), anti -
sense ribonucleic acid therapies, 
vasopressin antagonists other than 
tolvaptan , (eg, OPC -31260 
(mozavaptan), Vaprisol 
(conivaptan), agonists (eg, 
desm opressin) and cyst 
decompression surgery.
Continuous or short -term use of 
other medications, while not 
prohibited, may be restricted by the 
investigator because of their 
potential for interference with 
tolvaptan metabolism (see 
Section 3.2.1 and Section 3.2.2 ). 
A partial list of strong and 
moderate CYP3A4 inhibitors can 
be found in Table 4.1-1below :
...
Some drugs are known to alter 
creatinine concentrations so, while 
not prohibited, subjects should al ert 
their trial doctor, and any other 
health -care providers, to take this 
into consideration when considering 
changes in their prescribed or over -
the-counter medications.  A list 
would include:  non -steroidal anti -
inflammatory drugs like aspirin or 
ibuprof en, chemotherapy drugs, 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
101
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 101 06 Ma rch 2015Location Old Text Updated Text
and trimethoprim. cephalosporin, the combination of 
elvitegravir, cobicistat, 
emtricitabine, and tenofovir 
(StribildTM), dolutegravir, 
dronedarone, ranolazine, metformin, 
and trimethoprim.
Table 4.1 -1 N/A Please see end of Appendix 5 for this 
new ta ble.
Section 4.2, Dietary 
Restrictions and 
RecommendationsRestriction of excess dietary sodium 
and cooked meat protein may prove 
beneficial to subjects with a history 
of, or predisposition for, hypertension 
or kidney disease in general and 
should be applied to all subjects 
diagnosed with advanced ADPKD, 
particula rly if there is evidence for a 
propensity for rapid progression.  In 
the absence of alternate regional 
practices, dietary salt < 5g/day, 
dietary cooked meat protein < 1 
g/kg/day and a limit on caffeinated 
drinks/foods should also be given (no 
more than 2 c offee equivalents per 
day).  Restriction of excess dietary sodium 
and cooked meat protein may prove 
beneficial to subjects with a history 
of, or predisposition for, 
hypertension or kidney disease in 
general and should be applied to all 
subjects diagnosed with advanced 
ADPKD, particularly if there is 
evidence for a propensity for rapid 
progression.  In the absence of 
alternate regional practices, dietary 
salt < 5g/day, dietary cooked meat 
protein < 1 g/kg/day and a limit on 
caffeinated drinks/foods should a lso 
be given (no more than 2 coffee 
equivalents per day).  A history of 
alcohol and sm oking intake will be 
collected at screening.  Alcohol 
and tobacco consumption should 
be avoided or m inimized as much 
as possible.
Section 5, Reporting of 
Adverse EventsThe follow ing describes the methods 
and timing for assessing, recording, 
and analyzing safety parameters, as 
well as the procedures for eliciting 
reports of and recording and reporting 
AEs and intercurrent illnesses and the 
type and duration of the follow -up of 
subjects after AEs.The follow ing describes the methods 
and timing for assessing, recording, 
and analyzing safety parameters, as 
well as the procedures for eliciting 
reports of and recording and 
reporting AEs and intercurrent 
illnesses and the type a nd duration of 
the follow -up of subjects after AEs.
Medical follow up is expected for 
AEs which lead to discontinuation 
which are serious, or which are of 
special interest (eg, liver 
abnorm alities, skin neoplasms, 
glaucom a).
Section 5.5, Follow -up 
of Adv erse EventsFor this trial, AEs will be follow ed up 
for 21 days after the last dose of 
tolvaptan has been administered 
(follow -up period).
Subjects experiencing SAEs should 
be follow ed clinically until their 
health has returned to baseline status, 
or until all parameters have returned For this trial, AEs w ill be follow ed 
up for 7 days after the last dose of 
tolvaptan has been administered 
(follow -up period).
Subjects experiencing SAEs should 
be follow ed clinically until their 
health has returned to baseline status, 
or until all parameters have returned 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
102
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
WRQRUPDORUKDYHRWKHUZLVHEHHQ
H[SODLQHG
)RUVXEMHFWVZKRKDYHGLVFRQWLQXHGWROYDSWDQEXWKDYHQRWZLWKGUDZQIURPWKHWULDOYLWDOVWDWXV$(VFRQFRPLWDQWPHGLFDWLRQVDQGVFKHGXOHGODERUDWRU\GDWDLQFOXGLQJ
VHUXPFUHDWLQLQHGDWDDUHSODQQHGWR
EHFROOHFWHGUHJDUGOHVVRIWROYDSWDQGLVFRQWLQXDWLRQXQWLOWKHVFKHGXOHGHQGRIWKHWULDOWRQRUPDORUKDYHRWKHUZLVHEHHQ
H[SODLQHG









6HFWLRQ6DPSOH6L]H6DPSOHVL]HZDVQRWGHWHUPLQHGE\D
IRUPDOFRPSXWDWLRQWRDFKLHYHDWDUJHWSRZHU1RHIILFDF\DQDO\VHVDUHSODQQHG,WLVH[SHFWHGWKDWDSSUR[LPDWHO\VXEMHFWVPD\
HQUROOIURPSUHYLRXVWROYDSWDQWULDOV6DPSOHVL]HZDVQRWGHWHUPLQHGE\D
IRUPDOFRPSXWDWLRQWRDFKLHYHDWDUJHWSRZHU1RHIILFDF\ DQDO\VHV
DUHSODQQHG,WLVH[SHFWHGWKDWDSSUR[LPDWHO\ VXEMHFWVPD\
HQUROOIURPSUHYLRXVWROYDSWDQWULDOV
$SSHQGL[1DPHRI
6SRQVRU3HUVRQQHO 
86$
3KRQH
86$
3KRQH
$SSHQGL[,QVWLWXWLRQV
&RQFHUQHG:LWKWKH
7ULDO7UDYHOLQJ&RRUGLQDWRU$VVLVWDQW
3ULQFHWRQ0HGLFDO
5RXWHVRXWK
+LOOVERURXJK1-86$
3KRQH
)D[
&HQWUDO/DERUDWRU\6HUYLFH
&RYDQFH&HQWUDO/DERUDWRU\6HUYLFHV
6FL&RU'U
,QGLDQDSROLV,186$
3KRQH
7ROOIUHH
)D[7UDYHOLQJ&RRUGLQDWRU$VVLVWDQWURZ
GHOHWHG
&HQWUDO/DERUDWRU\6HUYLFHV
&RYDQFH&HQWUDO/DERUDWRU\
6HUYLFHV
6FL&RU'U
,QGLDQDSROLV,186$
3KRQH
7ROOIUHH
)D[ 
&RYDQFH$VLD3WH/WG
&HQWUDO/DERUDWRU\6HUYLFHV
6LQJDSRUH
,QWHUQDWLRQDO%XVLQHVV3DUN

7KH6\QHUJ\6LQJDSRUH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
PPDPPDCCI CCI
PPD
PPDPPD PPD
PPD PPD
PPD PPD
PPD PPD
PPD
PPD
PPD
PPDPPD
PPD
PPD
PPD
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
3KRQH
&RYDQFH&HQWUDO/DERUDWRU\
6HUYLFHV6\GQH\
(SSLQJ5G1RUWK5\GH
16:$XVWUDOLD
3KRQH
&RYDQFH&HQWUDO/DERUDWRU\
6HUYLFHV*HQHYD
5XH0RLVH0DUFLQKHV
0H\ULQ*HQHYD &+
6ZLW]HUODQG
3KRQH

3KRQH
 












8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCIPPD
PPD
PPD
PPD
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W















$SSHQGL[3URWRFRO$PHQGPHQW1$
3UHYLRXV)LJXUH 7ULDO'HVLJQ6FKHPDWLF
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 105 06 Ma rch 2015Revised Figure 3.1-1 - Trial Design Schematic:
Previous Table 3.2-1 - Trial Treatments:
Table 3.2-1 Trial Treatments
Trial Day Time Dose
Day 1 to last on -treatment visit 8:00 am 1 to 6 tolvaptan tablets (15 mg or 30 mg each)
4:00 to 5:00 pm 1 to 2 tolvaptan tablets (15 mg or 30 mg each)
Allowed doses are 45/15 mg, 60/30 mg, 
90/30 mg.  Down titration to 30/15 mg and 
15/15 mg will be allow ed after discussion 
with the medical monitor.  
Revised Table 3.2 -1 -Trial Treatments :
Table 3.2-1 Trial Treatments
Trial Day Time Dose
Day 1 to last on -treatment visit 8:00 am 1 to 6 tolvaptan tablets (15 mg or 30 mg each)
4:00 to 5:00 pm 1 to 2 tolvaptan tablets (15 mg or 30 mg each)
Allowed doses are 45/15 mg, 60/30 mg, 
90/30 mg.  Down titration to 30/15 mg and 
15/15 mg will be allow ed after discussion 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
106
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 106 06 Ma rch 2015with the medical monitor.  Further down 
titration to 30 or 15 m g once daily m ay be 
allowed only for metabolic drug -drug 
interaction an d requires medical m onitor 
approval.
Previous Table 3.4.2-1 â€“ Inclusion Criteria:
Table 3.4.2-1 Inclusion Criteria
1. Male and female subjects aged ï‚³18 years with ADPKD who have completed either trial 
156-13-210 or trial 156 -08-271
2. Diagnosis of ADPKD by modified Pei -Ravine criteria:
ï‚·With family history: several cysts per kidney (3 if by sonography, 5 if by computed 
tomography or MRI).
ï‚·Without family history: 10 cysts per kidney (by any radiologic method, above) and exclusion 
of other cystic kidne y diseases.  Conditions to be excluded include: multiple simple renal 
cysts, renal tubular acidosis, cystic dysplasia of the kidney, multicystic kidney, multilocular 
cysts of the kidney, medullary cystic kidney and acquired cystic disease of the kidney.
ï‚·Distribution and number of cysts consistent with the observed level of renal function deficit.
3. Estimated glomerular filtration rate  ï‚³20 mL/min/1.73 m2 (calculated using the CKD -EPI 
formula) within 45 days prior to the baseline visit.  Subjects who have an eGFR between 15 and 
19 mL/min/1.73 m2may be permitted with documented medical monitor approval prior to 
enrollment.
Revised Table 3.4.2-1 â€“ Inclusion Criteria:
Table 3.4.2-1 Inclusion Criteria
1. Male and female subjects aged ï‚³18 years with confirmed diagnosis of ADPKD ( during 
participation in prior tolvaptan trials) who have
ï‚·Completed and transferred from  the double -blind Trial 156-13-210 (12 -month 
period including post -treatment follow -up, regardless of whether this was on -
treatm ent or off -treatm ent), or 
ï‚·Completed Trial 156-08-271 or a prior tolvaptan trial, or 
ï‚·Interrupted or discontinued treatm ent in a tolvaptan trial other than 
Trial 156-13-210.  Subjects may be enrolled with the medical m onitor approval, and 
additional close m onitoring may be required at the beginning of the trial
ï‚·Renal function will be assessed during screening using historical laboratory values 
(in the last 30 days) for serum creatinine levels to calculate the estim ated 
glom erular filtration rate (eGFR).  The eGFR val ues will be estimated based on the 
Chronic Kidney Disease -Epidemiology (CKD -EPI) formula. (Levey AS et al. Ann 
Intern Med. 2009; 150:604 â€“612)
2. Estimated glomerular filtration rate  ï‚³20 mL/min/1.73 m2 (calculated using the CKD -EPI 
formula) within 45 days prior to the baseline visit.  Subjects who have an eGFR between 15 and 
19 mL/min/1.73 m2may be permitted with documented medical monitor approval prior to 
enrollment.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
107
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK3UHYLRXV7DEOHÂ±6FKHGXOHRI$VVHVVPHQWV
7DEOH 6FKHGXOHRI$VVHVVPHQWV
6FUHHQLQJ
WR
GD\V
SULRUWR
%DVHOLQHD%DVHOLQH
'D\0RQWKO\
Â“GD\V(YHU\PRQWKV
Â±Â±GD\V(DUO\
7HUPLQDWLRQ(QG
RI7ULDO9LVLW
PRQWKV7LWUDWLRQ
&RQWDFW
SKRQH
FRQWDFW)ROORZXS
GD\VSRVW
WUHDWPHQW
GD\V
,QIRUPHGFRQVHQW ;
,QFOXVLRQ([FOXVLRQ ; ;
'HPRJUDSKLFV0HGLFDO$'3.'KLVWRU\
E;
'LHWDU\UHYLHZ ; ; ; ;
9LWDO VLJQVF;; ; ; ;
&KHPLVWU\%ORRG6DPSOHVG
6HUXP&KHPLVWU\3DQHO ; ;H;
/LYHU)XQFWLRQWHVWV ;I;I;I;I;I
6RGLXP ; ; ;
&UHDWLQLQH ; ; ; ;
+HPDWRORJ\DQGFRDJXODWLRQ ;;
8ULQDO\VLV ;; ;
8ULQHRVPRODOLW\J;; ;
8ULQHVSHFLILFJUDYLW\ ;; ;
8ULQHSUHJQDQF\WHVW:2&%3RQO\K;; ; ;
8ULQHDWKRPHSUHJQDQF\WHVWNLWV
GLVSHQVHGL;;
3K\VLFDOH[DPLQDWLRQM;; ; ;
7ROHUDELOLW\'RVLQJ5HYLHZ ; ; ; ;
,QWHUDFWLYH5HVSRQVH7HFKQRORJ\(QWU\ ; ; ; ; ;N
'UXJGLVSHQVDWLRQ ; ; ;N
'UXJUHFRQFLOLDWLRQ ; ; ;N
$GYHUVHHYHQWV ;Oâ†  â†’
&RQFRPLWDQWPHGLFDWLRQVPâ†  â†’
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKD7KHVFUHHQLQJDQGEDVHOLQHYLVLWVPD\EHFRPELQHGZLWKWKHHQG RIWUHDWPHQW(R7[YLVLWIURPWKHSUHYLRXVSURWRFROZLWKDOOU HTXLUHGDVVHVVPHQWVIURPHDFK
YLVLWRQO\SHUIRUPHGRQFH
E,QFOXGHVSULRUWULDOLGHQWLILHUVVFUHHQLQJLGHQWLILFDWLRQ>,'@ VXEMHFW,'VLWH,'
F9LWDOVLJQVDWHDFKYLVLWLQFOXGHVHDWHGKHDUWUDWHFDOLEUDWHG EORRGSUHVVXUHDQGSRVWYRLGERG\ZHLJKW+HLJKWVKRXOGEHSH UIRUPHGRQO\DWVFUHHQLQJDQG
(7(R7[YLVLWV
G/RFDOQRQIDVWLQJ VHUXPODERUDWRU\WHVWV ZLOOEHSHUIRUPHG
â€¢)XOOFKHPLVWU\SDQHOLQFOXGLQJ VHUXPVRGLXPDQGV HUXPFUHDWLQLQHDWEDVHOLQHDQGHDUO\WHUPLQDWLRQHQGRIWUHDWPHQW (7(R7[
â€¢+HSDWLWLVWHVWLQJDW VFUHHQLQJZLOOEHRSWLRQDO
â€¢8SRQUHTXHVWLIFOLQLFDOO\LQGLFDWHGDQGDSSURYHGE\WKH PHGLFDOPRQLWRU VXEMHFWVPD\KDYHWKHIROORZLQJHYDOXDWLRQVLQDGGLWLRQWRWKH
SURWRFROVSHFLILHGFKHPLVWU\SDQHO VHUXPFDOFLXPSKRVSKRURXVSDUDW K\URLGKRUPRQHYLWDP LQ' DQGELFDUERQDWHOHYHOV
H/RFDO6WDQGDUGRI&DUHODERUDWRU\DVVHVVPHQWVZLOOEHSHUIRUPHG HYHU\PRQWKVSHUVXEMHFWÂ¶VLQGLYLGXDOFOLQLFDOPDQDJHPHQWQH HGV
I/LYHUIXQFWLRQWHVWVZLOOEHFRQGXFWHGDVIROORZV
â€¢$WEDVHOLQHDIXOOOLYHUIXQFWLRQSDQHOZLOOEHDVVHVVHG$/7 $67ELOLUXELQWRWDODQGGLUHFWDONDOLQHSKRVSKDWDVH
â€¢)RUVXEMHFWVHQUROOLQJIURPWKHGRXEOHEOLQG7ULDO $/7OHYHOVZLOOEHDVVHVVHGPRQWKO\IRUWKHILUVWPRQWKVTX DUWHUO\HYHU\
PRQWKVDIWHUPRQWKVRIWUHDWPHQWDWWKH(7(R7[DQGDWWKH IROORZXS'D\YLVLW
â€¢)RUVXEMHFWVHQUROOLQJIURPWKHRSHQODEHO7ULDO$/ 7OHYHOVZLOOEHDVVHVVHGTXDUWHUO\HYHU\PRQWKVDWWKH(7 (R7[DQGDWWKH
IROORZXS'D\YLVLW
$Q\VXEMHFWZLWKDQ$/7 HOHYDWLRQ![8/1DQG[8/1ZLOOEH PRQLWRUHGPRQWKO\IRUDQDGGLWLRQDOPRQWKVEH\RQGWKHGDWHR IHOHYDWLRQWRHVWDEO LVK
WKDWWKLVOHYHOLVVWDEOHDQGWKDWIXUWKHUHOHYDWLRQGRHVQRWR FFXU$Q\$/7OHYHO â‰¥[8/1Z LOOUHTXLUHWKHDGGLWLRQRIIXOO OLYHUIXQFWLRQSDQHO$ /7$67
ELOLUXELQWRWDODQGGLUHFWDONDOLQHSKRVSKDWDVHZLWKLQKRX UVRIWKHVLWHEHLQJDZDUHRIWKLVUHVXOW 
J8ULQHRVPRODOLW\LVRSWLRQDO
K$XULQHSUHJQDQF\WHVWIRUSUHJQDQF\IRU ZRPHQRIFKLOGEHDULQJSRWH QWLDO:2&%3Z LOOEHSHUIRUPHGDWVFUHHQLQJDWWKHTXDUWHUO\Y LVLWVDWWKH(R7[YLVLWDQG
DWWKHIROORZXSYLVLW2QVXVSLFLRQRISUHJQDQF\DQXQVFKHGX OHGXULQHRUVHUXPSUHJQDQF\WHVWLQJZLOOEHSHUIRUPHG3RVLWL YHXULQHSUHJQDQF\WHVWVVKRXOGEH
FRQILUPHGZLWKDVHUXPSUHJQDQF\WHVW
L$WKRPHXULQHSUHJQDQF\WHVWNLWVZLOOEHGLVSHQVHGWR:2&%3WR EHXVHGLIDPHQVWUXDOSHULRGLVPLVVHGEHWZHHQYLVLWV.LWV ZLOOEHGLVSHQVHGDVQHHGHG
WKURXJKRXWWKHWULDODWHDFKTXDUWHUO\YLVLW
M$IXOOSK\VLFDOH[DPLQDWLRQLVUHTXLUHGDWVFUHHQLQJWKLVPD\ EHFRPELQHGZLWKWKH(R7[YLVLWIURPWKHSUHYLRXVWULDO$WRW KHUYLVLWVDQRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ3.'UHODWHGV LJQVDQGV\PSWRPV
N,IGXULQJWKHWLWUDWLRQFRQWDFWWKHGHWHUPLQDWLRQLV PDGHWRDGM XVWWKHGRVHUHJLPHQWKHVXEMHFWVWDWXVZLOOEHHQWHUHGLQWR WKHLQWHUDFWLYHUHVSRQVHWHFKQRORJ\
,57DQGDUUDQJHPHQWVPDGHIRUGLVSHQVDWLRQRIDQHZ,03NLWD QGUHFRQFLOLDWLRQRIUHWXUQHG,03
O$WVFUHHQLQJ$(VUHSRUWHGDVRQJRLQJRUUHVROYHGDWWKHHQGRI WKHSULRUWULDOZLOOEHDVVHVVHGWRGHWHUPLQHHQWU\DVHLWKHU PHGLFDOKLVWRU\RURQJRLQJHYHQWIRU
WKLVWULDO
P2QO\FRQFRPLWDQWPHGLFDWLRQVRQJRLQJDWWKHEDVHOLQHYLVLWDQG WKURXJKRXWWKHWULDOZLOOEHUHFRUGHG
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK5HYLVHG7DEOH Â± 6FKHGXOHRI$VVHVVPHQWV
7DEOH 6FKHGXOHRI$VVHVVPHQWV
6FUHHQLQJ
WR  GD\V
SULRUWR%DVHOLQHD%DVHOLQH
'D\0RQWKO\E
Â“GD\V(YHU\
 PRQWKVE
Â±Â± GD\V(DUO\
7HUPLQDWLRQ(QG
RI7UHDWPHQW
GD\V7LWUDWLRQ
&RQWDFW
SKRQH
FRQWDFW)ROORZXS
GD\VSRVW
WUHDWPHQW
GD\V
,QIRUPHGFRQVHQW ;
,QFOXVLRQ([FOXVLRQ ; ;
'HPRJUDSKLFV
0HGLFDO$'3.'KLVWRU\F;
'LHWDU\UHYLHZ ; ; ; ; ;
9LWDOVLJQVG;; ; ; ; ;
&KHPLVWU\%ORRG 6DPSOHVH
6HUXP&KHPLVWU\3DQHO ;I;
/LYHU)XQFWLRQWHVWVJ;; ; ; ;
6RGLXP ; ; ; ;
&UHDWLQLQH ; ; ; ; ;
+HPDWRORJ\DQGFRDJXODWLRQ ;;
8ULQDO\VLV ;; ; ;
8ULQHRVPRODOLW\K;; ; ;
8ULQHVSHFLILFJUDYLW\ ;; ; ;
8ULQHSUHJQDQF\WHVW:2&%3
RQO\L;; ; ; ;
8ULQHDWKRPHSUHJQDQF\WHVW
NLWVGLVSHQVHGM;; ;
3K\VLFDOH[DPLQDWLRQN;; ; ; ;
7ROHUDELOLW\'RVLQJ5HYLHZ ; ; ; ; ;
,QWHUDFWLYH5HVSRQVH
7HFKQRORJ\(QWU\;; ; ; ; ;O;
'UXJGLVSHQVDWLRQ ; ; ; ;O
'UXJUHFRQFLOLDWLRQ ; ; ; ;O
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK6FUHHQLQJ
WR  GD\V
SULRUWR%DVHOLQHD%DVHOLQH
'D\0RQWKO\E
Â“GD\V(YHU\
 PRQWKVE
Â±Â± GD\V(DUO\
7HUPLQDWLRQ(QG
RI7UHDWPHQW
GD\V7LWUDWLRQ
&RQWDFW
SKRQH
FRQWDFW)ROORZXS
GD\VSRVW
WUHDWPHQW
GD\V

$GYHUVHHYHQWV ;Qâ†  â†’
&RQFRPLWDQWPHGLFDWLRQVRâ†  â†’
D7KHODVWYLVLWDVVHVVPHQWVIURPWKHSUHYLRXVSURWRFROFDQEHFR PELQHGZLWKWKHVFUHHQLQJYLVLWIRUWKLVWULDOZLWKDOOUHTXLU HGDVVHVVPHQWVIURPHDFKYLVLW
SHUIRUPHGRQO\RQFH 
E0RQWKO\YLVLWVDUHIRUVXEMHFWVPRQWKVRQWROYDSWDQDQGH YHU\PRQWKYLVLWVDUHIRUVXEMHFWV!PRQWKVRQWROYDSWDQ 
F,QFOXGHVSULRUWULDOLGHQWLILHUVVFUHHQLQJLGHQWLILFDWLRQ>,'@ VXEMHFW,'VLWH,'SULRUWROYDSWDQ$'3.'WULDOSURWRFROQXP EHU
G9LWDOVLJQVDWHDFKYLVLWLQFOXGHVHDWHGKHDUWUDWHFDOLEUDWHG EORRGSUHVVXUHDQGSRVWYRLGERG\ZHLJKW+HLJKWVKRXOGEHSH UIRUPHGRQO\DWVFUHHQLQJ
H&HQWUDOODERUDWRU\QRQIDVWLQJVHUXPODERUDWRU\WHVWVZLOOEHS HUIRUPHG$OOVXEMHFWVPXVWEHPRQLWRUHGIRUKHSDWLFVDIHW\PR QWKO\XQWLOWKH\KDYHNQRZQ
WROYDSWDQH[SRVXUHGDWDRIDWOHDVW PRQWKV$IWHUWKDWDQG IROORZLQJWKHDSSURYDORIWKHPHGLFDOPRQLWRUKHSDWLFPRQLWRUL QJZLOOWDNHSODFH HYHU\
 PRQWKV7ULDOVXEMHFWVZKRDUHHOLJLEOHIRUWKLVW ULDOZLOOKDYHWULDOYLVLWVKHSDWLFPRQLWRULQJPRQWKO\IRUWKH ILUVW PRQWKVRIWKLVWULDOWKHQ
HYHU\ PRQWKVWKHUHDIWHUEHFDXVHWKHLUWROYDSWDQH[SRVXUHZLOO EHXQNQRZQ2QFHXQEOLQGLQJRFFXUVLWFDQEHGHWHUPLQHGZKLF KVXEMHFWVUHFHLYHGWROYDSWDQ
LQ7ULDO7KHVHVXEMHFWVPD\KDYHWKHLUWULDOYLVLW VKHSDWLFWUDQVDPLQDVHPRQLWRULQJFKDQJHGWRHYHU\PRQWKVVRR QHUDVWKHLUSUHYLRXVWROYDSWDQ
H[SRVXUHLQ7ULDOFDQFRXQWWRZDUGVWKHPRQWKWKUH VKROG6XEMHFWVZKRHQUROOIURPRWKHU$'3.'WROYDSWDQWULDOVZ LOOEHPRQLWRUHGIRU
KHSDWLFVDIHO\PRQWKO\IRUWKHLUILUVW PRQWKVWKH\DUHLQWKL VWULDO
I+HSDWLWLVWHVWLQJDWVFUHHQLQJZLOOEHRSWLRQDO,IKHSDWLWLV WHVWLQJLVSHUIRUPHGWKHQERWKSUHDQGSRVWFRXQVHOLQJDFWLYLW LHVUHODWLQJWRKHSDWLWLVWHVWLQJDUHWREH
FDUULHGRXWEDVHGRQORFDOUHTXLUHPHQWVDQGEHVWSUDFWLFHV8S RQUHTXHVWLIFOLQLFDOO\LQGLFDWHGDQGDSSURYHGE\WKHPHGLFDO PRQLWRUVXEMHFWVPD\KDYHWKH
IROORZLQJHYDOXDWLRQVLQDGGLWLRQWRWKHSURWRFROVSHFLILHGFKH PLVWU\SDQHOVHUXPFDOFLXPSKRVSKRURXVSDUDWK\URLGKRUPRQH YLWDPLQ'DQGELFDUERQDWH
OHYHOV
J$IXOOOLYHUIXQFWLRQSDQHO$67$/7DONDOLQHSKRVSKDWDVH%7 ZLOOEHGRQHDW VFUHHQLQJ$OORWKHUOLYHUIXQFWLRQWHVWVDW VXEVHTXHQWYLVLWVDUHIRU$/7RQO\
XQOHVVRWKHUZLVHFOLQLFDOO\LQGLFDWHG$Q\WUDQVDPLQDVHRUELO LUXELQYDOXHVZKLFKH[FHHG Ã® 8/1VKRXOGSURPSWLPPHGLDWHUHWHVW LQJZLWKLQ KRXUV:KLOH
YDOXHVUHPDLQLQDQDEQRUPDOUDQJHWHVWLQJIUHTXHQF\VKRXOGEH LQFUHDVHGWRDWOHDVWZ HHNO\IRUWKHILUVWPRQWKJUDGXDOO\UH WXUQLQJWRPRQWKO\DQGHYHU\
 PRQWKVDVLQGLFDWHGE\WKHUHVXOWV/RFDOOLYHUIXQFWLRQSDQH ODQDO\VHVZLOODOVREHSHUIRUPHGPRUHIUHTXHQWO\LI QHFHVVDU\ 
K8ULQHRVPRODOLW\LVRSWLRQDO
L$XULQHSUHJQDQF\WHVWIRUSUHJQDQF\IRUZRPHQRIFKLOGEHDULQJ SRWHQWLDO:2&%3 ZLOOEHSHUIRUPHGDWVFUHHQLQJDWHYHU\ PRQ WKVYLVLWVDWWKH(QGRI
7UHDWPHQW(R7[ YLVLWDQGDWWKHIROORZXSYLVLW2QVXVSLFL RQRISUHJQDQF\DQXQVFKHGXOHGXULQHRU VHUXPSUHJQDQF\WHVWLQJ ZLOOEHSHUIRUPHG3RVLWLYH
XULQHSUHJQDQF\WHVWVVKRXOGEHFRQILUPHGZLWKDVHUXPSUHJQDQF \WHVW
M$WKRPHXULQHSUHJQDQF\WHVWNLWVZLOOEHGLVSHQVHGWR:2&%3WR EHXVHGLIDPHQVWUXDOSHULRGLVPLVVHGEHWZHHQYLVLWV.LWV ZLOOEHGLVSHQVHGDVQHHGHG
WKURXJKRXWWKHWULDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKN$IXOOSK\VLFDOH[DPLQDWLRQLVUHTXLUHGDWVFUHHQLQJ$WRWKHU YLVLWVDQRSWLRQDOÂ³GLUHFWHGÂ´SK\VLFDOH[DPLQDWLRQPD\EHSHU IRUPHGWRIRFXVRQ3.'UHODWHG
VLJQVDQGV\PSWRPV 
O,IGXULQJWKHWLWUDWLRQFRQWDFWWKHGHWHUPLQDWLRQLVPDGHWRDG MXVWWKHGRVH UHJLPHQGRVHDGMXVWPHQWVZLOOEHPDGHXVLQJGLVSH QVHGVXSSO\DQGGRVHLQVWUXFWLRQV
ZLOOEHSURYLGHGE\WKHLQYHVWLJDWRU7KHVXEMHFWÂ¶VFXUUHQWGR VHZLOOEHHQWHUHGLQWRWKHLQWHUDFWLYHUHVSRQVHWHFKQRORJ\,5 7DWHDFKYLVLW'UXJ
GLVSHQVDWLRQUHFRQFLOLDWLRQZLOOEHFRQGXFWHGRQDPRQWKO\EDVL VIRUVXEMHFWVZKRKDYHPRQWKO\WULDOYLVLWVDQGRQFHHYHU\ PR QWKVIRUVXEMHFWVZKRKDYHWULDO
YLVLWVHYHU\ PRQWKV
 

$WVFUHHQLQJ$(VUHSRUWHGDVRQJRLQJRUUHVROYHGDWWKHHQG RI WKHSULRUWULDOZLOOEHDVVHVVHGWRGHWHUPLQHHQWU\DVHLWKHUP HGLFDOKLVWRU\RURQJRLQJHYHQWIRU
WKLVWULDO
R2QO\FRQFRPLWDQWPHGLFDWLRQVRQJRLQJDWWKHEDVHOLQHYLVLWDQG WKURXJKRXWWKHWULDOZLOOEHUHFRUGHG7KLVZRXOGRFFXUDWWKH VFUHHQLQJYLVLWRQO\LIWKH
VFUHHQLQJYLVLWRFFXUVVLPXOWDQHRXVO\ZLWKWKHODVWYLVLWIURP DSUHYLRXVWROYDSWDQWULDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK3UHYLRXV7DEOH&OLQLFDO/DERUDWRU\$VVHVVPHQWV
7DEOH &OLQLFDO/DERUDWRU\$VVHVVPHQWV
+HPDWRORJ\DQG&RDJXODWLRQ3DQHO
+HPRJORELQ
0HDQFRUSXVFXODUKHPRJORELQFRQFHQWUDWLRQ0&+&
0HDQFRUSXVFXODUYROXPH0&9
5HGEORRGFHOO5%&FRXQW:KLWHEORRGFHOO:%&FRXQWZLWKGLIIHUHQWLDO3URWKURPELQWLPH37DVLQWHUQDWLRQDOQRUPDOL]HGUDWLR,15$FWLYDWHGSDUWLDOWKURPERSODVWLQWLPHD377
8ULQDO\VLV3DQHO
$SSHDUDQFH
&RORU%ORRG
*OXFRVH
0LFURVFRSLFDQDO\VLV:%&5%&FRXQWVSHUKLJKSRZHUILHOGS+3URWHLQ
8ULQH&KHPLVWU\
2VPRODOLW\
6SHFLILFJUDYLW\
$GGLWLRQDO7HVWV
8ULQHRUVHUXPSUHJQDQF\IRU:2&%3
+HSDWLWLVRSWLRQDO6HUXP&KHPLVWU\3DQHO
$OEXPLQ
%ORRGXUHDQLWURJHQ%816HUXPFDOFLXP
&DUERQGLR[LGH
6HUXPFKORULGH*DPPDJOXWDP\OWUDQVSHSWLGDVH&KROHVWHUROWRWDO*OXFRVH/DFWDWHGHK\GURJHQDVH/'+
3KRVSKRUXV
3RWDVVLXP3URWHLQWRWDO8ULFDFLG
/LYHU)XQFWLRQ3DQHO
$ONDOLQHSKRVSKDWDVH$/3
$ODQLQHDPLQRWUDQVIHUDVH$/7$VSDUWDWHDPLQRWUDQVIHUDVH$67%LOLUXELQWRWDO%7%LOLUXELQGLUHFW
&UHDWLQLQH 6RGLXP
:2&%3 ZRP HQRIFKLOGEHDULQJSRWHQWLDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 113 06 March 2015Revised Table 3.7.2.2-1 - Clinical Laboratory Assessments:
Table 3.7.2.2-1 Clinical Laboratory Assessments
Hem atology and Coagulation Panel:
Hem oglobin
Platelet count
Mean corpuscular hemoglobin concentration 
(MCHC)
Mean corpuscular volume (MCV)
Red blood cell (RBC) count
White blood cell (WBC) count w ith differential 
Prothrombin time (PT) as international normalized 
ratio (INR)
Activated partial thromboplastin time (aPTT)
Urinalysis Panel:
Appearance
Color 
Blood
Glucose
Microscopic analysis, WBC/RBC counts per high 
power field
pH
Protein 
Urine Chemistry
Osmolality (optional)
Specific gravity
Additional Tests:
Urine (or serum) pregnancy for WOCBP
Hepatitis (optional)Serum Chemistry Panel:
Albumin
Blood urea nitrogen (BUN)
Serum calcium
Carbon dioxide
Serum chloride
Gamma -glutamyl transpeptidase
Cholesterol , total
Glucose
Lactate dehydrogenase (LDH)
Phosphorus
Potassium
Protein , total 
Uric acid
Liver Function Panel :
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Bilirubin, total (BT)
Bilirubin, direct
Creatinine Sodium
WOCBP=w omen of childbearing potential.
New Table 4.1-1 Moderate and Strong CYP3A4 Inhibitors (partial list):
Table 4.1-1 Moderate and Strong CYP3A Inhibitors (partial list)
amprenavir atorvastin aprepitant chloramphenicol (if 
used orally)
cimetidine clarithromycin clotrimazole (if used 
orally)danazol
delavirdine diltiazem erythromycin fluconazole
fluvoxamine indinavir isoniazid itraconzazole
josamycin ketoconazole (if used 
orally)nelfinavir nefazadone
quinupristin/ dalfopristin ritonavir saquinavir troleandomycin
verapamil Seville orange products grapefruit products
ADDITIONAL RISK TO THE SUBJECT :
There is no additional risk to the subjects.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
114
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 114 06 March 2015Administrative Change Number: 1
Issue Date: 05 September 2014
PURPOSE:
This administrative change will not affect the safety  of subjects, the scope of the 
investigation, or the scientific quality  of the trial .
The main purpose of this administrative change was to align safet y endpoints between the 
synopsis and Section 3.5.1, and to clarify  the timeline for when I RE forms must be 
completed and submitted to the sponsor .  In addition ,a statement at the beginning of 
Section 3.5.1 explaining that the trial would have no form al endpoints had been 
inadvertently deleted in an earlier draft. 
BACKGROUND:
While reviewing the protocol before proceeding with the clinicaltrial.gov posting, a few 
inconsistencies were found.  I t was decided that fixing the inconsistencies would prov ide 
better clarity . 
Sectional Revisions
Location Old Text Updated Text
Section 3.5.1 Safety 
Endpoints   Safety endpoints will be as follow s:
ï‚·Adverse events
ï‚·Vital signs
ï‚·Clinical laboratory 
assessments
ï‚·Serum transaminase 
elevations for frequency (2x, 
3x, 5x and 10x ULN), time 
to onset, time to peak levels, 
time of offset (< 3x, 2x, or 
1x ULN), response to de -
challenge and re- challenge 
and frequency of progression 
to Hyâ€™s laboratory criteria 
(ALT or AST > 3x ULN and 
bilirubin, total (BT), 
>2xULN without alkaline 
phosphatase ï‚³2x ULN)
ï‚·Serum sodium excursions 
above 145, 150, or 
155mmol/L or below  135, This tr ial w ill have no formal 
endpoints.  Safety variables will be 
summarized by descriptive statistics, 
(eg, proportion, mean, median, 
standard deviation [SD], minimum, 
and maximum values).  In general, 
summary statistics, including 
changes from baseline, will be 
provided for safety variables based 
on all available data.  Safety 
endpoints will be as follows:
ï‚·Adverse events
ï‚·Vital signs
ï‚·Clinical laboratory 
assessments
ï‚·Serum transaminase 
elevations for frequency 
(2x, 3x, 5x and 10x ULN), 
time to onset, time to peak 
levels, time of offset (< 3x, 
2x, or 1x ULN), response to 
de-challenge and re-
challenge and frequency of 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
115
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 115 06 March 2015Location Old Text Updated Text
130, or 125 mmol/L
ï‚·Interruptions of protocol -
specifed therapies for 
hypernatremia or 
hyponatremiaprogression to Hyâ€™s 
laboratory criteria (ALT or 
AST > 3x ULN and 
bilirubin, total (BT), 
>2xULN without alkaline 
phosphatase ï‚³2x ULN)
ï‚·Serum sodium excursions 
above 145, 150, or 
155mmol/L or below  135, 
130, or 125 mmol/L
Section 5.3 ,
Immediately Reportable 
EventsThe investigator must immediately 
report within 24 hours after either the 
investigator or site personnel become 
aware of any SAE, an AE that 
necessitates IMP discontinuation, any 
new liver result meeting the AE 
laboratory threshold criteria, any AE 
of special interest or a confirmed 
pregnancy ,bytelephone or by fax to 
the sponsor as outlined in 
Appendix 1.  An IRE form must be 
completed and sent by f ax, email or 
overnight courier to the s ponsor.  
(Please note that the IRE form is 
NOT the AE eCRF ).The investigator must immediately 
report within 24 hours after either 
the investigator or site personnel 
become aware of any SAE, new liver 
laboratory abnormality requiring 
special liver eCRF completion, or 
confirmed pregnancy ,by telephone 
or by fax to the sponsor as outlined 
in Appendix 1.  An IRE form must 
be completed and sent by f ax, em ail,
or overnight courier to the s ponsor.  
(Please note that the IRE form is 
NOT the AE eCRF ).
Appendix 5, Title 
change Protocol Amendment Protocol Amendments and 
Administrative Changes
ADDITIONAL RISK TO THE SUBJECT :
There is no additional risk to the subjects.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
116
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 116 06 March 2015Amendment Number : 2
Issue Date: 06 Mar 2015
PURPOSE:
The purpose of this amendment was to increase the window from 30 days to up to 
3months to allow use of historical laboratory  values for screening , to add flexibility  and 
allow combining of screening and baseline visits in the trial, and to provide clarification 
on trial discontinuation. The list of vendors was updated. Minor linguistic changes were 
made for clarit y and t ypographical errors were corrected .  
BACKGROUND: 
Eligible subjects enrolling from Trials 156-08- 271 or 156 -13-210 can enroll before they  
complete the last visit in their respective trials, and the last visit as well as the screening 
and baseline visit in this trial c an be combined into one visit with all required assessments 
from each visit performed only  once, so long as the time between the last visit 
assessments from the previous trial and the screening visit for this trial is within 30 day s.  
Other Revisions
Figure 3.1 -1 -Trial Design Schematic
Table 3.4.2-1 - Inclusion Criteria 
Table 3.4.3-1 - Exclusion Criteria 
Table 3.7-1 - Schedule of Assessments footnotes
Sectional Revisions
Location Old Text Updated Text
Title page Clinical Protocol
A Phase 3b, Multi -center, Open -label 
Trial to Evaluate the Long Term 
Safety of Titrated Immediate -release 
Tolvaptan (OPC 41061, 30 mg to 120 
mg/day, Split dose) in Subjects with 
Autosomal Dominant Polycystic 
Kidney DiseaseRevised Clinical Protocol
A Phase 3b, Multi -center, Open -
label Trial to Evaluate the Long 
Term  Safety of Immediate -release 
Tolvaptan (OPC 41061, 30 mg to 
120 mg/day, Split dose) in Subjects 
with Autosomal Dominant 
Polycystic Kidney Disease
Synopsis, Protocol Title A Phase 3b, Multi -center, Open -label 
Trial to Evaluate the Long Term 
Safety of Titrated Immediate -release A Phase 3b, Multi -center, Open -
label Trial to Evaluate the Long 
Term  Safety of Immediate -release 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
117
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 117 06 March 2015Location Old Text Updated Text
Tolvaptan (OPC 41061, 30 mg to 120 
mg/day, Split dose) in Subjects with 
Autosomal Dominant Polycystic 
Kidney DiseaseTolvaptan (OPC 41061, 30 mg to 
120 mg/day, Split dose) in Subjects 
with Autosomal Dominant 
Polycystic Kidney Disease
Synopsis, Trial Design    
Subjects will be eligible for screening 
into this trial if they:
ï‚·Com pleted and transferred from 
the double -blind Trial 
156-13-210 (12 -month period 
including post treatment follow -
up, regardless of whether this 
was on-treatment or off -
treatment), or 
ï‚·Com pleted Trial 156 -08-271 or a 
prior tolvaptan ADPKD trial, or 
ï‚·Interrupted or discontinued 
treatment in a prior tolvaptan 
ADPKD trial (other than Trial 
156-13-210).  Subjects may be 
enrolled w ith medical monitor 
approval, and additional close 
monitoring may be required at 
the beginning of the trial   
Subjects will be eligible for 
screening into this trial if they:
ï‚·Com pleted and transferred from 
the double -blind Trial 
156-13-210 (12 -month period 
including post treatment follow -
up, regardless of whether this 
was on-treatment or off -
treatment), or have completed 
all but the last follow -up visit, 
which will be combined with the 
first visit in this trial or
ï‚·Com pleted Trial 156 -08-271 or 
a prior tolvaptan ADPKD trial, 
or have completed all but the 
end of trial visit, which will be 
combined with the first visit in 
this trial or
ï‚·Interrupted or discontinued 
treatment in a prior tolvaptan 
ADPKD trial (other than Trial 
156-13-210).  Subjects may be 
enrolled w ith medical monitor 
approval, and additional close 
monitoring may be required at 
the beginning of the trial
Synopsis, Inclusion and 
Exclusion Criteriaï‚·Estimated glomerular filtration 
rate (eGFR) 
ï‚³20mL/min/1.73m2within 
45days of the baseline visit.  
Subjects who have an eGFR 
betw een 15 and 
19mL/min/1.73m2may be 
enrolled w ith medical monitor 
approval
ï‚·Renal function will be assessed 
during screening by using 
historical values (in the last 
30days) for serum creatinine 
levels to calculate the eGFR.  
The eGFT values will be 
estimated based on the Chronic 
Kidn ey Disease â€“Epidem iology 
(CKD -EPI) formula.ï‚·Estimated glomerular filtration 
rate (eGFR) 
ï‚³20mL/min/1.73m2within 
3months of the baseline visit.  
Subjects who have an eGFR 
â‰¤20mL/min/1.73m2may be 
enrolled w ith medical monitor 
and sponsor approval and 
increased frequency of 
monitoring to ensure subjectsâ€™ 
safety .
ï‚·Renal function will be assessed 
during screening by using 
historical values (within 
3months from the screening 
visit) for serum creatinine levels 
to calculate the eGFR.  The 
eGFR values wi ll be estimated 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
118
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 118 06 March 2015Location Old Text Updated Text
based on the Chronic Kidney 
Disease â€“Epidem iology 
(CKD -EPI) formula.
Section 1.3, Known and 
Potential Risks and 
Benefits...
...Subjects enrolling in this trial who 
were in a previous ADPKD tolvaptan 
trial other than Trials 156 -13-210 and 
156-08-271 w ill have monthly visits 
and transaminase level assessments 
for the first 18 months....
...Subjects enrolling in this trial who 
were in a previous ADPKD 
tolvaptan trial other than Trials 
156-13-210 and 156 -08-271 will 
have monthly visits and alanine 
aminotransferase (ALT )level 
assessments for the first 18 months.
Section 2.1, Trial 
Rationale Evidence from previous studies 
suggests that during the first 
18months of long -term treatment in 
subjects with ADPKD, alanine 
aminotransferase (ALT) and/or 
aspartate aminotransferase (AST) 
elevations and evidence of 
idiosyncratic DILI occurs at a greater 
frequency in tolvaptan treated 
subjects.  ...Evidence from previous studies 
suggests that during the first 
18months of long -term treatment in 
subjects with ADPKD, ALT and/or 
aspartate aminotransferase (AST) 
elevations and evidence of 
idiosyncratic DILI occurs at a 
greater frequency in tolvaptan 
treated subjects.  ...
Section 3.1, 
Type/Design of Trial...
Eligible subjects w ill have an 
opportunity to enroll into Trial 
156-13-211 immediately following 
completion of the follow -up visit(s) 
of the previous trial.  The last visit 
assessments from the previous 
protocol can be combined w ith the 
screening visit for this trial, w ith all 
required assessments from each visit 
only performed once, as long as the 
time between the last follow -up visit 
assessments from the previous trial 
and the screening visit for this trial is 
within 30 days.
...
These subjects may have their trial 
visits/hepatic transaminase 
monitoring changed to every 
3months sooner as their previous 
tolvaptan exposure in 
Trial 156-13-210 can count towards 
the 18 -month threshold....
Eligible subjects w ill have an 
opportunity to enroll into Trial 
156-13-211 follow ing com pletion of 
the follow -up visit(s) of the previous 
trial.  Eligible subjects from 
Trials 156-08-271 and 156 -13-210 
can have the last visit assessments 
from their previous respective 
protocols (end of trial visit for 
156-08-271 subjects and last 
follo w-up visit for 
156-13-210subjects) overlap the 
first visit in this trial.  These last visit 
assessments can be combined with 
the screening and baseline visits for 
this trial, with all required 
assessments from each visit 
performed only once, so long as th e 
time between the last visit 
assessments from the previous trial 
and the screening visit for this trial is 
within 30 days.   If the first visit in 
this trial combines the last visit from 
a previous trial with both the 
screening and the baseline visits in 
this trial, the results from laboratory 
assessments performed at this 
combined visit will not be 
immediately available.  Should any 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
119
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 119 06 March 2015Location Old Text Updated Text
laboratory abnormalities be 
identified, the investigator w ill need 
to notify the subject and provide 
instructions regarding d osing or 
returning to the site for additional 
assessments.
...
These subjects may have their trial 
visits/hepatic transaminase 
monitoring changed to every 
3months sooner as their previous 
tolvaptan exposure in 
Trial 156-13-210 can count towards 
the 18 -month threshold.   Subjects 
from prior tolvaptan trials other than 
Trial 156 -08-271 w ill have monthly 
trial visits/ALT level assessments for 
the first 18 months.  After that, the 
trial visits/ALT monitoring will be 
conducted every 3 months after the 
change in frequency is confirmed 
with the medical monitor .
Figure 3.1 -1 Day 1
No clinic visit
First dose of the IMPDay 1
No clinic visit
First dose of the IMP in Trial 211
Table 3.4.2 -1, Inclusion 
Criteria1. Male and female subjects aged 
ï‚³18 years with confirmed diagnosis 
of ADPKD (during participation in 
prior tolvaptan trials) who have 
ï‚·Com pleted and transferred from 
the double -blind 
Trial 156-13-210 (12 -month 
period including post -treatment 
follow -up, regardless of whether 
this was on -treatment or off -
treatment), or
ï‚·Com pleted Trial 156-08-271 or a 
prior tolvaptan trial, or
ï‚·Interrupted or discontinued 
treatment in a tolvaptan trial 
other than Trial 156-13-210.  
Subjects may be enrolled w ith 
the medical monitor approval, 
and additional clo se monitoring 
may be required at the beginning 
of the trial
ï‚·Renal function will be assessed 
during screening by using 
historical laboratory values (in 
the last 30days) for serum Male and female subjects aged 
ï‚³18years with confirmed diagnosis 
of ADPKD (during participation in 
prior tolvaptan trials) who have 
ï‚·Com pleted and transferred from 
the double -blind 
Trial 156-13-210 (12 -month 
period including post -treatment 
follow -up, regardless of whether 
this was on -treatment or off -
treatment), or
ï‚·Com pleted Trial 156-08-271 or 
a prior tolvaptan trial, or
ï‚·Interrupted or discontinued 
treatment in a tolvaptan trial 
other than Trial 156-13-210.  
Subjects may be enrolled w ith 
the medical monitor approval, 
and additional clo se monitoring 
may be required at the 
beginning of the trial
ï‚·Renal function will be assessed 
during screening by using 
historical laboratory values (in 
the last 3months ) for serum 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
120
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 120 06 March 2015Location Old Text Updated Text
creatinine levels to calculate the 
estimated glomerular filtration 
rate (eGFR ).  The eGFR values 
will be estimated based on the 
Chronic Kidney Disease -
Epidemiology (CKD -EPI) 
formula. (Levey AS et al. Ann 
Intern Med. 2009; 150:604 â€“612)
2. Estimated glomerular filtration rate 
ï‚³20 mL/min/1.73 m2 (calculated 
using the CKD -EPI formul a) within 
45days prior to the baseline visit.  
Subjects who have an eGFR betw een 
15 and 19 mL/min/1.73 m2may be 
permitted with documented medical 
monitor approval prior to enrollmentcreatinine levels to calculate the 
estimated glomerular filtration 
rate (eGF R).  The eGFR values 
will be estimated based on the 
CKD -EPI formula. (Levey AS 
et al. Ann Intern Med. 2009; 
150:604 â€“612)
2. Estimated glomerular filtration 
rate ï‚³20 mL/min/1.73 m2 
(calculated using the CKD -EPI 
formula) within 3months prior to 
the baseline visit.  Subjects who 
have an eGFR â‰¤20mL/min/1.73 m2
may be permitted to enter the trial 
with  medical monitor and sponsor 
approval and increased frequency of 
monitoring to ensure safety of 
subjects.
At end of table, abbreviations added:
eGFR=estimated glomerular 
filtration rate; CKD -EPI= Chronic 
Kidney Disease -Epidemiology
Table 3.4.3 -1, 
Exclusion Criteria1. Women of childbearing potential 
(WOCBP) who do not agree to 
practice 2 different methods of birth 
control or remain abstinent during the 
trial and for 30 days after the last 
dose of IMP.  If employing birth 
control, 2 of the following 
precautions must be used: vasectomy 
of partner, tubal ligation, vaginal 
diaphragm, intrauterine device, birth 
control.
â€¦
4. Hepatic impairme nt based on liver 
function abnormalities other than that 
expected for ADPKD with cystic 
liver disease during screening.1. WOCBP w ho do not agree to 
practice 2 different methods of birth 
control or remain abstinent during 
the trial and for 30 days after th e last 
dose of IMP.  If employing birth 
control, 2 of the following 
precautions must be used: vasectomy 
of partner, tubal ligation, vaginal 
diaphragm, intrauterine device, birth 
control pill, birth control implant, 
birth control depot injection, 
condom, or sponge with spermicide.
â€¦
4. Hepatic impairment based on liver 
function abnormalities other than 
that expected for ADPKD with 
cystic liver disease during screening
based on recent historical laboratory 
values (in the last 3 months) .Section 3.7, Trial 
Procedures, Table 3.7 -1Footnote a:
aThe last visit assessments from the 
previous protocol can be combined 
with the screening visit for this trial, 
with all required assessments from 
each visit performed only once.
...
Footnote g:Footnote a:
aThe last visit assessments from the 
previous trial can be combined w ith 
the screening and baseline visits for 
this trial, with all required 
assessments from each visit 
performed only once .
...
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
121
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 121 06 March 2015Location Old Text Updated Text
gA full liver function pa nel (AST, 
ALT, alkaline phosphatase, BT) w ill 
be done at screening.  All other liver 
function tests at subsequent visits are 
for ALT only, unless otherwise 
clinically indicated.  Any 
transaminase or bilirubin values 
which exceed 2 Ã— ULN should 
prom pt immed iate retesting within 
72hours.  While values remain in an 
abnormal range, testing frequency 
should be increased to at least weekly 
for the first month, gradually 
returning to monthly, and every 
3months as indicated by the results.  
Local liver function p anel analyses 
will also be performed more 
frequently, if necessary.
...
Footnote l:
lIf during the titration contact the 
determination is made to adjust the 
dose regimen, dose adjustments will 
be made using dispensed supply, and 
dose instructions will be provided by 
the investigator.  The subjectâ€™s 
current dose will be entered into the 
interactive response technology (IRT) 
at each visit.  Drug 
dispensation/reconciliation will be 
conducted on a monthly basis for 
subjects who have monthly trial visits 
and on ce every 3 months for subjects 
who have trial visits every 3 months.  
...Footnote g:
gA full liver function panel (AST, 
ALT, alkaline phosphatase, BT) w ill 
be done at screening.  All other liver 
function tests at subsequent visits are
for ALT only, unless otherwise 
clinically indicated.  An ALT 
elevation > 2 Ã— ULN should trigger
prom pt testing of hepatic function 
within 72 hours .Any transaminase 
or bilirubin values which exceed 
2 Ã—ULN should prompt immediate 
retesting within 72 hour s.  While 
values remain in an abnormal range, 
testing frequency should be 
increased to at least weekly for the 
first month, gradually returning to 
monthly, and every 3 months as 
indicated by the results.  Local liver 
function panel analyses will also be 
performed more frequently, if 
necessary.
...
Footnote l:
lIf during the titration contact the 
determination is made to adjust the 
dose regimen, dose adjustments will 
be made using dispensed supply, and 
dose instructions will be provided by 
the investigator. The subjectâ€™s 
current dose will be entered into the 
interactive response technology 
(IRT) at each visit.  Drug 
dispensation/reconciliation will be 
conducted on a monthly basis for 
subjects who have monthly trial 
visits and once every 3 months for 
subjects who have trial visits every 
3months.  If additional drug supply 
is required for titration purposes, the 
site will arrange a subject visit for 
dispensation.
... Section 3.7.1.1, 
Screening ( -30days to 
1 day prior to Baseline)Screening for eligibility is required 
for all subjects.  The screening visit 
may be combined with the last visit 
from the previous protocol w ith all 
required assessments from each visit 
only performed once.  In some cases, 
if a subject enrolls in this trial from  a 
prior tolvaptan trial, the end of trial 
visit for that trial and the screening 
visit for this one may occur Screening for eligibility is required 
for all subjects.  The screening and 
baseline visit may be combined w ith 
the last visit from either the 
156-08-271 or 156 -13-210protocol 
with all required assessments from 
each visit perfor med only once.  
Therefore, in some cases, if a 
subject enrolls in this trial from a 
prior tolvaptan trial, the end of trial
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
122
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 122 06 March 2015Location Old Text Updated Text
simultaneously.  Required 
assessments are as follows :
1. Obtain subject consent.
2. Determine subject eligibility 
through inclusion/exclusi on criteria.  
3. Record demographic 
information and prior trial identifiers 
(screening identification [ID], subject 
ID, site ID, prior tolvaptan ADPKD 
trial protocol number).
4. Record medical/ADPKD 
history using prior trial data.
5. Revie w dietary 
recomm endations and compliance
â€¦.or last follow -upvisit for that trial 
and the screening and baseline visit 
for this one may occur 
simultaneously.  Required 
assessm ents for the screening visit 
are as follows :
1. Obtain subject consent.
2. Obtain subject â€™snew 
screening identification (ID)
assigned by interactive response 
technology (IRT) .
3. Determine subject 
eligibility through 
inclusion/exclusion criteria.  
4. Record demographic 
information and prior trial identifiers 
(screening ID, subject ID, prior 
tolvaptan ADPKD trial protocol 
number).
5. Record medical/ADPKD 
history using prior trial data.
6. Revie w dietary 
recommendations and compliance
â€¦
Section 3.7.2.4.1 Liver 
Test Abnormalities and 
Interruption/Discontinu
ation of Investigational 
Medical ProductThe appearance of any suspicious 
symptom or sign should trigger 
prom pt testing of hepatic function (ie, 
within 72 hours).  Local laboratory 
testing is ac ceptable, ideally with a 
concurrent central laboratory sample 
for confirmation.  An ALT elevation > 2 Ã—ULN or t he
appearance of any suspicious 
symptom or sign should trigger 
prom pt testing of hepatic function 
(ie, w ithin 72 hours).  Local 
laboratory tes ting is acceptable, 
ideally with a concurrent central 
laboratory sample for confirmation.
Section 3.7.5, 
Treatment Interruption 
and Discontinuation...
A subject who permanently 
discontinues IMP treatment may have 
the option to end trial participation 
(complete the early termination visit) 
or to continue participation off IMP 
and complete ongoing trial 
assessments as per protocol or w ith a 
modified (ie, less frequent) schedule 
as outlined in Section 3.8.3 ....
A subject who permanently 
discontinues IMP treatment end s
trial participation and the early 
termination visit should be 
completed.
Section 5.2, Eliciting 
and Reporting Adverse 
Eventsâ€¦ 
In addition, the sponsor must be 
notified immediately by telephone or 
fax of any immediately reportable 
events a ccording to the procedure 
outlined below  in Section 5.3.  â€¦â€¦ 
In addition, Quintiles (drug safety 
service) must be notified 
immediately by telephone or fax of 
any immediately reportable events 
according to the procedure outlined 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
123
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
EHORZLQ6HFWLRQ Â«
6HFWLRQ
,PPHGLDWHO\5HSRUWDEOH
(YHQWV7KHLQYHVWLJDWRUPXVWLPPHGLDWHO\
UHSRUWZLWKLQKRXUVDIWHUHLWKHUWKH
LQYHVWLJDWRURUVLWHSHUVRQQHOEHFRPHDZDUHRIDQ\6$(QHZOLYHUODERUDWRU\DEQRUPDOLW\UHTXLULQJVSHFLDOOLYHUH&5)FRPSOHWLRQRUFRQILUPHGSUHJQDQF\E\WHOHSKRQHRU
E\ID[WRWKHVSRQVRUDVRXWOLQHGLQ
$SSHQGL[ 
7KHLQYHVWLJDWRUPXVWLPPHGLDWHO\
UHSRUWZLWKLQKRXUVDIWHUHLWKHU
WKHLQYHVWLJDWRURUVLWHSHUVRQQHOEHFRPHDZDUHRIDQ\6$(QHZOLYHUODERUDWRU\DEQRUPDOLW\UHTXLULQJVSHFLDOOLYHUH&5)FRPSOHWLRQRUFRQILUPHGSUHJQDQF\E\WHOHSKRQH
RUE\ID[WR 4XLQWLOHVGUXJVDIHW\
VHUYLFHDVRXWOLQHGLQ $SSHQGL[ 

$SSHQGL[ 6DIHW\5HSRUWLQJ
4XLQWLOHV6RXWK0LDPL%OYG0RUULVYLOOH1&86$
3KRQH
)D[Â«,QYHVWLJDWRU3D\PHQWV&)6&OLQLFDO0DGLVRQ$YHVW)ORRU
$XGXERQ3$86$
3KRQH )D[Â«6DIHW\5HSRUWLQJ
4XLQWLOHV'UXJ6DIHW\6HUYLFH6RXWK0LDPL%OYG
0RUULVYLOOH1&86$
3KRQH)D[Â«,QYHVWLJDWRU3D\PHQWV4XLQWLOHV,QF
,QYHVWLJDWRU3D\PHQW$GPLQLVWUDWLRQ
'HSDUWPHQW7HOHVLV&RXUW6XLWH6DQ'LHJR&$86$
Â«
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCIPPD
PPD
PPD
PPDPPD
PPD
PPD
PPD
PPD
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 124 06 March 2015Previous Figure 3..-1 Trial Design Schematic
Revised Figure 3.1-1 Trial Design Schematic
ADDITIONAL RISK TO THE SUBJECT :
There is no additional risk to the subjects.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
125
Protocol 156 -13-211
Confidential -Otsuka Proprietary Information 125 06 March 2015Agreement
I,the undersigned principal investigator, have read and understand the protocol (including the 
Investigator's Brochure) and agree that it contains all the ethical, legal and scientific information 
necessary to conduct this trial in accordance with the princ iples of Good Clinical Practices and as 
described herein and in the sponsor's (or designee's) Clinical Research Agreement.
I will provide copies of the protocol to all physicians, nurses and other professional personnel to 
whom I delegate trial responsibi lities. I will discuss the protocol with them to ensure that they are 
sufficiently informed regarding the investigational new drug, [insert compound number], the 
concurrent medications, the efficacy  and safety parameters and the conduct of the trial in gen eral. 
I am aware that this protocol must be approved by the Institutional Review Board (IRB) or 
Independent Ethics Committee (IEC responsible for such matters in the clinical trial facility where 
[insert compound number] will be tested prior to commencemen t of this trial. I agree to adhere 
strictly to the attached protocol (unless amended in the manner set forth in Paragraph I of the 
sponsor's Clinical Research Agreement, at which time I agree to adhere strictly to the protocol as 
amended).
I understand th at this IRB -or IE C-approved protocol will be submitted to the appropriate 
regulator y authority/ies by the sponsor. I agree that clinical data entered on case report forms by 
me and my  staff will be utilized by the sponsor in various ways such as for submission to 
governmental regulator y authorities and/or in combination with clinical data gathered from other 
research sites, whenever applicable. I agree to allow sponsor monitors and auditors full access to 
all medical records at the research facility f or subjects screened or enrolled in the trial.
I agree to await IRB/IEC approval before implementation of any protocol amendments to this 
protocol. If, however, there is an immediate hazard to subjects, I will implement the amendment 
immediately, and prov ide the information to the IRB/IEC within 5 working day s. Administrative 
changes to the protocol will be transmitted to the IRB/IEC for informational purposes only.
I agree to provide all subjects with informed consent forms, as required by the applicable
regulations and by ICH guidelines. I agree to report to the sponsor any adverse experiences in 
accordance with the terms of the sponsor's Clinical Research Agreement and the relevant 
regional regulation(s) and guideline(s). I further agree to provide all required information 
regarding financial certification or disclosure to the sponsor for all investigators and sub -
investigators in accordance with the terms of the relevant regional regulation(s). I understand that 
participation in the protocol involves a commitment to publish the data from this trail in a 
cooperative publication prior to publication of efficacy and safety results on an individual basis.
________________________________________________
Principal or Coordinating Investigator Signature and Date
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
126
2WVXND3KDUPDFHXWLFDO'HYHORSPHQW	&RPPHUFLDOL]DWLRQ,QF
7KLVSDJHLVDPDQLIHVWDWLRQRIDQHOHFWURQLFDOO\FDSWXUHGVLJQ DWXUH
  
6,*1$785( 3$*(
'RFXPHQW1DPH
'RFXPHQW1XPEHU'RFXPHQW9HUVLRQ
6LJQHGE\ 0HDQLQJRI6LJQDWXUH6HUYHU'DWH
GG000\\\\ ++PPÂµ*07Â¶=23&
$0'


&OLQLFDO3KDUPDFRORJ\ 0DU*07
&OLQLFDO$SSURYDO 0DU*07%LRVWDWLVWLFV$SSURYDO 0DU*07
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
PPD
2WVXND3KDUPDFHXWLFDO
'HYHORSPHQW	&RPPHUFLDOL]DWLRQ,QF
,QYHVWLJDWLRQDO0HGLFLQDO3URGXFW
7ROYDSWDQ23&
5(9,6('&/,1,&$/35272&2/
$3KDVHE0XOWLFHQWHU2SHQODEHO7ULDOWR(YDOXDWHWKH/RQJ 7HUP6DIHW\RI
,PPHGLDWHUHOHDVH7ROYDSWDQ23&PJWRPJGD\6SO LWGRVHLQ6XEMHFWV
ZLWK$XWRVRPDO'RPLQDQW3RO\F\VWLF.LGQH\'LVHDVH
3URWRFRO1R
,1'1R
(XGUD&71R
&21),'(17,$/Â± 35235,(7$5<,1)250$7,21
&OLQLFDO'HYHORSPHQW3KDVH E
6SRQVRU 2WVXND3KDUPDFHXWLFDO'HYHORSPHQW	
&RPPHUFLDOL]DWLRQ,QF5HVHDUFK%RXOHYDUG5RFNYLOOH0DU\ODQG86$
6SRQVRU5HSUHVHQWDWLYHV*OREDO&OLQLFDO'LUHFWRU0HGLFDO'LUHFWRU
3KRQH )D[(PDLO
*OREDO&OLQLFDO'LUHFWRU
0HGLFDO'LUHFWRU
3KRQH )D[(PDLO
6U0DQDJHU&OLQLFDO'HYHORSPHQW
3KRQH
(PDLO
,PPHGLDWHO\5HSRUWDEOH(YHQW &OLQLFDO6DIHW\DQG3KDUPDFRYLJLODQ FH
3KRQH )D[
,VVXH'DWH  0D\
'DWHRI$PHQGPHQW  -XO\
'DWHRI$GPLQLVWUDWLYH&KDQJH 6HSWHPEHU
'DWHRI$PHQGPHQW 8. )HEUXDU\
'DWHRI$PHQGPHQW 8. 0DUFK
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
PPD
PPD
PPD PPD
PPD
PPD
PPD
PPD PPD
PPD
PPD
PPD
PPD
PPD PPD
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 2 06 March 2015Protocol Sy nopsis 
Name of Sponsor:  Otsuka Pharmaceutical Development 
& Commercialization, Inc.
Name of Investigational Medicinal Product: Tolvaptan 
(OPC -41061)Protocol # 156-13-211
IND#72,975
EudraCT# 2014-001516-
19
Protocol Title: A Phase 3b, Multi- center, Open- label Trial to Evaluate the 
Long Term Safet y of Immediate -release Tolvaptan ( OPC -
41061, 30 mg to 120 mg/day , Split dose) in Subjects with 
Autosomal Dominant Polycystic Kidney  Disease
Clinical Phase/Trial 
Type:Phase 3b/ Therapeutic use
Treatment Indication: Autosomal Dominant Polycystic Kidney  Disease (ADPKD)
Objective : The primary  objective of this trial is:
ï‚·To evaluate and describe the long -term safety  of tolvaptan.   
Trial Design: This trial is a phase 3b, multi -center, open- label extension trial.
Subjects will be eligible for screening into this trial if they :
ï‚·Completed and transferred from the double -blind 
Trial 156-13- 210 (12 -month period including 
post-treatment follow -up, regardless of whether this 
was on -treatment or off -treatment), or have completed 
all but the last follow -up visit, which will be combined 
with the first visit in this trial or
ï‚·Completed Trial 156-08- 271 or a prior tolvaptan 
ADPKD trial, or have completed all but the end of trial 
visit, which will be combined with the first visit in this 
trial or
ï‚·Interrupted or discontinued treatment in a prior 
tolvaptan ADPKD trial (other than Trial 156-13- 210).  
Subjects may  be enrolled with medical monitor 
approval, and additional close monitoring may  be 
required at the beginning of the trial
For purposes of ensuring subject safet y, all subjects will be 
monitored for hepatic safety  monthl y until they have 
accumulated 18 months of tolvaptan exposure .  After that, and 
following the approval from the medical monitor, hepatic 
monitoring will be required every  3months.  If subjects 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
129
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 3 06 March 2015approaching the 18 -month threshold have had prior 
transaminase abnormalities ( > 2 Ã— upper limit of normal 
[ULN]), the investigator is responsible for contacting the 
medical monitor to confirm the change in frequency  from 
monthly to every  3 months.  Until their prior treatment 
assignment is unblinded, all Trial 156-13- 210 subjects who are 
eligible for this trial are scheduled to have trialvisits/ hepatic 
monitoring monthly  for the first 18 months of this trial.  Once 
unblinding occurs, it can be determined which subjects 
received tolvaptan in Trial 156-13-210.  These subjects may 
have their trial visits/hepatic transaminase monitoring change 
to every  3months sooner as their previous tolvaptan exposure 
in Trial 156-13- 210 can count towards the 18- month threshold. 
Enrollment in this trial will be closed when the final eligible 
subject from Trial 156-13-210 enrolls in this trial.
Subject Population: This trial will include approximately 2,500 subjects over the 
age of 18 years with ADPKD diagnosed b y Pei -Ravine criteria
(modified by  magn etic resonance imaging [MRI ]), and who
have completed or participated in a prior ADPKD 
interventional investigational medicinal product (IMP) trial.
Inclusion/Exclusion 
Criteria:Main inclusion criteria:
ï‚·Male and female subjects ï‚³18 years with a confirmed 
diagnosis of ADPKD (during participation in prior 
tolvaptan trials) who have 
ï‚·Completed and transferred from the double -blind 
Trial 156-13- 210 (12 -month period including 
post-treatment follow -up, regardless of whether this 
was on -treatment or off -treatment), or 
ï‚·Completed Tr ial156-08- 271 or a prior ADPKD 
tolvaptan trial, or
ï‚·Interrupted or discontinued treatment in a prior 
tolvaptan ADPKD trial other than Trial 156-13- 210.  
Subjects may  be enrolled with the medical monitor 
approval, and additional close monitoring may  be 
required at the beginning of the trial
ï‚·Estimated glomerular filtration rate 
(eGFR )ï‚³20mL/min/1.73m2within 3months of the 
baseline visit.  Subjects who have an eGFR 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
130
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 4 06 March 2015â‰¤ 20 mL/min/1.73m2may be enrolled with medical 
monitor and sponsor approval and increased frequency  of 
monitoring to ensure subjectsâ€™ safety
ï‚·Renal function will be assessed during screening by  using 
historical laboratory  values ( within 3 months from the 
screening visit) for serum creatinine levels to calculate the 
eGFR.  The eGFR values will be estimated based on the 
Chronic Kidney  Disease - Epidemiology  (CKD -EPI) 
formula
Main exclusion criteria:
ï‚·Need for chronic diuretic use
ï‚·Hepatic impairment based on hepatic laboratory
assessments (a lanine aminotransferase [ALT], a spartate 
aminotransferase [AST], bilirubin , total [BT] ) other than 
that expected for ADPKD with cy stic liver disease
Trial Site(s): Approximately 220 enrolling sites including but not limite d to 
the following regions: North America, South America, Eastern
Europe, Western Europe, Russian Federation , and Australia.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
131
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 5 06 March 2015Investigational 
Medicinal Product(s), 
Dose, Dosage 
regimen, Treatment 
period, Formulation, 
Mode of 
Administration:The dose regimens to be used in this trial are 15/15 mg, 
30/15 mg, 45/15 mg, 60/30 mg , and 90/30 mg.
Tolvaptan tablets (15 mg or 30 mg ) will be self- administered 
orally  as split- dose regimens, twice dail y, once upon 
awakening and another approximately  8 to 9 hours later. 
Doses will be recorded as ea rly dose/late dose (eg, 60/ 30mg).  
Subjects will receive open-label tolvaptan for the duration of 
the trial. 
A subject â€™s starting dose in this trial will be dependent on the
trial in which they  were previously  enrolled :
ï‚·156-13-210- initiated on tolvaptan at a split- dose of 
45/15 mg with upward titration every  3 to 4 day s to 
60/30 mg or 90/30 mg per day  according to tolerability
ï‚·156-08-271- will retain the last dose level from 271 
and start at the same dose in this trial
ï‚·Prior tolvaptan trials -initiated on tolvapt an at a 
split-dose of 45/15 mg with upward titration every 3 to 
4 day s to 60/30 mg or 90/30 mg per day  according to 
tolerability
Down titration to 30/15 mg or 15/15 mg will be allowed at the 
discretion of the inv estigator according to individual 
tolerability  and with medical monitor notification .  Further 
down titration to 30 or 15 mg once dail y ma y be allowed only
for metabolic drug -drug interaction and requires medical 
monitor approval.
Trial Assessments: Screening : Informed consent, m edical history (including 
ADPKD updates, as required) , determination of eligibility  
through inclusion/exclusion criteria, dietary  review, vital signs, 
clinical laboratory  assessments, phy sical examination, urine 
pregnancy  test (women of child- bearing potential only
[WOC BP]), concomitant medication s and laboratory  tests to 
determine eligibility .
Safety :  Adverse event s(AEs) , vital signs, directed physical 
examination, dietary  review, self -assessed drug tolerability , 
serum chemi stry tests ( including serum transaminases, alkaline 
phosphatase, bilirubin, and serum sodium ) and concomitant 
medications.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
132
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK



&ULWHULDIRU(YDOXDWLRQ6DIHW\
â€¢$(V
â€¢9LWDOVLJQV
â€¢&OLQLFDOODERUDWRU\DVVHVVPHQWV
â€¢6HUXPWUDQVDPLQDVHHOHYDWLRQV IRUIUHTXHQF\[[
[DQG[8/1WLPHWRRQVHWWLPHWRSHDNOHYHOV
WLPHRIRIIVHW[[RU[ 8/1UHVSRQVHWRGHFKDOOHQJHDQGUHFKDOOHQJHDQGIUHTXHQF\RISURJUHVVLRQWR+\Â¶VODERUDWRU\FULWHULD$/7RU$67![8/1DQG%7![8/1ZLWKRXWDONDOLQH
SKRVSKDWDVH â‰¥[ 8/1
â€¢6HUXPVRGLXPH[FXUVLRQVDERYH RU
PPRO/RUEHORZRUPPRO/



6WDWLVWLFDO0HWKRGV 6DPSOHVL]H6DPSOHVL]HZDVQRWGHWHUPLQH GE\DIRUPDO
FRPSXWDWLRQWRDFKLHYHDWDUJHWSRZHU1RHIILFDF\DQDO\VHV
DUHSODQQHG,WLVH[SHFWHGWKDWDSSUR[LPDWHO\VXEMHFWVPD\HQUROOIURPSUHYLRXVWROYDSWDQWULDOV
$QDO\VLVGDWDVHWV
â€¢(QUROOHG3RSXODWLRQDOOVXEMHFWVZKRZHUHHQUROOHGWR
WKLVRSHQODEHOWULDO
â€¢6DIHW\3RSXODWLRQDOOVXEMHFWV LQWKH(QUROOHG
3RSXODWLRQZKRWDNHDWOHDVWGRVHRI,03
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 7 06 March 2015Safety  anal yses:  Safet y analysis will be conducted based on 
standard safet y variables, including AEs, clinical laboratory  
data, ph ysical examinations and vital signs.  Potentially  
clinically  significant results in laboratory  tests identified using 
prospectivel y defined criteria, including criteria on liver 
enzy me elevations, will be summarized.
Trial Duration: Trial duration is planned to continue 
ï‚·Until t he last subject from Trial 156-13- 210 completes 
18months of tolvaptan treatment in this trial
ï‚·All subjects will receive at least 18 months of tolvaptan 
treatment in the extension study .   Trial 156-13- 210 
subjectsor subjects enrolling from other trials may opt 
to conclude their participation in this trial if tolvaptan 
becomes available before they  complete 18 months of 
treatment in this trial 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
134
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK7DEOHRI&RQWHQWV
3URWRFRO6\QRSVLV  
7DEOHRI&RQWHQWV  
/LVWRI,QWH[W7DEOHV  
/LVWRI,QWH[W)LJXUHV  
/LVWRI$SSHQGLFHV  
/LVWRI$EEUHYLDWLRQVDQG'HILQLWLRQVRI7HUPV  
 ,QWURGXFWLRQ  
 1RQFOLQLFDO'DWD  
 &OLQLFDO'DWD  
 .QRZQDQG3RWHQWLDO5LVNVDQG%HQHILWV  
 7ULDO5DWLRQDOHDQG2EMHFWLYHV  
 7ULDO5DWLRQDOH  
 'RVLQJ5DWLRQDOH  
 7ULDO2EMHFWLYHV  
 7ULDO'HVLJQ  
 7\S H'HVLJQRI7ULDO  
 7UHDWPHQWV  
 'RVLQJZLWK&<3$3RWHQW,QKLELWRUV  
 'RVLQJZLWK&<3$0RGHUDWH,QKLELWRUV  
 7ULDO3RSXODWLRQ  
 (OLJLELOLW\&ULWHULD  
 ,QIRUPHG&RQVHQW  
 ,QFOXVLRQ&ULWHULD  
 ([FOXVLRQ&ULWHULD  
 7ULDO(QGSRLQWV  
 6DIHW\(QGSRLQWV  
 
 
 0HDVXUHVWR0LQLPL]H$YRLG%LDV  
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 7ULDO3URFHGXUHV  
 6FKHGXOHRI$VVHVVPHQWV  
 6FUHHQLQJ GD\VWRGD\SULRUWR%DVHOLQH 
 %DVHOLQH'D\  
 0RQWKO\9LVLW Â±GD\V  
 (YHU\0RQWKV Â±GD\V  
 (DUO\7HUPLQDWLRQ(QGRI7UHDWPHQWGD\V  
 GD\)ROORZ XS9LVLWGD\V  
 6DIHW\$VVHVVPHQWV  
 $GYHUVH(YHQWV  
 &OLQLFDO/DERUDWRU\$VVHVVPHQWV  
 3K\VLFDO([DPLQDWLRQDQG9LWDO6LJQV  
 $VVHVVPHQWRI/LYHU6\PSWRPV6LJQVRU7HVW$EQRUPDOLWLH V 
 
 
 
 
 
 7UHDWPHQW,QWHUUXSWLRQDQG'LVFRQWLQXDWLRQ  
 (QGRI7ULDO  
 ,QGHSHQGHQW'DWD0RQLWRULQJ&RPPLWWHH  
 6WRSSLQJ5XOHV:LWKGUDZDO&ULWHULDDQG3URFHGXUHV  
 (QWLUH7ULDO  
 ,QGLYLGXDO6LWH  
 ,QGLYLGXDO6XEMHFW  
 6FUHHQ)DLOXUHV  
 'HILQLWLRQRI&RPSOHWHG6XEMHFWV  
 'HILQLWLRQRI6XEMHFWV/RVWWR)ROORZXS  
 6XEMHFW&RPSOLDQFH  
 3URWRFRO'HYLDWLRQV  
 5HVWULFWLRQV  
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
CCICCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 3URKLELWHGRU5HVWULFWHG0HGLFDWLRQV  
 'LHWDU\5HVWULFWLRQVDQG5HFRPPHQGDWLRQV  
 5HSRUWLQJRI$GYHUVH(YHQWV  
 'HILQLWLRQV  
 (OLFLWLQJDQG5HSRUWLQJ$GYHUVH(YHQWV  
 ,PPHGLDWHO\5HSRUWDEOH(YHQWV  
 3UHJQDQF\  
 )ROORZXSRI$GYHUVH(YHQWV  
 )ROORZXS RI1RQVHULRXV$GYHUVH(YHQWV  
 )ROORZXSRI3RVW7ULDO6HULRXV$GYHUVH(YHQWV  
 )ROORZXSDQG5HSRUWLQJRI6HULRXV$GYHUVH(YHQWV2FFXUULQ JDIWHU
/DVW6FKHGXOHG&RQWDFW  
 
 6WDWLVWLFDO$QDO\VLV  
 6DPSOH6L]H  
 'DWDVHWIRU$QDO\VLV  
 +DQGOLQJRI0LVVLQJ'DWD  
 ,QWHULP$QDO\ VLV  
 7ULDO2XWFRPH$QDO\VHV  
 $QDO\VLVRI'HPRJUDSKLFDQG%DVHOLQH&KDUDFWHULVWLFV  
 6DIHW\$QDO\VLV  
 $GYHUVH(YHQWV  
 9LWDO6LJQV  
 &OLQLFDO/DERUDWRU\$VVHVVPHQWV  
 6HUXP6RGLXP  
 
 
 
 0DQDJHPHQWRI,QYHVWLJDWLRQDO0HGLFLQDO3URGXFW 
 3DFNDJLQJDQG/DEHOLQJ  
 6WRUDJH  
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCICCICCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 11 06 March 20158.3 Accountability ...................................................................................................59
8.4 Returns and Destruction ....................................................................................59
9 Records Management ......................................................................... 59
9.1 Source Documents .............................................................................................59
9.2 Data Collection ..................................................................................................59
9.3 File Management at the Trial Site .....................................................................60
9.4 Records Retention at the Trial Site ....................................................................60
10 Quality Control and Quality Assurance ........................................... 61
10.1 Monitoring .........................................................................................................61
10.2 Auditing .............................................................................................................61
11 Ethics and Responsibility ................................................................... 61
12 Confidentiality .................................................................................... 61
13 Amendment Policy .............................................................................. 62
14 References ............................................................................................ 63
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
138
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 12 06 March 2015List of In-text Tables
Table 1.2-1 Vasopressin Blockade Across Differing Severities of 
ADPKD: Effect on Rate of Estimated Glomerular Filtration 
Decline in Chronic Kidney  Dise ase Stages 1-3 .............................19
Table 3.2-1 Trial Treatments .............................................................................26
Table 3.4.2 -1 Inclusion Criteria ...........................................................................28
Table 3.4.3 -1 Exclusion Criteria ..........................................................................29
Table 3.7-1 Schedule of Assessments ...............................................................31
Table 3.7.2.2 -1 Clinical L aboratory  Assessments ...................................................40
Table 4.1-1 Strong and Moderate CYP3A I nhibitors (partial list) ....................48
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
139
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 13 06 March 2015List of In-text Figures
Figure 3.1 -1 Trial Design Schematic ..................................................................24
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
140
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/LVWRI$SSHQGLFHV
$SSHQGL[ 1DPHVRI6SRQVRU3HUVRQQHO  
$SSHQGL[ ,QVWLWXWLRQV&RQFHUQHG:LWKWKH7ULDO  
$SSHQGL[ 
$SSHQGL[  
$SSHQGL[  3URWRFRO$PHQGPHQWVDQG$GPLQLVWUDWLYH&KDQJHV 
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/LVWRI$EEUHYLDWLRQVDQG'HILQLWLRQVRI7HUPV
$EEUHYLDWLRQ 'HILQLWLRQ
$'3.' $XWRVRPDOGRPLQDQWSRO\F\VWLFNLGQH\GLVHDVH
$( $GYHUVHHYHQW$/7 $ODQLQHDPLQRWUDQVIHUDVH$67 $VSDUWDWHDPLQRWUDQVIHUDVH$93 $UJLQLQHYDVRSUHVVLQ%7 %LOLUXELQWRWDOF$03 F\FOLFDGHQRVLQHPRQRSKRVSKDWH&.' &KURQLFNLGQH\GLVHDVH&.'(3, &KURQLF.LGQH\'LVHDVH(SLGHPLRORJ\&5) &DVHUHSRUWIRUP&65 &OLQLFDOVWXG\UHSRUW',/, 'UXJLQGXFHGOLYHULQMXU\',/,1 'UXJLQGXFHGOLYHULQMXU\QHWZRUN
H&5) (OHFWURQLFFDVHUHSRUWIRUP
H*)5 HVWLPDWHGJORPHUXODUILOWUDWLRQUDWHH*)5&.'(3((VWLPDWHGJORPHUXODUILOWUDWLRQUDWHFDOFXODWHGE\WKH&KURQLF .LGQH\
'LVHDVH(SLGHPLRORJ\ &.'(3,IRUPXOD
(0$ (XURSHDQ0HGLFLQHV$JHQF\(R7[ (QGRIWUHDWPHQW(65' (QGVWDJHUHQDOGLVHDVH(XGUD&7 (XURSHDQ&OLQLFDO7ULDO'DWD%DVH*&3 *RRG&OLQLFDO3UDFWLFH+$& +HSDWLFDGMXGLFDWLRQFRPPLWWHH,% ,QYHVWLJDWRUÂ¶VEURFKXUH,&) ,QIRUPHGFRQVHQWIRUP,&+ ,QWHUQDWLRQDO&RQIHUHQFHRQ+DUPRQLVDWLRQ,' ,GHQWLILFDWLRQ,'0& ,QGHSHQGHQWGDWDPRQLWRULQJFRPPLWWHH,(& ,QGHSHQGHQWHWKLFVFRPPLWWHH,03 ,QYHVWLJDWLRQDOPHGLFLQDOSURGXFW,1' ,QYHVWLJDWLRQDO QHZGUXJ,5% ,QVWLWXWLRQDOUHYLHZERDUG,5( ,PPHGLDWHO\UHSRUWDEOHHYHQW,57 ,QWHUDFWLYHUHVSRQVHWHFKQRORJ\0HG'5$ 0HGLFDO'LFWLRQDU\ IRU5HJXODWRU\$FWLYLWLHV
0+5$ 0HGLFLQHVDQG+HDOWKFDUHSURGXFWV5HJXODWRU\$JHQF\05, 0DJQHWLFUHVRQDQFHLPDJLQJ23& 2WVXND3KDUPDFHXWLFDO&R23'& 2WVXND3KDUPDFHXWLFDO'HYHORSPHQW	&RPPHUFLDOL]DWLRQ,QF3.' 3RO\F\VWLFNLGQH\GLVHDVH6$( 6HULRXVDGYHUVHHYHQW
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 16 06 March 2015SAP Statistical Analy sis Plan
SD Standard deviation
TEAE Treatment -emergent adverse event
ULN Upper limit of normal
UK United Kingdom
US or USA United States or United States of America
WOCBP Women of childbearing potential
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
143
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 17 06 March 20151 Introduction
Tolvaptan (OPC -41061) is a selective arginine vasopressin (AVP) t ype 2 (V 2) receptor 
antagonist that is currently  approved in the United States (US), Europe, Australia, 
Canada, China, Hong Kong, Indonesia, Japan, Republic of Korea, and Taiwan, for 
various forms of h yponatremia, and in Japan for volume overload in heart failure or liver 
cirrhosis.
Tolvaptan is also being inves tigated for the use in adults to treat autosomal dominant 
polycystic kidney  disease (ADPKD), an inherited condition which leads to progressive 
destruction of normal kidney  structure leading to end -stage renal disease (ESRD).  The 
disease affects the struct ure of the kidney s through proliferation and growth of numerous 
fluid- filled cy sts.  The expanding cy sts compress normal tissue and blood vessels 
resulting in ischemia, inflammation and fibrosis leading to progressive nephron loss.  The 
remaining nephrons are initially  able to compensate through glomerular hyperfiltration up 
to a point when nephron loss is so great that compensation is no longer adequate and 
renal function begins to decline.  Clinical manifestations of kidney  disease may  be 
sporadic (hematu ria, infections, pain) or chronic (hy pertension, albuminuria, renal 
insufficiency ) and indicate ongoing and cumulative damage to the kidney .
The number of diagnosed ADPKD cases was estimated at 116,228 in the US in 2009.  
The estimated prevalence of diagno sed ADPKD is similar in Europe and estimated to be 
< 5 per 10,000.1  Though a rare genetic disease, it ranks as the 6thleading cause of ESRD 
in the US (2.3% of the new ESRD cases).2  An estimated 4 5% to 70% of patients with 
ADPKD progress to ESRD by  age 65.3  Over the past 30 y ears, the age of onset for 
ESRD among ADPKD patients has remained the same (median age of 54).  I n contrast, 
effective therap y has delayed the onset of ESRD in patients with nephropathy  due to 
hypertension, diabetes, and glomerulonephritis.
There are currently  no therapies which can slow the deterioration of kidney  function in 
ADPKD.  Current management focuses on ameliorating s ymptoms of pain, c ontrol of 
blood pressure, and treatment of infections with antibiotics.  None of these treatments 
target the underly ing cause of the disease.  Often, the only  definitive intervention for 
renal complications in ADPKD is kidney  transplantation, which ty pical ly occurs after 
years of hemodialysis.
In the US, the development program for tolvaptan for ADPKD was granted Fast -track 
designation on 20 Jan 2006 and orphan drug designation on 06 Apr 2012.  Tolvaptan was 
designated as an orphan drug for prevention of th e progression of ADPKD in Japan on 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
144
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 18 06 March 201511Aug 2006.  The European Medicines Agency (EMA) granted orphan designation for 
the use of tolvaptan for the treatment of ADPKD on 5 Aug 2013.
If approved, tolvaptan would be the first available therap y to slow kidney  disease 
progression in adults with ADPKD .4 5  Refer to the Tolvaptan Investigatorâ€™s Brochure 
(IB) for more information.4
1.1 Nonclinical Data
Rodent models of ADPKD and ex -vivo human ADPKD cell and tissue cultures have 
implicated AVP as a promoter of kidney  cyst growth.6 7  AVP -induced cyclic adenosine 
monophosphate (cAMP) increases proliferation of ADPKD renal tub ular epithelium and 
chloride -mediated, intra -cystic, fluid secretion.  This leads to cy st expansion which 
disrupts renal architecture leading to ischemia, kidney fibrosis, and irreversible damage 
to the kidney , ultimatel y impairing its function.  Tolvaptan inhibits cAMP production by  
blocking AVP binding to the renal AVP -V2receptor.  For information on nonclinical 
toxicology  and absorption, distribution and metabolism data on tolvaptan please refer to 
the most current version of the IB.4
1.2 Clinical Data
Tolvaptan was clinically  effective in delay ing decline of renal function, as determined by  
changes in serum creatinine concentrations over 3 years, in an international, multicenter, 
clinical trial in subjects with chronic kidney  disease (CKD) stage 1 to 3 due to ADPKD.8  
These effects were consistent across each of these CKD stages, supporting tolvaptanâ€™s 
potential utility  in earl y tomid-stage disease (Table 1.2-1) , and creating a compelling 
argument for long -term effectiveness in those initiating therapy  at an earl y stage and 
adhering to therap y as the disease progresses.  This trial also demonstrated an acute and 
persistent reduction on rate of kidney  cystic growth.  The reductions in rate of kidney  
growth correlated with reductions in kidney  pain and with preservation of renal function.  
Similar correlations were observed in a smaller, matched -control study  
(Study 156-09- 283).9  Thus, the clinical data have confirm ed the non- clinical effects seen 
in animals (see Section 1.1) and support approval of tolvaptan as the first agent to s low 
the progression of ADPKD.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
145
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK7DEOH 9DVRSUHVVLQ%ORFNDGH$FURVV'LIIHULQJ6HYHULWLHVRI
$'3.'(IIHFWRQ5DWHRI(VWLPDWHG*ORPHUXODU)LOWUDWLRQ
'HFOLQHLQ&KURQLF.LGQH\'LVHDVH6WDJHV
&.'6WDJH
E\H*)5 &.'(3,
P/PLQP1
7ROYDSWDQ
3ODFHERH*)56ORSH
7ROYDSWDQH*)56ORSH
3ODFHER (IIHFW6L]H5HODWLYH
(IIHFW6L]H
6WDJHâ‰¥   D 
6WDJH   D 
6WDJHE
D     
E     
H*)5&.'(3( HVWLPDWHGJORPHUXODUILOWUDWLRQUDWHFDOFXODWHG E\WKH&KURQLF.LGQH\'LVHDVH
(SLGHPLRORJ\&.'(3,IRUPXOD
D$OOS
E&.'6WDJHUHODWLYHHIIHFWVL]H1 WROYDSWDQSODFHER 
6RXUFH7ULDO FOLQLFDOVWXG\UHSRUW&65'DWDRQ ILOH






 .QRZQDQG3RWHQWLDO5LVNVDQG%HQHILWV
$'3.'LVDGHYDVWDWLQJSURJUHVVLYHGLVHDVHWKDWSODFHVDWUHPH QGRXVEXUGHQRQSDWLHQWV
DQGWKHLUIDPLOLHV7KHULVNDSDWLHQWLVZLOOLQJWRDFFHSWLV DSHUVRQDOGHFLVLRQEDVHGRQ
KLVKHULQGLYLGXDODQGIDPLOLDOH[SHULHQFHZLWKWKHGLVHDVH7 ROYDSWDQLVSRWHQWLDOO\WKH
ILUVWWKHUDS\WKDWRIIHUVSDWLHQWVDWUHDWPHQWRSWLRQWRVORZW KHLUGLVHDVHSURJUHVVLRQ
KRZHYHUDVRI-DQXDU\LWKDVQRW\HWEHHQDSSURYHGIRUW KLVLQGLFDWLRQ7KH
WUHDWPHQWULVNVDUHZHOOFKDUDFWHUL]HGPDQDJHDEOHDQGPXVWEH ZHLJKHGDJDLQVWWKH
FRQVHTXHQFHVRIQRWUHDWPHQW
$VRI0DUSRROHGH[SRVXUHGDWDDUHDYDLODEOHIURPW ULDOVLQYROYLQJ
 VXEMHFWVZRUOGZLGHFRPSULVLQJVXEMHFWVLQWULDOVIRU ZLWKKHDUWIDLOXUH
VXEMHFWVLQWULDOVIRUK\SRQDWUHPLDVXEMHFWVLQDORQJ WHUPWULDOIRU$'3.'
 VXEMHFWVLQDVKRUWWHUPWULDOIRU$'3.'RUUHQDOLPSDLUPHQW VXEMHFWVLQWULDOV
IRUFDUGLDFHGHPDVXEMHFWVLQWULDOVIRUKHSDWLFHGHPD VXEMHFWVZLWKUHQDO
LPSDLUPHQWLQDSKDVHWULDODQGKHDOWK\VXEMHFWVLQFO LQLFDOSKDUPDFRNLQHWLF
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 20 06 March 2015trials.  Overall, subjects were exposed to ora l doses of tolvaptan ranging from 3.75 to 
480mg.  The median exposure for all doses of oral formulations combined was 29 day s, 
with a mean exposur e of 228days (ï‚±346 day s).
Pooled safet y data from 80 trials indicate that the most commonly  reported (> 3%) 
treatment -emergent adverse events (TEAEs) for tolvaptan -treated subjects were thirst 
(25.8%), dr ymouth (10.8%) and pollakiuria (9.9%).
The most notable safet y issue associated with chronic tolvaptan use, which was new ly 
identified in Trial 156 -04-251, was the potential for idiosy ncratic hepatic toxicity . An 
imbal ance in the proportion of subjects with elevated transaminases (tolvaptan > placebo) 
led to identification of 3 subjects (total, combined from Trials 156 -04-251 and 
156-08- 271) with laboratory and clinical evidence of potentially  serious drug -induced 
liver injury  (DILI).10Based on the available data from the afore -mentioned trials, the 
sponsor proposes that appropriate subject monitoring and management be implemented to 
mitigate this potential risk in the ADPKD population.  
In this extension trial, subjects enrolling from the double -blind Trial 156- 13-210 will 
have monthly  visits and transaminase level assessments for the first 18 months while the 
treatment code from Trial 156-10- 210 remains blinded, to ensure that all subjects have 
adequate safet y monitoring during this pe riod of susceptibility .  Once unblinding occurs, 
it can be determined which subjects received tolvaptan in Trial 156-13- 210.  These 
subjects may  have their trial vis its/hepatic transaminase monitoring change to every  
3months sooner as their previous tolva ptan exposure in Trial 156-13- 210 can count 
towards the 18- month threshold.  If subjects approaching the 18 -month threshold have 
had prior transaminase abnormalities (> 2 Ã—upper limit of normal [ ULN ]),the 
investigator is responsible for contacting the medical monitor to confirm the change in 
frequency from monthl y to every  3months.  Subjects enrolling from the open- label 
Trial 156-08-271 will have transaminase assessments conducted every  3months , since 
they will have already  received tolvapt an for at le ast 18 months. The current IB lists all 
of the tolvaptan trials.   Subjects enrolling in this trial who were in a previous ADPKD 
tolvaptan trial other than Trials 156-13- 210 and 156-08- 271 will have monthly  visits and 
alanine aminotransferase (ALT) level assessments for the first 18 months .
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
147
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 7ULDO5DWLRQDOHDQG2EMHFWLYHV
 7ULDO5DWLRQDOH
(YLGHQFHIURPSUHYLRXVVWXGLHVVXJJHVWVWKDWGXULQJWKHILUVW PRQWKVRIORQJWHUP
WUHDWPHQWLQVXEMHFWVZLWK$'3.'$/7DQGRUDVSDUWDWHDPLQRWUD QVIHUDVH$67
HOHYDWLRQVDQGHYLGHQFHRILGLRV\QFUDWLF',/,RFFXUVDWDJUHDWH UIUHTXHQF\LQWROYDSWDQ
WUHDWHGVXEMHFWV+RZHYHUWKHUDWHRIQHZWUDQVDPLQDVHHOHYDW LRQVEH\RQGPRQWKV
DQGXSWR\HDUVZDVVLPLODUEHWZHHQWROYDSWDQWUHDWPHQWDQG SODFHERVXEMHFWV
2YHUWKH\HDUVRISODFHERFRQWUROOHGWUHDWPHQW$/7ZDVHOHYD WHGWRDJUHDWHUWKDQ
WKUHHWLPHVWKHXSSHUOLPLWRIQRUPDO! Ã®8/1LQRIWRO YDSWDQVXEMHFWV
FRPSDUHG ZLWKRISODFHERVXEMHFWV7RGDWH WROYDSWDQVXEMH FWVÂ¶WUDQVDPLQDVHVDQG
ELOLUXELQOHYHOVUHDFKHG+\Â¶VODERUDWRU\FULWHULD!Ã®DQG!Ã® 8/1UHVSHFWLYHO \
8SRQGLVFRQWLQXDWLRQDOOVXEMHFWVÂ¶OLYHUWHVWVVKRZHGUHYHUVLE LOLW\RIWKHHOHYDWLRQZLWKLQ
DSSUR[LPDWHO\PRQWKVDIWHUWROYDSWDQZDVGLVFRQWLQXHG1HYHU WKHOHVVZLWKRXW
DGHTXDWHPRQLWRULQJDQGPDQDJHPHQWLWLVHVWLPDWHGWKDWD ULVNIRULUUHYHUVLEOH
OLYHULQMXU\PD\H[LVW
7KURXJKPRUHIUHTXHQWHJPRQWKO\PRQLWRULQJRIOLYHUWUDQVDP LQDVHV WKHFXUUHQWWULDO
ZLOOPRUHSUHFLVHO\GHILQHWKHSRWHQWLDOIRU',/,SUHYLRXVO\RE VHUYHGLQ
7ULDO )UHTXHQWPRQLWRULQJZLOODOVRGHWHFW VPDOOHUH OHYDWLRQVHDUOLHU
SHUPLWWLQJFORVHUDQGPRUHWKRURXJKHYDOXDWLRQDQGLQWHUYHQWLRQ LQFOXGLQJGUXJ
LQWHUUXSWLRQRUGLVFRQWLQXDWLRQ7KLVLVH[SHFWHGWRPLWLJDWH WKHULVNRIVHULRXVRU
LUUHYHUVLEOHLQMXU\













8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK
7KLVWULDOZLOOH[WHQGRXUXQGHUVWDQGLQJRIWROYDSWDQÂ¶VORQJWH UPVDIHW\LQ$'3.'
SDWLHQWV
 'RVLQJ5DWLRQDOH
,QDQLPDOPRGHOVRIF\VWLFGLVHDVHVXFFHVVIXOWUHDWPHQWRIGLV HDVHSURJUHVVLRQDV
LQGLFDWHGE\NLGQH\VL]HDSSHDUHG WRUHTXLUHHDUO\FRQVWDQWLQKL ELWLRQRIWKHYDVRSUHVVLQ
9UHFHSWRU7KHFOLQLFDO IRUPXODWLRQRIWROYDSWDQUHTXLUHV VSOLWG RVLQJWRPDLQWDLQ
VXSSUHVVLRQRI$93DFWLRQDFURVVKRXUV$KLJKHUGRVHLVXV HGHDUO\LQWKHGD\ZLWKD
ORZHUGRVHDSSUR[LPDWHO\WRKRXUVODWHULQRUGHUWRSURGXFH DPD[LPDOLQKLELWLRQRQ
ZDNLQJZLWKDJUDGXDOIDOORIIRIHIIHFWGXULQJWKHQLJKWZKHQ IUHTXHQWXULQDWLRQFRXOG
OHDGWRDQLQWHUUXSWLRQRIVOHHS
 7ULDO2EMHFWLYHV
7KHSULPDU\REMHFWLYHRIWKLVWULDOLV
â€¢7RHYDOXDWHDQGGHVFULEHWKHORQJWHUPVDIHW\RIWROYDSWDQ
 7ULDO'HVLJQ
 7\SH'HVLJQRI7ULDO
7KLVWULDOLVDSKDVHEPXOWLFHQWHURSHQODEHOWULDO
(OLJLEOHVXEMHFWVZLOOKDYHDQRSSRUWXQLW\WRHQUROOLQWR7ULDO IROORZLQJ
FRPSOHWLRQRIWKHIROORZXSYLVLWVRIWKHSUHYLRXVWULDO(OLJ LEOHVXEMHFWVIURP
7ULDOV DQGFDQKDYHWKHODVWYLVLWDVVHVVP HQWVIURPWKHLUSUHYLRXV
UHVSHFWLYHSURWRFROVHQGRIWULDOYLVLWIRU VXEMHFWV DQGODVWIROORZXSYLVLWIRU
VXEMHFWVRYHUODSWKHILUVWYLVLWLQWKLVWULDO7K HVHODVWYLVLWDVVHVVPHQWVFDQ
EHFRPELQHGZLWKWKHVFUHHQLQJDQGEDVHOLQHYLVLWV IRUWKLVWULD OZLWKDOOUHTXLUHG
DVVHVVPHQWVIURPHDFKYLVLWSHUIRUPHGRQO\RQFHVRORQJDVWKHW LPHEHWZHHQWKHODVW
YLVLWDVVHVVPHQWVIURPWKHSUHYLRXVWULDODQGWKHVFUHHQLQJYLV LWIRUWKLVWULDOLVZLWKLQ
GD\V,IWKHILUVWYLVLWLQWKLVWULDOFRPELQHVWKHODVWYLV LWIURPDSUHYLRXVWULDOZLWK
ERWKWKHVFUHHQLQJDQGWKHEDVHOLQHYLVLWVLQWKLVWULDOWKHUH VXOWVIURPODERUDWRU\
DVVHVVPHQWVSHUIRUPHGDWWKLVFRPELQHGYLVLWZLOOQRWEHLPPHGL DWHO\DYDLODEOH6KRXOG
DQ\ODERUDWRU\DEQRUPDOLWLHVEHLGHQWLILHGWKHLQYHVWLJDWRUZL OOQHHGWRQRWLI\WKHVXEMHFW
DQGSURYLGHLQVWUXFWLRQVUHJDUGLQJGRVLQJRUUHWXUQLQJWRWKHVL WHIRUDGGLWLRQDO
DVVHVVPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 23 06 March 2015Medical monitor approval is needed for enrollment of subjects whose completion of the 
preceding trial prior to entry in this trial exceeds 3 month s, and these subjects willbe 
require d to undergo all screening and baseline assessments .
After consenting, subjects w ill be assigned a new screening number.  Subjects who are 
found to be eligible will retain the same subject number they  had been assigned in their 
previous tria l.  For purposes of ensuring subject safety , tolvaptan exposure of at least 
18 months is required for all subjects.  While Trial 156-13- 210 remains blinded, subjects 
enrolling from an y prior trial besides Trial 156-08-271 are schedule dto have monthly  
hepatic monitoring for the first 18 months of this trial.  After that, following the approval 
of the medical monitor, hepatic monitoring will take place every  3 months.  Subjects 
enrolling from Trial 156-08- 271 will have hepatic monitoring every  3months.  All 
Trial156-13- 210 subjects who are eligible for this trial will initially  be schedule dto have 
trial visits and hepatic monitoring monthly  for the first 18 months, then every  3 months
thereafter, because their tolvaptan exposure cannot be determined since Tria l 156-13-210 
is a double blind trial.  Once unblinding occurs, it can be determined which subjects 
received tolvaptan in Trial 156-13- 210.  These subjects may  have their trial vis its/hepatic 
transaminase monitoring change dto every  3months sooner as their previous tolvaptan 
exposure in Trial 156-13- 210 can count towards the 18- month threshold.   Subjects from 
prior tolvaptan trials other than Trial 156 -08-271 will have monthly  trial visits/AL T level 
assessments for the first 18 months.  After that, the trial visits/AL T monitoring will be 
conducted every  3 months after the change in frequency  is confirmed with the medical 
monitor.
Enrollment in this trial will be closed when the last eligible subject from 
Trial 156-13- 210 enr olls in this trial. 
The duration of this trial is planned to continue 
ï‚·Until t he last subject from Trial 156-13- 210 completes 18 months of tolvaptan 
treatment in this trial
ï‚·All subjects will receive at least 18 months of tolvaptan treatment in the extension 
study .  Trial 156-13- 210 subjects or subjects enrolling from other trials may opt to 
conclude their participation in this trial if tolvaptan becomes available before they  
complete 18 months of treatment in this trial 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
150
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 24
 06 March 2015Figure 3.1-1 Trial Design Schematic
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka confidential information and should not be duplicated 
or re -distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
151
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 25 06 March 20153.2 Treatments
The dose regimens to be used in this trial are 15/15 mg, 30/15 mg, 45/15 mg, 60/30 mg ,
and 90/30 mg.
Following consent , and once subjects have satisfied all of the inclusion criteria and none 
of the exclusion criteria , subjects will retain the subject number assigned from their 
previous trial .  Subjects will receive open -label tolvaptan for the duration of the trial. All 
subjects will be administered tolvaptan tablets in a daily  split -dose, once upon awakening 
and another approximately  8 to 9 hours later (twice daily  dosing).  The exact time of 
dosing may  be adjusted based on wake/sleep habits (eg, standard 8 AM and 5 PM may  be 
switched to 10 PM and 7 AM if working a night shift).  However, dosing times should be 
consistent for each individualâ€™s daily dose to maximize receptor suppression.  Doses will 
be recorded as early  dose/late dose (eg, 60/30 mg). 
A subjectâ€™s star ting dose in this trial will be dependent on the trial in which they  were 
previously  enrolled:
ï‚·156-13-210- initiated on tolvaptan at a split- dose of 45/15 mg with upward 
titration every  3 to 4 days to 60/30 mg or 90/30 mg per day  according to 
tolerability
ï‚·156-08-271- will retain the last dose level from 271 and start at the same dose in 
this trial
ï‚·Prior tolvaptan trials -initiated on tolvapt an at a split -dose of 45/15 mg with 
upward titration every  3 to 4 day s to 60/30 mg or 90/30 mg per day  according to 
tolerability
Down titration to 30/15 mg and 15/15 mg is also permitted at the discretion of the 
investigator according to subject tolerability with medical monitor notification.  Further 
down titration to 30 or15 mg once dail y ma y be allowed only for metab olic drug -drug 
interaction and requires medical monitor approval.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
152
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 26 06 March 2015Table 3.2-1 Trial Treatments
Trial Day Time Dose
Day 1 to last on -treatment visit 8:00 am 1to 6tolvaptan tablets (15 mg or 30 mg each)
4:00 to 5:00 pm 1to 2tolvaptan tablets (15 mg or 30 mg each)
Allowed doses are 45/15 mg, 60/30 mg, 
90/30 mg.  D own titration to 30/15 mg and 
15/15 mg will be allow ed after discussion 
with the medical monitor.  Further down 
titration to 30 or 15 mg once daily may be 
allow ed only for metabolic drug -drug 
interaction and requires medical monitor 
approval .
For subjects moving from the 156-13-210 trial and requiring tolvaptan titration ,it will be 
conducted in the following way: subjects will be instructed to take tolvaptan starting at a 
split dose of 45/15 mg (as 3 tablets upon waking and 1 tablet approximately 8 to9 hours 
later) and to titrate up every  3 to 4 day s; first to 60/30 mg, then up to the maximum dose 
of 90/30 mg.  Titration will be accomplished b y increasing the number of tablets/dose 
and/or switching from 15 mg tablets to 30 mg tablets.  Prior to each upward titration, the 
subjectâ€™s tolerability  to the current dose will be assessed by  asking, â€œCould y ou tolerate 
this dose of trial medication for the rest of your life?â€ Subjects will continue in the trial
with the regimen to which tolerability  was established.
While taking tolvaptan, all subjects should be instructed to ingest fluids in anticipation of, 
or at the first sign of thirst in order to avoid excessive thirst or dehy dration.  Additionally , 
subjects should ingest 1 to 2 cups of water before bedtime regardless of perceived thirst 
and replenish fluids overnight with each episode of nocturia.
3.2.1 Dosing with CYP3A 4 Potent Inhib itors
Tolvaptan is a sensitive CYP3A4 substrate with 4- fold or higher increases in exposure 
following administration with potent CYP3A4 inhibitors.4  
For subjects requiring treatment with a potent CYP3A4 inhibitor and on a total daily  
tolvaptan dose of 90 or 120 mg, tolvaptan treatment should be reduced to 30 mg once 
daily .  The dose may  be reduced to 15 mg once daily  for tolerability .  For subjects on a 
total daily  dose of 60 mg, tolvaptan treatment should be reduced to 15 mg once dail y.  
For subjects on lower total daily  doses, tolvaptan interruption should be considered if no 
alternative medications can be used. 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
153
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 27 06 March 20153.2.2 Dosing with CYP3A 4 Moderate Inhibitors
For subjects who require dosing with a moderate inhibitor, initial tolvaptan reductions as 
shown below should be tried, with further dose reductions or interruption as necessary  for 
tolerability .
ï‚·90/30 mg to 45/15 mg
ï‚·60/30 mg to 30/15 mg
ï‚·45/15 mg to 15/15 mg
ï‚·30/15 mg to 15 mg once daily
ï‚·15/15 mg to 15 mg once daily
A partial list of strong and moderate CYP3A4 inhibitors can be found in Section 4.1.
3.3 Trial Population
This trial will include approximately 2,500 subjects over the age of 18 y ears with 
ADPKD diagnosed b y Pei-Ravine criteria11 12(modified by magnetic resonance imaging 
[MRI ])who completed or participated in a prior tolvaptan trial.  
3.4 Eligibility  Criteria
3.4.1 Informed Consent
Each investigator has both ethical and legal responsibility  to ensure that subjects being 
considered for inclusion in this trial are given a full explanation of the protocol and of 
their role and responsibilities in the proposed research .  This shall be documented on a 
written informed consent form ( ICF)that shall be approved b ythe same institutional 
review board/independent ethics committee (I RB/IEC) responsible for approval of this 
protocol.  Each ICF will comply  with the International Conference on Harmonisation 
(ICH) Good Clinical Practice (GCP) Guideline14and local regulatory  requirements, and 
must adhere to the ethical principles that have their origin in the Declaration of Helsinki .  
The investigator agrees to obtain sponsor approval of any  written ICF used in the trial 
prior to submission to the IRB/IEC.
Investigators may discuss trial availability  and the possibility  for entry  with a potential 
subject without first obtaining consent.   However, informed consent will be obtained 
from all subjects (or their guardian or legal representative) and documented prior to 
initiation of any  procedures that are performed solely  for the purpose of determining 
eligibility  for this trial, including withdraw al from current medication(s).
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
154
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK2QFHDSSURSULDWHHVVHQWLDOLQIRUPDWLRQKDVEHHQSURYLGHGDQGIX OO\H[SODLQHGLQ
OD\PDQÂ¶VODQJXDJHWRWKHVXEMHFWE\WKHLQYHVWLJDWRURUDTXDO LILHGGHVLJQHHWKH
,5%,(&DSSURYHGZULWWHQ,&)ZLOOEHVLJQHGDQGGDWHGE\ERWKW KHVXEMHFWDQGWKH
SHUVRQREWDLQLQJFRQVHQWLQYHVWLJDWRURUGHVLJQHHDVZHOODV E\DQ\RWKHUSDUWLHV
UHTXLUHGE\WKH,5 %,(&7KHVXEMHFWZLOOUHFHLYHDFRS\RIWK HVLJQHG,&)WKHRULJLQDO
VKDOOEHNHSWRQILOHE\WKHLQYHVWLJDWRU





 ,QFOXVLRQ&ULWHULD
6XEMHFWVDUHUHTXLUHGWRPHHWWKHIROORZLQJLQFOXVLRQFULWHULDL Q7DEOH 
7DEOH ,QFOXVLRQ&ULWHULD
0DOHDQGIHPDOHVXEMHFWVDJHG â‰¥\HDUVZLWKFRQILUPHGGLDJQRVLVRI$'3.'GXULQJ
SDUWLFLSDWLRQLQSULRUWROYDSWDQWULDOVZKRKDYH
â€¢&RPSOHWHGDQGWUDQVIHUUHGIURPWKHGRXEOH EOLQG7ULDO PRQWKSHULRG
LQFOXGLQJSRVWWUHDWPHQWIROORZXSUHJDUGOHVVRIZKHWKHUWKLV ZDVRQWUHDWPHQWRURII
WUHDWPHQWRU
â€¢&RPSOHWHG7ULDO RUDSULRUWROYDSWDQWULDORU
â€¢,QWHUUXSWHGRUGLVFRQWLQXHGWUHDWPHQWLQDWROYDSWDQWULDORWKH UWKDQ7ULDO
6XEMHFWVPD\EHHQUROOHGZLWKWKHPHGLFDOPRQLWRUDSSURYDODQG DGGLWLRQDOFORVHPRQLWRULQJ
PD\EHUHTXLUHGDWWKHEHJLQQLQJRIWKHWULDO
â€¢5HQDOIXQFWLRQZLOOEHDVVHVVHGGXULQJVFUHHQLQJE\XVLQJKLVWR ULFDOODERUDWRU\YDOXHVLQWKH
ODVWPRQWKVIRUVHUXPFUHDWLQLQHOHYHOVWRFDOFXODWHWKHH*)5 7KHH*)5YDOXHVZLOOEH
HVWLPDWHGEDVHGRQWKH&.'(3,IRUPXOD/HYH\$6HWDO$QQ,QW HUQ0HGÂ±

(VWLPDWHGJORPHUXODUILOWUDWLRQUDWH â‰¥P/PLQPFDOFXODWHGXVLQJWKH&.'(3,
IRUPXODZLWKLQPR QWKVSULRUWRWKHEDVHOLQHYLVLW6XEMHFWVZKR KDYHDQH*)5
Â”P/PLQPPD\EHSHUPLWWHGWRHQWHUWKHWULDOZLWKPHGLFDOPRQLWRUDQGV SRQVRU
DSSURYDODQGLQFUHDVHGIUHTXHQF\RIPRQLWRULQJWRHQVXUHVDIHW\ RISDUWLFLSDQWV
H*)5 HVWLPDWHGJORPHUXODUILOWUDWLRQUDWH&.'(3, &KURQLF.LGQ H\'LVHDVH(SLGHPLRORJ\
 ([FOXVLRQ &ULWHULD
6XEMHFWVZLOOEHH[FOXGHGLIWKH\PHHWDQ\RIWKHH[FOXVLRQFUL WHULDLQ7DEOH 
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 29 06 March 2015Table 3.4.3-1 Exclusion Criteria
1. WOCBP who do not agree to practice 2 different methods of birth control or remain abstinent 
during the trial and for 30 days after the last dose of IMP. Ifemploying birth control, 2 of the 
following precautions must be used: vasectomy of partner, tubal ligation, vaginal diaphragm, 
intrauterine device, birth con trolpill, birth control implant, birth control depot injection, condom, 
or sponge with spermicide.
2. Wom en who are breast -feeding and/or who have a positive pregnancy test result prior to receiving
IMP.
3. Need for chronic diuretic use .
4. Hepatic impairm ent based on liver function abnormalities other than that expected for ADPKD 
with cystic liver disease during screening based on recent historical laboratory values (in the last 
3months) .
5. Subjects with contraindications to required trial assess ments (contraindications to optional 
assessments, eg, MRI are not a limitation) .
6. Subjects who, in the opinion of the investigator or medical monitor, have a medical history or 
medical finding inconsistent with safety or trial compliance.  This includes prior evidence of 
significant hepatic injury deemed to be related to tolvaptan use .
WOCBP=w omen of childbearing potential ; IMP=i nvestigational medicinal product
Non-childbea ring potential in women is defined as female subjects who are surgically  
sterile (ie, have undergone bilateral oophorectom y or hysterectom y) orfemale subjects 
who have been postmenopausal for at least 12 consecutive months.
Subjects may  be rescreened, at the discretion of the medical monitor, if the exclusion 
characteristic has changed or resolved.  In the event that a subject is rescreened, a new 
ICF must be signed and a new screening number assigned and screening procedures 
repeated.
3.5 Trial Endpoints
3.5.1 Safety Endpoints
This trial will have no formal endpoints.  Safet y variables will be summarized by  
descriptive statistics, (eg, proportion, mean, median, standard deviation [SD], minimum, 
and maximum values).  In general, summary statistics, including changes from baseline, 
will be provided for sa fety variables based on all available data.  Safet y endpoints will be
as follows:
ï‚·Adverse events
ï‚·Vital signs
ï‚·Clinical laboratory  assessments
ï‚·Serum transaminase elevations for frequency  (2x, 3x, 5x and 10x ULN), time to 
onset, time to peak levels, time of offset (< 3x, 2x, or 1x UL N), response to 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
156
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKGHFKDOOHQJHDQGUHFKDOOHQJHDQGIUHTXHQF\RISURJUHVVLRQWR+ \Â¶VODERUDWRU\
FULWHULD$/7RU$67![8/1DQGELOLUXELQ WRWDO%7 ![ 8/1Z LWKRXW
DONDOLQHSKRVSKDWDVH â‰¥[8/1
â€¢6HUXPVRGLXPH[FXUVLRQVDERYHRUPPRO/RUEHORZ  RU
PPRO/





 0HDVXUHVWR0LQLPL]H$YRLG%LDV
7KLVLVDQRSHQODEHOWULDO)RUVXEMHFWVHQWHULQJIURPSODFHE RFRQWUROOHGWULDOVSULRU
WKHUDS\SODFHERRUWROYDSWDQZLOOQRWEHNQRZQE\WULDO VLWH LQYHVWLJDWRURUVSRQVRU
DWWKHWLPHRIHQWU\LQWRWKLVWULDO
$OOEORRGDQGXULQHFKHPLVWU\ZLOOEHDQDO\]HGDQGUHSRUWHGE\ DFHQWUDO ODERUDWRU\
 7ULDO3URFHGXUHV
7ULDODVVHVVPHQWWLPHSRLQWVDUHVXPPDUL]HGLQ 7DEOH 
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK7DEOH 6FKHGXOHRI$VVHVVPHQWV
6FUHHQLQJ
WR  GD\V
SULRUWR%DVHOLQHD%DVHOLQH
'D\0RQWKO\E
Â“GD\V(YHU\
 PRQWKVE
Â±Â± GD\V(DUO\
7HUPLQDWLRQ(QG
RI7UHDWPHQW
GD\V7LWUDWLRQ
&RQWDFW
SKRQH
FRQWDFW)ROORZXS
GD\VSRVW
WUHDWPHQW
GD\V
,QIRUPHGFRQVHQW ;
,QFOXVLRQ([FOXVLRQ ; ;
'HPRJUDSKLFV0HGLFDO$'3.'KLVWRU\
F;
'LHWDU\UHYLHZ ; ; ; ; ;
9LWDOVLJQVG;; ; ; ; ;
&KHPLVWU\%ORRG 6DPSOHVH
6HUXP&KHPLVWU\3DQHO ;I;
/LYHU)XQFWLRQWHVWVJ;; ; ; ;
6RGLXP ; ; ; ;
&UHDWLQLQH ; ; ; ; ;
+HPDWRORJ\DQGFRDJXODWLRQ ;;
8ULQDO\VLV ;; ; ;
8ULQHRVPRODOLW\K;; ; ;
8ULQHVSHFLILFJUDYLW\ ;; ; ;
8ULQHSUHJQDQF\WHVW:2&%3
RQO\L;; ; ; ;
8ULQHDWKRPHSUHJQDQF\WHVWNLWVGLVSHQVHG
M;; ;
3K\VLFDOH[DPLQDWLRQN;; ; ; ;
7ROHUDELOLW\'RVLQJ5HYLHZ ; ; ; ; ;
,QWHUDFWLYH5HVSRQVH7HFKQRORJ\(QWU\;; ; ; ; ;
O;
'UXJGLVSHQVDWLRQ ; ; ; ;O
'UXJUHFRQFLOLDWLRQ ; ; ; ;O



8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCICCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 32 06 March 2015Screening 
(-30to-1days 
prior to Baseline)aBaseline/ 
Day 0Monthlyb
(Â± 7 days)Every 
3monthsb
(ï‚±14days)Early 
Termination/End 
of Treatm ent
(+ 7 day s)Titration 
Contact 
(phone 
contact)Follow -up
7 days post -
treatm ent
(+ 7 days)
Adverse events Xnï‚¬------------------------------------------------------------------------------------------------------------------- ï‚®
Concomitant medicationso ï‚¬------------------------------------------------------------------------------------------------------------------- ï‚®
aThe last visit assessments from the previous trialcan be combined with the screening and baseline visitsforthis trial, with all required assessments from each 
visit performed o nly o nce. 
bMonthly visits are for subjects < 18 months on tolvaptan, and every 3 month visits are for subjects > 18 months on tolvaptan.
cIncludes prior trial identifiers (screening identification [ID], subject ID, site ID, prior tolvaptan ADPKD trial protocol number).
dVital signs at each visit include seated heart rate, calibrated blood pressure and post void body weight.  Height should be perform ed only at screening.
e Central labo ratory non -fasting serum laboratory tests will be performed.  All subjects must be monitored for hepatic safety monthly until they have known 
tolvaptan exposure data of at least 18 months.  After that, and following the approval of the medical monitor, hep atic monitoring will take place every 
3months.  Trial 156 -13-210 subjects who are eligible for this trial will have trial vis its/hepatic monitoring monthly for the first 18 months of this trial then 
every 3 months thereafter, because their tolvaptan expos ure will be unknown.   Once unblinding occurs, it can be determined which subjects received tolvaptan 
in Trial 156 -13-210.  These subjects may have their trial vis its/hepatic transaminase monitoring change dto every 3 months sooner as their previous tolvapt an 
exposure in Trial 156 -13-210 can count tow ards the 18 month threshold. Subjects who enroll from other ADPKD tolvaptan trials will be monitored for 
hepatic safely monthly for their first 18 months they are in this trial.
f Hepatitis testing at screening will be optional.  If hepatitis testing is performed, then both pre -and post -counseling activities relating to hepatitis testing are to be 
carried out based on local requirements and best practices.  Upon request, if clinically indicated and approved by the medical monitor, subjects may have the 
following evaluations in addition to the protocol -specified chemistry panel: serum calcium, phosphorous, parathyroid hormone, vitamin D, and bicarbonate 
levels .  
gA full liver function panel (AST, ALT, alkaline phosphatase, BT) w ill be done at screeni ng.  All other liver function tests at subsequent visits are for ALT only, 
unless otherwise clinically indicated.  An ALT elevation > 2 Ã—ULN should trigger prom pttesting of hepatic function within 72 hours.  Any transaminase values 
which exceed 2 Ã—ULN should prompt immediate retesting within 72 hours.  While values remain in an abnormal range, testing frequency should be increased to 
at least weekly for the first month, gradually returning to monthly, and every 3 months as indicated by the results.  Local liver function panel analyses will also 
be performed more frequently, if necessary .  
hUrine osmolality is optional.
i A urine pregnancy test for pregnancy for women of childbearing potential (WOCBP) will be performed at screening, at every 3months visits, at the End of 
Treatment ( EoTx )visit,and at the follow -up visit.  On suspicion of pregnancy, an unscheduled urine orserum pregnancy testing will be performed.  Positive 
urine pregnancy tests should be confirmed w ith a serum pregnancy test. 
j At-home urine pregnancy test kits will be dispensed to WOCBP to be used if a menstrual period is missed betw een visits.  Kits wi ll be dispensed as needed 
throughout the trial. 
kA full physical examination is required at screening.  At other visits, an optional â€œdirectedâ€ physical examination may be perf ormed to focus on PKD -related 
signs and symptoms . 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka confidential information and should not be duplicated 
or re -distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
159
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKO,IGXULQJWKHWLWUDWLRQFRQWDFWWKHGHWHUPLQDWLRQLVPDGHWRDG MXVWWKHGRVH UHJLPHQGRVHDGMXVWPHQWVZLOOEHPDGHXVLQJGLVSH QVHGVXSSO\DQGGRVHLQVWUXFWLRQV
ZLOOEHSURYLGHGE\WKHLQYHVWLJDWRU7KHVXEMHFWÂ¶VFXUUHQWGR VHZLOOEH HQWHUHGLQWRWKHLQWHUDFWLYHUHVSRQVH WHFKQRORJ\,5 7DWHDFKYLVLW'UXJ
GLVSHQVDWLRQUHFRQFLOLDWLRQZLOOEHFRQGXFWHGRQDPRQWKO\EDVL VIRUVXEMHFWVZKRKDYHPRQWKO\WULDOYLVLWVDQGRQFHHYHU\ PR QWKVIRUVXEMHFWVZKRKDYHWULDO
YLVLWVHYHU\ PRQWKV,IDGGLWLRQDOGUXJVXSSO\LVUHTXLUHGIR UWLWUDWLRQSXUSRVHVWKHVLWHZLOODUUDQJHDVXEMHFWYLVLWIRU GLVSHQVDWLRQ

Q$WVFUHHQLQJ$(VUHSRUWHGDVRQJRLQJRUUHVROYHGDWWKHHQGRI WKHSULRUWULDOZLOOEHDVVHVVHGWRGHWHUPLQHHQWU\DVHLWKHU PHGLFDOKLVWRU\RURQJRLQJHYHQWIRU
WKLVWULDO
R2QO\FRQFRPLWDQWPHGLFDWLRQVRQJRLQJDWWKHEDVHOLQHYLVLWDQG WKURXJKRXWWKHWULDOZLOOEHUHFRUGHG7KLVZRXOGRFFXUDWWKH VFUHHQLQJYLVLWRQO\LIWKH
VFUHHQLQJYLVLWRFFXUVVLPXOWDQHRXVO\ZLWKWKHODVWYLVLWIURP DSUHYLRXVWROYDSWDQWULDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 34 06 March 20153.7.1 Schedule of A ssessments
3.7.1.1 Screening (-30 days to 1 day prior to Baseline)
Screening for eli gibility is required for all subjects. The screening and baseline visits
may be combined with the last visit from either Trials 156-08- 271 or 156- 13-210 with all 
required assessments from each visit performed only once . Therefore, i n some cases, if a 
subject enrolls in this trial from a prior tolvaptan trial, the end of trial or last follow -up 
visit for that trial and the screening and baseline visit for this one may  occur 
simultaneously .  Required assessments for the screening visit are as follows :
1. Obta in subject consent .
2.Obtain subjectâ€™s new screening identification (ID) assigned b y interactive 
response technology  (IRT)
3.Determine subject eligibility  through inclusion/exclusion criteria .
4. Record demographic information and prior trial identifiers (screening ID, subject 
ID, site ID , prior tolvaptan ADPKD trial protocol number ).
5.Record medical/ADPKD history  using prior trial data .
6.Review dietary  recommendations and compliance
7.Record vital signs (post -void weight and seated heart rate) and in -clinic calibrated 
blood pressure (BP) measurement.  Record height.
8.Collect bloo d for serum chemistry ,liver function panel (ALT, AST, BT , bilirubin 
[direct ], and alkaline phosphatase) , serum sodium, serum creatinine ,and 
hematology  and coagulation .Hepatitis testing is optional. If hepatitis testing is 
performed, then both pre -and post -counseling activities relating to hepatitis 
testing are to be carried out based on local requirements and best practices.  
9.Collect urine for urinal ysis, urine osmolality  (optional), and urine specific gravity .
10. Perform urine pregnancy test on women of childbearing potential (WOCBP).  If 
positive, a follow- up serum test will be performed .
11.Conduct full phy sical examination .
12.Enter subject into I RT including prior trial identif ier/information (protocol 
number, subject ID), confirmed dose regimen , and scheduled date of next visit .
13.Assess AEs reported as ongoing or resolved from prior trial to determine entry as 
medical history  or ongoing event for this trial.
14.Record ongoing conco mitant medications . (This will happen only  if the screening 
visit occurs simultaneously  with the last visit from a previous tolvaptan trial) .
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
161
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK %DVHOLQH 'D\
7KHEDVHOLQHYLVLWLVWKHEHJLQQLQJRIWKHWUHDWPHQWSHULRGLQ WKLVWULDO$W WKHEDVHOLQH
YLVLWVXEMHFWVZLOOUHWDLQWKHVXEMHFWQXPEHUDVVLJQHG LQWKHSUH YLRXVWROYDSWDQWULDO DQG
WKHIROORZLQJDVVHVVPHQWVDQGSURFHGXUHVZLOOEH SHUIRUPHG
 5HYLHZLQFOXVLRQH[FOXVLRQFULWHULD
 5HYLHZGLHWDU\UHFRPPHQGDWLRQVDQGFRPSOLDQFH
 5HFRUGYLWDOVLJQVSRVW YRLGZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 'LVSHQVHDWKRPHXULQHSUHJQDQF\WHVWNLWVWR:2&%3 WREHXVHG LIDPHQVWUXDO
SHULRGLVPLVVHGEHIRUHWKHQH[WYLVLW
 $QRSWLRQDO GLUHFWHGSK\VLFDOH[DPLQDWLRQ PD\EHSHUIRUPHG WRIRFXVRQ
3.'UHODWHGVLJQVDQGV\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJUHYLHZRILQYHVWLJDWLRQDOPHGLFLQD OSURGXFW,03 
 (QUROOVXEMHFWLQWRWULDOWKURXJK,57DQGREWDLQ,03 'LVSHQVH,03 VXIILFLHQWIRUPRQWKRU PRQWKVRIGRVLQJEDVHG RQWKH
VXEMHFWÂ¶VUHTXLUHGYLVLWVFKHGXOHIRUKHSDWLFHYDOXDWLRQDVHLWK HUPRQWKO\RUHYHU\
PRQWKV
3URYLGHVXEMHFWZLWKGRVLQJLQVWUXFWLRQVWREHJLQRQWKHIRO ORZLQJGD\
 5HFRUGRQJRLQJFRQFRPLWDQWPHGLFDWLRQV
 $VVHVV$(V
 0RQWKO\ 9LVLW Â±
Â±GD\V
7KHIROORZLQJVXEMHFWVZLOOUHWXUQ IRUDPRQWKO\YLVLWWRDVVHVV VDIHW\DQGWROHUDELOLW\RI
,03 DQGWRPRQLWRUOLYHUIXQFWLRQ
â€¢6XEMHFWVHQUROOLQJIURPWKHGRXEOHEOLQG7ULDOZLOO KDYHPRQWKO\ WULDO
YLVLWV$/7OHYHODVVHVVPHQWV IRUWKHILUVWPRQWKV ZKLOHWUHDWPHQWFRGHIURP
7ULDOUHPDLQVEOLQGHGWRHQVXUHWKDWWKH\ KDYHDGHTXDWHVDIHW\
PRQLWRULQJGXULQJWKLVSHULRGRIVXVFHSWLELOLW\ 2QFHXQEOLQGLQJ RFFXUVLWFDQEH
GHWHUPLQHGZKLFKVXEMHFWVUHFHLYHGWROYDSWDQLQ7ULDO 7KHVH
VXEMHFWVPD\KDYHWKHLUWULDOYLVLWVKHSDWLFWUDQVDPLQDVHPRQLW RULQJFKDQJHWR
HYHU\PRQWKVVRRQHUDVWKHLUSUHYLRXVWROYDSWDQH[SRVXUHLQ7 ULDO 
FDQFRXQWWRZDUGVWKHPRQWKWKUHVKROG7KHLQYHVWLJDWRUZLO OQHHGWRGLVFXVV
WKHFKDQJHLQIUHTXHQF\ZLWKWKHPHGLFDOPRQLWRUEHIRUHLQVWLWX WLQJWKHFKDQJH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKâ€¢6XEMHFWVIURPSULRUWROYDSWDQWULDOVRWKHUWKDQ7ULDO  ZLOOKDYHPRQWKO\
WULDOYLVLWV$/7OHYHODVVHVVPHQWVIRUWKHILUVWPRQWKV$I WHUWKDWWKHWULDO
YLVLWV$/7PRQLWRULQJZLOOEHFRQGXFWHGHYHU\ PRQWKVDIWHUWKH FKDQJHLQ
IUHTXHQF\LVFRQILUPHGZLWKWKHPHGLFDOPRQLWRU
â€¢6XEMHFWVHQUROOLQJIURPWKHRSHQODEHO7ULDOZKR KDYH JUHDWHUWKDQ
PRQWKVRIH[SRVXUHWRWROYDSWDQZLOOKDYHWULDOYLVLWV$/7PR QLWRULQJ
FRQGXFWHGHYHU\ PRQWKV
7KHIROORZLQJZLOOEHDVVHVVPHQWV ZLOOEHFRPSOHWHG
 5HYLHZGLHWDU\UHFRPPHQGDWLRQVDQGFRPSOLDQFH

 5HFRUGYLWDOVLJQVSRVWYRLGZHLJKWVHDWHGKHDUWUDWHDQG FDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUFHQWUDOODERUDWRU\DVVHVVPHQWVIRUVHUXPVRG LXP VHUXP
FUHDWLQLQHDQG$/7VHH 6HFWLRQ  


 8ULQDO\VLVXULQHRVPRODOLW\RSWLRQDOXULQHVSHFLILFJUDYL W\
 3HUIRUPXULQHSUHJQDQF\WHVWRQ:2&%3HYHU\PRQWKV,IS RVLWLYHD
IROORZXSVHUXPWHVWZLOOEHSHUIRUPHG
 'LVSHQVHDWKRPHXULQHSUHJQDQF\WHVWNLWVWR:2&%3DVUHTXL UHG
 $QRSWLRQDO GLUHFWHGSK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWR IRFXVRQ
3.'UHODWHGVLJQVDQGV\PSWRPV
$VVHVVWROHUDELOLW\GRVLQJUHYLHZRI ,03(QWHUVXEMHFWVWDWXVLQ,57LQFOXGLQJDQ\GRVHUHJLPHQFKDQJ HVDQGREWDLQ,03
DVVLJQPHQW
 &ROOHFWDQGUHFRQFLOHUHWXUQHG,03DVVHVVFRPSOLDQFH
 'LVSHQVH,03 EDVHGRQVXEMHFWÂ¶VUHTXLUHGYLVLWVFKHGXOHDQG SURYLGHVXEMHFWZLWK
GRVLQJLQVWUXFWLRQV
 8SGDWHFRQFRPLWDQWPHGLFDWLRQV
 $VVHVV$(V
 (YHU\0RQWKV Â±
Â±GD\V
 5HYLHZGLHWDU\UHFRPPHQGDWLRQVDQGFRPSOLDQFH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK
 5HFRUGYLWDOVLJQVSRVWYRLGZHLJKWVHDWHGKHDUWUDWHDQG FDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUFHQWUDO ODERUDWRU\DVVHVVPHQWV VHUXPVRGLXP VHUXPFUHDWLQLQH
$/7VHH 6HFWLRQ 
 
 8ULQDO\VLVXULQHRVPRODOLW\RSWLRQDOXULQHVSHFLILFJUDYL W\
 3HUIRUPXULQHSUHJQDQF\WHVWRQ:2&%3,ISRVLWLYHDIROORZ XSVHUXPWHVWZLOO
EHSHUIRUPHG
 'LVSHQVHDWKRPHXULQHSUHJQDQF\WHVWNLWVWR:2&%3DV UHTXLU HG
 

 $Q RSWLRQDOGLUHFWHGSK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWR IRFXVRQ
3.'UHODWHGVLJQVDQGV\PSWRPV
$VVHVVWROHUDELOLW\GRVLQJUHYLHZRI,03(QWHUVXEMHFWVWDWXVLQ,57LQFOXGLQJDQ\GRVHUHJLPHQFKDQ JHVDQGREWDLQ,03
DVVLJQPHQW
 &ROOHFWDQGUHFRQFLOHUHWXUQHG,03DVVHVVFRPSOLDQFH
(QWHUVXEMHFWVWDWXVLQ,57LQFOXGLQJDQ\GRVHUHJLPHQFKDQ JHV
'LVSHQVH,03EDVHGRQVXEMHFWÂ¶VYLVLWVFKHGXOHDQGSURYLGH VXEMHFWZLWKGRVLQJ
LQVWUXFWLRQV
 8SGDWHFRQFRPLWDQWPHGLFDWLRQV
 $VVHVV$(V
 (DUO\ 7HUPLQDWLRQ(QGRI7UHDWPHQW  GD\V
$WWKHHDUO\WHUPLQDWLRQHQGRIWUHDWPHQW (R7[YLVLWWKHIROOR ZLQJZLOOEHDVVHVVHG
 5HYLHZGLHWDU\UHFRPPHQGDWLRQVDQGFRPSOLDQFH
 5HFRUGYLWDOVLJQVSRVWYRLGZHLJKWVHDWHGKHDUWUDWHDQG FDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUVHUXPFKHPLVWU\VHUXPFUHDWLQLQH$/7VHU XPVRGLXPDQG
KHPDWRORJ\DQGFRDJXODWLRQ
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCICCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 
 
 &ROOHFWXULQHIRUXULQDO\VLVXULQHRVPRODOLW\RSWLRQDOXU LQHVSHFLILFJUDYLW\
 3HUIRUPXULQHSUHJQDQF\WHVWRQ:2&%3,ISRVLWLYHDIROORZ XSVHUXPWHVWZLOO
EHSHUIRUPHG
 $QRSWLRQDO GLUHFWHGSK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWR IRFXVRQ
3.'UHODWHGVLJQVDQGV\PSWRPV
$VVHVVWROHUDELOLW\GRVLQJUHYLHZRI,03(QWHUVXEMHFWVWDWXVLQ,57LQFOXGLQJDQ\GRVHUHJLPHQFKDQ JHV VLQFHWKH
SUHYLRXVHQWU\
 &ROOHFWDQGUHFRQFLOHUHWXUQHG,03DVVHVVFRPSOLDQFH 8SGDWHFRQFRPLWDQWPHGLFDWLRQV $VVHVV$(V
 GD\)ROORZ XS9LVLWGD\V
 5HFRUGYLWDOVLJQVSRVWYRLGZHLJKWVHDWHGKHDUWUDWHDQG FDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUVHUXPFUHDWLQLQHDQG$/7 

 3HUIRUPXULQHSUHJQDQF\WHVWRQ:2&%3,ISRVLWLYHDIROORZ XSVHUXPWHVWZLOO
EHSHUIRUPHG
 (QWHUVXEMHFWVWDWXVLQ,57
 8SGDWHFRQFRPLWDQWPHGLFDWLRQV $VVHVV$(V
 6DIHW\$VVHVVPHQWV
 $GYHUVH(YHQWV
5HIHUWR6HFWLRQ5HSRUWLQJRI$GYHUVH(YHQWV 
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK











$OLVWRIWKHVSHFLILFFOLQLFDOODERUDWRU\DVVHVVPHQWVLVSUHVH QWHGLQ7DEOH 
&OLQLFDOODERUDWRU\VDPSOHVZLOOEHFROOHFWHGDQGVHQWWRWKHF HQWUDOODERUDWRU\DWWKH
IROORZLQJWLPHSRLQWV
6FUHHQLQJ +HPDWRORJ\DQGFRDJXODWLRQSDQHOVHUXPFKHPLVWU\SDQ HOOLYHUIXQFWLRQ
SDQHO $67$/7DONDOLQHSKRVSKDWDVHELOLUXELQGLUHFW >%7@VHUX PVRGLXPVHUXP
FUHDWLQLQHXULQDO\ VLVSDQHOXULQHRVPRODOLW\RSWLRQDOXULQ HVSHFLILFJUDYLW\XULQH
SUHJQDQF\WHVW:2&%3DQGKHSDWLWLVRSWLRQDO
0RQWKO\YLVLWV Â“GD\V $/7IRUWKHILUVWPRQWKVIRUVXEMHF WVHQUROOHGIURP RWKHU
WROYDSWDQ$'3.'WULDOVDQG7ULDO  ZKLOHWULDOUHPDLQVEO LQGHG VHUXP
VRGLXPDQGVHUXPFUHDWLQLQHDOOVXEMHFWVXULQDO\VLVXULQHRVP RODOLW\RSWLRQDOXULQH
VSHFLILFJUDYLW\DQGXULQHSUHJQDQF\WHVWHYHU\PRQWKVLQ: 2&%3 
(YHU\PRQWKV Â“GD\V$/7DIWHUPRQWKVRIWUHDWPHQW I RUVXEMHFWVHQUROOHG
IURPRWKHU$'3.'WROYDSWDQWULDOVRUIURP7ULDODIW HUWKHWULDOLVXQEOLQGHG
DQGIRUVXEMHFWVHQUROOHGIURP7ULDOVHUXPVRGLXP DQGVHUXPFUHDWLQLQH
XULQDO\VLVSDQHOXULQHSUHJQDQF\WHVW:2&%3XULQHRVPRODOLW \RSWLRQDODQGXULQH
VSHFLILFJUDYLW\
(DUO\7HUPLQDWLRQ(R7[  GD\ V 6HUXPFKHPLVWU\SDQHOKHPDWROR J\DQGFRDJXODWLRQ
SDQHO$/7VHUXPVRGLXPDQGVHUXPFUHDWLQLQH XULQDO\VLV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCICCI
CCICCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 40 06 March 2015panel , urine pregnancy  test (WOCBP) , urine osmolality  (optional), and urine specific 
gravity .
7-day Follow -up visit (+7 day s):ALT, serum creatinine, and urine pregnancy  test
(WOCBP) .
Table 3.7.2.2-1 Clinical Laboratory Assessments
Hem atology and Coagulation Panel :
Hem oglobin
Platelet count
Mean corpuscular hemoglobin concentration
(MCHC)
Mean corpuscular volume (MCV)
Red blood cell (RBC) count
White blood cell (WBC) count w ith differential 
Prothromb in time (PT) as international normalized 
ratio (INR)
Activated partial thromboplastin time (aPTT)
Urinalysis Panel :
Appearance
Color 
Blood
Glucose
Microscopic analysis, WBC/RBC counts per high 
power field
pH
Protein 
Urine ChemistryOsmolality (optional)
Specific gravity
Additional Tests:
Urine (or serum) pregnancy for WOCBP
Hepatitis (optional)Serum Chemistry Panel :
Albumin
Blood urea nitrogen (BUN)
Serum calcium
Carbon dioxide
Serum chloride
Gamma -glutamyl transpeptidase
Cholesterol , total
Glucose
Lactate dehydrogenase (LDH)
Phosphorus
Potassium
Protein , total 
Uric acid
Liver Function Panel :Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Bilirubin, total (BT)
Bilirubin, direct
Creatinine Sodium
If liver function panel, sodium and/or serum che mistry  assessments are scheduled at the 
same visit, all values should be determined from the same blood sample.  Blood testing 
for hepatitis will be optional for all subjects.  Urine pregnancy  testin g will be performed 
with commerciall y available, high- sensitivity  kits supplied to the subject by the site 
(acquired b y the sponsor ).
3.7.2.3 Physical Examination and Vital Signs
A full phy sical ex amination will be performed and documented at the s creening visit 
although this may  be combined with the last visit from the previous trial. At other visits, 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
167
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 41 06 March 2015an optional directed ph ysical examination may be performed to focus on AD PKD -related 
signs and s ymptoms.  In some geographic regions, more frequent subject visits may be 
the norm; however vital signs and clinically  significant phy sical findings will be recorded 
as an unscheduled visit in the electronic case report form (e CRF )as applicable. Any 
changes in medication or AEs will be recorded in the eCRF.
Height will be measur ed only  at screening.  Body weight will be taken post -void.  I t is 
preferable to use the same scale for each measurement.  Clinic scales should be calibrated 
at least y early . The i nvestigator or his/her appointed designee is primarily  responsible to 
perform the ph ysical examination .  If the appointed designee is to perform the phy sical 
exam ination , he/she must be permitted to do so by  local regulations and his/her name 
must be included on an y globall y and locally required documents (eg, individual must be 
added for all sites on a US F ood and D rug Administration (FDA) Form 1572, where local 
regulations allow, while local regulations determine their being named in the I CF).  
Whenever possible, the same individual should perform all ph ysical exam inations.  Any  
undesirabl e condition present at a post -treatment phy sical exam ination that was not 
present at the b aseline exam ination should be documented as an AEand followe d to a 
satisfactory  conclusion.
Vital sign data ,including seated blood pressure ,heart rate , height, and weight will be 
taken at the visits identified in the Schedule of Assessments ( Table 3.7-1 ).
3.7.2.4 Assessment of Liver Sy mptoms, Signs or Test A bnormalities
Testing for hepatic transaminase (ALT/AST) , alkaline phosphatase, bilirubin direct, and 
BT will be perfo rmed during screening.  Subjects enrolling from the double -blind Trial 
156-13- 210 will have monthly  ALT assessments for the first 18 months while the 
treatment code from Trial 156-13- 210 remains blinded to ensure that all subjects have 
adequate safet y monitoring during this period of susceptibility .  Once unblinding occurs, 
it can be determined which subjects received tolvaptan in Trial 156-13- 210.  These 
subjects may  have their trial vis its/hepatic transaminase monitoring change dto eve ry 
3months sooner as their previous tolvaptan exposure in Trial 156-13- 210 can count 
towards the 18- month threshold.
Following the first 18months, AL T assessments will be made every  3months for 
Trial 156-13-210 subjects and for subjects from other tolvaptan ADPKD trials besides 
Trial 156-08-271.  
Subjects enrolling from the open -label Trial 156 -08-271 who have tolvaptan exposure 
greater than 18 months will continue with ALT monitoring every  3months.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
168
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 42 06 March 2015Subjects enrolling from prior tolvaptan trials besides Trial 156-08- 271 will have monthly  
ALT assessments for the first 18 months.  Upon reaching 18 months of exposure and 
after confirmation from the medical monitor, the frequency  of ALT monitoring for these 
subjects will occur every  3months.
ALT will also be assessed at the Earl y Termination/E oTxvisit and at the 7-day Follow -
up visit.
Management of liver abnormalities is disc ussed in the paragraphs below.
3.7.2.4.1 Liver Test A bnormalities and Interruption/Discontinuation of 
Investigational Medicinal Produ ct
An ALT elevation 2 Ã— ULN orthe appearance of any  suspicious s ymptom or sign should 
trigger prompt testing of hepatic function (ie, within 72 hours) .  Local laboratory  testing 
is acceptable, ideall y with a concurrent central laboratory  sample for confi rmation.   
Any transaminase or bilirubin values which exceed 2 Ã—ULN should also prompt 
immediate retesting within 72 hours.  While values remain in an abnormal range, testing 
frequency  should be increase dto at least weekl y for the first month, gradually returning 
to monthly , or every  three months as indicated b y the results .
Liver transaminase levels reaching or exceeding 2 Ã—ULN thathave an uncertain or 
rapidly  increasing trajectory should prompt at least temporary  IMP interruption. 
Tolvaptan should not be resumed until monitoring indicates abnormalities have resolve d, 
are stable ,or are not rapidly  increasing, and then only  with an incr eased frequency  of 
monitoring.
Subjects would not ty pically  be allo wed to resume treatment with tolv aptanif they  have:
ï‚·transaminase levels rise above 8 Ã—ULN,
ï‚·transaminase levels are > 5 Ã—ULN for more than 2 weeks, or
ï‚·concurrent elevations of transaminase > 3 Ã—ULN and BT > 2 Ã—ULN.
Subjects with these levels of abnormality  may  be re -challenged with IMP if abnormalities 
were adjudicated as having a < 50% likelihood of being related to IMP (per DILI network 
[DILIN] probabilit y criteria)10by an independent hepatic adjudication committee (HAC) 
and the investigator and medical monitor agree to an intensive monitoring plan to 
mitigate risk.  The subject must also be willing to comply  with these monitoring 
measures, be informed of the potential risks, and consent to I MP re -challenge.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
169
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 5HTXLUHPHQWVIRU6SHFLDO5HSRUWLQJ8VLQJWKH/LYHU'LV HDVH
(OHFWURQLF&DVH5HSRUW)RUPDQG,PPHGLDWHO\5HSRUWDEOH(YHQW)RUP
7KHSXUSRVHRIWKHOLYHUGLVHDVHH&5)DQGRSWLRQDODGGLWLRQDOW HVWLQJLVWRIDFLOLWDWH
UHYLHZRIHDFKVXEMHFWZKRSUHVHQWVZLWKRUGHYHORSVDOLYHUDE QRUPDOLW\GXULQJWKHWULDO
DQGWRGHWHUPLQHWKHSUREDEOHFDXVHVRIWKHVHDEQRUPDOLWLHV 7KHUHYLHZZLOOEH
SHUIRUPHGE\DEOLQGHGLQGHSHQGHQW +$&XVLQJ',/,1SUREDELOLW\ FULWHULD
 XQOLNHO\WR SRVVLEO\WR SUREDEO\W R YHU\
OLNHO\! GHILQLWH7KHUHVXOWRIWKHVHDQDO\VHVPD\EHSUHVHQWHGVHSDUDWHO\
IURPWKH&65
7KHLQYHVWLJDWRUPXVWFRPSOHWHDVSHFLDOOLYHUGLVHDVHH&5)IRU DQ\VXEMHFWZKR
 'LVFRQWLQXHVWUHDWPHQWGXHWRDOLYHUUHODWHG$(
 5HSRUWVDVHULRXVOLYHUUHODWHG$(
 +DVQRUPDOVFUHHQLQJOHYHOVDQGGHYHORSV$/7RU$67OHYHOV â‰¥[8/1
 +DVQRUPDOVFUHHQLQJOHYHOVDQGGHYHORSV%7OHYHOV â‰¥[8/1RU
 +DVDQDEQRUPDOVFUHHQLQJOHYHODQGGHYHORSVDEQRUPDOLWLHVLQW KDWWHVWWKDWDUH
![WKHXSSHUOLPLWRIWKHLUKLJKHVWVFUHHQLQJYDOXH


$GGLWLRQDOFOLQLFDOWHVWLQJVXFKDVWHVWLQJIRUKHSDWLWLVVH URORJ\
PD\DOVREHLQGLFDWHGDQGWKHLUUHVXOWVUHSRUWHGDFFRUGLQJWRO RFDOJXLGHOLQHV7KHOLYHU
H&5)DQG,PPHGLDWHO\5HSRUWDEOH(YHQW,5(IRUPVHH 6HFWLRQ VKRXOGEHXSGDWHG
DVQHZLQIRUPDWLRQEHFRPHVDYDLODEOH






8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK

















8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 45 06 March 20153.7.5 Treatment Interruption and Discontinuation
In this trial, it is expected that subjects may  possibly  have one or more planned or 
unplanned treatment interruptions.  If a subjectâ€™s IMP treatment must be interrupted for 
medical or surgical reasons ,liver test abnormalities ,use of a prohibited medication , or 
other reasons (e g, hospital admission for an invasive pro cedure, a m ajor medical 
condition, surgery ,dental work, or a temporary  situation that prevents subject compliance 
with the I MP administration schedule ), the i nvestigator should be notified as soon as 
possible and the reason for treatment interruption must be documented in the source 
documents and case report form ( CRF ).  If permissible, the subjectâ€™s IMP may be 
resumed following approval by  the medical m onitor.
If IMP treatment is permanently  discontinued, the reason for discontinuation must be 
recorded appropriatel y in the source document and in the CRF.
A subject who permanently  discontinues IMP treatment  end strialparticipation and the 
early termination visit should be completed.
3.7.6 End of Trial
The End of T rial d ate is defined as the last date of c ontac t or the date of final contact 
attempt from the p ost-treatm ent Follow -up CRF page for the last subject completing or 
withdrawing from the trial.
3.7.7 Independent Data Monitoring Committee
For this trial, an Independent Data Monitoring Committee (IDMC) , also known as a Data 
Safety  and Monitoring Committee , will be established.  The role of the IDMC shall be
delineated in a separate IDMC Charter document, but in general this group w ill meet on a 
regular basis to ensure the safe and ethical treatment of t rial subjects, ensure the scientific 
integrit y of the trial , and to ensure the trial is conducted within the bounds of ethical 
medical practice. Adjudication results as determined by  the HAC will be reported to the 
IDMC on a quarterl y basis or more freque ntly as necessary . This IDMC may  make 
recommendations to the sponsor and trial steering committee to amend or terminate the 
trial based on grounds of safet y, futility ,or greater than expected efficacy  as defined by  
the accepted statistical practices and procedures detailed in their Charter.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
172
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 46 06 March 20153.8 Stopping Rules, Withdrawal Criteria, and Procedures
3.8.1 Entire Trial 
If the sponsor terminates or suspends the trial for safet y or unanticipated other reasons, 
prompt notification will be given to investigators, I RBs/IECs, and regulatory  authorities 
in accordance with regulatory  requirements.
3.8.2 Individual Site
The investigator will notify  the sponsor promptly  if the trial is terminated by  the 
investigator or the IRB/IEC at the site. If the investigator, IRB/IEC or sponsor d ecides to 
terminate or suspend the trialâ€™s conduct at a particular center for safet y, non -enrollment 
of subjects, non -compliance with the protocol, or unanticipated other reasons, the above 
and other parties, as required by the applicable regulatory requir ements, will be promptly  
notified.
3.8.3 Individual Subject
If a subject discontinues the trial prematurel y, the reason must be fully evaluated and 
recorded appropriatel y in source documents and the CRF.  If the subject is being 
withdra wn because of an AE, that AE should be indicated as the reason for withdrawal.  
All subjects have the right to withdraw at an y time during treatment without prejudice.  
The investigator can discontinue a subjectâ€™s participation in the trial at any  time if 
medically  necessary .  Itis preferred that subjects who permanently  discontinue I MP will 
have the option to continue participation off IMP with regular scheduled visits or with a 
modified (ie, less frequent) schedule.  If subjects are unable or unwilling to complete the 
visits an d procedures off IMP, the earl y termination/EoTx visit should be completed .  
The investigator may continue to contact those who discontinue I MP through to the final 
completion date of the trial or thereafter if needed to determine outcomes ie, vital status.  
In addition, subjects meeting the following criteria must be withdrawn from the trial:
a) Occ urrence of an y AE, intercurrent illness, or abnormality  in a laboratory  assessment 
which, in the opinion of the investigator, warrants the subjectâ€™s permanent withdrawal 
from the trial;
b) Subject noncompliance, defined as refusal or inability  to adhere to the trial schedule or 
procedures (see Section 3.12);
c) At the request of the subject, investigator, sp onsor, or regulatory  authority ;
d) Subject is lost to follow-up.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
173
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 47 06 March 2015The investigator will notify  the sponsor promptly  when a subject is withdrawn.
3.9 Screen Failures
A screen failure subject is one from whom informed consent is obtained and is 
documented in writing (ie, subject signs an ICF), but who is not starte d on treatment .
3.10 Definition of Completed Subjects
For purposes of t his tria l, subjec ts who complete the E oTxvisit will be defined as trial 
completers.
3.11 Definition of Subjects Lost to Follow -up
Subjects, or the subjectâ€™s parent/guardian who cannot be contacted on or before their final 
visit prior to the trial termination d ate, who do not have a known reason for 
discontinuation (eg, withdrew consent or AE) and for whom a current health status at the 
end of the trial cannot be determined will be classified as â€œlost to follow -upâ€ as the 
reason for discontinuation.  Current hea lth status can be determined from a variet y of 
sources, either by obtaining acceptable documentation for death (ie, death certificate, 
medical records, public records, or statement b y a family member or primary care 
physician) or acceptable documentation f or life (ie, direct contact with the subject, 
medical records, successful telephone contact with the subject, statement b y a family 
member or primary  care phy sician, or public records).  I t is expected that 3 documented 
attempts will be made to determine a subjectâ€™s current health status before assigning a 
â€œlost to follow -upâ€ status.
3.12 Subject Compliance 
Subject compliance will be monitored by pill counts as IMPis returned.  Any  subject 
who, without the instruction of the investigator, discontinues tolvapta n investigational 
product, discontinues tolvaptan for 30consecutive day s or misses > 30% of the doses 
intended for a period between visits (whichever is greater) will be deemed non compliant. 
Depending on the circumstances leading to noncompliance, the subject may be 
withdrawn from the trial or discontinued from investigational product administration by  
the investigator and/or sponsor.  I t is preferred that subjects who discontinue tolvaptan, o r 
are withdrawn b y the investig ator for reasons other than noncompliance or lost to follow -
up, will continue with regularl y scheduled visits completing all procedures as provided in 
the protocol.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
174
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 48 06 March 20153.13 Protocol Deviations
This trial is to be conducted as describ ed in this protocol.  I n the event of a significant 
deviation from the protocol due to an emergency , accident or mistake (eg, violation of 
informed consent process, I MP dispensing or subject dosing error, subject enrolled in 
violation of eligibility  criter ia or concomitant medication criteria) , the investigator or 
designee must contact the sponsor at the earliest possible time.  This will allow an earl y 
joint decision regarding the subjectâ€™s continuation in the trial.  This decision will be 
documented b y the investigator and the sponsor, and reviewed b y the site monitor.
4 Restrictions
4.1 Prohibited or Restricted Medications
Medications or surgical therapies used for the purpose or potential for modify ing the 
progression of PKD cy st growth or development will be prohibited.  These include, but 
are not restricted to, somatostatin agonists, rapamune (sirolimus), a nti-sense ribonucleic 
acid therapies, vasopressin antagonists other than tolvaptan ,(eg, OPC -31260 
(mozavaptan), Vaprisol (conivaptan), agonists (eg, desm opressin) and cy st 
decompression surgery .
Continuous or short -term use of other medications, while not prohibited, may  be 
restricted b y the investigator because of their potential for interference with tolvaptan 
metabolism (see Section 3.2.1 and Section 3.2.2). 
A partial list of strong and moderate CYP3A4 inhibitors can be found in Table 4.1-1
below:
Table 4.1-1 Strong and Moderate CYP3A Inhibitors (partial list)
amprenavir atorvastin aprepitant chloramphenicol (if 
used orally)
cimetidine clarithromycin clotrimazole (if used 
orally)danazol
delavirdine diltiazem erythromycin fluconazole
fluvoxamine indinavir isoniazid itraconzazole
josamycin ketoconazole (if used 
orally)nelfinavir nefazadone
quinupristin/ dalfopristin ritonavir saquinavir troleandomycin
verapamil Seville orange products grapefruit products
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
175
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 49 06 March 2015Pharmacod ynamic interactions are a consideration for the use of diuretics, which may  be
only used intermittently , andnot within 7 day s of a urine assessment.  D iuretics are not 
generall y recommended in ADPKD due to their tendency to increase AVP levels through 
relative deh ydration or volume depletion; thus, chronic use of diuretics (eg, for 
hyperte nsion) will be prohibited and is an exclusionary  criterion for this trial. 
Some drugs are known to alter creatinine concentrations so, while not prohibited, subjects 
should alert their trial doctor, and an y other health -care providers, to take this into 
consideration when considering changes in their prescribed or over -the-counter 
medications.  A list would include:  non- steroidal anti -inflammatory  drugs like aspirin or 
ibuprofen, chemotherap y drugs, cephalosporin, the combination of elvitegravir, 
cobicistat, emtricitabine, and tenofovir (Stribild ïƒ”), dolutegravir, dronedarone, 
ranolazine, metformin, and trimethoprim.
4.2 Dietary  Restrictions and Recommendations
Restriction of excess dietary  sodium and cooked meat prote in may  prove beneficial to 
subjects with a history  of, or predisposition for, hypertension or kidney  disease in general 
and should be applied to all subjects diagnosed with advanced ADPKD, particularl y if 
there is evidence for a propensity  for rapid progre ssion.  I n the absence of alternate 
regional prac tices, dietary  salt < 5g/day ,dietary cooked meat protein < 1 g/kg/day  and a
limit on caffeinated drinks/foods should also be given (no more than 2 coffee equivalents 
per day ).  A history  of alcohol and smoking intake will be collected at screening.  
Alcohol and tobacco consumption should be avoided or minimized as much as possible.
Additionally , fluid intake is generall y encouraged in subjects with PKD.  Given the 
potential for dehydration with tolvaptan treatment, all subjects should be instructed to 
ingest fluids in anticipation of, or at the first sign of thirst in order to avoid excessive 
thirst or dehy dration.  Upon consent, all subjects should receive the recommendation to 
ingest at least 2 to 3 liters of fluid (including in solid, semi -solid, and liquid foods) per 
day, unless otherwise directed by  their trialdoctor.  This recommendation should start 
during screening and continue through the end of the trial.  Additionally ,subjects should 
ingest 1 to 2 cups of water before bedtime regardless of perceived thirst , and replenish 
fluids overnight with each episode of nocturia.  Dehy dration will be monitored by  subject 
self-assessment of changes in body  weight and reporting of s ymptoms.  Acute changes of 
>3% of bod y weight (increase or decrease) over any 7 -day period should be noted.  
Subjects should be instructed to report acute changes in bod y weight to the trial physician 
for further evaluation and recommendations.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
176
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 50 06 March 2015Subjects s hould be advised that the ingestion of pomelo, grapefruit, or Seville orange 
products would be expected to increase tolvaptan concentrations and these should be 
avoided.  In the event of an unintentional ingestion of such products, the investigator may  
askthe subject to temporarily  interrupt the IMP. 
5 Reporting of A dverse Events
The following describes the methods and timing for assessing, recording, and anal yzing 
safet y parameters, as well as the procedures for eliciting reports of and recording and 
reporting AEs and intercurrent illnesses and the t ype and duration of the follow -up of 
subjects after AEs.
Medical follow up is expected for AEs which lead to discontinuation which are serious, 
or which are of special interest (eg, liver abnormalities, skin ne oplasms, glaucoma).
ADPKD is a progressive disorder involving the kidney , liver and occasionally  other 
organ s ystems.  A number of AEs may  be associated with this disorder including urine 
concentration defects, hypertension, renal pain, renal infection, ne phrolithiasis, 
hematuria, and ESRD.  As such, these events are considered â€œexpectedâ€ in this trial 
population and will not qualify  for the purposes of regulatory  expedited reporting (eg, 
Suspected Unexpected Serious Adverse Reaction and investigational new drug [IND] 
safet y reports).
5.1 Definitions
An AE is defined as an y untoward medical occurrence associated with the use of a n IMP
in humans, whether or not considered IMP related.
A suspected adverse reaction means any  AE for which there is a reasonable possi bility  
that the IMPcaused the AE. For the purpose of IND safet y reporting, â€œreasonable 
possibility â€ means there is evidence to suggest a causal relationship between the IMPand 
the AE. Suspected adverse reaction implies a lesser degree of certainty  abou t causality .
A serious adverse event ( SAE )includes an y event that results in any of the following 
outcomes:
1. D eath
2. L ife-threatening, ie, the subject was, in the opinion of the investigator, at 
immediate risk of death from the event as it occurred.  I t does not include an 
event that, had it occurred in a more severe form, might have caused death.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
177
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 51 06 March 20153. P ersistent or significant incapacity  or substantial disruption of the ability  to 
conduct normal life functions .
4. R equires inpatient hospitalization or prolongs hospitalization
NOTE: A pre -scheduled hospitalization is not considered an SAE.
5. C ongenital anomal y/birth defect
6. O ther medicall y significant events that, based upon appropriate medical 
judgment, may  jeopardiz e the subject and may  require medical or surgical 
intervention to prevent one of the outcomes listed above, eg, allergic 
bronchospasm requiring intensive treatment in an emergency  room or home, 
blood dy scrasias or convulsions that do not result in hospitalization, or the 
development of drug dependency  or drug abuse.
Nonserious AEs are all AE s that do not meet the criter ia for a "serious" AE .
Immediately  Reportable Event (IRE):
ï‚·Any SAE
ï‚·Any AE (whether serious or nonserious) that necessitates discontinuation of IMP.
ï‚·Any subject with a new liver test abnormalit y meeting the AE (whether serious or 
nonserious) or laboratory threshold criteria (whether considered an AE or not) for 
hepatic eCRF reporting.
ï‚·Any subject reporting an AE of special interest (eg, skin neoplasms or glaucoma).
ï‚·Pregnancies are also defined as IREs.  Although normal pregnancy  is not an AE, 
it will mandate I MP discontinuation and must be reported on an I RE form to 
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).  
Pregnancy will only  be documented on the AE eCRF if there is an abnormality  or 
complication.
ï‚·Additionally , in the EU region, events involving overdose, misuse and abuse as 
well as reported lack of efficacy  must also be reported as IREs.
Clinical L aboratory  Changes :  It is the investigatorâ€™s responsibility  to review the results 
of all laboratory  tests as they  become available.  This review will be documented by  the 
investigatorâ€™s dated signature on the laboratory  report.  For each abnormal laboratory  test 
result, the investigator needs to ascertain if this is an abnormal (ie, clinically  significant) 
change from baseline for that individual subject. This determination, however, does not 
necessarily  need to be made the first time an abnormal value is observed.  The 
investigator may  repeat the laboratory  test or request additional tests to verify  the results 
of the original laboratory tests.  I f this laboratory  value is determined by  the investigator 
to be an abnormal change from baseline for that sub ject, this is consi dered an AE.
Severity :  Adverse events will be graded on a 3-point scale and reported as indicated on 
the CRF .  The intensity  of an adverse experience is defined as follows:
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
178
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 52 06 March 20151 = Mild: Discomfort noticed, but no disruption to daily  activity .
2 = Moderate: Discomfort sufficient to reduce or affect normal daily  activit y.
3 = Severe: Inability  to work or perform normal daily  activity .
IMP Causalit y:Assessment of causal relationship of an AE to the use of the IMP:
Related : There is a reasonable probability  orpossibility  of a temporal and 
causal relationship between the IMP and the AE .
Not Related : There is no temporal or causal relationship to the IMP 
administration.
5.2 Eliciting and Reporting A dverse Events
The investigator will periodically  assess subjects for the occurrence of AEs.  I n order to 
avoid bias in eliciting AEs, subjects should be asked the following non -leading question: 
â€œHow have you felt since your last visit? â€  All AEs (serious and non serious) reported b y 
the subject must be recorded on the source documents and eCRFs provided by  the 
sponsor.
In addition, Quintiles (drug safet y service) must be notified immediately  by telephone or 
fax of any  immediately  reportable events according to the proced ure outlined below in
Section 5.3.  Special attention should be paid to recording hospitalization and 
concomitant medications.
5.3 Immediately  Reportable Events
The investigator must immediately report within 24 hours after eit her the investigator or 
site personnel become aware of any SAE , new liver laboratory  abnormality  requiring 
special liver eCRF completion, or confirmed pregnancy ,by telephone or by  fax to 
Quintiles (drug safet y service) as outlined in A ppendix 1.  An I RE form must be 
completed and sent b y fax, email or overnight courier to the sponsor.  (Please note that 
the IRE form is NOT the AE eCRF ).
Nonserious events that require discontinuation of IMP (including laboratory 
abnormalit ies) should be reported to the s ponsor within 3 working day s.  The I RE form 
must be completed and sent by  fax, email ,or ove rnight courier to the sponsor.
Subjects experiencing SAEs should be followed clinically  until their health has returned 
to baseline status, or until all parameters ha ve returned to normal, or have otherwise been 
explained.  I t is expected that the investigator will provide or arrange appropriate 
supportive care for the subject.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
179
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 53 06 March 20155.4 Pregnancy
Women o f childbearing potential who are sexually  active must use an effective meth od of 
birth control during the course of the trial and for 30 day s after the last dose of IMP in a 
manner such that risk of failure is minimized.  Unless the subject is sterile (ie, women 
who have had an bilateral oophor ectomy  and/or hy sterectom y or have b een 
postmenopausal for at least 12 consecu tive months or remain s abstinent, 2 of the 
following precautions must be used: vasectom y, tubal lig ation, intrauterine device, birth 
control pills, birth control depot injection, birth control implant, condom or occlusive cap 
(diaphragm or cervical/vault caps) with spermicide.  Any  single method of birth control, 
including vasectomy  and tubal ligation, may  fail, leading to pregnancy .  Abstinence is 
only acceptable when part of the preferred and usual lifesty le of th e subject ;should that 
lifesty le change, double barrier contraceptive methods should be employ ed.
Before enrolling WOCBP in this clinical trial, investigators must review guidelines about 
trial participation for WOCBP.  The topics should generall y include:
ï‚·General information
ï‚·ICF
ï‚·Pregnancy  prevention information
ï‚·Drug interactions with hormonal contraceptives.
ï‚·Contraceptives in current use.
ï‚·Guidelines for the follow -up of a reported pregnancy .
Prior to trial enrollment, WOCBP must be advised of the importance of avoiding 
pregnancy  during trial participation and the potential risk factors for an unintentional 
pregnancy .  The subject must sign an ICFstating that the above -mentioned risk factors 
and the consequences were discussed with her.
During the trial, all WOCBP should be instructed to contact the investigator immediately  
if they  suspect they  might be pregnant (eg, missed or late menstrual cy cle).
If a subject or investigator suspects that thesubject may  be pregnant prior to I MP 
administration, the I MP administration must be withheld until the results of serum 
pregnancy  tests are available.  If the pregnancy  is confirmed, the subject must not re ceive 
the IMP and must not be enrolled in the trial.  If pregnancy  is suspected while the subject 
is taking IMP, the IMP must be withheld immediately  (if reasonable, taking into 
consideration an y potential withdrawal risks) until the result of the pregnanc y is known.  
If pregnancy  is confirmed, the I MP will be interrupted or withheld in an appropriate 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
180
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 54 06 March 2015manner (eg, dose tapering if necessary  for subject safet y) and the subject will continue to 
be monitored for the duration of the remainder of the trial or of their pregnancy .
The investigat or must immediately  notify  the s ponsor of any pregnancy  associated with 
IMP exposure, during the trial and for 30 day s after the last dose of IMP and record the 
event on the IRE form and forward it to the sponsor.  The s ponsor will forward 
Pregnancy  Surveillance Form(s) for monitorin g the outcome of the pregnancy .
Protocol required procedures for trial discontinuation and follow -up must be performed 
on the subject unless contraindicated b y pregnancy (eg, x -ray studies).  Other appropriate 
pregnancy  follow -up procedures should be considered if indicated.  In addition, the 
investigator must report to the s ponsor, on appropriate Pregnancy  Surveillance form(s), 
follow -up information regarding the course of the pregnancy , including perinatal and 
neonatal outcome.  Infants will be followed for a minimum of 6 months.
5.5 Follow -up of A dverse Events
For this trial, AEs will be followed up for 7days after the last dose of tolvaptan has been 
administered (follow -up period).
Subjects experien cing SAEs should be followed clinically  until their health has returned 
to baseline status, or until all parameters have returned to normal, or have otherwise been 
explained.
5.5.1 Follow -up of Non serious A dverse Events
Nonserious AE s that are identified on the last scheduled contact must be recorded on the 
AE eCRF wi th the current status noted.  All nonserious events that are ongoing at this 
time will be recorded as ongoing on the eCRF.
5.5.2 Follow -up o f Post -Trial Serious A dverse Events
Serious AEs that are identifi ed on the last scheduled contact must be recorded on the 
AE eCRF page and reported to the s ponsor according to the reporting procedures outlined 
in Section 5.3.  This may include unresolved previously reported SAE s, or new SAE s.  
The investigator w ill follow SAE s until the events are resolved, or the subject is lost to 
follow -up.  Resolution means the subject has returned to the baseline state of health, or 
the investigator does not expect any  further improvement or worsenin g of the subjectâ€™s 
condition.  The investigator will continue to report any  significant follow -up information 
to OPDC up to the point the event has been resolved.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
181
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK )ROORZXSDQG5HSRUWLQJRI6HU LRXV$GY HUVH(YHQWV2FFXUULQ J
DIWHU/DVW6FKHGXOHG&RQWDFW
$Q\QHZ6$( VUHSRUWHGE\WKHVXEMHFWWRWKHLQYHVWLJDWRUWKDWR FFXUDIWHUWKHODVW
VFKHGXOHGFRQWDFW DQGDUHGHWHUPLQHGE\WKHLQYHVWLJDWRUWREHUHDVRQDEO\DVVRF LDWHG
ZLWKWKHXVHRIWKH,03VKRXOGEHUHSRUWHGWR23'&7KLVPD\ LQFOXGH6$(VWKDWDUH
FDSWXUHGRQIROORZXSWHOHSKRQHFRQWDFWRUDWDQ\RWKHUWLPHSR LQWDIWHUWKHGHILQHGWULDO
SHULRGLHXSWRODVWVFKHGXOHGFRQWDFW7KHLQYHVWLJDWRUVKR XOGIROORZVHULRXVUHODWHG
$(VLGHQWLILHGDIWHUWKHODVWVFKHGXOHGFRQWDFWXQWLOWKHHYHQW VDUHUHVROYHGRUWKHVXEMHFW
LVORVWWRIROORZXS7KHLQYHVWLJDWRUVKRXOGFRQWLQXHWRUHSR UWDQ\VLJQLILFDQWIROORZXS
LQIRUPDWLRQWR23'&XSWRWKHSRLQWWKHHYHQWKDVEHHQUHVROYHG 





 6WDWLVWLFDO$QDO\VLV
 6DPSOH6L]H
6DPSOHVL]HZDVQRWGHWHUPLQHGE\DIRUPDOFRPSXWDWLRQWRDFKLH YHDWDUJHWSRZHU1R
HIILFDF\DQDO\VHVDUHSODQQHG,WLVH[SHFWHGWKDWDSSUR[LPDWH O\VXEMHFWVPD\
HQUROO IURPSUHYLRXVWROYDSWDQWULDOV
 'DWDVHW IRU$QDO\VLV
7KHIROORZLQJGDWDVHWVDUHGHILQHGIRUWKLVWULDO
â€¢(QUROOHG3RSXODWLRQDOOVXEMHFWVZKRZHUHHQUROOHGWRWKLVRSHQ ODEHOWULDO
â€¢6DIHW\3RSXODWLRQDOOVXEMHFWVLQWKH(QUROOHG6DPSOHZKRWDNH DWOHDVWRQHGRVHRI
,03
 +DQGOLQJRI0LVVLQJ'DWD
1RPLVVLQJGDWDZLOOEHLPSXWHGXQGHUWKHDVVXPSWLRQRIPLVVLQJ DWUDQGRP
 ,QWHULP$QDO\VLV
1RLQWHULPDQDO\VLVIRUWKLVWULDO LVSODQQHG
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK 7ULDO 2XWFRPH$QDO\VHV
 $QDO\VLVRI'HPRJUDSKLFDQG%DVHOLQH&KDUDFWHULVWLFV
'HPRJUDSKLFFKDUDFWHULVWLFVGLVHDVHVHYHULW\DQGPHGLFDOKLVW RU\DWSUHWUHDWPHQW
EDVHOLQHZLOOEHVXPPDUL]HGE\GHVFULSWLYHVWDWLVWLFVHJSURS RUWLRQPHDQPHGLDQ6'
PLQLPXPDQGPD[LPXPYDOXHV
 6DIHW\$QDO\VLV
6DIHW\DQDO\VLVZLOOEHFRQGXFWHGEDVHGRQWKH6DIHW\3RSXODWLR QZKLFKLVGHILQHGDVDOO
VXEMHFWVLQWKH(QUROOHG3RSXODWLRQZKRWDNHDWOHDVWRQHGRVHR I,036DIHW\YDULDEOHV
WREHDQDO\]HGLQFOXGHFOLQLFDOODERUDWRU\WHVWVYLWDOVLJQV DQG$(V 

,QJHQHUDOEDVHOLQHPHDVXUHPHQWVRIVDIHW\YDULDEOHVDUHGHILQ HGDVWKHODVW
PHDVXUHPHQWVSULRUWRWKHILUVWGRVHRI,03 LQ7ULDO  6DIHW\YDULDEOHVZLOOEH
VXPPDUL]HGE\GHVFULSWLYHVWDWLVWLFVHJSURSRUWLRQPHDQPH GLDQ6'PLQLPXPDQG
PD[LPXPYDOXHV6XPPDU\VWDWLVWLFVLQFOXGLQJFKDQJHVIURPED VHOLQHZLOOEH
SURYLGHGIRUVDIHW\YDULDEOHVEDVHGRQDOODYDLODEOHGDWD
 $GYHUVH(YHQWV
$OO$(VZLOOEHFRGHGE\V\VWHPRUJDQFODVV62&DQG0HGLFDO' LFWLRQDU\IRU
5HJXODWRU\$FWLYLWLHV0HG'5$SUHIHUUHGWHUP7KHLQFLGHQFHR IWKHIROORZLQJHYHQWV
ZLOOEHVXPPDUL]HG
D 7($(VE\VHYHULW\
E 7($(VSRWHQWLDOO\FDXVDOO\UHODWHGWRWROYDSWDQF 7($(VZLWKDQRXWFRPHRIGHDWKG 6HULRXV7($(VH 'LVFRQWLQXDWLRQVGXHWR7($(V
 9LWDO6LJQV
6XPPDU\VWDWLVWLFVIRUFKDQJHVIURPEDVHOLQHLQYLWDOVLJQVDQG SRWHQWLDOO\FOLQLFDOO\
VLJQLILFDQWUHVXOWVLQYLWDOVLJQVZLOOEHVXPPDUL]HG
 &OLQLFDO/DERUDWRU\$VVHVVPHQWV
6XPPDU\VWDWLVWLFVIRUFKDQJHVIURPEDVHOLQHLQFOLQLFDOODERUD WRU\PHDVXUHPHQWVZLOOEH
SURYLGHGIRUWKH6DIHW\3RSXODWLRQ3RWHQWLDOO\FOLQLFDOO\VLJ QLILFDQWUHVXOWVLQODERUDWRU\
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKWHVWVLGHQWLILHGXVLQJSURVSHFWLYHO\GHILQHGFULWHULDLQFOXGLQ JFULWHULDIRUOLYHUHQ]\PH
HOHYDWLRQVZLOODOVREHVXPPDUL]HGIRUWKH6DIHW\3RSXODWLRQ ,QDGGLWLRQE\VXEMHFW
OLVWLQJVZLOOEHSURYLGHGIRUGDWDRIORFDOODERUDWRU\WHVWV
,QDGGLWLRQODERUDWRU\PHDVXUHPHQWVWKDWVLJQDOWKHSRWHQWLDOI RU+\Â¶V/DZZLOOEH
UHSRUWHG$QLQFLGHQFHWDEOHDQGDOLVWLQJZLOOEHSURYLGHGIR UVXEMHFWVZKRPHHWRQHRU
FRPELQDWLRQVRIIROORZLQJFULWHULDZLWKRXWLQLWLDOILQGLQJVRI FKROHVWDVLV$/3DFWLYLW\
! Ã®8/1
â€¢$/7RU$67 â‰¥ Ã®8/1
â€¢%LOLUXELQ â‰¥ Ã®8/1
 6HUXP6RGLXP
7KHIROORZLQJZLOOEHVXPPDUL]HG
â€¢6HUXPVRGLXPH[FXUVLRQVDERYHRUPPRO/RUEHORZ  RU
PPRO/
â€¢,QWHUUXSWLRQVRISURWRFROVSHFLILHGWKHUDSLHVIRUK\SHUQDWUHPLD RUK\SRQDWUHPLD












8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK











 0DQDJHPHQWRI,QYHVWLJDWLRQDO0HGLFLQDO3URGXFW
 3DFNDJLQJDQG/DEHOLQJ
7ROYDSWDQZLOOEHSURYLGHGWRWKHLQYHVWLJDWRUVE\WKHVSRQVRU RUGHVLJQDWHGDJHQWDV
WDEOHWVRIRUPJWROYDSWDQ23&(DFKERWWOHZLOOEH ODEHOHGWRFOHDUO\
GLVFORVHWKHVXEMHFW,'FRPSRXQG,'WULDOQXPEHUVSRQVRU
VQ DPHDQGDGGUHVV
LQVWUXFWLRQVIRUXVHURXWHRIDGPLQLVWUDWLRQDSSURSULDWHSUHF DXWLRQDU\VWDWHPHQWVDQG
RWKHULQIRUPDWLRQUHTXLUHGE\ORFDOUHJXODWRU\DXWKRULWLHV$Q \UHJLRQVSHFLILF
UHTXLUHPHQWVZLOODSSHDULQWKHRIILFLDOODQJXDJHRIWKHFRXQWU \LQZKLFKWKH,03 LVWREH
XVHG
 6WRUDJH
7ROYDSWDQZLOOEHVWRUHGLQDVHFXUHO\ORFNHGFDELQHWRUHQFORVX UH$FFHVVZLOOEHOLPLWHG
WRLQYHVWLJDWRUVDQGWKHLUGHVLJQHHV1HLWKHULQYHVWLJDWRUVQR UDQ\GHVLJQHHVPD\SURYLGH
WROYDSWDQWRDQ\VXEMHFWQRWSDUWLFLSDWLQJLQWKLVSURWRFRO
7ROYDSWDQZLOOEHVWRUHGDW WKHFRQGLWLRQVVSHFLILHGLQWKH,03O DEHO7KHFOLQLFDOVLWH
VWDIIZLOOPDLQWDLQDWHPSHUDWXUHORJLQWKH,03 VWRUDJHDUHDUH FRUGLQJWKHWHPSHUDWXUHDW
OHDVWRQFHHDFKZRUNLQJGD\
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 59 06 March 20158.3 Accountability
The investigator or designee must maintain an inventory record of IMP received, 
dispensed, administered, and returned.
8.4 Returns and Destruction
Upon completion or termination of the trial, all unused and/or partially  used I MP must be 
returned to the sponsor or a designated agent.
All IMP returned to the sponsor must be accompanied by  appropriate documentation and 
be identified b y protocol number with trial site numbe r on the outermost shipping 
container.  Returned supplies should be in the original containers (eg, subject kits).  The 
assigned trial monitor will facilitate the return of unused and/or partially  used IMP.
9 Records Management
9.1 Source Documents
Source docume nts are defined as the results of original observations and activities of a 
clinical investigation.  Source documents will include but are not limited to progress 
notes, electronic data, screening logs, and recorded data from automated instruments.  All 
source documents pertaining to this trial will be maintained b y the investigators. 
Investigator(s)/institution(s) will permit trial- related monitoring, audits, I RB/IEC review, 
and regulatory  inspection(s) by  providing direct access to source data/documents b y
authorized persons as defined in the I CF.
9.2 Data Collection
During each subjectâ€™s visit to the clinic, a clinician participating in the trial will record 
progress notes to document all significant observations.  At a minimum, these notes will 
contain:
ï‚·Docu mentation of the informed consent process, including an y revised consents;
ï‚·The date of t he visit and the corresponding v isit or Day  in the trial schedule;
ï‚·General subject status remarks, including an y significant medical findings.  The 
severit y, frequency, duration, action taken, and outcome of any  AEs and the 
investigator's assessment of relationship to IMP must also be recorded;
ï‚·Any changes in concomitant medications or dosages;
ï‚·A general reference to the procedures completed; 
ï‚·The signature (or initials) and date of each clinician (or designee) who made an entry  
in the progress notes.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
186
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 60 06 March 2015In addition, any  contact with the subject via telephone or other means that provides 
significant clinical information will also be documented in the progress notes as 
descri bed above.  An y changes to information in the trial progress notes and other source 
documents will be initialed and dated on the day  the change is made by a site staff 
member authorized to make the change.  Changes will be made b y striking a single line 
through erroneous data (so as not to obliterate the original data), and clearly entering the 
correct data (eg, wrong data right data).  If the reason for the change is not apparent, a 
brief explanation for the change will be written in the source documentat ion by  the 
clinician.
Information from the trial progress notes and other source documents will be entered b y 
investigative site personnel directl y onto eCRFs in the sponsorâ€™s electronic data capture
system. Changes to the data will be captured by  an auto matic audit trail.
9.3 File Management at the Trial Site
The investigator will ensure that the trial site file is maintained in accordance with 
Section 8 of the I CH GCP Guideline and as required by  applicable local regulations. The 
investigator/institution wil l take measures to prevent accidental or premature destruction 
of these documents.
9.4 Records Retention at the Trial Site
Regulatory  requirements for the archival of records for this trial necessitate that 
participating investigators maintain detailed clinica l data for the longest of the following 
three periods:
ï‚·A period of at least 2 y ears following the date on which approval to market the IMPis 
obtained (or if IMP development is discontinued, the date regulatory  authorities were 
notified of discontinuation); OR
ï‚·A period of at least 3 y ears after the sponsor notifies the investigator that the final 
report has been filed with regulatory  authorities.
ï‚·Longer, region -specific storage requirements, if applicable .The investigator must not 
dispose of an y records relevant to this trial without either (1) written permission from the 
sponsor or (2) provision of an opportunity for sponsor to collect such records.  The 
investigator will be responsible to maintain adequate and accurate electronic or hard cop y 
source doc uments of all observations and data generated during this trial.  Such 
documentation is subject to inspection by  the sponsor and relevant regulatory  authorities.  
If the investigator withdraws from the trial (eg due to relocation or retirement), all trial -
related records should be transferred to a mutuall y agreed -upon designee within a 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
187
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 61 06 March 2015sponsor -specified timeframe.  Notice of such transfer will be gi ven to the sponsor in 
writing.
10 Quality  Control and Quality  Assurance 
10.1 Monitoring
The sponsor has ethical, lega l, and scientific obligations to follow this trial carefully  in a 
detailed and orderl y manner in accordance with established research principles, the I CH 
GCP Guideline, and applicable regulatory  requirements and local laws.  As part of a 
concerted effort to fulfill these obligations (maintain current personal knowledge of the 
progress of the trial), the sponsor's monitors will visit the site during the trial, as well as 
communicate frequentl y via telepho ne and written communications.
10.2 Auditing
The sponsor's Qualit y Management Unit (or representative) may conduct trial site audits.  
Audits will include but are not limited to IMPsupply , presence of required documents, 
the informed consent process, and comparison of e CRFs with source documents.  The 
investigato r agrees to participate with audits.
Regulatory  authorities may  inspect the investigator site during or after the trial.  The 
investigator will cooperate with such inspections and will contact the sponsor 
immediately  if such an inspection occurs.
11 Ethics an d Responsibility
This trial must be conducted in compliance with the protocol, the ICH GCP Guideline, 
and applicable local laws and regulatory  requirements. Each trial site will seek approval 
by an IRB or IEC according to regional requirements. The I RB/I EC will evaluate the 
ethical, scientific and medical appropriateness of the trial. Further, in preparing and 
handling CRFs, the investigator, sub -investigator and their staff will take measures to 
ensure adequate care in protecting subject privacy . To this end, a subject number and 
subject ID code will be used to identify  each subject. 
Financial aspects, subject insurance and the publication policy  for the trial will be 
documented in the agreement between the sponsor and the investigator.
12 Confidentiality
All information generated in this trial will be considered confidential and will not be 
disclosed to any one not directly  concerned with the trial without the sponsorâ€™s prior 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
188
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 62 06 March 2015written permission.  Subject confidentialit y requirements of the region(s) where the trial 
is conducted will be met.  However, authorized regulatory  officials and sponsor personnel 
(or their representatives) will be allowed full access to inspect and cop y the records.  All 
IMPs, subject bodil y fluids, and/or other materials collected s hall be used solely  in 
accordance with this protocol, unless otherwise agreed to in writing b y the sponsor.
Subjects will be identified only  by initials and unique subject numbers in e CRFs.  Their 
full names may , however, be made known to a regulatory  agen cy or other authorized 
officials if necessary .
13 Amendment Policy
The investigator will not make an y changes to this protocol without the sponsorâ€™s prior 
written consent and subsequent approval by  the IRB/IEC.  Any  permanent change to the 
protocol, whether it be an overall change or a change for specific trial site(s), m ust be 
handled as a protocol amendment.  An y amendment will be written by the sponsor.  Each 
amendment will be submitted to the I RB/IEC.  Except for â€œadministrativeâ€ or â€œnon -
substantialâ€ amendments, investigators will wait for I RB/IEC approval of the amended 
protocol before implementing the change(s).  Administrative amendments are defined as 
having no effect on the safet y of subjects, conduct or management of the trial, trial 
design, or the quality  or safet y of IMP(s) used in the trial.  A protocol change intended to 
eliminate an apparent immediate hazard to s ubjects should be implemented immediately , 
followed b y IRB/IEC notification within 5 working day s.  The sponsor will submit 
protocol amendments to the applicable regulatory  agencies.
When the I RB/IEC, investigators, and/or the sponsor conclude that the protocol 
amendment substantially  alters the trial design and/or increases the potential risk to the 
subject, the currently  approved written ICF will require similar modification.  I n such 
cases, repeat informed consent will be obtained from subjects enrolled in the trial before 
expecting continued participation.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
189
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 63 06 March 201514 References
1European Medicines Agency , Public summary  of opinion on orphan designation: 
Tolvaptan for the treatment of autosomal dominant poly cystic kidney  disease. 
Committee for Orphan Medicinal Products. 2013; EMA/COMP/444684/2013.
2U S Renal Data S ystem, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney  
Disease and End- Stage Renal Disease in the United States, National Institutes of 
Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 
MD, 2012
3Lentine KL, Xiao H, Machnicki G, Gheorghian A, Schnitzler MA. Renal function 
and healthcare costs in patients with poly cystic kidney  disease. Clin J Am Soc 
Nephrol. 2010 Aug;5(8):1471-9.
4OPC -41061 I nvestigatorâ€™s Brochure. Rockville (MD): Otsuka Pharmaceutical 
Development & Commercialization, I nc.; Edition 19 Otsuka Report, issued 11 July  
2013.
5OPC -41061 Common Technical Document.  Rockville (MD): Otsuka Pharmaceu tical 
Development & Commercialization, I nc.; Section 2.5: Clinical Overview; 2013.
6Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 
receptor antagonists OPC -31260 and OPC -41061 on poly cystic kidney  disease 
development in the P CK rat. J Am Soc Nephrol. 2005 Apr;16(4):846 -51. 
7Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP. Tolvaptan 
inhibits ERK -dependent cell proliferation, Cl- secretion, and in vitro cy st growth of 
human ADPKD cells stimulated by  vasopressin. Amer J Phy siol Ren al Phy siol. 2011 
Nov;301(5):F1005 -13.
8Torres VE, Chapman AB, Devuy st O, Gansevoort RT, Grantham JJ, Higashihara E, 
et al for the TEMPO 3:4 Trial Investigators.  Tolvaptan in patients with autosomal 
dominant poly cystic kidney  disease. N Engl J Med 2012;367:2407 -18.
9Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, et al. 
Tolvaptan in autosomal dominant poly cystic kidney  disease: three y ears' experience. 
Clin J Am Soc Nephrol. 2011 Oct;6(10):2499 -507.
10U.S. Food an d Drug Administration. Guidance for Industry . Drug -induced liver 
injury : premarketing clinical evaluation [report on the internet]. 2009 Jul [cited 2012 
Oct 10];[about 23 p.].  Available from: 
http://www.fda.gov/downloads/Drugs/GuidanceCompliance
Regulator yInformation/Guidances/UCM174090.pdf .
11Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of 
ADPKD. J Am Soc Nephrol 2010 20: 205-212.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
190
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 64 06 March 201512Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic 
criteria for autosomal dominant poly cystic kidney disease 1. Lancet 1994; 343:824-
827.
13Levey  AS, Stevens LA, et al. A new equation to estimate glomerular filtration rate.  
Ann Intern Med. 2009; 150:604-612.
14International Conference on Harmonisation; Good Clinical Practice: Consolidated 
Guideline; Notice of Availability , 62 C.F.R. Sect. 90 (1997).
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
191
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK$SSHQGL[ 1DPHVRI6SRQVRU3HUVRQQHO
5HSRUW,PPHGLDWHO\5HSRUWDEOH(YHQWVVHULRXVDGYHUVHHYHQWVS RWHQWLDO+\Â¶V/DZFDVHV
SUHJQDQFLHVDQGDGYHUVHHYHQWVUHTXLULQJGLVFRQWLQXDWLRQRI,03 WR
4XLQWLOHV
&OLQLFDO6DIHW\DQG3KDUPDFRYLJLODQFH6RXWK0LDPL%OYG0RUULVYLOOH1&86$3KRQH)D[(PDLO
)RU0HGLFDO(PHUJHQFLHV XVHRQO\LIVSRQVRUSHUVRQQHOOLVWHGDERYHDUHXQDYDLODEOH
*OREDO3URMHFW/HDGHUV
*OREDO&OLQLFDO'LUHFWRU
0HGLFDO'LUHFWRU3URJUDP/HDG 2WVXND3KDUPDFHXWLFDO'HYHORSPHQW	
&RPPHUFLDOL]DWLRQ,QF5HVHDUFK%OYG5RFNYLOOH0'86$3KRQH )D[
*OREDO&OLQLFDO'LUHFWRU 
0HGLFDO'LUHFWRU3URMHFW/HDG 2WVXND3KDUPDFHXWLFDO'HYHORSPHQW	
&RPPHUFLDOL]DWLRQ,QF&DUQHJLH&HQWHU'ULYH6XLWH3ULQFHWRQ1-86$3KRQH )D[
*OREDO&OLQLFDO0DQDJHPHQW
*OREDO&OLQLFDO0DQDJHPHQW
86$
3KRQH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
PPDPPD
PPD
PPD
PPD
PPD
PPD
PPD PPD
PPD
PPD
PPD PPD
PPD
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK$SSHQGL[ ,QVWLWXWLRQV&RQFHUQHG:LWKWKH7ULDO
/HDG3ULQFLSDO&RPPXQLFDWLQJ
,QYHVWLJDWRU6WHHULQJ&RPPLWWHH&KDLU
86$
3KRQH
,QGHSHQGHQW'DWD0RQLWRULQJ
&RPPLWWHH&KDLU
3KRQH
+HSDWLF$GMXGLFDWLRQ&RPPLWWHH&KDLU

3KRQH
)D[
*OREDO0HGLFDO0RQLWRULQJ 4XLQWLOHV
6RXWK0LDPL%OYG
0RUULVYLOOH1&86$
3KRQH
0RELOH
)D[
7ULDO0DQDJHP HQW 4XLQWLOHV
6RXWK0LDPL%OYG
0RUULVYLOOH1&86$
2IILFH
0RELOH
)D[
6DIHW\5HSRUWLQJ 4XLQWLOHV
'UXJ6DIHW\6HUYLFH
6RXWK0LDPL%OYG
0RUULVYLOOH1&86$
3KRQH
)D[
,QYHVWLJDWLRQDO0DWHULDOV $OPDF
)UHW]5G
6RXGHUWRQ3$ 86$
3KRQH
%XGJHWDQG&RQWUDFW1HJRWLDWLRQ ,1&5HVHDUFK//&
%HHFKOHDI&W
5DOHLJK1&86$
3KRQH
,QYHVWLJDWRU3D\PHQWV 4XLQWLOHV,QF
,QYHVWLJDWRU3D\PHQW$GPLQLVWUDWLRQ'HSDUWPHQW
7HOHVLV&RXUW6XLWH
6DQ'LHJR&$86$
3KRQH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK(OHFWURQLF'DWD&DSWXUH 0HGL'DWD6ROXWLRQV
)LIWK$YHQXHWK)ORRU
1HZ<RUN1< 86$
3KRQH
)D[
,576\VWHPV $OPDF&OLQLFDO7HFKQRORJLHV
)UHW]5RDG
6RXGHUWRQ3$86$
867HO
5R:7HO
&HQWUDO/DERUDWRU\6HUYLFHV &RYDQFH&HQWUDO/DERUDWRU\6HUYLFHV
6FL&RU'U
,QGLDQDSROLV,186$
3KRQH
7ROOIUHH
)D[ 
&RYDQFH$VLD3WH/WG
&HQWUDO/DERUDWRU\6HUYLFHV6LQJDSRUH
,QWHUQDWLRQDO%XVLQHVV3DUN
7KH6\QHUJ\6LQJDSRUH
3KRQH
&RYDQFH&HQWUDO/DERUDWRU\6HUYLFHV6 \GQH\
(SSLQJ5G1RUWK5\GH
16:$XVWUDOLD
3KRQH
&RYDQFH&HQWUDO/DERUDWRU\6HUYLFHV*HQHYD
5XH0RLVH0DUFLQKHV
0H\ULQ*HQHYD &+
6ZLW]HUODQG
3KRQH

3KRQH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCIPPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK$SSHQGL[






















8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK













8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK$SSHQGL[














8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK$SSHQGL[  3URWRFRO$PHQGPHQWVDQG$GPLQLVWUDWLYH&KDQJHV
$PHQGPHQW1XPEHU 
,VVXH'DWH -XO\
385326(
7KHSXUSRVHRIWKLVDPHQGPHQWZDVWRUHYLVHSURWRFROSURFHGXUHV WRDFFRPPRGDWHWKH
WUHDWPHQWDQGPRQLWRULQJRIVXEMHFWVZLWK$'3.'HQUROOLQJLQWR WKHSURWRFROIURP
DGGLWLRQDOWROYDSWDQWULDOV&RQVHTXHQWO\VDPSOHVL]HZDVLQFU HDVHGWKHLQFOXVLRQ
FULWHULDZHUHVOLJKWO\PRGLILHGVFKHGXOHVIRULQLWLDWLRQRIWU HDWPHQWDQGOLYHUIXQFWLRQ
WHVWLQJZHUHIXUWKHUGHILQHG 
'RZQWLWUDWLRQIRUPHWDEROLFGUXJGUXJLQWHUDFWLRQVZDVDGGHG WRWKH
V\QRSVLVDQGDGGLWLRQDOO\LWZDVUHTXLUHGWKDWPHGLFDOPRQLWRU DSSURYDOLVQHHGHG $
WDEOHRIVWURQJDQGPRGHUDWH&<3$LQKLELWRUVZDVDGGHGWRWKH WH[W7KHOLVWRI
YHQGRUVDQGVWXG\SHUVRQQHOZDVXSGDWHG0LQRUOLQJXLVWLFFKDQJ HVZHUHPDGHIRUFODULW\
DQGW\SRJUDSKLFDOHUURUVZHUHFRUUHFWHG
%$&.*5281'
,WZDVGHFLGHGWRDOORZVXEMHFWVIURPDGGLWLRQDOWROYDSWDQWULD OVHQWU\LQWRWKLVVDIHW\WULDO
IRUDQLQFUHDVHGXQGHUVWDQGLQJRIWROYDSWDQÂ¶VORQJWHUPVDIHW\ LQ$'3.'SDWLHQWVDQG
SURYLGHH[SDQGHGDFFHVVWRWROYDSWDQIRUWKRVHVXEMHFWVZKRZRX OGOLNHWRFRQWLQXH
WUHDWPHQWDIWHUFRPSOHWLQJWKHLUSUHYLRXVWULDO

2WKHU5HYLVLRQV
)LJXUH7ULDO'HVLJQ6FKHPDWLF
7DEOH7ULDO7UHDWPHQWV7DEOH ,QFOXVLRQ&ULWHULD7DEOH6FKHGXOHRI$VVHVVPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 72 06 March 2015Sectional Revisions
Location Old Text Updated Text
Synopsis, Trial Design Subjects will be eligible for screening 
into this trial if they:
ï‚·ï€ Participated in the double -blind 
Trial 156 -13-210 (only
upon successful completion of their 
randomized 12-month period 
including post -treatment follow -
up,regardless of whether this was on -
treatment or off -treatment),or
ï‚·ï€ Participated in the open -label 
Trial 156-08-271.
After consenting and screening, 
eligible subjects w ill be assigned a 
new subject number and adm inistered 
tolvaptan at a split-dose of 45/15 mg. 
Subjects will have the opportunity for
either up or dow n-titration to a 
maximum split tolvaptan dose of 
90/30 mg or a minimum split dose of 
15/15 mg at the discretion of the 
investigator according to individual
tolerability.
Subjects entering the trial from 
Trial 156-08-271 may receive up to 
33 months of open -label tolvaptan 
therapy, and subjects entering the trial 
from Trial 156 -13-210 may receive 
up to 15 to 21 months of open -label 
tolvaptan therapy .Subjects will be eligible for 
screening into this trial if they:
ï‚·Completed and 
transferred from  the 
double- blind 
Trial 156-13-210 
(12-month period 
including post -treatm ent 
follow -up, regardless of 
whether this was on -
treatm ent or off -
treatm ent), or 
ï‚·Comp leted 
Trial 156-08-271 or a 
prior tolvaptan ADPKD 
trial, or
ï‚·Interrupted or 
discontinued treatm ent in 
a prior tolvaptan ADPKD 
trial (other than 
Trial 156-13-210) .  
Subjects may be enrolled 
with the m edical monitor 
approval, and additional 
close m onitoring m ay be 
required at the beginning 
of the trial
For purposes of ensuring subject 
safety, all subjects will be 
monitored for hepatic safety 
monthly until 18 months of 
tolvaptan exposure has been 
collected. .  After that, and 
following the approval fromthe 
medical monitor, hepatic 
monitoring will berequired every 
3months.  Until their prior 
treatm ent assignment is 
unblinded, a ll Trial 156-13-210 
subjects who are eligible for this 
trial are scheduled to have trial 
visits/ hepatic monitoring monthly 
forthe first 18 months of this trial.  
Once unblinding occurs, it can be 
determined which subjects 
received tolvaptan in Trial 156-13-
210.  These subjects may have 
their trial vis its/hepatic 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
199
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 73 06 March 2015Location Old Text Updated Text
transam inase monitoring change 
to every 3 months sooner as their 
previous tolvaptan exposure in 
Trial 156-13-210 can count 
towards the 18 -month threshold.
Enrollment in this trial will be 
closed when the final eligible 
subject from  Trial 156-13-210 
enrolls in this trial.
Synopsis, Subject 
PopulationThis trial w ill include up to 2,450 
subjects over the age of 18 years w ith  
ADPKD diagnosed by Pei -Ravine 
criteria (modified by magnetic 
resonance imaging [MRI]) .
Renal function will be assessed 
during screening by using historical 
laboratory values for serum creatinine 
levels to calculate the estimated 
glomerular filtration rate (eGFR).  
The eGFR values will be estimated 
based on the Chronic Kidney Disease 
-Epidem iology (CKD -EPI) formula.This trial w ill include 
approximately 2,500 subjects over 
the ag e of 18 years with ADPKD 
diagnosed by Pei -Ravine criteria 
(modified by magnetic resonance 
imaging [MRI]) , and who have 
completed or participated in a 
prior tolvaptan ADPKD 
interventional investigational 
medicinal product (IMP) trial.
Synopsis, 
Inclusion/ Exclusion 
CriteriaMain inclusion criteria:
ï‚·ï€ Male and female subjects 
ï‚³ï€ 18years with ADPKD who have 
completed either Trial 156 -13-210 or 
Trial 156 -08-271
ï‚·ï€ Diagnosis of ADPKD by modified 
Pei-Ravine criteria
ï‚·ï€ eGFR ï‚³ï€ 20 mL/min/1.73m2within 
45 days of the baseline visit. Subjects 
who have an eGFR between 15 and 
19mL/min/1.73m2may be enrolled 
with medical monitor approval
Main exclusion criteria:
ï‚·Need for chronic diuretic use
ï‚·Hepatic impairment based on 
liver function assessments other 
than that expected for ADPKD 
with cystic liver diseaseMain inclusion criteria:
ï‚·Male and female subjects 
ï‚³18years with confirmed 
diagnosis of ADPKD (during 
participation in prior 
tolvaptan trials) who have 
ï‚·Completed and 
transferred from  the 
double- blind 
Trial 156-13-210 
(12-month period 
including post -treatm ent 
follow -up, regardless of 
whether this was on -
treatm ent or off -
treatm ent), or 
ï‚·Completed 
Trial 156-08-271 or a 
prior ADPKD t olvaptan 
trial, or
ï‚·Interrupted or 
discontinued treatm ent in 
a prior tolvaptan ADPKD 
trial other than 
Trial 156-13-210.  
Subjects may be enrolled 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
200
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 74 06 March 2015Location Old Text Updated Text
with the m edical monitor 
approval, and additional 
close m onitoring m ay be 
required at the beginning 
of the trial
ï‚·Estimated glomerular 
filtration rate
(eGFR )ï‚³20mL/min/1.73 m2 
within 45 days of the baseline 
visit.  Subjects who have an 
eGFR between 15 and 
19mL/min/1.73m2 may be 
enrolled w ith medical monitor 
approval
ï‚·Renal function will be assessed 
during screening by using 
historical laboratory values (in 
the last 30 days) f or serum  
creatinine levels to calculate 
the eGFR.  the eGFR values 
will be estim ated based on the 
Chronic Kidney Disease -
Epide miology (CKD -EPI) 
form ula
Main exclusion criteria:
ï‚·Need for chronic diuretic use
ï‚·Hepatic impairment based on 
hepatic laboratory assessments
(alanine am inotransferase 
[ALT], aspartate 
aminotransferase [AST], 
bilirubin, total [BT]) other than 
that expected for ADPKD with 
cystic liver disease
Synopsis, Trial Site(s) Up to 220 sites which may include 
North America, South America, 
Russian Federation and Australia.  Approxim ately 220 enrolling sites 
including but not limited to the 
following regions: North America, 
South America, Eastern Europe, 
Western Europe, Russian 
Federation, and Australia.   
Synopsis, 
Investigational 
Medicinal Product(s), 
Dose, Dosage regimen, 
Treatment period, 
Form ulation, Mode of 
AdministrationTolvaptan tablets (15 mg or 30 mg) 
will be self -administered orally as 
split-dose regimens, once upon 
awakening and another approximately 
8 to 9 hours later. Doses w ill be 
expressed as early dose/late dose (eg, 
60/30 mg). Allowed doses are 
15/15 mg, 30/15 mg, 45/15 mg, The dose regimen s to be used in 
this trial are 15/15 m g, 30/15 m g, 
45/15 m g, 60/30 m g, and 90/30 m g.
Tolvaptan tablets (15 mg or 3 0 mg) 
will be self -administered orally as 
split-dose regimens, twice daily,
once upon awakening and another 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
201
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 75 06 March 2015Location Old Text Updated Text
60/30 mg and 90/30 mg.
All subjects will be st arted at a split -
dose of tolvaptan 45/15 mg and 
titrated according to tolerability. The 
dose range permitted will be a 
maximum of 90/30 mg and a 
minimum of 15/15 mg.approximately 8 to 9 hours later.  
Doses will be record edas early 
dose/late dose (eg, 60/30 mg).  
Subjects will receive open -label 
tolvaptan for the duration of the 
trial.  
A subject â€™s starting dose in this 
trial will be dependent on thetrial 
in which they were previously 
enrolled :
ï‚·156-13-210- initiated on 
tolvaptan at a split -dose of 
45/15 mg with upward 
titration every 3 to 4 days to 
60/30 m g or 90/30 m g per day 
according to tolerability
ï‚·156-08-271- will retain the last 
dose level from  271 and start 
at the sam e dose in this trial 
ï‚·Prior tolvaptan trials -
initiated on tolvaptan at a 
split-dose of 4 5/15 m g with 
upward titration every 3 to 
4days to 60/30 m g or 
90/30 mg per day according to 
tolerability
Down titration to 30/15 m g or 
15/15 m g daily will be allowed at 
the discretion of the investigator 
according to individual tolerability 
and with m edical monitor 
notification.  Further down 
titration to 30 or 15 m g once daily 
may be allowed only for m etabolic 
drug -drug interaction and 
requires medical monitor 
approval.
Synopsis, Trial 
Assessmentsâ€¦
Screening: Informed consent, medical 
history (i ncluding ADPKD updates, 
as required), determination of 
eligibility through inclusion/exclusion 
criteria, dietary revie w, vital signs, 
clinical laboratory assessments, 
complete physical examination, urine 
pregnancy test (w omen of child -
bearing potential onl y [WOCBP ]), 
concomitant medications and 
laboratory tests to determine 
eligibility.
...â€¦
Screening: Informed consent, 
medical history (including ADPKD 
updates, as required), determination 
of eligibility through 
inclusion/exclusion criteria, dietary 
review, vital signs, clinical 
laboratory assessments, physical 
examination, urine pregnancy test 
(women of child -bearing potential 
only [WOCBP]), concomitant 
medications and laboratory tests to 
determine eligibility.
...
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
202
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W





6\QRSVLV&ULWHULDIRU(YDOXDWLRQ6DIHW\
â€¢$(V
â€¢9LWDOVLJQV
â€¢&OLQLFDOODERUDWRU\
DVVHVVPHQWV
â€¢6HUXPWUDQVDPLQDVH
HOHYDWLRQVIRUIUHTXHQF\[
[[DQG[XSSHUOLPLWQRUPDO>8/1@WLPHWRRQVHWWLPHWRSHDNOHYHOVWLPHRIRIIVHW[[RU
[8/1UHVSRQVHWRGH
FKDOOHQJHDQGUHFKDOOHQJHDQGIUHTXHQF\RISURJUHVVLRQWR+\Â¶VODERUDWRU\FULWHULD
DODQLQHDPLQRWUDQVIHUDVH
$/7 RUDVSDUWDWHDPLQRWUDQVIHUDVH$67 ![8/1DQGELOLUXELQWRWDO%7 ![8/1ZLWKRXW
DONDOLQHSKRVSKDWDVH
â‰¥[8/1
â€¢6HUXPVRGLXPH[FXUVLRQV
DERYHRU
 PPRO/RUEHORZ
RUPPRO/
â€¢,QWHUUXSWLRQVRISURWRFRO
VSHFLILHGWKHUDSLHVIRUK\SHUQDWUHPLDRU
K\SRQDWUHPLD6DIHW\
â€¢$(V
â€¢9LWDOVLJQV
â€¢&OLQLFDOODERUDWRU\
DVVHVVPHQWV
â€¢6HUXPWUDQVDPLQDVH
HOHYDWLRQVIRUIUHTXHQF\
[[[DQG[8/1
WLPHWRRQVHWWLPHWRSHDNOHYHOVWLPHRIRIIVHW[[RU[8/1UHVSRQVHWRGHFKDOOHQJHDQGUHFKDOOHQJHDQGIUHTXHQF\
RISURJUHVVLRQWR+\Â¶V
ODERUDWRU\FULWHULD$/7RU$67![8/1DQG%7! [8/1ZLWKRXWDONDOLQH
SKRVSKDWDVH â‰¥[8/1
â€¢6HUXPVRGLXPH[FXUVLRQV
DERYHRU
 PPRO/RUEHORZRUPPRO/
6\QRSVLV6WDWLVWLFDO0HWKRGV6DPSOHVL]H6DPSOHVL]HZDVQRW
GHWHUPLQHGE\DIRUPDOFRPSXWDWLRQ
WRDFKLHYHDWDUJHWSRZHU1R6DPSOHVL]H6DPSOHVL]HZDVQRW
GHWHUPLQHGE\DIRUPDOFRPSXWDWLRQ
WRDFKLHYHDWDUJHWSRZHU1R
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
HIILFDF\DQDO\VHVDUHSODQQHG,WLV
H[SHFWHGWKDWDSSUR[LPDWHO\
VXEMHFWVPD\HQUROOIURPSUHYLRXVWROYDSWDQWULDOV
$QDO\VLVGDWDVHWV
â€¢(QUROOHG3RSXODWLRQDOO
VXEMHFWVZKRZHUHHQUROOHG
WRWKLVRSHQODEHOWULDO
â€¢6DIHW\3RSXODWLRQDOO
VXEMHFWVLQWKH(QUROOHG3RSXODWLRQZKRWDNHDWOHDVW
GRVHRILQYHVWLJDWLRQDO
PHGLFLQDOSURGXFW,03HIILFDF\DQDO\VHVDUHSODQQHG,WLV
H[SHFWHGWKDWDSSUR[LPDWHO\ 
VXEMHFWVPD\HQUROOIURPSUHYLRXVWROYDSWDQWULDOV
$QDO\VLVGDWDVHWV
â€¢(QUROOHG3RSXODWLRQDOO
VXEMHFWVZKRZHUHHQUROOHG
WRWKLVRSHQODEHOWULDO
â€¢6DIHW\3RSXODWLRQDOO
VXEMHFWVLQWKH(QUROOHG3RSXODWLRQZKRWDNHDWOHDVW
GRVHRI,03
6\QRSVLV7ULDO
'XUDWLRQ7KLVWULDOLVSODQQHGWREHFRQWLQXHG
XQWLORQHRIWKHIROORZLQJKDVRFFXUUHG$OOVXEMHFWVHQWHULQJIURP7ULDOZLOOEH HOLJLEOHIRUXSWR
PRQWKVLQ7ULDO
$IWHUXSWRPRQWKVSDUWLFLSDWLRQIRUVXEMHFWVIURP7ULDO 
DQGIRUDOOVXEMHFWVHQWHULQJIURP7ULDO SDUWLFLSDWLRQPD\
FRQWLQXHXQWLOWKH ILUVWRI
â€¢ WKHWULDOFRQFOXGHVODVWVXEMHFWIURP
7ULDO UHDFKHVDWOHDVW
 PRQWKVSDUWLFLSDWLRQ RU-XO\RU
â€¢ WROYDSWDQLVDSSURYHGIRUXVHLQ
$'3.'LQWKHLU UHJLRQRU
â€¢ 7ULDOGXUDWLRQLVSODQQHGWR
FRQWLQXH
â€¢8QWLOWKHODVWVXEMHFWIURP
7ULDOFRPSOHWHV PRQWKVRI
WROYDSWDQWUHDWPHQWLQ
WKLVWULDO
â€¢6XEMHFWVHQUROOLQJIURP
RWKHUWULDOVZLOOFRQFOXGHWKHLUSDUWLFLSDWLRQRQFHWROYDSWDQEHFRPHV
DYDLODEOH WKURXJKURXWLQH
SUHVFULSWLRQRUWKURXJKD

7ULDO VXEMHFWV
PD\RSWWRFRQFOXGHWKHLU
SDUWLFLSDWLRQLQWKLVWULDOLIWROYDSWDQEHFRPHVDYDLODEOHEHIRUHWKH\FRPSOHWHPRQWKVRIWUHDWPHQWLQWKLVWULDO
6HFWLRQ&OLQLFDO
'DWD1$ 










8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W






6HFWLRQ.QRZQDQG
3RWHQWLDO5LVNVDQG
%HQHILWV,QWKLVH[WHQVLRQWULDOVXEMHFWV
HQUROOLQJIURPWKHGRXEOHEOLQG
7ULDO ZLOOKDYHPRQWKO\
WUDQVDPLQDVHOHYHODVVHVVPHQWVIRUWKHILUVWPRQWKVZKLOHWKHWUHDWPHQWFRGHIURP7ULDO 
UHPDLQVEOLQGHGWRHQVXUHWKDWDOO
VXEMHFWVKDYHDGHTXDWHVDIHW\
PRQLWRULQJGXULQJWKLVSHULRGRIVXVFHSWLELOLW\0RQLWRULQJZLOOEHTXDUWHUO\IRUWKHVH VXEMHFWVIROORZLQJ
WKHILUVWPRQWKVRINQRZQ
H[SRVXUHWRWROYDSWDQ6XEMHFWV
HQUROOLQJIURPWKHRSHQ ODEHO7ULDO
ZLOOKDYHTXDUWHUO\
WUDQVDPLQDVHDVVHVVPHQWVFRQGXFWHGVLQFHWKH\ZLOOKDYHDOUHDG\UHFHLYHGWROYDSWDQIRU\HDUVRUPRUH,QWKLVH[WHQVLRQWULDOVXEMHFWV
HQUROOLQJIURPWKHGRXEOHEOLQG
7ULDO ZLOOKDYHPRQWKO\
YLVLWVDQG WUDQVDPLQDVHOHYHO
DVVHVVPHQWVIRUWKHILUVWPRQWKVZKLOHWKHWUHDWPHQWFRGHIURP7ULDO UHPDLQVEOLQGHGWR
HQVXUHWKDWDOOVXEMHFWVKDYH
DGHTXDWHVDIHW\PRQLWRULQJGXULQJWKLVSHULRGRIVXVFHSWLELOLW\ 2QFH
XQEOLQGLQJRFFXUVLWFDQEH
GHWHUPLQHGZKLFKVXEMHFWV
UHFHLYHGWROYDSWDQLQ
7ULDO 7KHVHVXEMHFWVPD\KDYHWKHLUWULDO YLVLWVKHSDWLFWUDQVDPLQDVHPRQLWRULQJFKDQJHGWRHYHU\ PRQWKVVRRQHUDVWKHLUSUHYLRXVWROYDSWDQH[SRVXUHLQ
7ULDOFDQFRXQW
WRZDUGVWKHPRQWKWKUHVKROG,IVXEMHFWVDSSURDFKLQJWKHPRQWKWKUHVKROGKDYHKDGSULRUWUDQVDPLQDVHDEQRUPDOLWLHV! Ã®XSSHUOLPLWRIQRUPDO
>8/1@WKHLQYHVWLJDWRULV
UHVSRQVLEOHIRUFRQWDFWLQJWKHPHGLFDOPRQLWRUWRFRQILUPWKHFKDQJHLQIUHTXHQF\IURPPRQWKO\
WRHYHU\ PRQWKV 6XEMHFWV
HQUROOLQJIURPWKHRSHQ ODEHO7ULDO
ZLOOKDYHWUDQVDPLQDVH
DVVHVVPHQWVFRQGXFWHG HYHU\
 PRQWKV VLQFHWKH\ZLOOKDYH
DOUHDG\UHFHLYHGWROYDSWDQIRU DW
OHDVW PRQWKV 7KHFXUUHQW,%
OLVWVDOORIWKHWROYDSWDQWULDOV
6XEMHFWVHQUROOLQJLQWKLVWULDOZKRZHUHLQDSUHYLRXV$'3.'WULDORWKHUWKDQ7ULDOVDQGZLOOKDYHPRQWKO\
YLVLWVDQGWUDQVDPLQDVHOHYHO
DVVHVVPHQWVIRUWKHILUVW
PRQWKV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 79 06 March 2015Location Old Text Updated Text
Section 2.1, Trial 
Rationale...
Over the 3 years of placebo -
controlled treatment, ALT w as 
elevated to a greater than three times 
the upper limit of normal (> 3 Ã— 
ULN) in 4.4% of tolvaptan subjec ts 
compared with 1% of placebo 
subjects.  To date, 3 tolvaptan 
subjectsâ€™ transaminases and bilirubin 
levels reached Hyâ€™s laboratory 
criteria (> 3 Ã— and > 2 Ã— ULN, 
respectively).  Upon discontinuation, 
all subjectsâ€™ liver tests showed 
reversibility of the elevation within 
approximately 4 months after 
tolvaptan was discontinued.  
Nevertheless, without adequate 
monitoring and management, it is 
estimated that a 1:3,000 risk for 
irreversible liver injury may existâ€¦
Over the 3 years of placebo -
controlled treatment, ALT w as 
elevated to a greater than three times 
the upper limit of normal (> 3 Ã— 
ULN) in 4.4% of tolvaptan subjects 
compared with 1% of placebo 
subjects.  To date, 3 tolvaptan 
subjectsâ€™ transaminases and bilirubin 
levels reached Hyâ€™s laboratory 
criteria (> 3 Ã— and > 2 Ã— ULN, 
respectively).  Upon discontinuation, 
all subjectsâ€™ liver tests showed 
reversibility of the elevation within 
approximately 4 months after 
tolvaptan was discontinued.  
Nevertheless, without adequate 
monitoring and management, i t is 
estimated that a 1: 4,000 risk for 
irreversible liver injury may exist
Section 3.1, 
Type/Design of TrialThis trial is a phase 3b, multi -center, 
open -label trial.
Subjects will be eligible for screening 
into this trial if they:
ï‚·ï€ Participated in t he double -blind 
Trial 156 -13-210 (only upon 
successful completion of their 
randomized 12 -month period 
including post -treatment follow -up, 
regardless of whether this was on -
treatment or off -treatment), or
ï‚·ï€ Participated in the open -label 
Trial 156-08-271
Upon the successful completion of 
Trial 156 -13-210 or Trial 156 -08-
271, subjects w ill have an opportunity 
to enroll into Trial 156 -13-211 
immediately following completion of 
the follow -up visit(s) of the previous 
trial. The last follow -up visit 
assessments can be utilized for 
screening into this trial. However, for 
subjects who require a longer period 
betw een com pletion of the preceding 
trial and entry into this trial, this may This trial is a phase 3b, multi -center, 
open -label trial.
Eligible subjects will have an 
opportunity to enroll into 
Trial 156-13-211 immediately 
following completion of the 
follow -up visit(s) of the previous 
trial.  The last visit assessments 
from  the previous protocol can be 
combined with the screening visit 
for this trial, with all required 
assessments from each visit only 
perform ed once, as long as the 
time between the last follow -up 
visit assessments from the 
previous trial and the screening 
visit for this trial is within 30 days.  
Medical m onitor approval is 
needed for enrollment of subjects 
whose com pletion of the preceding 
trial prior to entry in this trial 
exceeds 3 months , and these 
subjects will be required to 
undergo all screening and baseline 
assessments.
After consenting, subjects will be 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
206
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
EHDOORZHGDWWKHGLVFUHWLRQRIWKH
PHGLFDOPRQLWRU
$IWHUFRQVHQWLQJDQGVFUHHQLQJ
HOLJLEOHVXEMHFWVZLOOEHDVVLJQHGDQHZVXEMHFWQXPEHUDQGDGPLQLVWHUHGWROYDSWDQDWDVSOLWGRVHRIPJ
6XEMHFWVZLOOKDYHWKHRSSRUWXQLW\IRU
HLWKHUXSRUGRZQWLWUDWLRQWRDPD[LPXPWROYDSWDQVSOLWGRVHRIPJRUDPLQLPXPVSOLWGRVHRIPJDWWKHGLVFUHWLRQRIWKH
LQYHVWLJDWRUDFFRUGLQJWRLQGLYLGXDO
WROHUDELOLW\
6XEMHFWVHQWHULQJWKHWULDOIURP7ULDO
PD\UHFHLYHXSWR
PRQWKVRIRSHQODEHOWROYDSWDQ
WKHUDS\DQGVXEMHFWVHQWHULQJWKHWULDO
IURP7ULDO PD\UHFHLYH
XSWRWRPRQWKVRIRSHQODEHOWROYDSWDQWKHUDS\
7KLVWULDOLVSODQQHGWRFRQWLQXHXQWLO
RQHRIWKHIROORZLQJKDVRFFXUUHG
$OOVXEMHFWVHQWHULQJIURP7ULDO
ZLOOEHHOLJLEOHIRUXSWR
PRQWKVLQ7ULDO
$IWHUXSWRPRQWKVSDUWLFLSDWLRQ
IRUVXEMHFWVIURP7ULDODQGIRUDOOVXEMHFWVHQWHULQJIURP7ULDO SDUWLFLSDWLRQPD\
FRQWLQXHXQWLOWKHILUVWRI
â€¢ WKHWULDOFRQFOXGHVODVWVXEMHFWIURP
7ULDO UHDFKHVDWOHDVW
 PRQWKVRU-XO\RU
â€¢ WROYDSWDQLVDSSURYHGIRUXVHLQ
$'3.'LQWKHLUUHJLRQRU
DVVLJQHGDQHZVFUHHQLQJQXPEHU
6XEMHFWVZKRDUHIRXQGWREH
HOLJLEOHZLOOUHWDLQWKHVDPHVXEMHFWQXPEHUWKH\KDGEHHQDVVLJQHGLQWKHLUSUHYLRXVWULDO)RUSXUSRVHVRIHQVXULQJVXEMHFWVDIHW\WROYDSWDQH[SRVXUHRIDW
OHDVW PRQWKVLVUHTXLUHGIRUDOO
VXEMHFWV:KLOH7ULDOUHPDLQVEOLQGHG VXEMHFWVHQUROOLQJIURPDQ\SULRUWULDOEHVLGHV7ULDO  DUH
VFKHGXOHGWRKDYHPRQWKO\KHSDWLF
PRQLWRULQJIRUWKHILUVWPRQWKVRIWKLVWULDO$IWHUWKDWIROORZLQJWKHDSSURYDORIWKHPHGLFDOPRQLWRUKHSDWLFPRQLWRULQJZLOOWDNHSODFHHYHU\ PRQWKV
6XEMHFWVHQUROOLQJIURP7ULDO
ZLOOKDYHKHSDWLFPRQLWRULQJHYHU\PRQWKV$OO7ULDOVXEMHFWVZKRDUHHOLJLEOHIRUWKLVWULDOZLOOLQLWLDOO\EHVFKHGXOHGWRKDYHWULDO YLVLWV
DQGKHSDWLFPRQLWRULQJPRQWKO\
IRUWKHILUVW PRQWKVWKHQHYHU\PRQWKVWKHUHDIWHUEHFDXVHWKHLUWROYDSWDQH[SRVXUHFDQQRWEHGHWHUPLQHGVLQFH7ULDO
LVDGRXEOHEOLQGWULDO2QFH
XQEOLQGLQJRFFXUVLWFDQEHGHWHUPLQHGZKLFKVXEMHFWVUHFHLYHGWROYDSWDQLQ7ULDO 7KHVHVXEMHFWVPD\KDYHWKHLUWULDO YLVLWVKHSDWLF
WUDQVDPLQDVHPRQLWRULQJFKDQJHG
WRHYHU\ PRQWKVVRRQHUDVWKHLUSUHYLRXVWROYDSWDQH[SRVXUHLQ7ULDOFDQFRXQWWRZDUGVWKHPRQWKWKUHVKROG
(QUROOPHQWLQWKLVWULDOZLOOEH
FORVHGZKHQWKHODVWHOLJLEOH
VXEMHFWIURP7ULDO
HQUROOVLQWKLVWULDO
7KHGXUDWLRQRIWKLV WULDOLVSODQQHG
WRFRQWLQXH
â€¢8QWLOWKHODVWVXEMHFW IURP
7ULDO FRPSOHWHV
 PRQWKVRIWROYDSWDQ
WUHDWPHQWLQWKLVWULDO
â€¢6XEMHFWVHQUROOLQJIURP
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
C
CI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
RWKHUWULDOVZLOOFRQFOXGH
WKHLUSDUWLFLSDWLRQLQWKLV
WULDORQFHWROYDSWDQEHFRPHVDYDLODEOHWKURXJKURXWLQHSUHVFULSWLRQRUWKURXJKD

7ULDO VXEMHFWVPD\RSWWRFRQFOXGHWKHLUSDUWLFLSDWLRQLQWKLVWULDOLIWROYDSWDQEHFRPHV
DYDLODEOHEHIRUHWKH\
FRPSOHWH PRQWKVRIWUHDWPHQWLQWKLVWULDO
6HFWLRQ)LJXUH6HHSUHYLRXV)LJXUHDWWKHHQGRI
$SSHQGL[ 6HHSUHYLRXV)LJXUHDWWKHHQGRI
$SSHQGL[
6HFWLRQ7UHDWPHQWV )ROORZLQJFRQVHQWDQGRQFHVXEMHFWV
KDYHVDWLVILHGDOORIWKHLQFOXVLRQFULWHULDDQGQRQHRIWKHH[FOXVLRQ
FULWHULDVXEMHFWVZLOOEHDVVLJQHGD
QHZVXEMHFWQXPEHUDQGDGPLQLVWHUHGWROYDSWDQDWDVSOLW GRVHRI PJ
6XEMHFWVZLOOEHWLWUDWHGXSWR PJDQG PJDFFRUGLQJWRVXEMHFWWROHUDELOLW\'RZQWLWUDWLRQWR
PJDQGPJLVDOVR
SHUPLWWHGDWWKHGLVFUHWLRQRIWKHPHGLFDOPRQLWRUDQGLQGLYLGXDOVXEMHFWWROHUDELOLW\
$OOVXEMHFWVZLOOEHDGPLQLVWHUHG
WROYDSWDQWDEOHWVLQDGDLO\VSOLWGRVHRQFHXSRQDZDNHQLQJDQGDQRWKHUDSSUR[LPDWHO\WRKRXUVODWHU7KHH[DFWWLPHRIGRVLQJPD\EHDGMXVWHGEDVHGRQZDNHVOHHSKDELWVHJ
VWDQGDUG$0DQG30PD\EH
VZLWFKHGWR30DQG$0LIZRUNLQJDQLJKWVKLIW+RZHYHUGRVLQJWLPHVVKRXOGEHFRQVLVWHQWIRUHDFKLQGLYLGXDOÂ¶VGDLO\GRVHWRPD[LPL]HUHFHSWRUVXSSUHVVLRQ
'RVHVZLOOEHH[SUHVVHGDVHDUO\
GRVHODWHGRVHHJPJ
:KLOHWDNLQJWROYDSWDQDOOVXEMHFWV
VKRXOGEHLQVWUXFWHGWRLQJHVWIOXLGVLQ
DQWLFLSDWLRQRIRUDWWKHILUVWVLJQRI
WKLUVWLQRUGHUWRDYRLGH[FHVVLYH7KHGRVH UHJLPHQVWREHXVHGLQ
WKLVWULDODUHP JPJ
 PJPJDQG PJ
)ROORZLQJFRQVHQWDQGRQFH
VXEMHFWVKDYHVDWLVILHGDOORIWKHLQFOXVLRQFULWHULDDQGQRQHRIWKHH[FOXVLRQFULWHULDVXEMHFWVZLOO
UHWDLQWKHLUVXEMHFWQXPEHU
DVVLJQHGIURPWKHLUSUHYLRXVWULDO
6XEMHFWVZLOOUHFHLYHRSHQODEHOWROYDSWDQIRUWKHGXUDWLRQRIWKH
WULDO$OOVXEMHFWVZLOOEH
DGPLQLVWHUHGWROYDSWDQWDEOHWVLQD
GDLO\VSOLWGRVHRQFHXSRQ
DZDNHQLQJDQGDQRWKHUDSSUR[LPDWHO\WRKRXUVODWHUWZLFHGDLO\GRVLQJ7KHH[DFWWLPHRIGRVLQJPD\EHDGMXVWHGEDVHGRQZDNHVOHHSKDELWVHJVWDQGDUG
$0DQG30PD\EHVZLWFKHGWR
30DQG$0LIZRUNLQJDQLJKWVKLIW+RZHYHUGRVLQJWLPHVVKRXOGEHFRQVLVWHQWIRUHDFKLQGLYLGXDOÂ¶VGDLO\GRVHWRPD[LPL]HUHFHSWRUVXSSUHVVLRQ'RVHVZLOOEH
UHFRUGHG DVHDUO\GRVHODWHGRVHHJ
PJ
$VXEMHFWÂ¶VVWDUWLQJGRVHLQWKLV
WULDOZLOOEHGHSHQGHQWRQWKH WULDO
LQZKLFKWKH\ZHUHSUHYLRXVO\
HQUROOHG
â€¢LQLWLDWHGRQ
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 82 06 March 2015Location Old Text Updated Text
thirst or dehydration.  Additionally, 
subjects should ingest 1 to 2 cups of 
water before bedtime regar dless of 
perceived thirst and replenish fluids 
overnight with each episode of 
nocturia.tolvaptan at a split -dose of 
45/15 m g with upward 
titration every 3 to 4 days to 
60/30 m g or 90/30 m g per day 
according to tolerability
ï‚·156-08-271- will retain the last 
dose level from  271 and start 
at the sam e dose in this trial 
ï‚·Prior tolvaptan trials -
initiated on tolvaptan at a 
split-dose of 45/15 m g with 
upward titration every 3 to 
4days to 60/30 m g or 90/30 
mg per day according to 
tolerability
Down titration to 30/15 mg and 
15/15 mg is also permitted at the 
discretion of the investigator 
according to subject tolerability 
with medical monitor notification .  
Further down titration to 30 or 
15mg once daily may be allowed 
only for m etabolic drug -drug 
interaction and requires medical 
monitor approval.
For subjects m oving from  the 
156-13-210 trial and requiring 
tolvaptan titration it will be
conducted in the following way: 
Subjects will be instructed to take 
tolvaptan starting at a split dose of 
45/15 mg (as 3 tablets upon 
wakin g and 1 tablet approximately 
8to9hours later) and to titrate up 
every 3 to 4 days; first to 60/30 mg, 
then up to the m aximum dose of 
90/30 m g.  Titration will be 
accom plished by increasing the 
number of tablets/dose and /or 
switching from  15 m g tablets t o 
30mg tablets.  Prior to each 
upward titration, the subjectâ€™s 
tolerability to the current dose will 
be assessed by asking, â€œCould you 
tolerate this dose of trial 
medication for the rest of your 
life?â€ Subjects will continue in the 
trialwith the regim en to which 
tolerability was established.
While taking tolvaptan, all subjects 
should be instructed to ingest fluids 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
209
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
LQDQWLFLSDWLRQRIRUDWWKHILUVWVLJQ
RIWKLUVWLQRUGHUWRDYRLGH[FHVVLYH
WKLUVWRUGHK\GUDWLRQ$GGLWLRQDOO\VXEMHFWVVKRXOGLQJHVWWRFXSVRIZDWHUEHIRUHEHGWLPHUHJDUGOHVVRISHUFHLYHGWKLUVWDQGUHSOHQLVKIOXLGVRYHUQLJKWZLWKHDFKHSLVRGHRI
QRFWXULD
7DEOH7ULDO
7UHDWPHQWV3UHYLRXV7DEOHLVDWWKHHQGRI
$SSHQGL[8SGDWHG7DEOHZLWKWUDFNHGFKDQJHV
LVDWWKHHQGRI $SSHQGL[
6HFWLRQ'RVLQJ
ZLWK&<3$0RGHUDWH,QKLELWRUV)RUVXEMHFWVZKRUHTXLUHGRVLQJZLWK
DPRGHUDWHLQKLELWRULQLWLDOWROYDSWDQUHGXFWLRQVDVVKRZQEHORZVKRXOGEHWULHGZLWKIXUWKHUGRVHUHGXFWLRQVRULQWHUUXSWLRQDVQHFHVVDU\IRU
WROHUDELOLW\
â€¢PJWRPJ
â€¢PJWRPJ
â€¢PJWRPJ
â€¢PJWRPJRQFHGDLO\
â€¢PJWRPJRQFHGDLO\)RUVXEMHFWVZKRUHTXLUHGRVLQJZLWK
DPRGHUDWHLQKLELWRULQLWLDOWROYDSWDQUHGXFWLRQVDVVKRZQEHORZVKRXOGEHWULHGZLWKIXUWKHUGRVHUHGXFWLRQVRULQWHUUXSWLRQDVQHFHVVDU\IRU
WROHUDELOLW\
â€¢PJWRPJ
â€¢PJWRPJ
â€¢PJWRPJ
â€¢PJWRPJRQFHGDLO\
â€¢PJWRPJRQFHGDLO\
$SDUWLDOOLVWRIVWURQJDQG
PRGHUDWH &<3$LQKLELWRUVFDQEHIRXQGLQ6HFWLRQ
6HFWLRQ7ULDO
3RSXODWLRQ7KLVWULDOZLOOLQFOXGHXSWR
VXEMHFWVRYHUWKHDJHRI\HDUVZLWK
$'3.'GLDJQRVHGE\3HL 5DYLQH
FULWHULDPRGLILHGE\P DJQHWLF
UHVRQDQFHLPDJLQJ>05,@5HQDOIXQFWLRQZLOOEHDVVH VVHG
GXULQJVFUHHQLQJXVLQJKLVWRULFDO
ODERUDWRU\YDOXHVIRUVHUXPFUHDWLQLQH
OHYHOVWRFDOFXODWHWKHHVWLPDWHGJORPHUXODUILOWUDWLRQUDWHH*)57KHH*)5YDOXHVZLOOEHHVWLPDWHGEDVHGRQWKH&KURQLF.LGQH\'LVH DVHÂ±
(SLGHPLRORJ\&.'(3,IRUPXOD
7KLVWULDOZLOOLQFOXGH
DSSUR[LPDWHO\ VXEMHFWVRYHU
WKHDJHRI \HDUVZLWK$'3.'GLDJQRVHGE\3HL5DYLQHFULWHULD
 
PRGLILHGE\PDJQHWLFUHVRQDQFHLPDJLQJ>05,@ ZKRFRPSOHWHGRU
SDUWLFLSDWHGLQDSULRUWROYDSWDQ
WULDO
7DEOH,QFOXVLRQ
&ULWHULD3UHYLRXV7DEOHLVDWWKHHQGRI
$SSHQGL[8SGDWHG7DEOHZLWKWUDFNHGFKDQJHV
LVDWWKHHQGRI $SSHQGL[
6HFWLRQ 6DIHW\
(QGSRLQWV,QWHUUXSWLRQRISURWRFROVSHFLILHG
WKHUDSLHVIRUK\SHUQDWUHPLDRUK\SRQDWUHPLD(QGSRLQWGHOHWHG



6HFWLRQ
([SORUDWRU\(QGSRLQWV 
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
























6HFWLRQ0HDVXUHV
WR0LQLPL]H$YRLG
%LDVROGWH[WVHFWLRQ
QXPEHUZDV$OOEORRGDQGXULQHFKHPLVWU\ZLOOEH
DQDO\]HGDQGUHSRUWHGE\DORFDO
ODERUDWRU\$OOEORRGDQGXULQHFKHPLVWU\ZLOO
EHDQDO\]HGDQGUHSRUWHGE\D
FHQWUDOODERUDWRU\
6HFWLRQ
7DEOH 6FKHGXOH
RI$VVHVVPHQWV6HHSUHYLRXVWDEOHDWWKHHQGRI
$SSHQGL[6HHUHYLVHG7DEOHDWWKHHQGRI
$SSHQGL[ 
7KHFKDQJHVPDGHLQFOXGH6FUHHQLQJFKDQJHGIURPWR GD\V
/DQJXDJHRXWOLQLQJDVVHVVPHQWV
EDVHGRQVXEMHFWVÂ¶SUHYLRXVWULDOH[SDQGHG&HQWUDOUDWKHUWKDQORFDOODERUDWRU\ZLOOEHXVHG

+HSDWLWLVWHVWLQJZRUGLQJDGGHG
6HFWLRQ
6FUHHQLQJROGWH[W6HFWLRQ6FUHHQLQJGD\VWRGD\VSULRUWR
%DVHOLQH
6FUHHQLQJIRUHOLJLELOLW\LVUHTXLUHG
IRUDOOVXEMHFWV7KHVFUHHQLQJDQGEDVHOLQHYLVLWVPD\EHFRPELQHGZLWK
WKH(R7[YLVLWIURPWKHSUHYLRXV
SURWRFROZLWKDOOUHTXLUHGDVVHVVPHQWVIURPHDFKYLVLWRQO\SHUIRUPHGRQFH5HTXLUHGDVVHVVPHQWVDUHDVIROORZV
 2EWDLQVXEMHFWFRQVHQW6FUHHQLQJ GD\VWRGD\SULRU
WR%DVHOLQH
6FUHHQLQJIRUHOLJLELOLW\LVUHTXLUHG
IRUDOOVXEMHFWV 7KHVFUHHQLQJDQGEDVHOLQHYLVLWVPD\EHFRPELQHG
ZLWKWKHODVWYLVLWIURPWKHSUHYLRXV
SURWRFROZLWKDOOUHTXLUHGDVVHVVPHQWVIURPHDFKYLVLWRQO\SHUIRUPHGRQFH ,QVRPHFDVHVLID
VXEMHFWHQUROOVLQWKLVWULDOIURPD
SULRU WROYDSWDQWULDOWKHHQGRI
WULDO YLVLWIRUWKDWWULDODQGWKH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 85 06 March 2015Location Old Text Updated Text
2.Determine subject eligibility 
through inclusion/exclusion 
criteria
3.Record demographic 
information and prior trial 
identifiers (screening
identification [ID], subject 
ID, site ID)
4.Record medical/ADPKD 
history using prior trial data
5.Revie w dietary 
recommendations and 
compliance
6.Record vital signs (post -void 
weight and seated heart rate) 
and in -clinic calibrated 
blood pressure (BP) 
measuremen t.  Record 
height
7.Collect blood for serum 
chemistry, liver function 
panel (ALT, AST, bilirubin, 
total (BT), bilirubin (direct), 
and alkaline phosphatase), 
serum sodium, creatinine 
and hematology and 
coagulation .  Hepatitis 
testing is optional
8.Collect urine for urinalysis, 
urine osmolality (optional), 
and urine specific gravity
9.Perform urine pregnancy test 
on w omen of childbearing 
potential (WOCBP).  If 
positive, a follow -up serum 
test will be performed
10.Conduct full physical 
examination
11.Enter subject into in teractive 
response technology (IRT) 
including prior trial 
identifier/information screening visit for this one may 
occur simultaneously. Required 
assess ments are as follows:
1.Obtain subject consent .
2.Determine subject 
eligibility through 
inclusion/exclusion criteria .
3.Record demographic 
information and prior trial 
identifiers (screening 
identification [ID], subject 
ID, site ID) , prior 
tolvaptan ADPKD trial 
protocol number).
4.Record medical/ADPKD 
history using prior trial 
data.
5.Revie w dietary 
recommendations and
compliance.
6.Record vital signs (post -
void w eight and seated 
heart rate) and in -clinic 
calibrated blood pressure 
(BP) measurement.  Record 
height .
7.Collect blood for serum 
chemistry, liver function 
panel (ALT, AST, bilirubin, 
total [BT], bilirubin 
[direct ], and alkaline 
phosphatase), serum 
sodium, creatinine, and 
hematology and 
coagulation .  Hepatitis 
testing is optional .  If 
hepatitis testing is 
performed, then both pre -
and post -counseling 
activities relating to 
hepatitis testing are to be 
carried out based on local 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
212
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 86 06 March 2015Location Old Text Updated Text
(protocol number, subject 
ID), confirmed dose regimen 
and scheduled date of next 
visit
12.Assess AEs reported as 
ongoing or resolved from 
prior trial to determine entry 
as medica l history or 
ongoing event for this trialrequirements and best 
practices.  
8.Collect urine for urinalysis, 
urine osmolality (optional), 
and urine specific gravity .
9.Perform urine pregnancy 
test on women of 
childbearing potential 
(WOCBP).  If positive, a 
follow -up serum test will be 
performed .
10.Conduct full physical 
examination .
11.Enter subject into 
interactive response 
technology (IRT) including 
prior trial 
identifier/information 
(protocol number, subject 
ID), confirmed dose 
regimen ,and scheduled 
date of next visit .
12.Assess AEs reported as 
ongoing or resolved from 
prior trial to determine 
entry as medical history or 
ongoing event for this trial .
13.Record ongoing 
concom itant medications. 
(This may be done if the 
screening visit occurs 
simultaneously with the 
last visit from  a previous 
tolvaptan trial).
Section 3.7.1.2, 
Baseline (old text 
Section 3.6.1.2)The baseline visit is the beginning of 
the treatment period in this trial.  At 
the baseline visit, subjects w ill be 
assigned a ne w subject number and 
the following assessments and 
procedures w ill be performed:
1.Revie w inclusion/exclusion The baseline visit is the beginning of 
the treatment period in this trial.  At 
the baseline visit, subjects w ill 
retain the subject number assigned
in the previous tolvaptan trial, and 
the following assessments and 
procedures w ill be performed:
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
213
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
FULWHULD
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH
 
 5HFRUGYLWDOVLJQVSRVWYRLG
ZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 'LVSHQVHDWKRPHXULQH
SUHJQDQF\WHVWNLWVWR:2&%3WREHXVHGLIDPHQVWUXDOSHULRGLVPLVVHGEHIRUHWKHQH[WYLVLW
 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHG WRIRFXVRQ3.'UHODWHGVLJQVDQGV\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QUROOVXEMHFWLQWRWULDO
WKURXJK,57DQGREWDLQ,03
 'LVSHQVH,03VXIILFLHQWIRU
PRQWKRIGRVLQJ
 3URYLGHVXEMHFWZLWKGRVLQJ
LQVWUXFWLRQVWREHJLQRQWKHIROORZLQJGD\
 5HFRUGRQJRLQJFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V
 5HYLHZLQFOXVLRQH[FOXVLRQ
FULWHULD
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH
 
 5HFRUGYLWDOVLJQVSRVW
YRLGZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 'LVSHQVHDWKRPHXULQH
SUHJQDQF\WHVWNLWVWR:2&%3WREHXVHGLIDPHQVWUXDOSHULRGLVPLVVHG
EHIRUHWKHQH[WYLVLW
 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ
3.'UHODWHGVLJQVDQG
V\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QUROOVXEMHFWLQWRWULDO
WKURXJK,57DQGREWDLQ
,03
 'LVSHQVH,03VXIILFLHQW
IRUPRQWK RU PRQWKV RI
GRVLQJEDVHGRQVXEMHFWÂ¶V
UHTXLUHGYLVLWVFKHGXOH IRU
KHSDWLFHYDOXDWLRQDVHLWKHUPRQWKO\RUHYHU\
 PRQWKV 
 3URYLGHVXEMHFWZLWKGRVLQJ
LQVWUXFWLRQVWREHJLQRQWKHIROORZLQJGD\
 5HFRUGRQJRLQJ
FRQFRPLWDQWPHGLFDWLRQV
 $VVHVV$(V
6HFWLRQ
0RQWKO\9LVLWROGWH[W6HFWLRQ0RQWKO\9LVLWÂ“GD\V
6XEMHFWVZLOOUHWXUQIRUDPRQWKO\0RQWKO\9LVLWÂ“ GD\V
7KHIROORZLQJV XEMHFWVZLOOUHWXUQ
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
YLVLWWRDVVHVVVDIHW\DQGWROHUDELOLW\
RI,03DQGWRPRQLWRUOLYHUIXQFWLRQ
6XEMHFWVHQUROOLQJIURPWKHGRXEOHEOLQG7ULDOZLOOKDYHPRQWKO\$/7OHYHODVVHVVPHQWVIRUWKHILUVWPRQWKVZKLOHWUHDWPHQWFRGHIURP7ULDO UHPDLQV
EOLQGHGWRHQVXUHWKDWWKH\KDYH
DGHTXDWHVDIHW\PRQLWRULQJGXULQJWKLVSHULRGRIVXVFHSWLELOLW\7KHIROORZLQJZLOOEHDVVHVVHG
 &ROOHFWEORRGIRUVRGLXP
DQGFUHDWLQLQH
 &ROOHFWEORRGIRU$/7IRU
WKHILUVWPRQWKVRIWROYDSWDQWUHDWPHQWLQ
VXEMHFWVHQUROOLQJIURP7ULDO
,IDWDQ\WLPH
ZLWKLQWKHILUVWPRQWKVRIWROYDSWDQWUHDWPHQWWKH$/7
HOHYDWHVWR![8/1WR
[8/1$/7ZLOOEHPRQLWRUHGPRQWKO\IRUDQDGGLWLRQDOPRQWKVEH\RQGWKHGDWHRIHOHYDWLRQWR
HQVXUHWKDWWKHOHYHOLVVWDEOH
DQGGRHVQRWH[FHHGWKLVWKUHVKROG,IDWDQ\WLPHWKH
$/7HOHYDWHV â‰¥[8/1D
IXOOOLYHUIXQFWLRQSDQHOLV
UHTXLUHG$/7$67%7DQGDONDOLQHSKRVSKDWDVHZLWKLQKRXUVRIWKHVLWH
EHLQJDZDUHRIWKLVUHVXOW






 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EH
SHUIRUPHGWRIRFXVRQ3.'IRUDPRQWKO\YLVLWWRDVVHVVVDIHW\
DQGWROHUDELOLW\RI,03DQGWR
PRQLWRUOLYHUIXQFWLRQ
â€¢6XEMHFWVHQUROOLQJIURPWKH
GRXEOHEOLQG7ULDOZLOOKDYHPRQWKO\ WULDO
YLVLWV$/7OHYHO
DVVHVVPHQWVIRUWKHILUVW PRQWKVZKLOHWUHDWPHQWFRGHIURP7ULDO
UHPDLQVEOLQGHGWRHQVXUH
WKDWWKH\KDYHDGHTXDWHVDIHW\PRQLWRULQJGXULQJWKLVSHULRGRIVXVFHSWLELOLW\
2QFHXQEOLQGLQJRFFXUVLW
FDQEHGHWHUPLQHGZKLFK
VXEMHFWVUHFHLYHGWROYDSWDQLQ7ULDO 7KHVHVXEMHFWVPD\KDYHWKHLU
WULDOYLVLWVKHSDWLF
WUDQVDPLQDVHPRQLWRULQJFKDQJHWRHYHU\PRQWKVVRRQHUDVWKHLUSUHYLRXV
WROYDSWDQH[SRVXUHLQ
7ULDOFDQFRXQWWRZDUGVWKHPRQWKWKUHVKROG7KHLQYHVWLJDWRUZLOOQHHGWR
GLVFXVVWKHFKDQJHLQ
IUHTXHQF\ZLWKWKHPHGLFDOPRQLWRUEHIRUHLQVWLWXWLQJWKHFKDQJH
â€¢6XEMHFWVIURPSULRU
WROYDSWDQWULDOVRWKHUWKDQ7ULDOZLOOKDYHPRQWKO\WULDOYLVLWV$/7OHYHODVVHVVPHQWVIRUWKH
ILUVWPRQWKV$IWHU
WKDWWKHWULDOYLVLWV$/7PRQLWRULQJZLOOEHFRQGXFWHGHYHU\PRQWKV
DIWHUWKHFKDQJHLQ
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
UHODWHGVLJQVDQGV\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QWHUVXEMHFWVWDWXVLQ,57
LQFOXGLQJDQ\GRVHUHJLPHQ
FKDQJHVDQGREWDLQ,03
DVVLJQPHQW
 &ROOHFWDQGUHFRQFLOH
UHWXUQHG,03
 'LVSHQVH,03
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(VIUHTXHQF\LVFRQILUPHG
ZLWKWKHPHGLFDOPRQLWRU
â€¢6XEMHFWVHQUROOLQJIURP
WKHRSHQODEHO7ULDOZKR
KDYHJUHDWHUWKDQ
 PRQWKVRIFXPXODWLYHH[SRVXUHWRWROYDSWDQZLOOKDYHWULDOYLVLWV$/7PRQLWRULQJFRQGXFWHG
HYHU\ PRQWKV
7KHIROORZLQJ DVVHVVPHQWV ZLOOEH
FRPSOHWHG 
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH
 
 5HFRUGYLWDOVLJQVSRVW
YRLGZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRG IRUFHQWUDO
ODERUDWRU\DVVHVVPHQWV IRU
VHUXPVRGLXPVHUXP
FUHDWLQLQH DQG$/7VHH
6HFWLRQ 
 









8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
 8ULQDO\VLVXULQH
RVPRODOLW\RSWLRQDO
XULQHVSHFLILFJUDYLW\
 3HUIRUPXULQHSUHJQDQF\
WHVWRQ:2&%3HYHU\
PRQWKV,ISRVLWLYHD
IROORZXSVHUXPWHVWZLOOEHSHUIRUPHG
 'LVSHQVHDWKRPHXULQH
SUHJQDQF\WHVWNLWVWR
:2&%3DVUHTXLUHG
 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ3.'UHODWHGVLJQVDQG
V\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QWHUVXEMHFWVWDWXVLQ,57
LQFOXGLQJDQ\GRVHUHJLPHQ
FKDQJHVDQGREWDLQ,03DVVLJQPHQW
 &ROOHFWDQGUHFRQFLOH
UHWXUQHG,03 DVVHVV
FRPSOLDQFH
 'LVSHQVH,03 EDVHGRQ
VXEMHFWÂ¶VUHTXLUHGYLVLW
VFKHGXOH DQG
SURYLGHVXEMHFWZLWK
GRVLQJLQVWUXFWLRQV
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V
6HFWLRQ(YHU\
 0RQWKV(YHU\ 0RQWKVÂ“ GD\V
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH

 5HFRUGYLWDOVLJQVSRVWYRLG
ZHLJKWVHDWHGKHDUWUDWHDQG(YHU\ 0RQWKVÂ“ GD\V
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH
 
 5HFRUGYLWDOVLJQVSRVW
YRLGZHLJKWVHDWHGKHDUW
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
FDOLEUDWHGEORRGSUHVVXUH
PHDVXUHPHQW
 &ROOHFWEORRGIRUORFDO
VWDQGDUGRIFDUHODERUDWRU\DVVHVVPHQWV
 8ULQDO\VLVXULQHRVPRODOLW\
RSWLRQDOXULQHVSHFLILFJUDYLW\
 3HUIRUPXULQHSUHJQDQF\WHVW
RQ:2&%3,ISRVLWLYHD
IROORZXSVHUXPWHVWZLOOEH
SHUIRUPHG
 'LVSHQVHDWKRPHXULQH
SUHJQDQF\WHVWNLWVWR:2&%3DVUHTXLUHG
 &ROOHFWEORRGIRU$/7,IDW
DQ\WLPHWKH$/7HOHYDWHVWR![8/1WR[8/1$/7ZLOOEHPRQLWRUHG
PRQWKO\IRUDQDGGLWLRQDO
PRQWKVEH\RQGWKHGDWHRIHOHYDWLRQWRHQVXUHWKDWWKHOHYHOLVVWDEOHDQGGRHVQRWH[FHHGWKLVWKUHVKROG,IDW
DQ\WLPHWKH$/7HOHYDWHV â‰¥
[8/1DIXOOOLYHUIXQFWLRQ
SDQHOLVUHTXLUHG$/7
$67%7DQGDONDOLQH
SKRVSKDWDVHZLWKLQKRXUVRIWKHVLWHEHLQJDZDUHRIWKLVUHVXOW 





 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(VUDWHDQGFDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRU FHQWUDO
ODERUDWRU\DVVHVVPHQWV
VHUXPVRGLXPVHUXP
FUHDWLQLQH$/7VHH
6HFWLRQ 
 


 8ULQDO\VLVXULQHRVPRODOLW\
RSWLRQDOXULQHVSHFLILFJUDYLW\
 3HUIRUPXULQHSUHJQDQF\
WHVWRQ:2&%3,I
SRVLWLYHDIROORZXSVHUXPWHVWZLOOEHSHUIRUPHG
 'LVSHQVHDWKRPHXULQH
SUHJQDQF\WHVWNLWVWR
:2&%3DVUHTXLUHG
 






 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ3.'UHODWHGVLJQVDQG
V\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QWHUVXEMHFWVWDWXVLQ
,57LQFOXGLQJ DQ\GRVH
UHJLPHQFKDQJHVDQGREWDLQ,03DVVLJQPHQW
 &ROOHFWDQGUHFRQFLOH
UHWXUQHG,03DVVHVV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
FRPSOLDQFH
 (QWHUVXEMHFWVWDWXVLQ
,57LQFOXGLQJDQ\GRVHUHJLPHQFKDQJHV
 'LVSHQVH,03EDVHGRQ
VXEMHFWÂ¶VYLVLWVFKHGXOH
DQGSURYLGHVXEMHFWZLWKGRVLQJLQVWUXFWLRQV
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V
6HFWLRQ (DUO\
7HUPLQDWLRQ(QGRI7UHDWPHQWROGWH[W6HFWLRQ(DUO\7HUPLQDWLRQ(QGRI7UHDWPHQW
  PRQWKV
$WWKHHDUO\WHUPLQDWLRQHQGRI
WUHDWPHQWYLVLWWKHIROORZLQJZLOOEH
DVVHVVHG
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH

 5HFRUGYLWDOVLJQVSRVWYRLG
ZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUH
PHDVXUHPHQW
 &ROOHFWEORRGIRUVHUXP
FKHPLVWU\FUHDWLQLQHVHUXPVRGLXPDQGKHPDWRORJ\DQGFRDJXODWLRQ
 &ROOHFWEORRGIRU$/7,I
WKH$/7HOHYDWHV â‰¥[8/1
DIXOOOLYHUIXQFWLRQSDQHOLV
UHTXLUHG$/7$67%7
DQGDONDOLQHSKRVSKDWDVH
ZLWKLQKRXUVRIWKHVLWHEHLQJDZDUHRIWKLVUHVXOW




(DUO\7HUPLQDWLRQ(QGRI7UHDWPHQW
 GD\V
$WWKHHDUO\WHUPLQDWLRQHQGRI
WUHDWPHQWYLVLWWKHIROORZLQJZLOOEH
DVVHVVHG
 5HYLHZGLHWDU\
UHFRPPHQGDWLRQVDQGFRPSOLDQFH
 
 5HFRUGYLWDOVLJQVSRVW
YRLGZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRG
SUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUVHUXP
FKHPLVWU\ VHUXP
FUHDWLQLQH $/7VHUXP
VRGLXPDQGKHPDWRORJ\DQG
FRDJXODWLRQ
 








8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCICCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W

 &ROOHFWXULQHIRUXULQDO\VLV
XULQHRVPRODOLW\RSWLRQDOXULQHVSHFLILFJUDYLW\
 3HUIRUPXULQHSUHJQDQF\
WHVWRQ:2&%3,ISRVLWLYHDIROORZXSVHUXPWHVWZLOOEHSHUIRUPHG
 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EH
SHUIRUPHGWRIRFXVRQ3.'UHODWHGVLJQVDQGV\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QWHUVXEMHFWVWDWXVLQ,57
LQFOXGLQJDQ\GRVHUHJLPHQFKDQJHVVLQFHWKHSUHYLRXVHQWU\
 &ROOHFWDQGUHFRQFLOH
UHWXUQHG,03
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V &ROOHFWXULQHIRUXULQDO\VLV
XULQHRVPRODOLW\RSWLRQDO
XULQHVSHFLILFJUDYLW\
 3HUIRUPXULQHSUHJQDQF\
WHVWRQ:2&%3,I
SRVLWLYHDIROORZXSVHUXP
WHVWZLOOEHSHUIRUPHG
 $QRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ
3.'UHODWHGVLJQVDQG
V\PSWRPV
 $VVHVVWROHUDELOLW\GRVLQJ
UHYLHZRI,03
 (QWHUVXEMHFWVWDWXVLQ,57
LQFOXGLQJDQ\GRVHUHJLPHQ
FKDQJHVVLQFHWKHSUHYLRXVHQWU\
 &ROOHFWDQGUHFRQFLOH
UHWXUQHG,03 DVVHVV
FRPSOLDQFH
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V
6HFWLRQ
)ROORZXS9LVLW)ROORZXS9LVLW'D\VGD\V GD\)ROORZXS9LVLWGD\V
6HFWLRQ
)ROORZXS9LVLWROGWH[W6HFWLRQ 5HFRUGYLWDOVLJQVSRVWYRLG
ZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRUFUHDWLQLQH
 &ROOHFWEORRGIRU$/7,I
WKH$/7HOHYDWHV â‰¥[8/1
DIXOOOLYHUIXQFWLRQSDQHOLV
UHTXLUHG$/7$67%7
DQGDONDOLQHSKRVSKDWDVHZLWKLQKRXUVRIWKHVLWHEHLQJDZDUHRIWKLVUHVXOW


 5HFRUGYLWDOVLJQVSRVW
YRLGZHLJKWVHDWHGKHDUWUDWHDQGFDOLEUDWHGEORRGSUHVVXUHPHDVXUHPHQW
 &ROOHFWEORRGIRU VHUXP
FUHDWLQLQH DQG$/7
 






 3HUIRUPXULQHSUHJQDQF\
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W



 3HUIRUPXULQHSUHJQDQF\WHVW
RQ:2&%3,ISRVLWLYHD
IROORZXSVHUXPWHVWZLOOEHSHUIRUPHG
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(VWHVWRQ:2&%3,I
SRVLWLYHDIROORZXSVHUXP
WHVWZLOOEHSHUIRUPHG
 (QWHUVXEMHFWVWDWXVLQ
,57
 8SGDWHFRQFRPLWDQW
PHGLFDWLRQV
 $VVHVV$(V
6HFWLRQ&OLQLFDO
/DERUDWRU\$VVHVVPHQWVROGWH[W6HFWLRQ,WLVSUHIHUDEOHWRFROOHFWWKHFOLQLFDO
ODERUDWRU\VDPSOHVIURPHDFKVXEMHFWDWDFRQVLVWHQWWLPHRIGD\WKURXJKRXWWKHWULDODQGWRUHFRPPHQGWKDWWKHVXEMHFWKDYHDVLPLODUGLHWDYRLGLQJ
YDULDWLRQLQSURWHLQLQWDNHHVSHFLDOO\
FRRNHGPHDWSURWHLQDQGH[HUFLVHSDWWHUQLQRUGHUWRUHGXFHYDULDELOLW\LQWKHVDPSOHVRYHUWLPH:KLOHVHUXPFUHDWLQLQHLVEHLQJ
FROOHFWHGSULPDULO\IRUVDIHW\
UHSRUWLQJSXUSRVHVLWLVDNH\PHDVXUHLQWKHPDQDJHPHQWRISDWLHQWVZLWK$'3.' 




7KHUHIRUHJUHDW
FDUHVKRXOGEHWDNHQLQHQVXULQJWKHVHPHDVXUHPHQWVDUHFROOHFWHGDQGDQDO\]HGLQDVXQLIRUPDPDQQHUDV
SRVVLEOHSUHIHUDEO\XVLQJLVRWRSH
GLOXWLRQPDVVVSHFWURVFRS\,'06WUDFHDEOHPHWKRGRORJLHV
&OLQLFDOODERUDWRU\VDPSOHVZLOOEH
FROOHFWHGDWWKHIROORZLQJWLPHSRLQWV
6FUHHQLQJ+HPDWRORJ\DQG
FRDJXODWLRQSDQHOVHUXPFKHPLVWU\
SDQHOOLYHUIXQFWLRQSDQHO$67$/7DONDOLQHSKRVSKDWDVHELOLUXELQ
GLUHFW>%7@VHUXPVRGLXPXULQDO\VLV
SDQHOXULQHRVPRODOLW\RSWLRQDOXULQHVSHFLILFJUDYLW\XULQH&HQWUDOODERUDWRU\QRQIDVWLQJ
VHUXPODERUDWRU\WHVWVZLOOEH
SHUIRUPHG ,WLVSUHIHUDEOHWR
FROOHFWWKHFOLQLFDOODERUDWRU\
VDPSOHVIURPHDFKVXEMHFWDWD
FRQVLVWHQWWLPHRIGD\WKURXJKRXWWKHWULDODQGWRUHFRPPHQGWKDWWKHVXEMHFWKDYHDVLPLODUGLHWDYRLGLQJ
YDULDWLRQLQSURWHLQLQWDNHHVSHFLDOO\
FRRNHGPHDWSURWHLQDQGH[HUFLVHSDWWHUQLQRUGHUWRUHGXFHYDULDELOLW\LQWKHVDPSOHVRYHUWLPH
:KLOHVHUXPFUHDWLQLQHLVEHLQJ
FROOHFWHGSULPDULO\IRUVDIHW\
UHSRUWLQJSXUSRVHVLWLVDNH\PHDVXUHLQWKHPDQDJHPHQWRISDWLHQWVZLWK$'3.' 





7KHH*)5YDOXHVZLOOEH
FDOFXODWHGE\&.'(3,IURPWKH
FHQWUDOODERUDWRU\VHUXP
FUHDWLQLQHFRQFHQWUDWLRQVWDNHQGXULQJHYHU\WULDOYLVLW
&OLQLFDOODERUDWRU\VDPSOHVZLOOEH
FROOHFWHG DQGVHQWWRWKHFHQWUDO
ODERUDWRU\ DWWKHIROORZLQJWLPH
SRLQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
CCI
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
SUHJQDQF\WHVW:2&%3DQG
KHSDWLWLVRSWLRQDO
0RQWKO\YLVLWVÂ“GD\V$/7IRU
WKHILUVWPRQWKVLQVXEMHFWV
HQUROOHGIURP7ULDODQG
VHUXPVRGLXPFUHDWLQLQHDOO
VXEMHFWV
(YHU\PRQWKV Â“GD\V$/7
DIWHUPRQWKVRIWUHDWPHQWLQ
VXEMHFWVHQUROOHGIURP
7ULDO DQGIRUDOOVXEMHFWV
HQUROOHGIURP7ULDOVWDQGDUGRIFDUHODERUDWRU\DVVHVVPHQWVXULQDO\VLVSDQHOXULQHSUHJQDQF\WHVW:2&%3XULQH
RVPRODOLW\RSWLRQDODQGXULQH
VSHFLILFJUDYLW\
(DUO\7HUPLQDWLRQ(QGRI7UHDWPHQW
 PRQWKV6HUXPFKHPLVWU\
SDQHOKHPDWRORJ\DQGFRDJXODWLRQ
SDQHO$/7FUHDWLQLQHVHUXPVRGLXPXULQDO\VLVSDQHOXULQHSUHJQDQF\WHVW:2&%3XULQHRVPRODOLW\RSWLRQDODQGXULQH
VSHFLILFJUDYLW\
)ROORZXSYLVLWGD\V $/7
FUHDWLQLQHDQGXULQHSUHJQDQF\WHVW
:2&%3
Â«
,IOLYHUIXQFWLRQSDQHOVRGLXPDQGRUVHUXPFKHPLVWU\DVVHVVPHQWVDUHVFKHGXOHGDWWKHVDPHYLVLWDOOYDOXHVVKRXOGEHGHWHUPLQHGIURPWKHVDPHEORRGVDPSOH8ULQHSUHJQDQF\
WHVWLQJZLOOEHSHUIRUPHGZLWK
FRPPHUFLDOO\DYDLODEOHKLJKVHQVLWLYLW\NLWVVXSSOLHGWRWKHVXEMHFWE\WKHVLWHDFTXLUHGE\WKHVSRQVRU6FUHHQLQJ+HPDWRORJ\DQG
FRDJXODWLRQSDQHOVHUXPFKHPLVWU\
SDQHOOLYHUIXQFWLRQSDQHO$67$/7DONDOLQHSKRVSKDWDVHELOLUXELQGLUHFW>%7@VHUXPVRGLXP VHUXP
FUHDWLQLQH XULQDO\VLVSDQHOXULQH
RVPRODOLW\RSWLRQDOXULQHVSHFLILFJUDYLW\XULQHSUHJQDQF\WHVW:2&%3DQGKHSDWLWLVRSWLRQDO
0RQWKO\YLVLWVÂ“GD\V$/7IRU
WKHILUVWPRQWKV IRUVXEMHFWV
HQUROOHGI URPRWKHUWROYDSWDQ
$'3.'WULDOVDQG
7ULDO ZKLOHWULDO
UHPDLQVEOLQGHG VHUXPVRGLXP
DQGVHUXP FUHDWLQLQHDOOVXEMHFWV
XULQDO\VLVXULQHRVPRODOLW\
RSWLRQDOXULQHVSHFLILFJUDYLW\DQGXULQHSUHJQDQF\WHVWHYHU\PRQWKVLQ:2&%3 

(YHU\PRQWKV Â“ GD\V$/7
DIWHU PRQWKVRIWUHDWPHQW IRU
VXEMHFWVHQUROOHGIURP RWKHU
$'3.'WROYDSWDQWULDOVRUIURP
7ULDO DIWHUWKH WULDOLV
XQEOLQGHG DQGIRUVXEMHFWVHQUROOHG
IURP7ULDO VHUXP
VRGLXPDQGVHUXPFUHDWLQLQH
XULQDO\VLVSDQHOXULQHSUHJQDQF\WHVW
:2&%3XULQHRVPRODOLW\RSWLRQDODQGXULQHVSHFLILFJUDYLW\

(DUO\7HUPLQDWLRQ(QGRI7UHDWPHQW
 GD\V6HUXPFKHPLVWU\SDQHO
KHPDWRORJ\DQGFRDJXODWLRQSDQHO
$/7VHUXPVRGLXPDQG VHUXP
FUHDWLQLQH 
XULQDO\VLVSDQHOXULQH
SUHJQDQF\WHVW:2&%3XULQHRVPRODOLW\RSWLRQDODQGXULQHVSHFLILFJUDYLW\
GD\)ROORZXSYLVLWGD\V
$/7VHUXPFUHDWLQLQHDQGXULQH
SUHJQDQF\WHVW:2&%3
Â«
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCICCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 96 06 March 2015Location Old Text Updated Text
If liver function panel, sodium 
and/or serum chemistry assessments 
are scheduled at the same visit, all 
values should be determined from 
the same blood sample.  Blood 
testing for hepatitis will be 
optional for all subjects.  Urine 
pregnancy testing will be performed 
with commercially available, high -
sensitivity kits supplied to the 
subject by the site (acquired by the 
sponsor).
Table 3.7.2.2 -, Clinical 
Laboratory 
AssessmentsPlease see original table at the end of 
Appendix 5,Please see revised tabl e at the end of 
Appendix 5,
Section 3.7.2.3, 
Physical Examination 
and Vital Signs (old 
text, Section 3.6.2.3)A full physical examination will be 
performed and documented at the 
screening visit although this may be 
combined with the EoTx visit from 
the previous trial.  At other visits, an 
optional directed physical 
examination may be performed to 
focus on ADPKD- related signs and 
symptoms.  In some geographic 
regions, more frequent subject visits 
may be the norm; however vital signs 
and clinically signif icant physical 
findings will be recorded as an 
unscheduled visit in the electronic 
case report form (eCRF) as 
applicable.  Any changes in 
medication or AEs will be recorded in 
the eCRF.
Body  weight will be taken post -void.  
It is preferable to use the sam e scale 
for each measurement.  Clinic scales 
should be calibrated at least yearly.  
The investigator or his/her appointed 
designee is primarily responsible to 
perform the physical examination.  ...A full physical examination will be 
performed and document ed at the 
screening visit although this may be 
combined with the lastvisit from the 
previous trial.  At other visits, an 
optional directed physical 
examination may be performed to 
focus on ADPKD- related signs and 
symptoms.  In some geographic 
regions, mo re frequent subject visits 
may be the norm; however vital 
signs and clin ically significant 
physical findings will be recorded as 
an unscheduled visit in the electronic 
case report form (eCRF) as 
applicable.  Any changes in 
medication or AEs will be recorde d 
in the eCRF.
Height will be measur ed only at 
screening.   Body  weight will be 
taken post -void.  It is preferable to 
use the same scale for each 
measurement.  Clinic scales should 
be calibrated at least yearly.  The 
investigator or his/her appointed 
designee is primarily responsible to 
perform the physical exami nation.  
...Section 3.7.2.4, 
Assessment of Liver 
Symptoms, Signs or 
Test Abnormalities (old 
text, Section 3.6.2.4)Testing for hepatic transaminase 
(ALT/AST), alkaline phosphatase, 
bilirubin direct, and BT w ill be 
performed during screening.  Subjects 
enrolling from the double -blind Trial 
156-13-210 w ill have monthly ALT 
assessments for the first 18 months 
while the treatment code from Trial 
156-13-210 remains blinded to ensure Testing for hepatic transaminase 
(ALT/AST), alkaline phosphatase, 
bilirubin direct, and BT w ill be 
performed during screening .  
Subjects enrolling from the double -
blind Trial 1 56-13-210 w ill have 
monthly ALT assessments for the 
first 18 months while the treatment 
code from Trial 156 -13-210 remains 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
223
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 97 06 March 2015Location Old Text Updated Text
that all subjects have adequate safety 
monitoring during this period of 
suscep tibility.  Following the first 
18months, ALT assessments will be 
made quarterly for these subjects.  
Subjects enrolling from the open -
label Trial 156 -08-271 will have 
quarterly ALT assessments since they 
will have already received tolvaptan 
for 2 years or more.  Management of 
liver abnormalities is discussed in the 
paragraphs below .blinded to ensure that all subjects 
have adequate safety monitoring 
during this period of susceptibility.  
Once unblinding occurs, it can be 
determined which subjects 
received tolvaptan in Trial 156-13-
210.  These subjects may have 
their trialvisits/hepatic 
transam inase monitoring change d
to every 3 months sooner as their 
previous tolvaptan exposure in 
Trial 156-13-210 can count 
toward s the 18 -month threshold.
Follow ing the first 18 months, ALT 
assessments will be made every 
3months forTrial 156-13-210 
subjects and for subjects from 
other tolvaptan ADPKD trials 
besides Trial 156-08-271.  Subjects 
enrolling from the open -label Trial 
156-08-271 who have tolvaptan 
exposure greater than 18 m onths 
will continue with ALT 
monitoring every 3 months.  
Subjects enrolling from  prior 
tolvaptan trials besides 
Trial 156-08-271 will have 
monthly ALT assessments for the 
first 18 months.   Upon reaching 
18months of exposure and after 
confirm ation from  the medical 
monitor, the frequency of ALT 
monitoring for these subjects will 
occur every 3 months.
ALT will also be assessed at the 
Early Termination/End of 
Treatm ent visit and at the 7-day
Follow -up visit.
Management of liver abnormalities 
is discussed in the paragraphs below .
Section 3.7.2.4.1, Liver 
Test Abnormalities and 
Interruption/
Discontinuation of 
Investigational 
Medicinal Product
(old text 
Section 3.6.2.4.1)The appearance of any suspicious 
symptom or sign should trigger 
prom pt testing of hepatic function (ie, 
within 72 hours).  Liver transaminase 
or bilirubin levels ï‚³2 Ã—ULN should 
prom pt immediate retesting within The appearance of any suspicious 
symptom or sign should tr igger 
prom pt testing of hepatic function 
(ie, w ithin 72 hours).  Local 
laboratory testing is acceptable, 
ideally with a concurrent central 
laboratory sam ple for 
confirm ation.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
224
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
 KRXUVDQGWROYDSWDQVKRXOGEH
WHPSRUDULO \LQWHUUXSWHG7ROYDSWDQ
VKRXOGQRWEHUHVXPHGXQWLOPRQLWRULQJLQGLFDWHVDEQRUPDOLWLHVKDYHUHVROYHGDUHVWDEOHRUDUHQRW
LQFUHDVLQJDQGWKHQRQO\ZLWKDQ
LQFUHDVHGIUHTXHQF\RIPRQLWRULQJ
6XEMHFWVZRXOGQRWW\SLFDOO\EH
DOORZHGWRUHVXPHWUHDWPHQWZLWKWROYDSWDQLIWKH\KDYH
â€¢WUDQVDPLQDVHOHYHOVULVH
DERYH Ã® 8/1
â€¢WUDQVDPLQDVHOHYHOVDUH
!  Ã® 8/1IRUPRUHWKDQ ZHHNVRU
â€¢FRQFXUUHQWHOHYDWLRQVRI
WUDQVDPLQDVH!  Ã® 8/1DQG%7!  Ã® 8/1$Q\WUDQVDPLQDVHRUELOLUXELQ
YDOXHVZKLFKH[FHHGÃ®8/1VKRXOGDOVRSURPSWLPPHGLDWHUHWHVWLQJZLWKLQKRXUV:KLOHYDOXHVUHPDLQLQDQDEQRUPDOUDQJHWHVWLQJIUHTXHQF\VKRXOGEH
LQFUHDVHGWRDWOHDVWZHHNO\IRUWKH
ILUVWPRQWKJUDGXDOO\UHWXUQLQJWRPRQWKO\RUHYHU\WKUHHPRQWKVDVLQGLFDWHGE\WKHUHVXOWV
/LYHUWUDQVDPLQDVHRUELOLUXELQ
OHYHOVUHDFKLQJRUH[FHHGLQJ Ã®8/1WKDWKDYHDQXQFHUWDLQRUUDSLGO\LQFUHDVLQJWUDMHFWRU\VKRXOGSURPSWDWOHDVWWHP SRUDU\
,03LQWHUUXSWLRQ 7ROYDSWDQ
VKRXOGQRWEHUHVXPHGXQWLO
PRQLWRULQJLQGLFDWHVDEQRUPDOLWLHVKDYHUHVROYHGDUHVWDEOH RUDUHQRWUDSLGO\LQFUHDVLQJDQGWKHQRQO\
ZLWKDQLQFUHDVHGIUHTXHQF\RI
PRQLWRULQJ
6XEMHFWVZRXOGQRWW\SLFDOO\EH
DOORZHGWRUHVXPHWUHDWPHQWZLWKWROYDSWDQLIWKH\KDYH
â€¢WUDQVDPLQDVHOHYHOVULVH
DERYH Ã® 8/1
â€¢WUDQVDPLQDVHOHYHOVDUH
!  Ã® 8/1 IRUPRUHWKDQ ZHHNVRU
â€¢FRQFXUUHQWHOHYDWLRQVRI
WUDQVDPLQDVH!  Ã® 8/1
DQG%7!  Ã® 8/1










8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W




6HFWLRQ
7UHDWPHQW,QWHUUXSWLRQ
DQG'LVFRQWLQXDWLRQ1$ ,QWKLVWULDOLWLVH[SHFWHGWKDW
VXEMHFWVPD\SRVVLEO\KDYHRQHRU
PRUHSODQQHGRUXQSODQQHGWUHDWPHQWLQWHUUXSWLRQV,IDVXEMHFWÂ¶V,03WUHDWPHQWPXVWEHLQWHUUXSWHGIRUPHGLFDORUVXUJLFDOUHDVRQVOLYHUWHVWDEQRUPDOLWLHVXVH
RIDSURKLELWHGPHGLFDWLRQRURWKHU
UHDVRQVHJKRVSLWDODGPLVVLRQIRUDQLQYDVLYHSURFHGXUHDPDMRUPHGLFDOFRQGLWLRQVXUJHU\GHQWDOZRUNRUDWHPSRUDU\VLWXDWLRQWKDW
SUHYHQWVVXEMHFWFRPSOLDQFHZLWKWKH
,03DGPLQLVWUDWLRQVFKHGXOHWKHLQYHVWLJDWRUVKRXOGEHQRWLILHGDVVRRQDVSRVVLEOHDQGWKHUHDVRQIRUWUHDWPHQWLQWHUUXSWLRQPXVWEHGRFXPHQWHGLQWKHVRXUFHGRFXPHQWV
DQG&5),ISHUPLVVLEOHWKH
VXEMHFWÂ¶V,03PD\EHUHVXPHGIROORZLQJDSSURYDOE\WKHPHGLFDOPRQLWRU,I,03WUHDWPHQWLVSHUPDQHQWO\GLVFRQWLQXHG WKHUHDVRQIRU
GLVFRQWLQXDWLRQPXVWEHUHFRUGHG
DSSURSULDWHO\LQWKHVRXUFHGRFXPHQWDQGLQWKH&5)$VXEMHFWZKR SHUPDQHQWO\
GLVFRQWLQXHV,03WUHDWPHQWPD\KDYHWKHRSWLRQWRHQGWULDO
SDUWLFLSDWLRQFRPSOHWHWKHHDUO\
WHUPLQDWLRQYLVLWRUWRFRQWLQXHSDUWLFLSDWLRQRII,03 DQGFRPSOHWHRQJRLQJWULDODVVHVVPHQWVDVSHUSURWRFRORUZLWKDPRGLI LHGLHOHVV
IUHTXHQWVFKHGXOHDVRX WOLQHGLQ
6HFWLRQ
6HFWLRQ  (QWLUH7ULDORU7UHDWPHQW
$UPV (QWLUH7ULDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 100 06 March 2015Location Old Text Updated Text
Section 3.8.3, 
Individual Subject...  
All subjects have the right to 
withdraw at any time during 
treatment without prejudice.  The 
investigator can discontinue a 
subjectâ€™s participation in the trial at 
any time if medically necessary.  In 
addition, subjects meeting the 
following criteria must be w ithdrawn 
from the trial:
a) Occurrence of any AE, intercurrent 
illness, or abnormality in a laboratory 
assessment which, in the opinion of 
the investigator, w arrants the 
subjectâ€™s permanent withdrawal from 
the trial;
b) Treatment with a prohibited 
concomit ant medication other than 
the use of appropriate medications for 
the treatment of AEs under direction 
of the investigator;
c) Subject noncompliance, defined as 
refusal or inability to adhere to the 
trial schedule or procedures (see 
Section 3.12);
d) At the request of the subject, 
investigator, sponsor, or regulatory 
authority;
e) Subject becomes pregnant; or 
f) Subject is lost to follow -up.
The investigator will notify the 
sponsor promptly when a subject is 
withdrawn....
All subjects have the right to 
withdraw at any time during 
treatment without prejudice.  The 
investigator can discontinue a 
subjectâ€™s participation in the trial at 
any time if medically necessary.  It 
is preferred that subjects who 
perm anently discontinue IMP will 
have the option to continue 
participation off IMP with regular 
scheduled visits or with a modified 
(ie, less frequent) schedule.  If 
subjects are unable or unwilling to 
complete the visits and procedures 
off IMP, the early 
term ination/EoTx visit s hould be 
completed.  The investigator may
continue to contact those who 
discontinue IMP through to the 
final com pletion date of the trial 
or thereafter if needed to 
determine outcomes ie, vital 
status.  
In addition, subjects meeting the 
following criteria must be w ithdrawn 
from the trial:
a) Occurrence o f any AE, 
intercurrent illness, or abnormality in 
a laboratory assessment which, in 
the opinion of the investigator, 
warrants the subjectâ€™s permanent 
withdrawal from the trial;
b) Subject noncompliance, def ined 
as refusal or inability to adhere to the 
trial schedule or procedures (see 
Section 3.11);
c) At the request of the subject, 
investigator, sponsor, or regulatory 
authority;
d) Subject is lost to follow -up.
The investigator will notify the 
sponsor promp tly when a subject is 
withdrawn.
Section 3.12, Subject 
Com plianceSubject compliance will be monitored 
by pill counts as IMP is returned.  
Any subject who, without the 
instruction of the investigator, 
discontinues tolvaptan investigational Subject compliance will be 
monitored by pill counts as IMP is 
returned.  Any subject w ho, without 
the instruction of the investigator, 
discontinues tolvaptan 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
227
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 101 06 March 2015Location Old Text Updated Text
product w ithout the instruction of the 
investigator, discontinues tolvaptan 
for 30 consecutive days or misses > 
30% of the doses intended for a 
period betw een visits (whichever is 
greater) w ill be deemed 
noncompliant.  ...investigational product, discontinues 
tolvaptan for 30 consecutive days or 
misses > 30% of the dos es intended 
for a period betw een visits 
(whichever is greater) w ill be 
deemed noncompliant.  ...
Section 3.13, Protocol
DeviationsThis trial is to be conducted as 
described in this protocol.  In the 
event of a significant deviation from 
the protocol due to an emergency, 
accident or mistake, the investigator 
or designee must contact the sponsor 
at the earliest possible time.  This will 
allow  an early joint decision 
regarding the subjectâ€™s continuation 
in the trial.  This decision will be 
documented by the investigator and 
the sponsor, and reviewed by the 
monitor.This trial is to be conducted as 
described in this protocol.  In the 
event of a significant deviation from 
the protocol due to an emergency, 
accident or mistake (eg, violation of 
inform ed consent p rocess, IMP 
dispensing or subject dosing error, 
subject enrolled in violation of 
eligibility criteria or concomitant 
medication criteria) , the 
investigator or designee must contact 
the sponsor at the earliest possible 
time.  This will allow an early joint 
decision regarding the subjectâ€™s 
continuation in the trial.  This 
decision will be documented by the 
investigator and the sponsor, and 
reviewed by the sitemonitor.
Section 4.1, Prohibited 
or Restricted 
Medications Medications or surgical therapies 
used for the purpose or potential for 
modifying the progression of PKD 
cyst growth or development will be 
prohibited.  These include, but are not 
restricted to, somatostatin agonists, 
rapamune (sirolimus), anti -sense 
ribonucleic acid therapies, tolvaptan, 
and other vasopressin antagonists, 
(eg, OPC -31260 (mozavaptan), 
Vaprisol (conivaptan), agonists (eg, 
desm opressin) and cyst 
decompression surg ery.
Continuous or short -term use of other 
medications, while not prohibited, 
may be restricted by the investigator 
because of their potential for 
interference with tolvaptan 
metabolism (see Section 3.2.1 and 
Section 3.2.2 ). 
...
Some drugs are known to alter 
creatinine concentrations so, while 
not prohibited, subjects should alert 
their trial doctor, and any other 
health -care providers, to take this into Medications or surgical therapies 
used for the purpose or potential for 
modifying the progression of PKD 
cyst growth or development will be 
prohibited.  These include, but are 
not restricted to, somatostatin 
agonists, rapamune (sirolimus), anti -
sense ribonucleic acid therapies, 
vasopressin antagonists other than 
tolvaptan , (eg, OPC -31260 
(mozavaptan), Vaprisol 
(conivaptan), agonists (eg, 
desm opressin) and cyst 
decompression surgery.
Continuous or short -term use of 
other medications, while not 
prohibited, may be restricted by the 
investigator because of their 
potential for interference with 
tolvaptan metabolism (see 
Section 3.2.1 and Section 3.2.2 ). 
A partial list of strong and 
moderate CYP3A4 inhibitors can 
be found in Table 4.1-1below :
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
228
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 102 06 March 2015Location Old Text Updated Text
consideration when considering 
changes in their prescribed or over -
the-counter medications.  A list 
would include:  cimetidine, non -
steroidal anti -inflammatory drugs like 
aspirin or ibuprofen, chemotherapy 
drugs, cephalosporin, the 
combination of elvitegravir, 
cobicistat, emtricitabine, and 
tenofovir (StribildTM), dolutegravir, 
dronedarone, ranolazine, metformin, 
and trimethoprim....
Some drugs are known to alter 
creatinine concentrations so, while 
not prohibited, subjects should alert 
their trial doctor, and any other 
health -care providers, to take this 
into consideration when considering 
changes in their prescribed or over -
the-counter medications.  A list 
would include:  non -steroidal anti -
inflammatory drugs like aspirin or 
ibuprofen, chemotherapy drugs, 
cephalosporin, the combination of 
elvitegravir, cobicistat, 
emtricitabine, and tenofovir 
(StribildTM), dolutegravir, 
dronedarone, ranolazine, metformin, 
and trimethoprim.
Table 4.1 -1 N/A Please see end of Appendix 5 for this 
new table.
Section 4.2, Dietary 
Restrictions and 
RecommendationsRestriction of excess dietary sodium 
and cooked meat protein may prove 
beneficial to subjects with a history 
of, or predisposition for, hypertension 
or kidney disease in general and 
should be applied to all subjects 
diagnosed with advanced ADPKD, 
particula rly if there is evidence for a 
propensity for rapid progression.  In 
the absence of alternate regional 
practices, dietary salt < 5g/day, 
dietary cooked meat protein < 1 
g/kg/day and a limit on caffeinated 
drinks/foods should also be given (no 
more than 2 c offee equivalents per 
day).  Restriction of excess dietary sodium 
and cooked meat protein may prove 
beneficial to subjects with a history 
of, or predisposition for, 
hypertension or kidney disease in 
general and should be applied to all 
subjects diagnosed with advanced 
ADPKD, particularly if there is 
evidence for a propensity for rapid 
progression.  In the absence of 
alternate regional practices, dietary 
salt < 5g/day, dietary cooked meat 
protein < 1 g/kg/day and a limit on 
caffeinated drinks/foods should a lso 
be given (no more than 2 coffee 
equivalents per day).  A history of 
alcohol and sm oking intake will be 
collected at screening.  Alcohol 
and tobacco consumption should 
be avoided or m inimized as much 
as possible.
Section 5, Reporting of 
Adverse EventsThe follow ing describes the methods 
and timing for assessing, recording, 
and analyzing safety parameters, as 
well as the procedures for eliciting 
reports of and recording and reporting 
AEs and intercurrent illnesses and the 
type and duration of the follow -up of 
subjects after AEs.The follow ing describes the methods 
and timing for assessing, recording, 
and analyzing safety parameters, as 
well as the procedures for eliciting 
reports of and recording and 
reporting AEs and intercurrent 
illnesses and the type a nd duration of 
the follow -up of subjects after AEs.
Medical follow up is expected for 
AEs which lead to discontinuation 
which are serious, or which are of 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
229
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
VSHFLDOLQWHUHVWHJOLYHU
DEQRUPDOLWLHVVNLQQHRSODVPV
JODXFRPD
6HFWLRQ)ROORZXSRI$GYHUVH(YHQWV)RUWKLVWULDO$(VZLOOEHIROORZHGXS
IRUGD\VDIWHUWKHODVWGRVHRIWROYDSWDQKDVEHHQDGPLQLVWHUHGIROORZXSSHULRG
6XEMHFWVH[SHULHQFLQJ6$(VVKRXOG
EHIROORZHGFOLQLFDOO\XQWLOWKHLUKHDOWKKDVUHWXUQHGWREDVHOLQHVWDWXVRUXQWLODOOSDUDPHWHUVKDYHUHWXUQHGWRQRUPDORUKDYHRWKHUZLVHEHHQH[SODLQHG
)RUVXEMHFWVZKRKDYHGLVFRQWLQXHG
WROYDSWDQEXWKDYHQRWZLWKGUDZQIURPWKHWULDOYLWDOVWDWXV$(VFRQFRPLWDQWPHGLFDWLRQVDQGVFKHGXOHGODERUDWRU\GDWDLQFOXGLQJ
VHUXPFUHDWLQLQHGDWDDUHSODQQHGWR
EHFROOHFWHGUHJDUGOHVVRIWROYDSWDQGLVFRQWLQXDWLRQXQWLOWKHVFKHGXOHGHQGRIWKHWULDO)RUWKLVWULDO$(VZLOOEHIROORZHG
XSIRUGD\VDIWHUWKHODVWGRVHRIWROYDSWDQKDVEHHQDGPLQLVWHUHGIROORZXSSHULRG
6XEMHFWVH[SHULHQFLQJ6$(VVKRXOG
EHIROORZHGFOLQLFDOO\XQWLOWKHLUKHDOWKKDVUHWXUQHGWREDVHOLQHVWDWXVRUXQWLODOOSDUDPHWHUVKDYHUHWXUQHGWRQRUPDORUKDYHRWKHUZLVHEHHQH[SODLQHG









6HFWLRQ6DPSOH
6L]H6DPSOHVL]HZDVQRWGHWHUPLQHGE\D
IRUPDOFRPSXWDWLRQWRDFKLHYHDWDUJHWSRZHU1RHIILFDF\DQDO\VHVDUHSODQQHG,WLVH[SHFWHGWKDWDSSUR[LPDWHO\VXEMHFWVPD\
HQUROOIURPSUHYLRXVWROYDSWDQWULDOV6DPSOHVL]HZDVQRWGHWHUPLQHGE\D
IRUPDOFRPSXWDWLRQWRDFKLHYHDWDUJHWSRZHU1RHIILFDF\DQDO\VHVDUHSODQQHG,WLVH[SHFWHGWKDWDSSUR[LPDWHO\ VXEMHFWVPD\
HQUROOIURPSUHYLRXVWROYDSWDQWULDOV
$SSHQGL[1DPHRI6SRQVRU3HUVRQQHO 
86$
3KRQH
86$
3KRQH
$SSHQGL[,QVWLWXWLRQV&RQFHUQHG:LWKWKH
7ULDO7UDYHOLQJ&RRUGLQDWRU$VVLVWDQW
3ULQFHWRQ0HGLFDO
5RXWHVRXWK
+LOOVERURXJK1-86$
3KRQH
)D[7UDYHOLQJ&RRUGLQDWRU$VVLVWDQWURZ
GHOHWHG
&HQWUDO/DERUDWRU\6HUYLFHV
&RYDQFH&HQWUDO/DERUDWRU\
6HUYLFHV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
PPD
PPD
PPDCCI
PPDPPDPPD PPD
PPD PPD
PPD
PPD PPD
PPD
PPD
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
&HQWUDO/DERUDWRU\6HUYLFH
&RYDQFH&HQWUDO/DERUDWRU\6HUYLFHV
6FL&RU'U
,QGLDQDSROLV,186$
3KRQH
7ROOIUHH
)D[6FL&RU'U
,QGLDQDSROLV,186$
3KRQH
7ROOIUHH
)D[ 
&RYDQFH$VLD3WH/WG
&HQWUDO/DERUDWRU\6HUYLFHV
6LQJDSRUH
,QWHUQDWLRQDO%XVLQHVV3DUN

7KH6\QHUJ\6LQJDSRUH
3KRQH
&RYDQFH&HQWUDO/DERUDWRU\
6HUYLFHV6\GQH\
(SSLQJ5G1RUWK5\GH
16:$XVWUDOLD
3KRQH
&RYDQFH&HQWUDO/DERUDWRU\
6HUYLFHV*HQHYD
5XH0RLVH0DUFLQKHV
0H\ULQ*HQHYD &+
6ZLW]HUODQG
3KRQH

3KRQH

















8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCIPPD
PPDPPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W






















$SSHQGL[3URWRFRO
$PHQGPHQW1$
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 106 06 March 2015Previous Figure 3.1- 1 -Trial Design Schematic:
Revised Figure 3.1 -1 -Trial Design Schematic:
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
233
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 107 06 March 2015Previous Table 3.2-1 - Trial Treatments:
Table 3.2-1 Trial Treatments
Trial Day Time Dose
Day 1 to last on -treatment visit 8:00 am 1 to 6 tolvaptan tablets (15 mg or 30 mg each)
4:00 to 5:00 pm 1 to 2 tolvaptan tablets (15 mg or 30 mg each)
Allowed doses are 45/15 mg, 60/30 mg, 
90/30 mg.  Down titration to 30/15 mg and 
15/15 mg will be allow ed after discussion 
with the medical monitor.  
Revised Table 3.2 -1 -Trial Treatments :
Table 3.2-1 Trial Treatments
Trial Day Time Dose
Day 1 to last on-treatment visit 8:00 am 1 to 6 tolvaptan tablets (15 mg or 30 mg each)
4:00 to 5:00 pm 1 to 2 tolvaptan tablets (15 mg or 30 mg each)
Allowed doses are 45/15 mg, 60/30 mg, 
90/30 mg.  Down titration to 30/15 mg and 
15/15 mg will be allow ed after discussion 
with the medical monitor.  Further down 
titration to 30 or 15 m g once daily m ay be 
allowed only for metabolic drug -drug 
interaction an d requires medical m onitor 
approval.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
234
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 108 06 March 2015Previous Table 3.4.2-1 â€“ Inclusion Criteria:
Table 3.4.2-1 Inclusion Criteria
1. Male and female subjects aged ï‚³18 years with ADPKD who have completed either trial 
156-13-210 or trial 156 -08-271
2. Diagnosis of ADPKD by modified Pei -Ravine criteria:
ï‚·With family history: several cysts per kidney (3 if by sonography, 5 if by computed 
tomography or MRI).
ï‚·Without family history: 10 cysts per kidney (by any radiologic method, above) and exclusion 
of other cystic kidne y diseases.  Conditions to be excluded include: multiple simple renal 
cysts, renal tubular acidosis, cystic dysplasia of the kidney, multicystic kidney, multilocular 
cysts of the kidney, medullary cystic kidney and acquired cystic disease of the kidney.
ï‚·Distribution and number of cysts consistent with the observed level of renal function deficit.
3. Estimated glomerular filtration rate  ï‚³20 mL/min/1.73 m2 (calculated using the CKD -EPI 
formula) within 45 days prior to the baseline visit.  Subjects who have an eGFR between 15 and 
19 mL/min/1.73 m2may be permitted with documented medical monitor approval prior to 
enrollment.
Revised Table 3.4.2-1 â€“ Inclusion Criteria:
Table 3.4.2-1 Inclusion Criteria
1. Male and female subjects aged ï‚³18 years with confirmed diagnosis of ADPKD ( during 
participation in prior tolvaptan trials) who have
ï‚·Completed and transferred from  the double -blind Trial 156-13-210 (12 -month 
period including post -treatment follow -up, regardless of whether this was on -
treatm ent or off -treatm ent), or 
ï‚·Completed Trial 156-08-271 or a prior tolvaptan trial, or 
ï‚·Interrupted or discontinued treatm ent in a tolvaptan trial other than 
Trial 156-13-210.  Subjects may be enrolled with the medical m onitor approval, and 
additional close m onitoring may be required at the beginning of the trial
ï‚·Renal function will be assessed during screening using historical laboratory values 
(in the last 30 days) for serum creatinine levels to calculate the estim ated 
glom erular filtration rate (eGFR).  The eGFR val ues will be estimated based on the 
Chronic Kidney Disease -Epidemiology (CKD -EPI) formula. (Levey AS et al. Ann 
Intern Med. 2009; 150:604 â€“612)
2. Estimated glomerular filtration rate  ï‚³20 mL/min/1.73 m2 (calculated using the CKD -EPI 
formula) within 45 days prior to the baseline visit.  Subjects who have an eGFR between 15 and 
19 mL/min/1.73 m2may be permitted with documented medical monitor approval prior to 
enrollment.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
235
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK3UHYLRXV7DEOHÂ±6FKHGXOHRI$VVHVVPHQWV
7DEOH 6FKHGXOHRI$VVHVVPHQWV
6FUHHQLQJ
WR
GD\V
SULRUWR
%DVHOLQHD%DVHOLQH
'D\0RQWKO\
Â“GD\V(YHU\PRQWKV
Â±Â±GD\V(DUO\
7HUPLQDWLRQ(QG
RI7ULDO9LVLW
PRQWKV7LWUDWLRQ
&RQWDFW
SKRQH
FRQWDFW)ROORZXS
GD\VSRVW
WUHDWPHQW
GD\V
,QIRUPHGFRQVHQW ;
,QFOXVLRQ([FOXVLRQ ; ;
'HPRJUDSKLFV0HGLFDO$'3.'KLVWRU\
E;
'LHWDU\UHYLHZ ; ; ; ;
9LWDOVLJQVF;; ; ; ;
&KHPLVWU\%ORRG6DPSOHVG
6HUXP&KHPLVWU\3DQHO ; ;H;
/LYHU)XQFWLRQWHVWV ;I;I;I;I;I
6RGLXP ; ; ;
&UHDWLQLQH ; ; ; ;
+HPDWRORJ\DQGFRDJXODWLRQ ;;
8ULQDO\VLV ;; ;
8ULQHRVPRODOLW\J;; ;
8ULQHVSHFLILFJUDYLW\ ;; ;
8ULQHSUHJQDQF\WHVW:2&%3RQO\K;; ; ;
8ULQHDWKRPHSUHJQDQF\WHVWNLWV
GLVSHQVHGL;;
3K\VLFDOH[DPLQDWLRQM;; ; ;
7ROHUDELOLW\'RVLQJ5HYLHZ ; ; ; ;
,QWHUDFWLYH5HVSRQVH7HFKQRORJ\ (QWU\ ; ; ; ; ;N
'UXJGLVSHQVDWLRQ ; ; ;N
'UXJUHFRQFLOLDWLRQ ; ; ;N
$GYHUVHHYHQWV ;Oâ†  â†’
&RQFRPLWDQWPHGLFDWLRQVPâ†  â†’
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKD7KHVFUHHQLQJDQGEDVHOLQHYLVLWVPD\EHFRPELQHGZLWKWKHHQG RIWUHDWPHQW(R7[YLVLWIURPWKHSUHYLRXVSURWRFROZLWKDOOU HTXLUHGDVVHVVPHQWVIURPHDFK
YLVLWRQO\SHUIRUPHGRQFH
E,QFOXGHVSULRUWULDOLGHQWLILHUVVFUHHQLQJLGHQWLILFDWLRQ>,'@ VXEMHFW,'VLWH,'
F9LWDOVLJQVDWHDFKYLVLWLQFOXGHVHDWHGKHDUWUDWHFDOLEUDWHG EORRGSUHVVXUHDQGSRVWYRLGERG\ZHLJKW+HLJKWVKRXOGEHSH UIRUPHGRQO\DWVFUHHQLQJDQG
(7(R7[YLVLWV
G/RFDOQRQIDVWLQJ VHUXPODERUDWRU\WHVWV ZLOOEHSHUIRUPHG
â€¢)XOOFKHPLVWU\SDQHOLQFOXGLQJ VHUXPVRGLXPDQGV HUXPFUHDWLQLQHDWEDVHOLQHDQGHDUO\WHUPLQDWLRQHQGRIWUHDWPHQW (7(R7[
â€¢+HSDWLWLVWHVWLQJDW VFUHHQLQJZLOOEHRSWLRQDO
â€¢8SRQUHTXHVWLIFOLQLFDOO\LQGLFDWHGDQGDSSURYHGE\WKH PHGLFDOPRQLWRU VXEMHFWVPD\KDYHWKHIROORZLQJHYDOXDWLRQVLQDGGLWLRQWRWKH
SURWRFROVSHFLILHGFKHPLVWU\SDQHO VHUXPFDOFLXPSKRVSKRURXVSDUDW K\URLGKRUPRQHYLWDP LQ' DQGELFDUERQDWHOHYHOV
H/RFDO6WDQGDUGRI&DUHODERUDWRU\DVVHVVPHQWVZLOOEHSHUIRUPHG HYHU\PRQWKVSHUVXEMHFWÂ¶VLQGLYLGXDOFOLQLFDOPDQDJHPHQWQH HGV
I/LYHUIXQFWLRQWHVWVZLOOEHFRQGXFWHGDVIROORZV
â€¢$WEDVHOLQHDIXOOOLYHUIXQFWLRQSDQHOZLOOEHDVVHVVHG$/7 $67ELOLUXELQWRWDODQGGLUHFWDONDOLQHSKRVSKDWDVH
â€¢)RUVXEMHFWVHQUROOLQJIURPWKHGRXEOHEOLQG7ULDO $/7OHYHOVZLOOEHDVVHVVHGPRQWKO\IRUWKHILUVWPRQWKVTX DUWHUO\HYHU\
PRQWKVDIWHUPRQWKVRIWUHDWPHQWDWWKH(7(R7[DQGDWWKH IROORZXS'D\YLVLW
â€¢)RUVXEMHFWVHQUROOLQJIURPWKHRSHQODEHO7ULDO$/ 7OHYHOVZLOOEHDVVHVVHGTXDUWHUO\HYHU\PRQWKVDWWKH(7 (R7[DQGDWWKH
IROORZXS'D\YLVLW
$Q\VXEMHFWZLWKDQ$/7 HOHYDWLRQ![8/1DQG[8/1ZLOOEH PRQLWRUHGPRQWKO\IRUDQDGGLWLRQDOPRQWKVEH\RQGWKHGDWHR IHOHYDWLRQWRHVWDEO LVK
WKDWWKLVOHYHOLVVWDEOHDQGWKDWIXUWKHUHOHYDWLRQGRHVQRWR FFXU$Q\$/7OHYHO â‰¥[8/1Z LOOUHTXLUHWKHDGGLWLRQRIIXOO OLYHUIXQFWLRQSDQHO$ /7$67
ELOLUXELQWRWDODQGGLUHFWDONDOLQHSKRVSKDWDVHZLWKLQKRX UVRIWKHVLWHEHLQJDZDUHRIWKLVUHVXOW 
J8ULQHRVPRODOLW\LVRSWLRQDO
K$XULQHSUHJQDQF\WHVWIRUSUHJQDQF\IRU ZRPHQRIFKLOGEHDULQJSRWH QWLDO:2&%3Z LOOEHSHUIRUPHGDWVFUHHQLQJDWWKHTXDUWHUO\Y LVLWVDWWKH(R7[YLVLWDQG
DWWKHIROORZXSYLVLW2QVXVSLFLRQRISUHJQDQF\DQXQVFKHGX OHGXULQHRUVHUXPSUHJQDQF\WHVWLQJZLOOEHSHUIRUPHG3RVLWL YHXULQHSUHJQDQF\WHVWVVKRXOGEH
FRQILUPHGZLWKDVHUXPSUHJQDQF\WHVW
L$WKRPHXULQHSUHJQDQF\WHVWNLWVZLOOEHGLVSHQVHGWR:2&%3WR EHXVHGLIDPHQVWUXDOSHULRGLVPLVVHGEHWZHHQYLVLWV.LWV ZLOOEHGLVSHQVHGDVQHHGHG
WKURXJKRXWWKHWULDODWHDFKTXDUWHUO\YLVLW
M$IXOOSK\VLFDOH[DPLQDWLRQLVUHTXLUHGDWVFUHHQLQJWKLVPD\ EHFRPELQHGZLWKWKH(R7[YLVLWIURPWKHSUHYLRXVWULDO$WRW KHUYLVLWVDQRSWLRQDOGLUHFWHG
SK\VLFDOH[DPLQDWLRQPD\EHSHUIRUPHGWRIRFXVRQ3.'UHODWHGV LJQVDQGV\PSWRPV
N,IGXULQJWKHWLWUDWLRQFRQWDFWWKHGHWHUPLQDWLRQLV PDGHWRDGM XVWWKHGRVHUHJLPHQWKHVXEMHFWVWDWXVZLOOEHHQWHUHGLQWR WKHLQWHUDFWLYHUHVSRQVHWHFKQRORJ\
,57DQGDUUDQJHPHQWVPDGHIRUGLVSHQVDWLRQRIDQHZ,03NLWD QGUHFRQFLOLDWLRQRIUHWXUQHG,03
O$WVFUHHQLQJ$(VUHSRUWHGDVRQJRLQJRUUHVROYHGDWWKHHQGRI WKHSULRUWULDOZLOOEHDVVHVVHGWRGHWHUPLQHHQWU\DVHLWKHU PHGLFDOKLVWRU\RURQJRLQJHYHQWIRU
WKLVWULDO
P2QO\FRQFRPLWDQWPHGLFDWLRQVRQJRLQJDWWKHEDVHOLQHYLVLWDQG WKURXJKRXWWKHWULDOZLOOEHUHFRUGHG
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK5HYLVHG7DEOH Â± 6FKHGXOHRI$VVHVVPHQWV
7DEOH 6FKHGXOHRI$VVHVVPHQWV
6FUHHQLQJ
WR  GD\V
SULRUWR%DVHOLQHD%DVHOLQH
'D\0RQWKO\E
Â“GD\V(YHU\
 PRQWKVE
Â±Â± GD\V(DUO\
7HUPLQDWLRQ(QG
RI7UHDWPHQW
GD\V7LWUDWLRQ
&RQWDFW
SKRQH
FRQWDFW)ROORZXS
GD\VSRVW
WUHDWPHQW
GD\V
,QIRUPHGFRQVHQW ;
,QFOXVLRQ([FOXVLRQ ; ;
'HPRJUDSKLFV
0HGLFDO$'3.'KLVWRU\F;
'LHWDU\UHYLHZ ; ; ; ; ;
9LWDOVLJQVG;; ; ; ; ;
&KHPLVWU\%ORRG 6DPSOHVH
6HUXP&KHPLVWU\3DQHO ;I;
/LYHU)XQFWLRQWHVWVJ;; ; ; ;
6RGLXP ; ; ; ;
&UHDWLQLQH ; ; ; ; ;
+HPDWRORJ\DQGFRDJXODWLRQ ;;
8ULQDO\VLV ;; ; ;
8ULQHRVPRODOLW\K;; ; ;
8ULQHVSHFLILFJUDYLW\ ;; ; ;
8ULQHSUHJQDQF\WHVW:2&%3
RQO\L;; ; ; ;
8ULQHDWKRPHSUHJQDQF\WHVW
NLWVGLVSHQVHGM;; ;
3K\VLFDOH[DPLQDWLRQN;; ; ; ;
7ROHUDELOLW\'RVLQJ5HYLHZ ; ; ; ; ;
,QWHUDFWLYH5HVSRQVH
7HFKQRORJ\(QWU\;; ; ; ; ;O;
'UXJGLVSHQVDWLRQ ; ; ; ;O
'UXJUHFRQFLOLDWLRQ ; ; ; ;O
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCICCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK6FUHHQLQJ
WR  GD\V
SULRUWR%DVHOLQHD%DVHOLQH
'D\0RQWKO\E
Â“GD\V(YHU\
 PRQWKVE
Â±Â± GD\V(DUO\
7HUPLQDWLRQ(QG
RI7UHDWPHQW
GD\V7LWUDWLRQ
&RQWDFW
SKRQH
FRQWDFW)ROORZXS
GD\VSRVW
WUHDWPHQW
GD\V

$GYHUVHHYHQWV ;Qâ†  â†’
&RQFRPLWDQWPHGLFDWLRQVRâ†  â†’
D7KHODVWYLVLWDVVHVVPHQWVIURPWKHSUHYLRXVSURWRFROFDQEHFR PELQHGZLWKWKHVFUHHQLQJYLVLWIRUWKLVWULDOZLWKDOOUHTXLU HGDVVHVVPHQWVIURPHDFKYLVLW
SHUIRUPHGRQO\RQFH 
E0RQWKO\YLVLWVDUHIRUVXEMHFWVPRQWKVRQWROYDSWDQDQGH YHU\PRQWKYLVLWVDUHIRUVXEMHFWV!PRQWKVRQWROYDSWDQ 
F,QFOXGHVSULRUWULDOLGHQWLILHUVVFUHHQLQJLGHQWLILFDWLRQ>,'@ VXEMHFW,'VLWH,'SULRUWROYDSWDQ$'3.'WULDOSURWRFROQXP EHU
G9LWDOVLJQVDWHDFKYLVLWLQFOXGHVHDWHGKHDUWUDWHFDOLEUDWHG EORRGSUHVVXUHDQGSRVWYRLGERG\ZHLJKW+HLJKWVKRXOGEHSH UIRUPHGRQO\DWVFUHHQLQJ
H&HQWUDOODERUDWRU\QRQIDVWLQJVHUXPODERUDWRU\WHVWVZLOOEHS HUIRUPHG$OOVXEMHFWVPXVWEHPRQLWRUHGIRUKHSDWLFVDIHW\PR QWKO\XQWLOWKH\KDYHNQRZQ
WROYDSWDQH[SRVXUHGDWDRIDWOHDVW PRQWKV$IWHUWKDWDQG IROORZLQJWKHDSSURYDORIWKHPHGLFDOPRQLWRUKHSDWLFPRQLWRUL QJZLOOWDNHSODFHHYHU\
 PRQWKV7ULDOVXEMHFWVZKRDUHHOLJLEOHIRUWKLVW ULDOZLOOKDYHWULDOYLVLWVKHSDWLFPRQLWRULQJPRQWKO\IRUWKH ILUVW PRQWKVRIWKLVWULDOWKHQ
HYHU\ PRQWKVWKHUHDIWHUEHFDXVHWKHLUWROYDSWDQH[SRVXUHZLOO EHXQNQRZQ2QFHXQEOLQGLQJRFFXUVLWFDQEHGHWHUPLQHGZKLF KVXEMHFWVUHFHLYHGWROYDSWDQ
LQ7ULDO7KHVHVXEMHFWVPD\KDYHWKHLUWULDOYLVLW VKHSDWLFWUDQVDPLQDVHPRQLWRULQJFKDQJHGWRHYHU\PRQWKVVRR QHUDVWKHLUSUHYLRXVWROYDSWDQ
H[SRVXUHLQ7ULDOFDQFRXQWWRZDUGVWKHPRQWKWKU HVKROG6XEMHFWVZKRHQUROOIURPRWKHU$'3.'WROYDSWDQWULDOV ZLOOEHPRQLWRUHGIRU
KHSDWLFVDIHO\PRQWKO\IRUWKHLUILUVW PRQWKVWKH\DUHLQWKL VWULDO
I+HSDWLWLVWHVWLQJDWVFUHHQLQJZLOOEHRSWLRQDO,IKHSDWLWLV WHVWLQJLVSHUIRUPHGWKHQERWKSUHDQGSRVWFRXQVHOLQJDFWLYLW LHVUHODWLQJWRKHSDWLWLVWHVWLQJDUHWREH
FDUULHGRXWEDVHGRQORFDOUHTXLUHPHQWVDQGEHVWSUDFWLFHV8S RQUHTXHVWLIFOLQLFDOO\LQGLFDWHGDQGDSSURYHGE\WKHPHGLFDO PRQLWRUVXEMHFWVPD\KDYHWKH
IROORZLQJHYDOXDWLRQVLQDGGLWLRQWRWKHSURWRFROVSHFLILHGFKH PLVWU\SDQHOVHUXPFDOFLXPSKRVSKRURXVSDUDWK\URLGKRUPRQH YLWDPLQ'DQGELFDUERQDWH
OHYHOV
J$IXOOOLYHUIXQFWLRQSDQHO$67$/7DONDOLQHSKRVSKDWDVH%7 ZLOOEHGRQHDWVFUHHQLQJ$OORWKHUOLYHUIXQFWLRQWHVWVDW VXEVHTXHQWYLVLWVDUHIRU$/7RQO\
XQOHVVRWKHUZLVHFOLQLFDOO\LQGLFDWHG$Q\WUDQVDPLQDVHRUELO LUXELQYDOXHVZKLFKH[FHHG Ã® 8/1VKRXOGSURPSWLPPHGLDWHUHWHVW LQJZLWKLQ KRXUV:KLOH
YDOXHVUHPDLQLQDQDEQRUPDOUDQJHWHVWLQJIUHTXHQF\VKRXOGEH LQFUHDVHGWRDWOHDVWZ HHNO\IRUWKHILUVWPRQWKJUDGXDOO\UH WXUQLQJWRPRQWKO\DQGHYHU\
 PRQWKVDVLQGLFDWHGE\WKHUHVXOWV/RFDOOLYHUIXQFWLRQSDQH ODQDO\VHVZLOODOVREHSHUIRUPHGPRUHIUHTXHQWO\LIQHFHVVDU\ 
K8ULQHRVPRODOLW\LVRSWLRQDO
L$XULQHSUHJQDQF\WHVWIRUSUHJQDQF\IRUZRPHQRIFKLOGEHDULQJ SRWHQWLDO:2&%3 ZLOOEHSHUIRUPHGDWVFUHHQLQJDWHYHU\ PRQ WKVYLVLWVDWWKH(QGRI
7UHDWPHQW(R7[ YLVLWDQGDWWKHIROORZXSYLVLW2QVXVSLFL RQRISUHJQDQF\DQXQVFKHGXOHGXULQHRU VHUXPSUHJQDQF\WHVWLQJ ZLOOEHSHUIRUPHG3RVLWLYH
XULQHSUHJQDQF\WHVWVVKRXOGEHFRQILUPHGZLWKDVHUXPSUHJQDQF \WHVW
M$WKRPHXULQHSUHJQDQF\WHVWNLWVZLOOEHGLVSHQVHGWR:2&%3WR EHXVHGLIDPHQVWUXDOSHULRGLVPLVVHGEHWZHHQYLVLWV.LWV ZLOOEHGLVSHQVHGDVQHHGHG
WKURXJKRXWWKHWULDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFKN$IXOOSK\VLFDOH[DPLQDWLRQLVUHTXLUHGDWVFUHHQLQJ$WRWKHU YLVLWVDQRSWLRQDOÂ³GLUHFWHGÂ´SK\VLFDOH[DPLQDWLRQPD\EHSHU IRUPHGWRIRFXVRQ3.'UHODWHG
VLJQVDQGV\PSWRPV 
O,IGXULQJWKHWLWUDWLRQFRQWDFWWKHGHWHUPLQDWLRQLVPDGHWRDG MXVWWKHGRVH UHJLPHQGRVHDGMXVWPHQWVZLOOEHPDGHXVLQJGLVSH QVHGVXSSO\DQGGRVHLQVWUXFWLRQV
ZLOOEHSURYLGHGE\WKHLQYHVWLJDWRU7KHVXEMHFWÂ¶VFXUUHQWGR VHZLOOEHHQWHUHGLQWRWKHLQWHUDFWLYHUHVSRQVHWHFKQR ORJ\,57DWHDFKYLVLW'UXJ
GLVSHQVDWLRQUHFRQFLOLDWLRQZLOOEHFRQGXFWHGRQDPRQWKO\EDVL VIRUVXEMHFWVZKRKDYHPRQWKO\WULDOYLVLWVDQGRQFHHYHU\ PR QWKVIRUVXEMHFWVZKRKDYHWULDO
YLVLWVHYHU\ PRQWKV
 

$WVFUHHQLQJ$(VUHSRUWHGDVRQJRLQJRUUHVROYHGDWWKHHQG RI WKHSULRUWULDOZLOOEHDVVHVVHGWRGHWHUPLQHHQWU\DVHLWKHUP HGLFDOKLVWRU\RURQJRLQJHYHQWIRU
WKLVWULDO
R2QO\FRQFRPLWDQWPHGLFDWLRQVRQJRLQJDWWKHEDVHOLQHYLVLWDQG WKURXJKRXWWKHWULDOZLOOEHUHFRUGHG7KLVZRXOGRFFXUDWWKH VFUHHQLQJYLVLWRQO\LIWKH
VFUHHQLQJYLVLWRFFXUVVLPXOWDQHRXVO\ZLWKWKHODVWYLVLWIURP DSUHYLRXVWROYDSWDQWULDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXNDFRQILGHQWLDO LQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHG
RUUHGLVWULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$PHQGPHQWV
CCI
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK3UHYLRXV7DEOH&OLQLFDO/DERUDWRU\$VVHVVPHQWV
7DEOH &OLQLFDO/DERUDWRU\$VVHVVPHQWV
+HPDWRORJ\DQG&RDJXODWLRQ3DQHO
+HPRJORELQ
0HDQFRUSXVFXODUKHPRJORELQFRQFHQWUDWLRQ0&+&
0HDQFRUSXVFXODUYROXPH0&9
5HGEORRGFHOO5%&FRXQW:KLWHEORRGFHOO:%&FRXQWZLWKGLIIHUHQWLDO3URWKURPELQWLPH37DVLQWHUQDWLRQDOQRUPDOL]HGUDWLR,15$FWLYDWHGSDUWLDOWKURPERSODVWLQWLPHD377
8ULQDO\VLV3DQHO
$SSHDUDQFH
&RORU%ORRG
*OXFRVH
0LFURVFRSLFDQDO\VLV:%&5%&FRXQWVSHUKLJKSRZHUILHOGS+3URWHLQ
8ULQH&KHPLVWU\
2VPRODOLW\
6SHFLILFJUDYLW\
$GGLWLRQDO7HVWV
8ULQHRUVHUXPSUHJQDQF\IRU:2&%3
+HSDWLWLVRSWLRQDO6HUXP&KHPLVWU\3DQHO
$OEXPLQ
%ORRGXUHDQLWURJHQ%816HUXPFDOFLXP
&DUERQGLR[LGH
6HUXPFKORULGH*DPPDJOXWDP\OWUDQVSHSWLGDVH&KROHVWHUROWRWDO*OXFRVH/DFWDWHGHK\GURJHQDVH/'+
3KRVSKRUXV
3RWDVVLXP3URWHLQWRWDO8ULFDFLG
/LYHU)XQFWLRQ3DQHO
$ONDOLQHSKRVSKDWDVH$/3
$ODQLQHDPLQRWUDQVIHUDVH$/7$VSDUWDWHDPLQRWUDQVIHUDVH$67%LOLUXELQWRWDO%7%LOLUXELQGLUHFW
&UHDWLQLQH 6RGLXP
:2&%3 ZRP HQRIFKLOGEHDULQJSRWHQWLDO
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 115 06 March 2015Revised Table 3.7.2.2-1 - Clinical Laboratory Assessments:
Table 3.7.2.2-1 Clinical Laboratory Assessments
Hem atology and Coagulation Panel:
Hem oglobin
Platelet count
Mean corpuscular hemoglobin concentration 
(MCHC)
Mean corpuscular volume (MCV)
Red blood cell (RBC) count
White blood cell (WBC) count w ith differential 
Prothrombin time (PT) as international normalized 
ratio (INR)
Activated partial thromboplastin time (aPTT)
Urinalysis Panel:
Appearance
Color 
Blood
Glucose
Microscopic analysis, WBC/RBC counts per high 
power field
pH
Protein 
Urine Chemistry
Osmolality (optional)
Specific gravity
Additional Tests:
Urine (or serum) pregnancy for WOCBP
Hepatitis (optional)Serum Chemistry Panel:
Albumin
Blood urea nitrogen (BUN)
Serum calcium
Carbon dioxide
Serum chloride
Gamma -glutamyl transpeptidase
Cholesterol , total
Glucose
Lactate dehydrogenase (LDH)
Phosphorus
Potassium
Protein , total 
Uric acid
Liver Function Panel :
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Bilirubin, total (BT)
Bilirubin, direct
Creatinine Sodium
WOCBP=w omen of childbearing potential.
New Table 4.1-1 Moderate and Strong CYP3A4 Inhibitors (partial list):
Table 4.1-1 Moderate and Strong CYP3A Inhibitors (partial list)
amprenavir atorvastin aprepitant chloramphenicol (if 
used orally)
cimetidine clarithromycin clotrimazole (if used 
orally)danazol
delavirdine diltiazem erythromycin fluconazole
fluvoxamine indinavir isoniazid itraconzazole
josamycin ketoconazole (if used 
orally)nelfinavir nefazadone
quinupristin/ dalfopristin ritonavir saquinavir troleandomycin
verapamil Seville orange products grapefruit products
ADDITIONAL RISK TO THE SUBJECT :
There is no additional risk to the subjects.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
242
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 116 06 March 2015Administrative Change Number: 1
Issue Date: 05 September 2014
PURPOSE:
This administrative change will not affect the safety  of subjects, the scope of the 
investigation, or the scientific quality  of the trial .
The main purpose of this administrative change was to align safet y endpoints between the 
synopsis and Section 3.5.1, and to clarify  the timeline for when I RE forms must be 
completed and submitted to the sponsor .  In addition ,a statement at the beginning of 
Section 3.5.1 explaining that the trial would have no form al endpoints had been 
inadvertently deleted in an earlier draft. 
BACKGROUND:
While reviewing the protocol before proceeding with the clinicaltrial.gov posting, a few 
inconsistencies were found.  I t was decided that fixing the inconsistencies would prov ide 
better clarity . 
Sectional Revisions
Location Old Text Updated Text
Section 3.5.1 Safety 
Endpoints   Safety endpoints will be as follow s:
ï‚·Adverse events
ï‚·Vital signs
ï‚·Clinical laboratory 
assessments
ï‚·Serum transaminase 
elevations for frequency (2x, 
3x, 5x and 10x ULN), time 
to onset, time to peak levels, 
time of offset (< 3x, 2x, or 
1x ULN), response to de -
challenge and re- challenge 
and frequency of progression 
to Hyâ€™s laboratory criteria 
(ALT or AST > 3x ULN and 
bilirubin, total (BT), 
>2xULN without alkaline 
phosphatase ï‚³2x ULN)
ï‚·Serum sodium excursions 
above 145, 150, or 
155mmol/L or below  135, This trial w ill have no formal 
endpoints.  Safety variables will be 
summarized by descriptive statistics, 
(eg, proportion, mean, median, 
standard deviation [SD], minimum, 
and maximum values).  In general, 
summary statistics, including 
changes from baseline, wil l be 
provided for safety variables based 
on all available data.  Safety 
endpoints will be as follows:
ï‚·Adverse events
ï‚·Vital signs
ï‚·Clinical laboratory 
assessments
ï‚·Serum transaminase 
elevations for frequency 
(2x, 3x, 5x and 10x ULN), 
time to onset, time to peak 
levels, time of offset (< 3x, 
2x, or 1x ULN), response to 
de-challenge and re-
challenge and frequency of 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
243
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 117 06 March 2015Location Old Text Updated Text
130, or 125 mmol/L
ï‚·Interruptions of protocol -
specifed therapies for 
hypernatremia or 
hyponatremiaprogression to Hyâ€™s 
laboratory criteria (ALT or 
AST > 3x ULN and 
bilirubin, total (BT), 
>2xULN without alkaline 
phosphatase ï‚³2x ULN)
ï‚·Serum sodium excursions 
above 145, 150, or 
155mmol/L or below  135, 
130, or 125 mmol/L
Section 5.3 ,
Immediately Reportable 
EventsThe investigator must immediately 
report within 24 hours after either the 
investigator or site personnel become 
aware of any SAE, an AE that 
necessitates IMP discontinuation, any 
new liver result meeting the AE 
laboratory threshold criteria, any AE 
of special interest or a confirmed 
pregnancy ,by telephone or by fax to 
the sponsor as outlined in 
Appendix 1.  An IRE form must be 
completed and sent by f ax, email or 
overnight courier to the s ponsor.  
(Please note that the IRE form is 
NOT the AE eCRF ).The investigator must immediately 
report within 24 hours after either 
the investigator or site personnel 
become aware of any SAE, new liver 
laboratory abnormality requiring 
special liver eCRF completion, or 
confirmed pregnancy ,by telephone 
or by fax to the sponsor as outlined 
in Appendix 1.  An IRE form must 
be completed and sent by f ax, em ail,
or overnight courier to the s ponsor.  
(Please note that the IRE form is 
NOT the AE eCRF ).
Appendix 5, Title 
change Protocol Amendment Protocol Amendments and 
Administrative Changes
ADDITIONAL RISK TO THE SUBJECT :
There is no additional risk to the subjects.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
244
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK$PHQGPHQW1XPEHU 
,VVXH'DWH )HEUXDU\
385326(
7KHSULPDU\SXUSRVHRIWKLVDPHQGPHQWZDVWRDGGDGGLWLRQDOODQ JXDJHDWWKHUHTXHVWRI
WKH8QLWHG.LQJGRP 8.Â¶V0HGLFLQHVDQG+HDOWKFDUHSURGXFWV5HJX ODWRU\$JHQF\
0+5$DQGWRFRUUHFWWKHIRRWQRWHLQWKH6FKHGXOHRI$VVHVVPHQW VWDEOHWREHFRQVLVWHQW
ZLWKSURWRFROWH[W
%$&.*5281'
7KH8.0+5$ZDQWHGDPRUHFOHDUO\GHILQHGHQGRIWULDOGDWHDQG PRUHGHWDLOHG
ODQJXDJHUHJDUGLQJDEVWLQHQFHDVDELUWKFRQWUROPHWKRG
6HFWLRQDO5HYLVLRQV
/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
6\QRSVLV7ULDO
'XUDWLRQDQG
6HFWLRQ
7\SH'HVLJQRI7ULDO7ULDOGXUDWLRQLVSODQQHGWRFRQWLQXH
â€¢ 8QWLOWKHODVWVXEMHFWIURP
7ULDO FRPSOHWHV
 PRQWKVRIWROYDSWDQWUHDWPHQWLQWKLVWULDO
â€¢ 6XEMHFWVHQUROOLQJIURPRWKHUWULDOV
ZLOOFRQFOXGHWKHLUSDUWLFLSDWLRQRQFHWROYDSWDQEHFRPHVDYDLODEOHWKURXJK
URXWLQHSUHVFULSWLRQRUWKURXJKD

7ULDOVXEMHFWV
PD\RSWWRFRQFOXGHWKHLUSDUWLFLSDWLRQLQWKLVWULDOLIWROYDSWDQ
EHFRPHVDYDLODEOHEHIRUHWKH\
FRPSOHWHPRQWKVRIWUHDWPHQWLQWKLVWULDO7ULDOGXUDWLRQLVSODQQHGWRFRQWLQXH
â€¢ 8QWLOWKHODVWVXEMHFWIURP
7ULDO FRPSOHWHV
 PRQWKVRIWROYDSWDQWUHDWPHQWLQWKLVWULDO
â€¢ $OOVXEMHFWVZLOOUHFHLYHDWOHDVW
 PRQWKVRIWROYDSWDQWUHDWPHQWLQWKHH[WHQVLRQVWXG\
7ULDO VXEMHFWVRUVXEMHFWV
HQUROOLQJIURPRWKHUWULDOVPD\RSWWRFRQFOXGHWKHLUSDUWLFLSDWLRQLQWKLVWULDOLIWROYDSWDQEHFRPHVDYDLODEOHEHIRUHWKH\FRPSOHWHPRQWKVRI
WUHDWPHQWLQWKLVWULDO
6HFWLRQ7ULDO
3URFHGXUHV
7DEOH 6FKHGXOH
RI$VVHVVPHQWV)RRWQRWHJ
J$IXOOOLYHUIXQFWLRQSDQHO$67
$/7DONDOLQHSKRVSKDWDVH%7ZLOOEHGRQHDWVFUHHQLQJ$OORWKHUOLYHU
IXQFWLRQWHVWVDWVXEVHTXHQWYLVLWVDUH
IRU$/7RQO\XQOHVVRWKHUZLVHFOLQLFDOO\LQGLFDWHG$Q\WUDQVDPLQDVHRUELOLUXELQYDOXHVZKLFKH[FHHGÃ® 8/1VKRXOGSURPSWLPPHGLDWHUHWHVWLQJZLWKLQ)RRWQRWHJ
J$IXOOOLYHUIXQFWLRQSDQHO$67
$/7DONDOLQHSKRVSKDWDVH%7ZLOOEHGRQHDWVFUHHQLQJ$OORWKHUOLYHU
IXQFWLRQWHVWVDWVXEVHTXHQWYLVLWVDUH
IRU $/7RQO\XQOHVVRWKHUZLVHFOLQLFDOO\LQGLFDWHG$Q\WUDQVDPLQDVHYDOXHVZKLFKH[FHHG Ã®8/1VKRXOGSURPSWLPPHGLDWHUHWHVWLQJZLWKLQKRXUV:KLOH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 119 06 March 2015Location Old Text Updated Text
72hours.  While values remain in an 
abnormal range, testing frequency 
should be increased to at least weekly 
for the first month, gradually 
returning to monthly, and every 
3months as indicated by the results.   
Local liver function panel analyses 
will also be performe d more 
frequently, if necessary .values remain in an abnormal range, 
testing frequency should be 
increased to at least weekly for the 
first month, gradually returning to 
monthly, and every 3 months as 
indicated by the results.  Local liver 
function panel analyses will also be 
performed more frequently, if 
necessary.
Section 5. 4, Pregnancy Wom en of childbearing potential who 
are sexually active must use an 
effective method of birth control 
during the course of the trial and for 
30 days after the last dose of IMP in a 
manner such that risk of failure is 
minimized.  Unless the subject is 
sterile (ie, w omen who have had an 
bilateral oophorect omy and/or 
hysterectomy or have been 
postmenopausal for at least 
12consecutive months or remains 
abstinent, 2 of the following 
precautions must be used: vasectomy, 
tubal ligation, intrauterine device, 
birth control pills, birth control depot 
injection, bi rth control implant, 
condom or occlusive cap (diaphragm 
or cervical/vault caps) with 
spermicide.  Any single method of 
birth control, including vasectomy 
and tubal ligation, may fail, leading to 
pregnancy.Wom en of childbearing potential 
who are sexually a ctive must use an 
effective method of birth control 
during the course of the trial and for 
30 days after the last dose of IMP in 
a manner such that risk of failure is 
minimized.  Unless the subject is 
sterile (ie, w omen who have had an 
bilateral oophorecto my and/or 
hysterectomy or have been 
postmenopausal for at least 
12consecutive months or remains 
abstinent, 2 of the following 
precautions must be used: 
vasectomy, tubal ligation, 
intrauterine device, birth control 
pills, birth control depot injection, 
birth control implant, condom or 
occlusive cap (diaphragm or 
cervical/vault caps) with spermicide.  
Any single method of birth control, 
including vasectomy and tubal 
ligation, may fail, leading to 
pregnancy.   Abstinence is only 
acceptable w hen part of the pre ferred 
and usual lifestyle of the subject ;
should that lifestyle change double 
barrier contraceptive methods should 
be employed .
ADDITIONAL RISK TO THE SUBJECT :
There is no additional risk to the subjects.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
246
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 120 06 March 2015Amendment Number : 3
Issue Date: 06 Mar 2015
PURPOSE:
The purpose of this amendment was to increase the window from 30 days to up to 
3months to allow use of historical laboratory  values for screening, to add flexibility  and 
allow combining of screening and baseline visits in the trial, and to provide clarification 
on trial discontinuation.  The list of vendors was updated. Minor linguistic changes were 
made for clarit y and t ypographical errors were corrected.  
BACKGROUND: 
Eligible subjects enrolling from Trials 156-08- 271 or 156 -13-210 can enroll before they  
complete the last visit in their respective trials, and the last visit as well as the screening 
and baseline visit in this trial can be combined into one visit with all required assessments 
from each visit performed only  once, so long as the time between the last visit 
assessments from the previous trial and the screening visit for this trial is within 30 day s.  
Other Revisions
Figure 3.1-1 - Trial Design Schematic
Table 3.4.2-1 - Inclusion Criteria 
Table 3.4.3-1 - Exclusion Criteria 
Table 3.7-1 - Schedule of Assessments footnotes
Sectional Revisions
Location Old Text Updated Text
Title page A Phase 3b, Multi -center, Open -label 
Trial to Evaluate the Long Term 
Safety of Titrated Immediate -release 
Tolvaptan (OPC 41061, 30 mg to 120 
mg/day, Split dose) in Subjects with 
Autosomal Dominant Polycystic 
Kidney Disease
â€¦A Phase 3b, Multi -center, Open -
label Trial to Evaluate the Long 
Term Safety of Immediate -release 
Tolvaptan (OPC -41061, 30 mg to 
120 mg/day, Split dose) in Subjects 
with Autosomal Dominant 
Polycystic Kidney Disease
â€¦
Date of Amendment 3, UK
06 March 2015
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
247
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 121 06 March 2015Location Old Text Updated Text
Synopsis, Protocol Title A Phase 3b, Multi -center, Open -label 
Trial to Evaluate the Long Term 
Safety of Titrated Immediate -release 
Tolvaptan (OPC 41061, 30 mg to 120 
mg/day, Split dose) in Subjects with 
Autosomal Dominant Polycystic 
Kidney DiseaseA Phase 3b, Multi -center, Open -
label Trial to Evaluate the Long 
Term  Safety of Immediate -release 
Tolvaptan (OPC -41061, 30 mg to 
120 mg/day, Split dose) in Subjects 
with Autosomal Dominant 
Polycystic Kidney Disease
Synopsis, Trial Design    
Subjects will be eligible for screening 
into this trial if they:
ï‚·Com pleted and tran sferred from 
the double -blind Trial 
156-13-210 (12 -month period 
including post treatment follow -
up, regardless of whether this 
was on-treatment or off -
treatment), or 
ï‚·Com pleted Trial 156 -08-271 or a 
prior tolvaptan ADPKD trial, or 
ï‚·Interrupted or discontin ued 
treatment in a prior tolvaptan 
ADPKD trial (other than Trial 
156-13-210).  Subjects may be 
enrolled w ith medical monitor 
approval, and additional close 
monitoring may be required at 
the beginning of the trial   
Subjects will be eligible for 
screening into this trial if they:
ï‚·Com pleted and transferred from 
the double -blind Trial 
156-13-210 (12 -month period 
including post treatment follow -
up, regardless of whether this 
was on-treatment or off -
treatment), or have completed 
all but the last follo w-up visit, 
which will be combined with the 
first visit in this trial or
ï‚·Com pleted Trial 156 -08-271 or 
a prior tolvaptan ADPKD trial, 
or have completed all but the 
end of trial visit, which will be 
combined with the first visit in 
this trial or
ï‚·Interrupted or discontinued 
treatment in a prior tolvaptan 
ADPKD trial (other than Trial 
156-13-210).  Subjects may be 
enrolled w ith medical monitor 
approval, and additional close 
monitoring may be required at 
the beginning of the trial
Synopsis, Inclusion and 
Exclusion Criteriaï‚·Estimated glomerular filtration 
rate (eGFR) 
ï‚³20mL/min/1.73m2within 
45days of the baseline visit.  
Subjects who have an eGFR 
betw een 15 and 
19mL/min/1.73m2may be 
enrolled w ith medical monitor 
approval
ï‚·Renal function will be assessed 
during screening by using 
historical values (in the last 
30days) for serum creatinine 
levels to calculate the eGFR.  
The eGFT values will be ï‚·Estimated glomerular filtration 
rate(eGFR) 
ï‚³20mL/min/1.73m2within 
3months of the baseline visit.  
Subjects who have an eGFR 
â‰¤20mL/min/1.73m2may be 
enrolled w ith medical monitor 
and sponsor approval and 
increased frequency of 
monitoring to ensure subjectsâ€™ 
safety .
ï‚·Renal function will be assessed 
during screening by using 
historical values (within 
3months from the screening 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
248
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
HVWLPDWHGEDVHGRQWKH&KURQLF
.LGQH\'LVHDVHÂ± (SLGHPLRORJ\
&.'(3,IRUPXODYLVLWIRUVHUXPFUHDWLQLQHOHYHOV
WRFDOFXODWHWKHH*)57KH
H*)5 YDOXHVZLOOEHHVWLPDWHGEDVHGRQWKH&KURQLF.LGQH\'LVHDVHÂ± (SLGHPLRORJ\
&.'(3,IRUPXOD
6HFWLRQ.QRZQDQG
3RWHQWLDO5LVNVDQG
%HQHILWV
6XEMHFWVHQUROOLQJLQWKLVWULDOZKR
ZHUHLQDSUHYLRXV$'3.'WROYDSWDQWULDORWKHUWKDQ7ULDOVDQGZLOOKDYHPRQWKO\YLVLWV
DQGWUDQVDPLQDVHOHYHODVVHVVPHQWVIRUWKHILUVWPRQWKV
6XEMHFWVHQUROOLQJLQWKLVWULDOZKR
ZHUHLQDSUHYLRXV$'3.'WROYDSWDQWULDORWKHUWKDQ7ULDOVDQG ZLOO
KDYHPRQWKO\YLVLWVDQG DODQLQH
DPLQRWUDQVIHUDVH$/7 OHYHO
DVVHVVPHQWVIRUWKHILUVWPRQWKV
6HFWLRQ7ULDO
5DWLRQDOH(YLGHQFHIURPSUHYLRXVVWXGLHV
VXJJHVWVWKDWGXULQJWKHILUVW PRQWKVRIORQJWHUPWUHDWPHQWLQVXEMHFWVZLWK$'3.'DODQLQHDPLQRWUDQVIHUDVH$/7DQGRUDVSDUWDWHDPLQRWUDQVIHUDVH$67
HOHYDWLRQVDQGHYLGHQFHRI
LGLRV\QFUDWLF',/,RFFXUVDWDJUHDWHUIUHTXHQF\LQWROYDSWDQWUHDWHGVXEMHFWV








(YLGHQFHIURPSUHYLRXVVWXGLHV
VXJJHVWVWKDWGXULQJWKHILUVW PRQWKVRIORQJWHUPWUHDWPHQWLQVXEMHFWVZLWK$'3.'$/7DQGRUDVSDUWDWHDPLQRWUDQVIHUDVH$67HOHYDWLRQVDQGHYLGHQFHRI
LGLRV\QFUDWLF',/,RFFXUVDWD
JUHDWHUIUHTXHQF\LQWROYDSWDQWUHDWHGVXEMHFWV









6HFWLRQ
7\SH'HVLJQRI7ULDO
(OLJLEOHVXEMHFWVZLOOKDYHDQRSSRUWXQLW\WRHQUROOLQWR7ULDO
LPPHGLDWHO\IROORZLQJ
FRPSOHWLRQRIWKHIROORZXSYLVLWVRIWKHSUHYLRXVWULDO7KHODVWYLVLWDVVHVVPHQWVIURPWKHSUHYLRXVSURWRFROFDQEHFRPELQHGZLWKWKHVFUHHQLQJYLVLWIRUWKLVWULDOZLWKDOO
UHTXLUHGDVVHVVPHQWVIURPHDFKYLVLW
RQO\SHUIRUPHGRQFHDVORQJDVWKHWLPHEHWZHHQWKHODVWIROORZXSYLVLWDVVHVVPHQWVIURPWKHSUHYLRXVWULDODQGWKHVFUHHQLQJYLVLWIRUWKLVWULDOLVZLWKLQGD\V

(OLJLEOHVXEMHFWVZLOOKDYHDQRSSRUWXQLW\WRHQUROOLQWR7ULDO
IROO RZLQJFRPSOHWLRQRI
WKHIROORZXSYLVLWVRIWKHSUHYLRXVWULDO(OLJLEOHVXEMHFWVIURP7ULDOVDQGFDQKDYHWKHODVWYLVLWDVVHVVPHQWVIURPWKHLUSUHYLRXVUHVSHFWLYH
SURWRFROVHQGRIWULDOYLVLWIRU
VXEMHFWVDQGODVW
IROORZXSYLVLWIRU VXEMHFWVRYHUODSWKH
ILUVWYLVLWLQWKLVWULDO7KHVHODVWYLVLWDVVHVVPHQWVFDQEHFRPELQHGZLWK
WKHVFUHHQLQJDQGEDVHOLQHYLVLWVIRU
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCI
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 123 06 March 2015Location Old Text Updated Text
These subjects may have their trial 
visits/hepatic transaminase 
monitoring changed to every 
3months sooner as their previous 
tolvaptan exposure in 
Trial 156-13-210 can count towards 
the 18 -month threshold.this trial, with all required 
assessments from each visit 
performed only once, so long as the 
time between the last visit 
assessments from the previous trial 
and the screening visit for this trial is 
within 30 days.   If the first visit in 
this trial combines the last visit from 
a previous trial with both the 
screening and the baseline visits in
this trial, the results from laboratory 
assessments performed at this 
combined visit will not be 
immediately available.  Should any 
laboratory abnormalities be 
identified, the investigator w ill need 
to notify the subject and provide 
instructions regarding dosing or 
returning to the site for additional 
assessments.
...
These subjects may have their trial 
visits/hepatic transaminase 
monitoring changed to every 
3months sooner as their previous 
tolvaptan exposure in 
Trial 156-13-210 can count towards 
the 18 -month threshold.   Subjects 
from prior tolvaptan trials other than 
Trial 156 -08-271 w ill have monthly 
trial visits/ALT level assessments for 
the first 18 months.  After that, the 
trial visits/ALT monitoring will be 
conducted every 3 months after the 
change in frequency is confirmed 
with the medical monitor .Figure 3.1 -1 Day 1
No clinic visit
First dose of the IMPDay 1
No clinic visit
First dose of the IMP in Trial 211
Table 3.4.2 -1, Inclusion 
Criteria1. Male and female subjects aged 
ï‚³18 years with confirmed diagnosis 
of ADPKD (during participation in 
prior tolvaptan trials) who have 
ï‚·Com pleted and transferred from 
the double -blind 
Trial 156-13-210 (12 -month 
period including post -treatment 
follow -up, regardless of whether 
this was on -treatment or off -
treatment), orMale and female subjects aged 
ï‚³18years with confirmed diagnosis 
of ADPKD (during participation in 
prior tolvaptan trials) who have 
ï‚·Com pleted and transferred from 
the double -blind 
Trial 156-13-210 (12 -month 
period including post -treatme nt 
follow -up, regardless of whether 
this was on -treatment or off -
treatment), or
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
250
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 124 06 March 2015Location Old Text Updated Text
ï‚·Com pleted Trial 156-08-271 or a 
prior tolvaptan trial, or
ï‚·Interrupted or discontinued 
treatment in a tolvaptan trial 
other than Trial 156-13-210.  
Subjects may be enrolled w ith 
the medical monitor approval, 
and additional clo se monitoring 
may be required at the beginning 
of the trial
ï‚·Renal function will be assessed 
during screening by using 
historical laboratory values (in 
the last 30days) for serum 
creatinine levels to calculate the 
estimated glomerular filtration 
rate (eGFR).  The eGFR values 
will be estimated based on the 
Chronic Kidney Disease -
Epidemiology (CKD -EPI) 
formula. (Levey AS et al. Ann 
Intern Med. 2009; 150:604 â€“612)
2. Esti mated glomerular filtration rate 
ï‚³20 mL/min/1.73 m2 (calculated 
using the CKD -EPI formula) within 
45days prior to the baseline visit.  
Subjects who have an eGFR betw een 
15 and 19 mL/min/1.73 m2may be 
permitted with documented medical 
monitor approval pr ior to enrollmentï‚·Com pleted Trial 156-08-271 or 
a prior tolvaptan trial, or
ï‚·Interrupted or discontinued 
treatment in a tolvaptan trial 
other than Trial 156-13-210.  
Subjects may be enrolled w ith
the medical monitor approval, 
and additional close monitoring 
may be required at the 
beginning of the trial
ï‚·Renal function will be assessed 
during screening by using 
historical laboratory values (in 
the last 3months ) for serum 
creatinine levels to calcul ate the 
eGFR.  The eGFR values will be 
estimated based on the 
CKD -EPI formula. (Levey AS 
et al. Ann Intern Med. 2009; 
150:604 â€“612)
2. Estimated glomerular filtration 
rate ï‚³20mL/min/1.73 m2 
(calculated using the CKD -EPI 
formula) within 3months prior to 
the baseline visit.  Subjects who 
have an eGFR â‰¤20mL/min/1.73 m2
may be permitted to enter the trial 
with medical monitor and sponsor 
approval and increased frequency of 
monitoring to ensure safety of 
participants.
At end of table, abbreviatio ns added:
eGFR=estimated glomerular 
filtration rate; CKD -EPI= Chronic 
Kidney Disease -Epidemiology
Table 3.4.3 -1, 
Exclusion Criteria1. Women of childbearing potential 
(WOCBP) who do not agree to 
practice 2 different methods of birth 
control or remain abstinent during the 
trial and for 30 days after the last 
dose of IMP.  If employing birth 
control, 2 of the following 
precautions must be used: vasectomy 
of partner, tubal ligation, vaginal 
diaphragm, intrauterine device, birth 
control.
â€¦
4. Hepatic imp airment based on liver 
function abnormalities other than that 1. WOCBP w ho do not agree to 
practice 2 different methods of birth 
control or remain abstinent during 
the trial and for 30 days aft er the last 
dose of IMP.  If employing birth 
control, 2 of the following 
precautions must be used: vasectomy 
of partner, tubal ligation, vaginal 
diaphragm, intrauterine device, birth 
control pill, birth control implant, 
birth control depot injection, 
condo m, or sponge with spermicide.
â€¦
4. Hepatic impairment based on liver 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
251
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 125 06 March 2015Location Old Text Updated Text
expected for ADPKD with cystic 
liver disease during screening.function abnormalities other than 
that expected for ADPKD with 
cystic liver disease during screening
based on recent historical laboratory 
values (in the last 3 months) .
Section 3.7, T rial 
Procedures, Table 3.7 -1Footnote a:
aThe last visit assessments from the 
previous protocol can be combined 
with the screening visit for this trial, 
with all required assessments from 
each visit performed only once.
...
Footnote g:
gA full liver function panel (AST, 
ALT, alkaline phosphatase, BT) w ill 
be done at screening.  All other liver 
function tests at subsequent visits are 
for ALT only, unless otherwise 
clinically indicated.  Any 
transaminase values which exceed 2 
Ã— ULN should prompt immedia te 
retesting within 72 hours.  While 
values remain in an abnormal range, 
testing frequency should be increased 
to at least w eekly for the first month, 
gradually returning to monthly, and 
every 3 months as indicated by the 
results.  Local liver function pan el 
analyses will also be performed more 
frequently, if necessary.
...
Footnote l:
lIf during the titration contact the 
determination is made to adjust the 
dose regimen, dose adjustments will 
be made using dispensed supply, and 
dose instructions will be pro vided by 
the investigator.  The subjectâ€™s 
current dose will be entered into the 
interactive response technology (IRT) 
at each visit.  Drug 
dispensation/reconciliation will be 
conducted on a monthly basis for 
subjects who have monthly trial visits 
and once every 3 months for subjects 
who have trial visits every 3 months.  
...Footnote a:
aThe last visit assessments from the 
previous trial can be combined w ith 
the screening and baseline visits for 
this trial, with all required 
assessments from each visit 
performed only once .
...
Footnote g:
gA full liver function panel (AST, 
ALT, alkaline phosphatase, BT) w ill 
be done at screening.  All other liver 
function tests at subsequent visits are
for ALT only, unless otherwise 
clinically indicated .  An ALT 
elevation > 2 Ã—ULN should trigger 
prom pt testing of hepatic function 
within 72 hours.   Any transaminase 
values which exceed 2 Ã—ULN 
should prompt immediate retesting 
within 72 hours.  While val ues 
remain in an abnormal range, testing 
frequency should be increased to at 
least weekly for the first month, 
gradually returning to monthly, and 
every 3 months as indicated by the 
results.  Local liver function panel 
analyses will also be performed 
more frequently, if necessary.
...
Footnote l:
lIf during the titration contact the 
determination is made to adjust the 
dose regimen, dose adjustments will 
be made using dispensed supply, and 
dose instructions will be provided by 
the investigator.  The subjectâ€™ s 
current dose will be entered into the 
interactive response technology 
(IRT) at each visit.  Drug 
dispensation/reconciliation will be 
conducted on a monthly basis for 
subjects who have monthly trial 
visits and once every 3 months for 
subjects who have tri al visits every 
3months.  If additional drug supply 
is required for titration purposes, the 
site will arrange a subject visit for 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
252
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 126 06 March 2015Location Old Text Updated Text
dispensation.
...
Section 3.7.1.1, 
Screening ( -30days to 
1 day prior to Baseline)Screening for eligibility is required 
forall subjects.  The screening visit 
may be combined with the last visit 
from the previous protocol w ith all 
required assessments from each visit 
only performed once.  In some cases, 
if a subject enrolls in this trial from a 
prior tolvaptan trial, the end o f trial 
visit for that trial and the screening 
visit for this one may occur 
simultaneously.  Required 
assessments are as follows :
1. Obtain subject consent.
2. Determine subject eligibility 
through inclusion/exclusion criteria.  
3. Record demographic 
information and prior trial identifiers 
(screening identification [ID], subject 
ID, site ID, prior tolvaptan ADPKD 
trial protocol number).
4. Record medical/ADPKD 
history using prior trial data.
5. Revie w dietary 
recommendations and compliance
â€¦Screening for eligibility is required 
for all subjects.  The screening and 
baseline visitsmay be combined 
with the last visit from either the 
156-08-271 or 156 -13-210protocol 
with all required assessments from 
each visit performed only once.  
Therefore, in some cases , if a 
subject enrolls in this trial from a 
prior tolvaptan trial, the end of trial
or last follow -upvisit for that trial 
and the screening and baseline visit 
for this one may occur 
simultaneously.  Required 
assessments for the screening visit 
are as follows :
1. Obtain subject consent.
2. Obtain subjectâ€™s new 
screening identifcation (ID) 
assigned by interactive response 
technology (IRT).
3. Determine subject 
eligibility through 
inclusion/exclusion criteria.  
4. Record demographic 
information and prior trial identifiers 
(screening ID, subject ID, prior 
tolvaptan ADPKD trial protocol 
number).
5. Record medical/ADPKD 
history using prior trial data.
6. Revie w dietary 
recommendations and compliance
â€¦
Section 3.7.2.4.1 Liver 
Test Abnormalities and 
Interruption/Discontinu
ation of Investigational 
Medical ProductThe appearance of any suspicious 
symptom or sign should trigger 
prom pt testing of hepatic function (ie, 
within 72 hours).  Local laboratory 
testing is acceptable, ideally with a 
concurrent cen tral laboratory sample 
for confirmation.  An ALT elevation > 2 Ã—ULN or the
appearance of any suspicious 
symptom or sign should trigger 
prom pt testing of hepatic function 
(ie, w ithin 72 hours).  Local 
laboratory testing is acceptable, 
ideally with a co ncurrent central 
laboratory sample for confirmation.  
Section 3.7.5, 
Treatment Interruption 
and Discontinuation...
A subject who permanently 
discontinues IMP treatment may have 
the option to end trial participation 
(complete the early termination visit) ...
A subject who permanently 
discontinues IMP treatment end s
trial participation and t he early 
termination visit should be 
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
253
3URWRFRO
&RQILGHQWLDO2WVXND3URSULHWDU\,QIRUPDWLRQ  0DUFK/RFDWLRQ 2OG7H[W 8SGDWHG7H[W
RUWRFRQWLQXHSDUWLFLSDWLRQRII,03
DQGFRPSOHWHRQJRLQJWULDO
DVVHVVPHQ WVDVSHUSURWRFRORUZLWKD
PRGLILHG LHOHVVIUHTXHQWVFKHGXOH
DVRXWOLQHG LQ6HFWLRQFRPSOHWHG
6HFWLRQ(OLFLWLQJ
DQG5HSRUWLQJ$GYHUVH(YHQWVÂ«
,QDGGLWLRQ WKHVSRQVRUPXVWEH
QRWLILHGLPPHGLDWHO\E\WHOHSKRQHRU
ID[RIDQ\LPPHGLDWHO\UHSRUWDEOH
HYHQWVDFFRUGLQJWRWKHSURFHGXUHRXWOLQHGE HORZLQ6HFWLRQÂ«Â«
,QDGGLWLRQ4XLQWLOHVGUXJVDIHW\VHUYLFHPXVWEHQRWLILHG
LPPHGLDWHO\E\WHOHSKRQHRUID[RI
DQ\LPPHGLDWHO\UHSRUWDEOHHYHQWVDFFRUGLQJWRWKHSURFHGXUHRXWOLQHGEHORZLQ6HFWLRQÂ«
6HFWLRQ,PPHGLDWHO\5HSRUWDEOH(YHQWV7KHLQYHVWLJDWRUPXVWLPPHGLDWHO\
UHSRUWZLWKLQKRXUVDIWHUHLWKHUWKHLQYHVWLJDWRURUVLWHSHUVRQQHOEHFRPH
DZDUHRIDQ\6$(QHZOLYHU
ODERUDWRU\DEQRUPDOLW\UHTXLULQJVSHFLDOOLYHUH&5)FRPSOHWLRQRUFRQILUPHGSUHJQDQF\E\WHOHSKRQHRUE\ID[WR WKHVSRQVRUDVRXWOLQHGLQ$SSHQGL[
7KHLQYHVWLJDWRUPXVWLPPHGLDWHO\
UHSRUWZLWKLQKRXUVDIWHUHLWKHUWKHLQYHVWLJDWRURUVLWHSHUVRQQHO
EHFRPHDZDUHRIDQ\6$(QHZOLYHU
ODERUDWRU\DEQRUPDOLW\UHTXLULQJVSHFLDOOLYHUH&5)FRPSOHWLRQRUFRQILUPHGSUHJQDQF\E\WHOHSKRQHRUE\ID[WR 4XLQWLOHVGUXJVDIHW\
VHUYLFHDVRXWOLQHGLQ $SSHQGL[ 

$SSHQGL[ 6DIHW\5HSRUWLQJ
4XLQWLOHV6RXWK0LDPL%OYG0RUULVYLOOH1&86$3KRQH)D[
Â«
,QYHVWLJDWRU3D\PHQWV&)6&OLQLFDO0DGLVRQ$YHVW)ORRU$XGXERQ3$86$3KRQH 
)D[
Â«
3KRQH6DIHW\5HSRUWLQJ
4XLQWLOHV'UXJ6DIHW\6HUYLFH6RXWK0LDPL%OYG0RUULVYLOOH1&86$3KRQH
)D[
Â«,QYHVWLJDWRU3D\PHQWV4XLQWLOHV,QF,QYHVWLJDWRU3D\PHQW$GPLQLVWUDWLRQ'HSDUWPHQW
7HOHVLV&RXUW6XLWH
6DQ'LHJR&$86$
Â«
3KRQH
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
CCICCIPPD
PPD
PPD
PPDPPD
PPD
PPD
PPD
PPD
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 128 06 March 2015Previous Figure 3..-1 Trial Design Schematic
Revised Figure 3.1-1 Trial Design Schematic
ADDITIONAL RISK TO THE SUBJECT :
There is no additional risk to the subjects.
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
255
Protocol 156-13-211
Confidential -Otsuka Proprietary Information 129 06 March 2015Agreement
I, the undersigned principal investigator, have read and understand the protocol (including the 
Investigator's Brochure) and agree that it contains all the ethical, legal and scientific information 
necessary to conduct this trial in accordance with the principles of Good Clinical Practices and as 
described herein and in the sponsor's (or designee's) Clinical Research Agreement.
I will provide copies of the protocol to all physicians, nurses and other professional personnel to 
whom I delegate trial responsibilities. I will discuss the protocol with them to ensure that they are 
sufficiently informed regarding the investigational new drug, [insert compound n umber], the 
concurrent medications, the efficacy  and safety parameters and the conduct of the trial in general. 
I am aware that this protocol must be approved by the Institutional Review Board (IRB) or 
Independent Ethics Committee (IEC responsible for such matters in the clinical trial facility where 
[insert compound number] will be tested prior to commencement of this trial. I agree to adhere 
strictly to the attached protocol (unless amended in the manner set forth in Paragraph I of the 
sponsor's Clinical Research Agreement, at which time I agree to adhere strictly to the protocol as 
amended).
I understand that this IRB -or IE C-approved protocol will be submitted to the appropriate 
regulator y authority/ies by the sponsor. I agree that clinical data entered on case report forms by 
me and my  staff will be utilized by the sponsor in various ways such as for submission to 
governmental regulator y authorities and/or in combination with clinical data gathered from other 
research sites, whenever applicable. I agree to allow sponsor monitors and auditors full access to 
all medical records at the research facility for subjects screened or enrolled in the trial.
I agree to await IRB/IEC approval before implementation of any protocol amendments to this 
protocol. If, ho wever, there is an immediate hazard to subjects, I will implement the amendment 
immediately, and provide the information to the IRB/IEC within 5 working day s. Administrative 
changes to the protocol will be transmitted to the IRB/IEC for informational purposes only.
I agree to provide all subjects with informed consent forms, as required by the applicable 
regulations and by ICH guidelines. I agree to report to the sponsor any adverse experiences in 
accordance with the terms of the sponsor's Clinical Researc h Agreement and the relevant 
regional regulation(s) and guideline(s). I further agree to provide all required information 
regarding financial certification or disclosure to the sponsor for all investigators and sub -
investigators in accordance with the term s of the relevant regional regulation(s). I understand that 
participation in the protocol involves a commitment to publish the data from this trail in a 
cooperative publication prior to publication of efficacy and safety results on an individual basis.
________________________________________________
Principal or Coordinating Investigator Signature and Date
Until the information herein is released by Otsuka to the publ ic domain, the contents of this document are Otsuka 
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.Clinical Study Report 156-13-211 16.1.1 Protocol and Protocol Amendments
256
2WVXND3KDUPDFHXWLFDO'HYHORSPHQW	&RPPHUFLDOL]DWLRQ,QF
7KLVSDJHLVDPDQLIHVWDWLRQRIDQHOHFWURQLFDOO\FDSWXUHGVLJQ DWXUH
  
6,*1$785( 3$*(
'RFXPHQW1DPH
'RFXPHQW1XPEHU'RFXPHQW9HUVLRQ
6LJQHGE\ 0HDQLQJRI6LJQDWXUH6HUYHU'DWH
GG000\\\\ ++PPÂµ*07Â¶=23&
$0'8.


&OLQLFDO3KDUPDFRORJ\ 0DU*07
&OLQLFDO$SSURYDO 0DU*07%LRVWDWLVWLFV$SSURYDO 0DU*07
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO$P HQGPHQWV
PPD